[
    {
        "ticker": "lly",
        "sector": "Healthcare",
        "data": [
            {
                "index": 3,
                "date": "2023-06-23",
                "press_title": "Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight",
                "release_url": "http://lilly.mediaroom.com/2023-06-23-Lillys-phase-2-results-published-in-the-New-England-Journal-of-Medicine-show-orforglipron,-a-once-daily-oral-nonpeptide-GLP-1-receptor-agonist,-achieved-up-to-14-7-mean-weight-reduction-at-36-weeks-in-adults-with-obesity-or-overweight",
                "content": "In additional phase 2 data, published in The Lancet, orforglipron achieved mean reduction in A1C up to 2.1% at 26 weeks in adults with type 2 diabetes Lilly is investigating orforglipron, its...",
                "1d_change": -0.9364763104,
                "index_price": -0.585612215,
                "norm_price": -0.3508640954
            },
            {
                "index": 4,
                "date": "2023-06-21",
                "press_title": "US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older",
                "release_url": "http://lilly.mediaroom.com/2023-06-21-US-FDA-approves-Jardiance-R-empagliflozin-for-the-treatment-of-type-2-diabetes-in-children-10-years-and-older",
                "content": "- Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population - More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and",
                "1d_change": 0.6948070107,
                "index_price": 0.0429123286,
                "norm_price": 0.6518946821
            },
            {
                "index": 5,
                "date": "2023-06-20",
                "press_title": "Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions",
                "release_url": "http://lilly.mediaroom.com/2023-06-20-Lilly-to-present-new-research-in-the-treatment-of-diabetes-and-obesity-at-the-American-Diabetes-Associations-R-83rd-Scientific-Sessions",
                "content": "Full SURMOUNT-2 phase 3 data on the efficacy and safety of tirzepatide for chronic weight management in adults with obesity or overweight and type 2 diabetes New phase 2 data for retatrutide and...",
                "1d_change": 1.576162174,
                "index_price": -0.6967952897,
                "norm_price": 2.2729574638
            },
            {
                "index": 6,
                "date": "2023-06-20",
                "press_title": "Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch \"Tap the Cap\"",
                "release_url": "http://lilly.mediaroom.com/2023-06-20-Lilly-Teams-up-with-the-American-Diabetes-Association-and-Adam-Duvall-to-Launch-Tap-the-Cap",
                "content": "Nationwide effort to inform people living with diabetes about how to access affordable insulin and give back to the diabetes community INDIANAPOLIS, June 20, 2023 /PRNewswire/ -- Eli Lilly and...",
                "1d_change": 1.576162174,
                "index_price": -0.6967952897,
                "norm_price": 2.2729574638
            },
            {
                "index": 7,
                "date": "2023-06-20",
                "press_title": "Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology",
                "release_url": "http://lilly.mediaroom.com/2023-06-20-Lilly-to-Acquire-DICE-Therapeutics-to-Advance-Innovation-in-Immunology",
                "content": "Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE. DICE is a biopharmaceutical company that leverages...",
                "1d_change": 1.576162174,
                "index_price": -0.6967952897,
                "norm_price": 2.2729574638
            },
            {
                "index": 8,
                "date": "2023-06-16",
                "press_title": "First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention",
                "release_url": "http://lilly.mediaroom.com/2023-06-16-First-Of-Its-Kind-Head-to-Head-Clinical-Trial-Reaffirms-the-Efficacy-of-Emgality-in-Episodic-Migraine-Prevention",
                "content": "Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality...",
                "1d_change": -0.8518587193,
                "index_price": -1.1903323491,
                "norm_price": 0.3384736298
            },
            {
                "index": 9,
                "date": "2023-06-02",
                "press_title": "Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2023-06-02-Lilly-Highlights-Verzenio-R-abemaciclib-and-Jaypirca-TM-pirtobrutinib-Data-at-2023-ASCO-R-Annual-Meeting",
                "content": "New analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in node-positive, high risk early breast cancer show similar efficacy across age groups and in patients who had dose...",
                "1d_change": 0.9679057795,
                "index_price": 0.7670071093,
                "norm_price": 0.2008986702
            },
            {
                "index": 10,
                "date": "2023-05-30",
                "press_title": "Lilly to Participate in Goldman Sachs Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2023-05-30-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023. Anat Ashkenazi, Lilly executive vice president and chief financial...",
                "1d_change": 1.3202587023,
                "index_price": -1.1215738902,
                "norm_price": 2.4418325926
            },
            {
                "index": 11,
                "date": "2023-05-22",
                "press_title": "Lilly ESG Report Highlights Progress Towards Sustainability Goals",
                "release_url": "http://lilly.mediaroom.com/2023-05-22-Lilly-ESG-Report-Highlights-Progress-Towards-Sustainability-Goals",
                "content": "Reduced greenhouse gas emissions by 20% Improved access to Lilly insulins in the U.S. Nearly doubled patients reached in resource-limited settings through global health efforts INDIANAPOLIS, May...",
                "1d_change": -4.9857060394,
                "index_price": -1.0903107932,
                "norm_price": -3.8953952463
            },
            {
                "index": 12,
                "date": "2023-05-18",
                "press_title": "Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine",
                "release_url": "http://lilly.mediaroom.com/2023-05-18-Lillys-peresolimab-Phase-2a-rheumatoid-arthritis-trial-published-in-The-New-England-Journal-of-Medicine",
                "content": "Peresolimab met the primary efficacy endpoint in patients with refractory rheumatoid arthritis (RA) Study evaluated a novel approach to treating patients with autoimmune diseases INDIANAPOLIS, May...",
                "1d_change": 1.3269123949,
                "index_price": 0.8182244392,
                "norm_price": 0.5086879556
            },
            {
                "index": 13,
                "date": "2023-05-11",
                "press_title": "Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2023-05-11-Loxo-Lilly-Announces-Details-of-Presentations-at-2023-European-Hematology-Association-EHA-Annual-Meeting",
                "content": "Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the 2023 European Hematology Association (EHA) Annual...",
                "1d_change": -0.2617293942,
                "index_price": -0.1978660961,
                "norm_price": -0.0638632981
            },
            {
                "index": 14,
                "date": "2023-05-09",
                "press_title": "Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation",
                "release_url": "http://lilly.mediaroom.com/2023-05-09-Lillys-Social-Impact-Venture-Capital-Portfolio-Poised-to-Grow-to-300-Million-with-New-50-Million-Allocation",
                "content": "Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting the company's commitment to going beyond the...",
                "1d_change": 0.9520151216,
                "index_price": 0.3236177211,
                "norm_price": 0.6283974004
            },
            {
                "index": 15,
                "date": "2023-05-09",
                "press_title": "Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis",
                "release_url": "http://lilly.mediaroom.com/2023-05-09-Lilly-Discloses-First-in-Class,-Interim-Phase-2-Data-in-Pediatric-Patients-and-New-Analysis-from-Phase-3-Program-in-Adult-Patients-for-Mirikizumab-in-Ulcerative-Colitis",
                "content": "- First interim Phase 2 data of an IL-23p19 antagonist in pediatric patients - New analysis from the pivotal Phase 3 LUCENT-1 and LUCENT-2 studies INDIANAPOLIS, May 9, 2023 /PRNewswire/ -- Eli...",
                "1d_change": 0.9520151216,
                "index_price": 0.3236177211,
                "norm_price": 0.6283974004
            },
            {
                "index": 16,
                "date": "2023-05-03",
                "press_title": "Lilly to Participate in Bank of America Securities 2023 Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2023-05-03-Lilly-to-Participate-in-Bank-of-America-Securities-2023-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2023 Healthcare Conference, May 9-11, 2023. Patrik Jonsson, executive vice president, president of Lilly...",
                "1d_change": 3.1299621627,
                "index_price": -1.5027511373,
                "norm_price": 4.6327132999
            },
            {
                "index": 17,
                "date": "2023-05-03",
                "press_title": "Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease",
                "release_url": "http://lilly.mediaroom.com/2023-05-03-Lillys-Donanemab-Significantly-Slowed-Cognitive-and-Functional-Decline-in-Phase-3-Study-of-Early-Alzheimers-Disease",
                "content": "Nearly half (47%) of the participants on donanemab (compared to 29% on placebo) had no clinical progression at 1 year (defined as no decline in CDR-SB) Phase 3 trial met primary endpoint and all...",
                "1d_change": 3.1299621627,
                "index_price": -1.5027511373,
                "norm_price": 4.6327132999
            },
            {
                "index": 18,
                "date": "2023-05-02",
                "press_title": "Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana",
                "release_url": "http://lilly.mediaroom.com/2023-05-02-Lilly-Provides-500,000-in-Grants-to-Support-Equitable-Access-to-Education-for-Dreamers-in-Indiana",
                "content": "To remove barriers and create more equitable, affordable post-high school education opportunities for Indiana's growing immigrant population, Eli Lilly and Company (NYSE: LLY) today announced...",
                "1d_change": 5.6100601084,
                "index_price": -1.7930721177,
                "norm_price": 7.4031322261
            },
            {
                "index": 19,
                "date": "2023-05-01",
                "press_title": "Lilly Declares Second-Quarter 2023 Dividend",
                "release_url": "http://lilly.mediaroom.com/2023-05-01-Lilly-Declares-Second-Quarter-2023-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on June...",
                "1d_change": 1.7169658817,
                "index_price": -1.1459896407,
                "norm_price": 2.8629555225
            },
            {
                "index": 20,
                "date": "2023-05-01",
                "press_title": "Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis",
                "release_url": "http://lilly.mediaroom.com/2023-05-01-Up-to-73-of-Atopic-Dermatitis-Patients-Taking-Lillys-Lebrikizumab-Had-Improved-or-Cleared-Skin-on-Face-or-Hands-in-New-Analysis",
                "content": "New secondary analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or...",
                "1d_change": 1.7169658817,
                "index_price": -1.1459896407,
                "norm_price": 2.8629555225
            },
            {
                "index": 21,
                "date": "2023-04-27",
                "press_title": "Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum",
                "release_url": "http://lilly.mediaroom.com/2023-04-27-Lilly-Reports-First-Quarter-2023-Financial-Results,-Highlights-Continued-Core-Business-Growth-and-Pipeline-Momentum",
                "content": "Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1 2023 increased 10%, driven by volume growth...",
                "1d_change": 1.1620164419,
                "index_price": 2.2590333051,
                "norm_price": -1.0970168632
            },
            {
                "index": 22,
                "date": "2023-04-27",
                "press_title": "Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2",
                "release_url": "http://lilly.mediaroom.com/2023-04-27-Lillys-tirzepatide-achieved-up-to-15-7-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-SURMOUNT-2",
                "content": "Participants with obesity or overweight and type 2 diabetes taking tirzepatide lost up to 34.4 lb. (15.6 kg) Lilly plans to complete rolling submission to the FDA in the coming weeks INDIANAPOLIS,...",
                "1d_change": 1.1620164419,
                "index_price": 2.2590333051,
                "norm_price": -1.0970168632
            },
            {
                "index": 23,
                "date": "2023-04-24",
                "press_title": "Lilly to Divest BAQSIMI to Amphastar",
                "release_url": "http://lilly.mediaroom.com/2023-04-24-Lilly-to-Divest-BAQSIMI-to-Amphastar",
                "content": "Lilly focused on delivering the company's unprecedented pipeline of next-generation medicines to help patients Amphastar is the ideal company to continue Lilly's mission to help more people...",
                "1d_change": -0.1039403443,
                "index_price": -1.4844163921,
                "norm_price": 1.3804760478
            },
            {
                "index": 24,
                "date": "2023-04-17",
                "press_title": "Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities",
                "release_url": "http://lilly.mediaroom.com/2023-04-17-Lilly-to-Make-Record-Breaking-Investment-in-Indiana-Manufacturing-Facilities",
                "content": "In addition to $3.7 billion investment in Boone County, Lilly will commit $15 million to Ivy Tech to foster a diverse talent pipeline for high-tech manufacturing jobs INDIANAPOLIS, April 17, 2023...",
                "1d_change": -1.3760046363,
                "index_price": 0.4260107973,
                "norm_price": -1.8020154336
            },
            {
                "index": 25,
                "date": "2023-04-13",
                "press_title": "U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab",
                "release_url": "http://lilly.mediaroom.com/2023-04-13-U-S-Food-and-Drug-Administration-Issues-Complete-Response-Letter-for-Mirikizumab",
                "content": "Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the mirikizumab biologic license application (BLA) for the...",
                "1d_change": 0.5630786967,
                "index_price": 0.9087329109,
                "norm_price": -0.3456542142
            },
            {
                "index": 26,
                "date": "2023-04-13",
                "press_title": "Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2023-04-13-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2023-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023. Lilly will also conduct a conference call that day with the investment...",
                "1d_change": 0.5630786967,
                "index_price": 0.9087329109,
                "norm_price": -0.3456542142
            },
            {
                "index": 27,
                "date": "2023-03-14",
                "press_title": "Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2023-03-14-Lilly-Announces-Details-of-Presentations-at-2023-American-Association-for-Cancer-Research-AACR-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14...",
                "1d_change": 1.6450706548,
                "index_price": -0.0534459294,
                "norm_price": 1.6985165842
            },
            {
                "index": 28,
                "date": "2023-03-08",
                "press_title": "Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease",
                "release_url": "http://lilly.mediaroom.com/2023-03-08-Lilly-Provides-Update-on-A4-Study-of-Solanezumab-for-Preclinical-Alzheimers-Disease",
                "content": "Results showed solanezumab did not slow cognitive decline in preclinical Alzheimer's disease or reduce risk of progression to symptomatic Alzheimer's disease Solanezumab targets soluble amyloid...",
                "1d_change": 2.0040991575,
                "index_price": -1.7668281116,
                "norm_price": 3.7709272691
            },
            {
                "index": 29,
                "date": "2023-03-08",
                "press_title": "US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2023-03-08-US-FDA-accepts-supplemental-New-Drug-Application-for-Jardiance-R-for-children-10-years-and-older-with-type-2-diabetes",
                "content": "The application is based on phase III results from the DINAMO trial showing Jardiance® (empagliflozin) tablets significantly reduced A1c (a marker of average blood sugar) versus placebo in...",
                "1d_change": 2.0040991575,
                "index_price": -1.7668281116,
                "norm_price": 3.7709272691
            },
            {
                "index": 30,
                "date": "2023-03-06",
                "press_title": "Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study",
                "release_url": "http://lilly.mediaroom.com/2023-03-06-Intensive-education-at-clinics-about-multidisciplinary-care-improved-likelihood-that-adults-with-type-2-diabetes-and-cardiovascular-disease-were-receiving-guideline-directed-medicines,-according-to-real-world-study",
                "content": "The findings, from the COORDINATE-Diabetes trial, demonstrate the benefit of clinic-level educational interventions, including a focus on coordinating care between cardiology and diabetes care...",
                "1d_change": -2.0313564603,
                "index_price": -1.7253737895,
                "norm_price": -0.3059826708
            },
            {
                "index": 31,
                "date": "2023-03-03",
                "press_title": "U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer",
                "release_url": "http://lilly.mediaroom.com/2023-03-03-U-S-FDA-Broadens-Indication-for-Verzenio-R-abemaciclib-in-HR-,-HER2-,-Node-Positive,-High-Risk-Early-Breast-Cancer",
                "content": "High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade, regardless of Ki-67 score Approval supported by four-year data from the...",
                "1d_change": 0.8120134645,
                "index_price": 1.2449277327,
                "norm_price": -0.4329142682
            },
            {
                "index": 32,
                "date": "2023-03-01",
                "press_title": "Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month",
                "release_url": "http://lilly.mediaroom.com/2023-03-01-Lilly-Cuts-Insulin-Prices-by-70-and-Caps-Patient-Insulin-Out-of-Pocket-Costs-at-35-Per-Month",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket...",
                "1d_change": 1.6029145486,
                "index_price": 0.4523593586,
                "norm_price": 1.15055519
            },
            {
                "index": 33,
                "date": "2023-02-21",
                "press_title": "Lilly to Participate in Cowen's 43rd Annual Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2023-02-21-Lilly-to-Participate-in-Cowens-43rd-Annual-Health-Care-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 43rd Annual Health Care Conference on Monday, March 6, 2023. Mike Mason, executive vice president and president, Lilly Diabetes and...",
                "1d_change": 0.5834723017,
                "index_price": -1.5359378629,
                "norm_price": 2.1194101647
            },
            {
                "index": 34,
                "date": "2023-02-13",
                "press_title": "Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh",
                "release_url": "http://lilly.mediaroom.com/2023-02-13-Lilly-and-IABL-Collaborate-to-Ensure-Patient-Access-to-High-Quality-Affordable-Insulin-in-Bangladesh",
                "content": "Lilly offers its human insulin API at reduced price to IABL to support insulin production in Bangladesh INDIANAPOLIS and DHAKA, Bangladesh, Feb. 13, 2023 /PRNewswire/ -- Eli Lilly and Company...",
                "1d_change": 0.6350979501,
                "index_price": 0.9552351291,
                "norm_price": -0.320137179
            },
            {
                "index": 35,
                "date": "2023-02-07",
                "press_title": "Lilly to Participate in SVB Securities Global Biopharma Conference",
                "release_url": "http://lilly.mediaroom.com/2023-02-07-Lilly-to-Participate-in-SVB-Securities-Global-Biopharma-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the SVB Securities Global Biopharma Conference on Thursday, Feb. 16, 2023. Ilya Yuffa, executive vice president and president, Lilly...",
                "1d_change": 1.3735277474,
                "index_price": 0.3037928934,
                "norm_price": 1.069734854
            },
            {
                "index": 36,
                "date": "2023-02-03",
                "press_title": "Lilly to Participate in Guggenheim Oncology Conference",
                "release_url": "http://lilly.mediaroom.com/2023-02-03-Lilly-to-Participate-in-Guggenheim-Oncology-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on Thursday, Feb. 9, 2023. Jacob Van Naarden, executive vice president and CEO, Loxo@Lilly and David Hyman,...",
                "1d_change": 1.3948883005,
                "index_price": -0.6229473227,
                "norm_price": 2.0178356232
            },
            {
                "index": 37,
                "date": "2023-02-02",
                "press_title": "Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook",
                "release_url": "http://lilly.mediaroom.com/2023-02-02-Lilly-Reports-Fourth-Quarter-2022-Financial-Results,-Core-Business-Growth-and-Pipeline-Advancements-Support-Strong-Long-Term-Outlook",
                "content": "Revenue in Q4 2022 decreased 9%. Excluding COVID-19 antibodies, revenue in Q4 2022 increased 5%, or 10% on a constant currency basis, driven by volume growth of key growth products, partially...",
                "1d_change": 1.4981644239,
                "index_price": -0.5366929229,
                "norm_price": 2.0348573468
            },
            {
                "index": 38,
                "date": "2023-01-27",
                "press_title": "U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor",
                "release_url": "http://lilly.mediaroom.com/2023-01-27-U-S-FDA-Approves-Jaypirca-TM-pirtobrutinib-,-the-First-and-Only-Non-Covalent-Reversible-BTK-Inhibitor,-for-Adult-Patients-with-Relapsed-or-Refractory-Mantle-Cell-Lymphoma-After-at-Least-Two-Lines-of-Systemic-Therapy,-Including-a-BTK-Inhibitor",
                "content": "Jaypirca is the first BTK inhibitor of any kind specifically approved for patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor In the BRUIN Phase 1/2 trial, covalent...",
                "1d_change": -1.647578844,
                "index_price": -0.8947737426,
                "norm_price": -0.7528051014
            },
            {
                "index": 39,
                "date": "2023-01-26",
                "press_title": "Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity",
                "release_url": "http://lilly.mediaroom.com/2023-01-26-Lilly-Supports-Direct-Reliefs-Efforts-to-Expand-Access-to-Medicines-by-Improving-Cold-Chain-Capacity",
                "content": "$1.15M contribution from Lilly will fund the purchase and installation of 150 refrigeration units by Direct Relief in low- and middle-income countries around the world INDIANAPOLIS and SANTA...",
                "1d_change": -2.6015706511,
                "index_price": 0.8470574067,
                "norm_price": -3.4486280577
            },
            {
                "index": 40,
                "date": "2023-01-24",
                "press_title": "Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park",
                "release_url": "http://lilly.mediaroom.com/2023-01-24-Lilly-Plans-to-Invest-Additional-450-million-at-Manufacturing-Site-in-Research-Triangle-Park",
                "content": "Expansion of manufacturing facility in North Carolina will increase the number of patients who may benefit from the company's medicines INDIANAPOLIS, Jan. 24, 2023 /PRNewswire/ -- Eli Lilly and...",
                "1d_change": 1.0665399524,
                "index_price": 0.3605375347,
                "norm_price": 0.7060024178
            },
            {
                "index": 41,
                "date": "2023-01-20",
                "press_title": "US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease",
                "release_url": "http://lilly.mediaroom.com/2023-01-20-US-FDA-accepts-supplemental-New-Drug-Application-for-Jardiance-R-for-adults-with-chronic-kidney-disease",
                "content": "The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial, which showed Jardiance® (empagliflozin) tablets significantly reduced the risk of kidney...",
                "1d_change": -1.3997278996,
                "index_price": 2.7556033225,
                "norm_price": -4.1553312221
            },
            {
                "index": 42,
                "date": "2023-01-19",
                "press_title": "U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab",
                "release_url": "http://lilly.mediaroom.com/2023-01-19-U-S-Food-and-Drug-Administration-Issues-Complete-Response-Letter-for-Accelerated-Approval-of-Donanemab",
                "content": "Accelerated approval application was based on Phase 2 trial showing amyloid plaque lowering Complete response letter based on limited number of patients with 12-month drug exposure data in the...",
                "1d_change": -1.8204460773,
                "index_price": 1.5297252408,
                "norm_price": -3.3501713181
            },
            {
                "index": 43,
                "date": "2023-01-19",
                "press_title": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2023-01-19-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2022-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2022 financial results on Thursday, Feb. 2, 2023. Lilly will also conduct a conference call that day with the investment...",
                "1d_change": -1.8204460773,
                "index_price": 1.5297252408,
                "norm_price": -3.3501713181
            },
            {
                "index": 44,
                "date": "2023-01-04",
                "press_title": "Lilly to Participate in the J.P. Morgan Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2023-01-04-Lilly-to-Participate-in-the-J-P-Morgan-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023. David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat at",
                "1d_change": -1.5936695308,
                "index_price": -0.8471418539,
                "norm_price": -0.7465276769
            },
            {
                "index": 45,
                "date": "2022-12-22",
                "press_title": "Lilly and ProQR to Expand RNA Editing Collaboration",
                "release_url": "http://lilly.mediaroom.com/2022-12-22-Lilly-and-ProQR-to-Expand-RNA-Editing-Collaboration",
                "content": "New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR's Axiomer technology INDIANAPOLIS and LEIDEN, Netherlands and...",
                "1d_change": 0.1576493096,
                "index_price": -0.2195146003,
                "norm_price": 0.3771639099
            },
            {
                "index": 46,
                "date": "2022-12-14",
                "press_title": "Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa",
                "release_url": "http://lilly.mediaroom.com/2022-12-14-Lilly-and-EVA-Pharma-Announce-Collaboration-to-Enhance-Sustainable-Access-to-Affordable-Insulin-in-Africa",
                "content": "For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million...",
                "1d_change": 0.2777654773,
                "index_price": -3.0748903051,
                "norm_price": 3.3526557825
            },
            {
                "index": 47,
                "date": "2022-12-13",
                "press_title": "Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines",
                "release_url": "http://lilly.mediaroom.com/2022-12-13-Lilly-Announces-2023-Financial-Guidance,-Plans-to-Launch-up-to-Four-New-Medicines",
                "content": "Lilly expects to deliver strong financial and operational performance in 2023, highlighted by volume-driven revenue growth; potential launches for donanemab, mirikizumab, lebrikizumab and...",
                "1d_change": 0.5144466521,
                "index_price": -1.8536641167,
                "norm_price": 2.3681107688
            },
            {
                "index": 48,
                "date": "2022-12-12",
                "press_title": "Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2022-12-12-Loxo-Lilly-Presents-Updated-Pirtobrutinib-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-at-the-2022-American-Society-of-Hematology-Annual-Meeting",
                "content": "Pirtobrutinib demonstrates activity across covalent BTK inhibitor pre-treated B-cell malignancies and multiple patient subgroups INDIANAPOLIS, Dec. 12, 2022 /PRNewswire/ -- Loxo@Lilly, the...",
                "1d_change": -1.1905366097,
                "index_price": 1.9991756803,
                "norm_price": -3.18971229
            },
            {
                "index": 49,
                "date": "2022-12-12",
                "press_title": "Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend",
                "release_url": "http://lilly.mediaroom.com/2022-12-12-Lilly-Announces-15-Dividend-Increase,-First-Quarter-2023-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2023 of $1.13 per share on...",
                "1d_change": -1.1905366097,
                "index_price": 1.9991756803,
                "norm_price": -3.18971229
            },
            {
                "index": 50,
                "date": "2022-12-07",
                "press_title": "Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2022-12-07-Phase-III-trial-demonstrated-Jardiance-R-is-the-first-SGLT2-inhibitor-to-show-statistically-significant-reduction-in-blood-sugar-levels-in-children-and-adolescents-with-type-2-diabetes",
                "content": "Jardiance® (empagliflozin) is the first SGLT2 inhibitor to demonstrate a statistically significant reduction in the primary outcome of HbA1c (a marker of average blood sugar) in participants aged...",
                "1d_change": 0.6643598085,
                "index_price": 0.7627073073,
                "norm_price": -0.0983474987
            },
            {
                "index": 51,
                "date": "2022-12-06",
                "press_title": "Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology",
                "release_url": "http://lilly.mediaroom.com/2022-12-06-Lilly-Announces-Updated-Data-from-the-Verzenio-R-abemaciclib-Phase-3-monarchE-Trial-Presented-at-SABCS-and-Simultaneously-Published-in-The-Lancet-Oncology",
                "content": "The benefit of adjuvant Verzenio in combination with endocrine therapy continues to deepen with additional follow-up, now demonstrating an absolute improvement in invasive disease-free survival...",
                "1d_change": 1.3361305339,
                "index_price": -1.5940833109,
                "norm_price": 2.9302138448
            },
            {
                "index": 52,
                "date": "2022-12-01",
                "press_title": "Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases",
                "release_url": "http://lilly.mediaroom.com/2022-12-01-Lilly-Completes-Acquisition-of-Akouos-Expanding-Efforts-to-Help-People-with-Genetic-Diseases",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly's efforts in genetic medicines to...",
                "1d_change": -0.0080003881,
                "index_price": -0.3792013555,
                "norm_price": 0.3712009674
            },
            {
                "index": 53,
                "date": "2022-11-30",
                "press_title": "Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease",
                "release_url": "http://lilly.mediaroom.com/2022-11-30-Lilly-Shares-Positive-Donanemab-Data-in-First-Active-Comparator-Study-in-Early-Symptomatic-Alzheimers-Disease",
                "content": "- Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm® (aducanumab-avwa)-treated patients at 6 months - Donanemab...",
                "1d_change": 1.4203426575,
                "index_price": 2.9286909023,
                "norm_price": -1.5083482448
            },
            {
                "index": 54,
                "date": "2022-11-30",
                "press_title": "Lilly and Akouos Announce Expiration of Akouos Tender Offer",
                "release_url": "http://lilly.mediaroom.com/2022-11-30-Lilly-and-Akouos-Announce-Expiration-of-Akouos-Tender-Offer",
                "content": "Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares (\"Shares\") of Akouos's common stock in...",
                "1d_change": 1.4203426575,
                "index_price": 2.9286909023,
                "norm_price": -1.5083482448
            },
            {
                "index": 55,
                "date": "2022-11-29",
                "press_title": "Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement",
                "release_url": "http://lilly.mediaroom.com/2022-11-29-Lilly-Confirms-Date-and-Conference-Call-for-2023-Financial-Guidance-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022. Lilly will also conduct a conference call on that day with the investment community and...",
                "1d_change": 1.740867494,
                "index_price": 2.8411038664,
                "norm_price": -1.1002363725
            },
            {
                "index": 56,
                "date": "2022-11-21",
                "press_title": "Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium",
                "release_url": "http://lilly.mediaroom.com/2022-11-21-Lilly-Announces-Details-of-Presentations-at-2022-San-Antonio-Breast-Cancer-Symposium",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS),...",
                "1d_change": 0.1357661267,
                "index_price": 1.1826939073,
                "norm_price": -1.0469277805
            },
            {
                "index": 57,
                "date": "2022-11-16",
                "press_title": "Lilly to Participate in Evercore ISI HealthCONx Conference",
                "release_url": "http://lilly.mediaroom.com/2022-11-16-Lilly-to-Participate-in-Evercore-ISI-HealthCONx-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30, 2022. Jacob Van Naarden, Lilly executive vice president and CEO of...",
                "1d_change": 2.9852770992,
                "index_price": -0.7667439318,
                "norm_price": 3.752021031
            },
            {
                "index": 58,
                "date": "2022-11-07",
                "press_title": "Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform",
                "release_url": "http://lilly.mediaroom.com/2022-11-07-Lilly-to-begin-rollout-of-Tempo-R-Personalized-Diabetes-Management-Platform",
                "content": "Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose logging Data shared through platform interface may help healthcare...",
                "1d_change": 2.361860846,
                "index_price": 1.2382127252,
                "norm_price": 1.1236481208
            },
            {
                "index": 59,
                "date": "2022-11-04",
                "press_title": "Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease",
                "release_url": "http://lilly.mediaroom.com/2022-11-04-Landmark-EMPA-KIDNEY-trial-showed-significant-benefit-of-Jardiance-R-in-reducing-kidney-disease-progression-or-cardiovascular-death-by-28-vs-placebo-in-people-with-chronic-kidney-disease",
                "content": "- EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice - Phase III trial also...",
                "1d_change": -0.0356131801,
                "index_price": 1.0460246887,
                "norm_price": -1.0816378687
            },
            {
                "index": 60,
                "date": "2022-11-03",
                "press_title": "Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2022-11-03-Loxo-Lilly-Announces-Details-of-Presentations-at-the-2022-American-Society-of-Hematology-Annual-Meeting",
                "content": "Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the BRUIN Phase 1/2 trial of pirtobrutinib at the American...",
                "1d_change": 0.9373004324,
                "index_price": 0.989246883,
                "norm_price": -0.0519464505
            },
            {
                "index": 61,
                "date": "2022-11-01",
                "press_title": "Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress",
                "release_url": "http://lilly.mediaroom.com/2022-11-01-Lilly-Reports-Solid-Third-Quarter-2022-Financial-Results-and-Continued-Pipeline-Progress",
                "content": "Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially offset by lower realized prices and lower Alimta...",
                "1d_change": 2.5721210784,
                "index_price": -3.7795695887,
                "norm_price": 6.3516906672
            },
            {
                "index": 62,
                "date": "2022-10-27",
                "press_title": "Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration",
                "release_url": "http://lilly.mediaroom.com/2022-10-27-Lilly-commits-92-5-million-to-Purdue-to-establish-an-innovative-pharmaceutical-manufacturing-scholarship-program-and-to-extend-research-collaboration",
                "content": "Scholarships will prioritize students from underrepresented groups, who have overcome disadvantages or are first generation to attend college Research collaboration aims to develop new methods for...",
                "1d_change": 0.2528516376,
                "index_price": 1.7013354368,
                "norm_price": -1.4484837992
            },
            {
                "index": 63,
                "date": "2022-10-19",
                "press_title": "Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2022-10-19-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2022-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2022 financial results on Tuesday, Nov. 1, 2022. Lilly will also conduct a conference call on that day with the investment...",
                "1d_change": -1.8780159678,
                "index_price": -1.0183392846,
                "norm_price": -0.8596766832
            },
            {
                "index": 64,
                "date": "2022-10-18",
                "press_title": "Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss",
                "release_url": "http://lilly.mediaroom.com/2022-10-18-Lilly-to-Acquire-Akouos-to-Discover-and-Develop-Treatments-for-Hearing-Loss",
                "content": "Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide Transaction valued at approximately...",
                "1d_change": -1.4728689634,
                "index_price": -1.3828927265,
                "norm_price": -0.0899762369
            },
            {
                "index": 65,
                "date": "2022-10-17",
                "press_title": "Lilly Declares Fourth-Quarter 2022 Dividend",
                "release_url": "http://lilly.mediaroom.com/2022-10-17-Lilly-Declares-Fourth-Quarter-2022-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2022 of $0.98 per share on outstanding common stock. The dividend is payable on Dec....",
                "1d_change": 0.6686026157,
                "index_price": 2.1863041885,
                "norm_price": -1.5177015729
            },
            {
                "index": 66,
                "date": "2022-10-06",
                "press_title": "Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities",
                "release_url": "http://lilly.mediaroom.com/2022-10-06-Lilly-receives-U-S-FDA-Fast-Track-designation-for-tirzepatide-for-the-treatment-of-adults-with-obesity,-or-overweight-with-weight-related-comorbidities",
                "content": "The Fast Track designation accelerates tirzepatide's path to U.S. FDA submission for the treatment of adults with obesity, or overweight with weight-related comorbidities INDIANAPOLIS, Oct. 6,...",
                "1d_change": -0.3918417045,
                "index_price": -3.635231362,
                "norm_price": 3.2433896575
            },
            {
                "index": 67,
                "date": "2022-09-21",
                "press_title": "FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type",
                "release_url": "http://lilly.mediaroom.com/2022-09-21-FDA-Approves-Lillys-Retevmo-R-selpercatinib-,-the-First-and-Only-RET-Inhibitor-for-Adults-with-Advanced-or-Metastatic-Solid-Tumors-with-a-RET-Gene-Fusion,-Regardless-of-Type",
                "content": "Tumor-agnostic data supporting approval demonstrated an overall response rate (ORR) of 44% across multiple tumor types FDA simultaneously grants traditional approval in adults with locally...",
                "1d_change": 3.1749602731,
                "index_price": -3.0178343318,
                "norm_price": 6.1927946049
            },
            {
                "index": 68,
                "date": "2022-09-08",
                "press_title": "Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials",
                "release_url": "http://lilly.mediaroom.com/2022-09-08-Lebrikizumab-Dosed-Every-Four-Weeks-Maintained-Durable-Skin-Clearance-in-Lillys-Phase-3-Monotherapy-Atopic-Dermatitis-Trials",
                "content": "New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity...",
                "1d_change": 1.8098670732,
                "index_price": 2.6410291486,
                "norm_price": -0.8311620754
            },
            {
                "index": 69,
                "date": "2022-09-07",
                "press_title": "Lilly Announces Details of Presentations at ESMO Congress 2022",
                "release_url": "http://lilly.mediaroom.com/2022-09-07-Lilly-Announces-Details-of-Presentations-at-ESMO-Congress-2022",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib) and Retevmo® (selpercatinib) will be presented at the 2022 European Society for Medical...",
                "1d_change": 2.13313545,
                "index_price": 2.4150188372,
                "norm_price": -0.2818833872
            },
            {
                "index": 70,
                "date": "2022-08-31",
                "press_title": "Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2022-08-31-Lilly-to-Participate-in-Morgan-Stanley-20th-Annual-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022. Anat Ashkenazi, Lilly's senior vice president and chief...",
                "1d_change": 0.6437307359,
                "index_price": -0.8525611855,
                "norm_price": 1.4962919213
            },
            {
                "index": 71,
                "date": "2022-08-25",
                "press_title": "Lilly to Participate in Citi's 17th Annual BioPharma Conference",
                "release_url": "http://lilly.mediaroom.com/2022-08-25-Lilly-to-Participate-in-Citis-17th-Annual-BioPharma-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend Citi's 17th Annual BioPharma Conference on Wednesday, Sept. 7, 2022. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and...",
                "1d_change": -1.5971559723,
                "index_price": -2.3560341573,
                "norm_price": 0.758878185
            },
            {
                "index": 72,
                "date": "2022-08-11",
                "press_title": "Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly",
                "release_url": "http://lilly.mediaroom.com/2022-08-11-Lilly-Announces-Leadership-Transition-in-Human-Resources-and-New-Chief-Commercial-Officer-for-Loxo-Lilly",
                "content": "- Stephen Fry to retire at the end of 2022 - Eric Dozier named Senior Vice President, Human Resources and Diversity - Winselow Tucker to join Lilly as Senior Vice President and Chief Commercial...",
                "1d_change": 2.6063114985,
                "index_price": 1.2324334709,
                "norm_price": 1.3738780277
            },
            {
                "index": 73,
                "date": "2022-08-08",
                "press_title": "Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience",
                "release_url": "http://lilly.mediaroom.com/2022-08-08-Lillys-Taltz-R-ixekizumab-Now-Available-in-New,-Citrate-Free-Formulation-to-Reduce-Injection-Site-Pain-for-Improved-Patient-Experience",
                "content": "Since the medicine's first approval in 2016, nearly 130,000 people in the U.S. have been treated with Taltz INDIANAPOLIS, Aug. 8, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced...",
                "1d_change": 0.7821260634,
                "index_price": -0.8116483369,
                "norm_price": 1.5937744003
            },
            {
                "index": 74,
                "date": "2022-08-04",
                "press_title": "Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results",
                "release_url": "http://lilly.mediaroom.com/2022-08-04-Lilly-Updates-Conference-Call-Start-Time-for-Second-Quarter-2022-Financial-Results",
                "content": "Eli Lilly and Company (NYSE: LLY) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time due to third-party technical difficulties....",
                "1d_change": -2.9470531117,
                "index_price": -0.2330449602,
                "norm_price": -2.7140081514
            },
            {
                "index": 75,
                "date": "2022-08-04",
                "press_title": "Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements",
                "release_url": "http://lilly.mediaroom.com/2022-08-04-Lilly-Reports-Second-Quarter-Financial-Results,-Highlights-Momentum-of-New-Medicines-and-Pipeline-Advancements",
                "content": "Lilly's revenue in Q2 2022 decreased 4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue following the entry of generics more than offset...",
                "1d_change": -2.9470531117,
                "index_price": -0.2330449602,
                "norm_price": -2.7140081514
            },
            {
                "index": 76,
                "date": "2022-07-21",
                "press_title": "Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2022-07-21-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2022-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2022 financial results on Thursday, Aug. 4, 2022. Lilly will also conduct a conference call on that day with the investment...",
                "1d_change": 2.2205354542,
                "index_price": 0.1554893388,
                "norm_price": 2.0650461154
            },
            {
                "index": 77,
                "date": "2022-06-29",
                "press_title": "Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options",
                "release_url": "http://lilly.mediaroom.com/2022-06-29-Lilly-will-supply-an-additional-150,000-doses-of-bebtelovimab-to-U-S-government-in-ongoing-effort-to-provide-COVID-19-treatment-options",
                "content": "Bebtelovimab continues to maintain neutralization against all known variants of interest and concern INDIANAPOLIS, June 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a...",
                "1d_change": 1.8721272563,
                "index_price": -1.0490414782,
                "norm_price": 2.9211687345
            },
            {
                "index": 78,
                "date": "2022-06-27",
                "press_title": "Lilly Declares Third-Quarter 2022 Dividend",
                "release_url": "http://lilly.mediaroom.com/2022-06-27-Lilly-Declares-Third-Quarter-2022-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2022 of $0.98 per share on outstanding common stock. The dividend is payable on Sept....",
                "1d_change": -2.0810997464,
                "index_price": -2.5960659855,
                "norm_price": 0.5149662391
            },
            {
                "index": 79,
                "date": "2022-06-13",
                "press_title": "FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata",
                "release_url": "http://lilly.mediaroom.com/2022-06-13-FDA-Approves-Lilly-and-Incytes-OLUMIANT-R-baricitinib-As-First-and-Only-Systemic-Medicine-for-Adults-with-Severe-Alopecia-Areata",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib), a once-daily pill, as a...",
                "1d_change": 0.1238219972,
                "index_price": -2.748506816,
                "norm_price": 2.8723288132
            },
            {
                "index": 80,
                "date": "2022-06-07",
                "press_title": "Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials",
                "release_url": "http://lilly.mediaroom.com/2022-06-07-Eight-out-of-Ten-Patients-Maintained-Skin-Clearance-at-One-Year-in-Lillys-Lebrikizumab-Atopic-Dermatitis-Monotherapy-Trials",
                "content": "80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observed Data supported both once every two week...",
                "1d_change": 3.0303957125,
                "index_price": 0.4689233022,
                "norm_price": 2.5614724103
            },
            {
                "index": 81,
                "date": "2022-06-06",
                "press_title": "New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®",
                "release_url": "http://lilly.mediaroom.com/2022-06-06-New-analyses-of-Mounjaro-TM-tirzepatide-injection-for-the-treatment-of-adults-with-type-2-diabetes-presented-at-the-American-Diabetes-Associations-R-82nd-Scientific-Sessions-R",
                "content": "Mounjaro led to significantly greater fat mass reductions compared to placebo and to injectable semaglutide 1 mg in adults with type 2 diabetes in mechanism of action study Exploratory analysis...",
                "1d_change": -0.9708403766,
                "index_price": 0.6239355067,
                "norm_price": -1.5947758833
            },
            {
                "index": 82,
                "date": "2022-06-05",
                "press_title": "Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study",
                "release_url": "http://lilly.mediaroom.com/2022-06-05-Jardiance-R-decreased-relative-risk-of-hospitalization-for-heart-failure-by-50-versus-DPP-4-inhibitors-and-by-30-versus-GLP-1-receptor-agonists-in-adults-with-type-2-diabetes-in-real-world-evidence-study",
                "content": "Jardiance showed a reduction in relative risk of all-cause mortality by 40% compared with DPP-4 inhibitors in the subset of people with Medicare coverage Data from these final analyses of EMPRISE...",
                "1d_change": -0.9708403766,
                "index_price": 0.6239355067,
                "norm_price": -1.5947758833
            },
            {
                "index": 83,
                "date": "2022-06-04",
                "press_title": "Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo",
                "release_url": "http://lilly.mediaroom.com/2022-06-04-Lillys-AWARD-PEDS-trial-investigating-use-of-Trulicity-R-dulaglutide-in-youth-and-adolescents-with-type-2-diabetes-showed-superiority-in-A1C-reduction-vs-placebo",
                "content": "AWARD-PEDS results presented at ADA's 82nd Scientific Sessions® and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity compared...",
                "1d_change": -0.9708403766,
                "index_price": 0.6239355067,
                "norm_price": -1.5947758833
            },
            {
                "index": 84,
                "date": "2022-06-04",
                "press_title": "Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight",
                "release_url": "http://lilly.mediaroom.com/2022-06-04-Lillys-SURMOUNT-1-results-published-in-The-New-England-Journal-of-Medicine-show-tirzepatide-achieved-between-16-0-and-22-5-weight-loss-in-adults-with-obesity-or-overweight",
                "content": "Detailed results from Lilly's first phase 3 trial in obesity or overweight presented at the American Diabetes Association's® 82nd Scientific Sessions® and simultaneously published in NEJM...",
                "1d_change": -0.9708403766,
                "index_price": 0.6239355067,
                "norm_price": -1.5947758833
            },
            {
                "index": 85,
                "date": "2022-06-03",
                "press_title": "Lilly to Participate in Goldman Sachs Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2022-06-03-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022. Anne White, senior vice president and president, Lilly...",
                "1d_change": 0.395567035,
                "index_price": -0.3916031025,
                "norm_price": 0.7871701376
            },
            {
                "index": 86,
                "date": "2022-05-26",
                "press_title": "Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2022-05-26-Lilly-Announces-Details-of-Presentations-at-2022-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June...",
                "1d_change": 5.6417725489,
                "index_price": 4.1758082009,
                "norm_price": 1.465964348
            },
            {
                "index": 87,
                "date": "2022-05-25",
                "press_title": "Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana",
                "release_url": "http://lilly.mediaroom.com/2022-05-25-Lilly-plans-to-invest-2-1-billion-in-new-manufacturing-sites-in-Indiana",
                "content": "Eli Lilly and Company (NYSE: LLY) plans to expand its manufacturing footprint in Indiana by investing $2.1 billion in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research...",
                "1d_change": 2.060871434,
                "index_price": 3.1605484007,
                "norm_price": -1.0996769667
            },
            {
                "index": 88,
                "date": "2022-05-24",
                "press_title": "Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study",
                "release_url": "http://lilly.mediaroom.com/2022-05-24-Fifty-Percent-of-Patients-with-Ulcerative-Colitis-Treated-with-Mirikizumab-Achieved-Clinical-Remission-at-One-Year-in-Lillys-Pivotal-Phase-3-Study",
                "content": "Nearly all mirikizumab-treated patients who achieved clinical remission at one year were not taking steroids INDIANAPOLIS, May 24, 2022 /PRNewswire/ -- In Eli Lilly and Company's (NYSE:LLY)...",
                "1d_change": 1.0748904245,
                "index_price": 0.8995342544,
                "norm_price": 0.1753561701
            },
            {
                "index": 89,
                "date": "2022-05-23",
                "press_title": "Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA",
                "release_url": "http://lilly.mediaroom.com/2022-05-23-Lilly-Announces-Webcast-to-Provide-Diabetes-and-Obesity-Portfolio-Update-at-ADA",
                "content": "Eli Lilly and Company (NYSE: LLY) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its presentations at the American Diabetes Association's...",
                "1d_change": 1.7518529762,
                "index_price": 0.5596897283,
                "norm_price": 1.1921632479
            },
            {
                "index": 90,
                "date": "2022-05-20",
                "press_title": "CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)",
                "release_url": "http://lilly.mediaroom.com/2022-05-20-CHMP-Recommends-Approval-of-Lilly-and-Incytes-OLUMIANT-R-baricitinib-as-the-First-and-Only-Centrally-Authorized-Treatment-for-Adults-with-Severe-Alopecia-Areata-AA",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive...",
                "1d_change": 3.9226616053,
                "index_price": 1.1573448313,
                "norm_price": 2.765316774
            },
            {
                "index": 91,
                "date": "2022-05-16",
                "press_title": "Lilly to Participate in UBS Global Healthcare Conference 2022",
                "release_url": "http://lilly.mediaroom.com/2022-05-16-Lilly-to-Participate-in-UBS-Global-Healthcare-Conference-2022",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 24, 2022. Michael Mason, senior vice president, president of Lilly Diabetes, will participate in...",
                "1d_change": 3.0822778578,
                "index_price": 1.8545575483,
                "norm_price": 1.2277203095
            },
            {
                "index": 92,
                "date": "2022-05-13",
                "press_title": "FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2022-05-13-FDA-approves-Lillys-Mounjaro-TM-tirzepatide-injection,-the-first-and-only-GIP-and-GLP-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes",
                "content": "Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials While not indicated for weight loss, Mounjaro led to significantly greater weight reductions...",
                "1d_change": 2.2546728524,
                "index_price": 1.1005488338,
                "norm_price": 1.1541240186
            },
            {
                "index": 93,
                "date": "2022-05-11",
                "press_title": "FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19",
                "release_url": "http://lilly.mediaroom.com/2022-05-11-FDA-Approves-Lilly-and-Incytes-OLUMIANT-R-baricitinib-for-the-Treatment-of-Certain-Hospitalized-Patients-with-COVID-19",
                "content": "error_http",
                "1d_change": 2.7861359048,
                "index_price": -1.5266864493,
                "norm_price": 4.3128223541
            },
            {
                "index": 94,
                "date": "2022-05-06",
                "press_title": "Mary Lynne Hedley Elected to Lilly Board of Directors",
                "release_url": "http://lilly.mediaroom.com/2022-05-06-Mary-Lynne-Hedley-Elected-to-Lilly-Board-of-Directors",
                "content": "The Board of Directors of Eli Lilly and Company (NYSE:LLY) has elected Mary Lynne Hedley, Ph.D., as a new member, effective May 15, 2022. As a member of Lilly's board, she will serve on both the...",
                "1d_change": -0.3250068327,
                "index_price": -3.4307616674,
                "norm_price": 3.1057548348
            },
            {
                "index": 95,
                "date": "2022-05-03",
                "press_title": "Lilly to Participate in Bank of America Securities 2022 Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2022-05-03-Lilly-to-Participate-in-Bank-of-America-Securities-2022-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the Bank of America Securities 2022 Healthcare Conference, May 10-11, 2022. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical...",
                "1d_change": 2.1261332231,
                "index_price": 3.2647578879,
                "norm_price": -1.1386246648
            },
            {
                "index": 96,
                "date": "2022-05-02",
                "press_title": "Lilly Declares Second-Quarter 2022 Dividend",
                "release_url": "http://lilly.mediaroom.com/2022-05-02-Lilly-Declares-Second-Quarter-2022-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2022 of $0.98 per share on outstanding common stock. The dividend is payable on June...",
                "1d_change": -1.0969708195,
                "index_price": 1.0746098029,
                "norm_price": -2.1715806223
            },
            {
                "index": 97,
                "date": "2022-04-28",
                "press_title": "Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022",
                "release_url": "http://lilly.mediaroom.com/2022-04-28-Solid-First-Quarter-Financial-Results-Reflect-Lillys-Continued-Momentum-into-2022",
                "content": "Lilly's revenue growth in Q1 2022 increased 15%, driven by volume growth of 20%. Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022 revenue grew 10%. Outside of revenue from COVID-19...",
                "1d_change": -1.3213018525,
                "index_price": -2.1938875656,
                "norm_price": 0.8725857131
            },
            {
                "index": 98,
                "date": "2022-04-28",
                "press_title": "Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1",
                "release_url": "http://lilly.mediaroom.com/2022-04-28-Lillys-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-obesity-or-overweight-in-SURMOUNT-1",
                "content": "Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study 63% of participants taking tirzepatide 15 mg achieved at least 20% body weight reductions as a key secondary...",
                "1d_change": -1.3213018525,
                "index_price": -2.1938875656,
                "norm_price": 0.8725857131
            },
            {
                "index": 99,
                "date": "2022-04-20",
                "press_title": "Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care",
                "release_url": "http://lilly.mediaroom.com/2022-04-20-Tackling-Health-Disparities-and-Inequities-for-Women-with-Heart-Failure-New-Program-Encourages-Black-and-Latina-Women-to-Demand-More-From-Their-Care",
                "content": "Boehringer Ingelheim and Lilly launch Hear Your Heart™, an empowering health initiative to provide resources and education for women with heart failure, especially Black and Latina women, to...",
                "1d_change": -2.5586051738,
                "index_price": -1.7889323839,
                "norm_price": -0.7696727899
            },
            {
                "index": 100,
                "date": "2022-04-19",
                "press_title": "Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2022-04-19-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2022-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2022 financial results on Thursday, April 28, 2022. Lilly will also conduct a conference call on that day with the investment...",
                "1d_change": -1.8742561815,
                "index_price": 1.5432465772,
                "norm_price": -3.4175027587
            },
            {
                "index": 101,
                "date": "2022-04-11",
                "press_title": "Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis",
                "release_url": "http://lilly.mediaroom.com/2022-04-11-Lillys-Lebrikizumab-Combined-with-Topical-Corticosteroids-Showed-Significant-Improvements-in-Disease-Severity-for-Atopic-Dermatitis",
                "content": "Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, including skin and itch, in pivotal combination trial that met all primary and key...",
                "1d_change": -1.6262046705,
                "index_price": -1.482448658,
                "norm_price": -0.1437560125
            },
            {
                "index": 102,
                "date": "2022-04-01",
                "press_title": "Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress",
                "release_url": "http://lilly.mediaroom.com/2022-04-01-Lilly-Presents-Updated-Data-on-Retevmo-R-selpercatinib-in-Advanced-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer-NSCLC-at-the-2022-European-Lung-Cancer-Congress",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® (selpercatinib 40 mg & 80 mg capsules) in patients with RET fusion-positive...",
                "1d_change": 1.8083996649,
                "index_price": 0.9234919443,
                "norm_price": 0.8849077206
            },
            {
                "index": 103,
                "date": "2022-03-26",
                "press_title": "Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies",
                "release_url": "http://lilly.mediaroom.com/2022-03-26-Nearly-40-of-Adults-with-Alopecia-Areata-Taking-OLUMIANT-R-4-mg-Saw-at-Least-80-Scalp-Hair-Coverage-at-52-Weeks-in-Lillys-Pivotal-Phase-3-Studies",
                "content": "New England Journal of Medicine published OLUMIANT 36-week alopecia areata data today INDIANAPOLIS, March 26, 2022 /PRNewswire/ -- Adults with severe alopecia areata (AA) who took OLUMIANT®...",
                "1d_change": -1.0194352743,
                "index_price": 1.95418974,
                "norm_price": -2.9736250143
            },
            {
                "index": 104,
                "date": "2022-03-26",
                "press_title": "Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies",
                "release_url": "http://lilly.mediaroom.com/2022-03-26-Majority-of-Patients-Treated-with-Lebrikizumab-Achieved-Skin-Clearance-in-Lillys-Pivotal-Phase-3-Atopic-Dermatitis-Studies",
                "content": "More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab...",
                "1d_change": -1.0194352743,
                "index_price": 1.95418974,
                "norm_price": -2.9736250143
            },
            {
                "index": 105,
                "date": "2022-03-24",
                "press_title": "Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/2022-03-24-Lilly-Announces-Complete-Response-Letter-for-Sintilimab-in-Combination-with-Pemetrexed-and-Platinum-Chemotherapy-for-the-First-Line-Treatment-of-People-with-Nonsquamous-Non-Small-Cell-Lung-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the Biologics License Application (BLA) for the...",
                "1d_change": 0.9445646573,
                "index_price": 1.6086091133,
                "norm_price": -0.664044456
            },
            {
                "index": 106,
                "date": "2022-03-16",
                "press_title": "Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease",
                "release_url": "http://lilly.mediaroom.com/2022-03-16-Jardiance-R-phase-III-EMPA-KIDNEY-trial-will-stop-early-due-to-clear-positive-efficacy-in-people-with-chronic-kidney-disease",
                "content": "The Independent Data Monitoring Committee recommended that the EMPA-KIDNEY trial be stopped early, following a formal interim assessment EMPA-KIDNEY is the largest and broadest dedicated SGLT2...",
                "1d_change": 2.6829105541,
                "index_price": 2.8000686213,
                "norm_price": -0.1171580672
            },
            {
                "index": 107,
                "date": "2022-03-08",
                "press_title": "Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR)",
                "release_url": "http://lilly.mediaroom.com/2022-03-08-Lilly-Announces-Details-of-Presentations-at-2022-American-Association-for-Cancer-Research-AACR",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that data from the pirtobrutinib and Verzenio® (abemaciclib) development programs will be presented at the 2022 American Association for Cancer...",
                "1d_change": 1.0883173818,
                "index_price": 1.758341249,
                "norm_price": -0.6700238672
            },
            {
                "index": 108,
                "date": "2022-03-03",
                "press_title": "Lilly to Participate in Barclays Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2022-03-03-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 15, 2022. Patrik Jonsson, Lilly senior vice president, president of Lilly...",
                "1d_change": 3.0585544449,
                "index_price": -1.6734145272,
                "norm_price": 4.7319689721
            },
            {
                "index": 109,
                "date": "2022-03-01",
                "press_title": "Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial",
                "release_url": "http://lilly.mediaroom.com/2022-03-01-Jardiance-R-provided-a-significant-clinical-benefit-in-adults-stabilized-in-hospital-following-acute-heart-failure-in-EMPULSE-phase-III-trial",
                "content": "Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance® (empagliflozin) following stabilization and prior to...",
                "1d_change": 2.6006276938,
                "index_price": 0.533447823,
                "norm_price": 2.0671798708
            },
            {
                "index": 110,
                "date": "2022-02-28",
                "press_title": "Lilly to Participate in Cowen Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2022-02-28-Lilly-to-Participate-in-Cowen-Health-Care-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Cowen Health Care Conference on Tuesday, March. 8, 2022. Anat Ashkenazi, Lilly senior vice president and chief financial officer, will...",
                "1d_change": 1.3466878351,
                "index_price": -1.1125700459,
                "norm_price": 2.459257881
            },
            {
                "index": 111,
                "date": "2022-02-24",
                "press_title": "US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction",
                "release_url": "http://lilly.mediaroom.com/2022-02-24-US-FDA-approves-Jardiance-R-empagliflozin-to-treat-adults-with-heart-failure-regardless-of-left-ventricular-ejection-fraction",
                "content": "The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart...",
                "1d_change": 6.2467667762,
                "index_price": 5.2200264083,
                "norm_price": 1.026740368
            },
            {
                "index": 112,
                "date": "2022-02-22",
                "press_title": "Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site",
                "release_url": "http://lilly.mediaroom.com/2022-02-22-Lilly-Announces-the-Institute-for-Genetic-Medicine-and-700-Million-investment-in-Boston-Seaport-Site",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the launch of the Lilly Institute for Genetic Medicine and an investment of approximately $700 million to establish a state-of-the-art facility at...",
                "1d_change": -0.3776542648,
                "index_price": -2.5379300527,
                "norm_price": 2.1602757879
            },
            {
                "index": 113,
                "date": "2022-02-18",
                "press_title": "Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study",
                "release_url": "http://lilly.mediaroom.com/2022-02-18-Nearly-Two-Thirds-of-Patients-Respond-to-Mirikizumab-Treatment-at-12-Weeks-in-Lillys-First-in-Class-Ulcerative-Colitis-Phase-3-LUCENT-1-Study",
                "content": "Patients with moderately-to-severely active ulcerative colitis (UC) who took mirikizumab achieved statistically superior rates of clinical remission at 12 weeks compared to patients taking placebo...",
                "1d_change": 0.4641740619,
                "index_price": -1.8539956453,
                "norm_price": 2.3181697071
            },
            {
                "index": 114,
                "date": "2022-02-16",
                "press_title": "Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence",
                "release_url": "http://lilly.mediaroom.com/2022-02-16-Lilly-and-Breast-Cancer-Advocacy-Organizations-Collaborate-to-Drive-Awareness-of-the-Complexities-of-Early-Breast-Cancer-and-the-Risk-of-Recurrence",
                "content": "Lilly, Breastcancer.org, For the Breast of Us, Living Beyond Breast Cancer, and Susan G. Komen join together for new education initiative to support people with early breast cancer at high risk...",
                "1d_change": -0.6681237205,
                "index_price": -1.7234191216,
                "norm_price": 1.055295401
            },
            {
                "index": 115,
                "date": "2022-02-11",
                "press_title": "Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19",
                "release_url": "http://lilly.mediaroom.com/2022-02-11-Lillys-bebtelovimab-receives-Emergency-Use-Authorization-for-the-treatment-of-mild-to-moderate-COVID-19",
                "content": "The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly...",
                "1d_change": -1.5107142194,
                "index_price": -2.3763730473,
                "norm_price": 0.8656588279
            },
            {
                "index": 116,
                "date": "2022-02-10",
                "press_title": "Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options",
                "release_url": "http://lilly.mediaroom.com/2022-02-10-Lilly-will-supply-up-to-600,000-doses-of-bebtelovimab-to-U-S-government-in-ongoing-effort-to-provide-COVID-19-treatment-options",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to supply up to 600,000 doses of investigational drug bebtelovimab for at least $720 million. The U.S....",
                "1d_change": -1.7646532535,
                "index_price": -3.0461882727,
                "norm_price": 1.2815350191
            },
            {
                "index": 117,
                "date": "2022-02-10",
                "press_title": "Cynthia Cardona Elected as President of the Lilly Foundation",
                "release_url": "http://lilly.mediaroom.com/2022-02-10-Cynthia-Cardona-Elected-as-President-of-the-Lilly-Foundation",
                "content": "The Eli Lilly and Company Foundation, Inc., a tax-exempt organization supported by Eli Lilly and Company (NYSE: LLY), has elected Cynthia Cardona as its president. Additionally, Lilly has selected...",
                "1d_change": -1.7646532535,
                "index_price": -3.0461882727,
                "norm_price": 1.2815350191
            },
            {
                "index": 118,
                "date": "2022-02-03",
                "press_title": "Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients",
                "release_url": "http://lilly.mediaroom.com/2022-02-03-Lilly-Reports-Solid-Fourth-Quarter-and-Full-Year-2021-Financial-Results,-Recent-Late-Stage-Pipeline-Successes-Set-Up-Next-Wave-of-Innovative-Medicines-for-Patients",
                "content": "Eli Lilly and Company (NYSE: LLY) announced financial results for the fourth quarter and full year of 2021 today. \"Lilly had a remarkable year of growth and pipeline success in 2021, despite the...",
                "1d_change": -2.1587510519,
                "index_price": -0.7750281136,
                "norm_price": -1.3837229383
            },
            {
                "index": 119,
                "date": "2022-02-02",
                "press_title": "UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents",
                "release_url": "http://lilly.mediaroom.com/2022-02-02-UNICEF-and-Lilly-Collaborate-to-Help-Improve-Health-Outcomes-for-10-Million-Children-and-Adolescents",
                "content": "Eli Lilly and Company (NYSE: LLY) and UNICEF have today announced a new collaboration to help improve health outcomes for 10 million children and adolescents living with chronic, non-communicable...",
                "1d_change": -0.2205771767,
                "index_price": -1.9866306746,
                "norm_price": 1.7660534979
            },
            {
                "index": 120,
                "date": "2022-02-01",
                "press_title": "Lilly to Participate in Guggenheim Oncology Conference",
                "release_url": "http://lilly.mediaroom.com/2022-02-01-Lilly-to-Participate-in-Guggenheim-Oncology-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on Wednesday, Feb. 9, 2022. Jake Van Naarden, CEO of Loxo Oncology at Lilly and president, Lilly Oncology...",
                "1d_change": 1.5069856427,
                "index_price": 1.5211218155,
                "norm_price": -0.0141361728
            },
            {
                "index": 121,
                "date": "2022-01-28",
                "press_title": "Lilly announces $1 billion investment in new manufacturing facility in North Carolina",
                "release_url": "http://lilly.mediaroom.com/2022-01-28-Lilly-announces-1-billion-investment-in-new-manufacturing-facility-in-North-Carolina",
                "content": "Eli Lilly and Company (NYSE: LLY) plans to invest over $1 billion to create a new manufacturing site, along with nearly 600 new jobs in Concord, North Carolina. The brand-new facility will utilize...",
                "1d_change": 3.2193699462,
                "index_price": 3.972049275,
                "norm_price": -0.7526793288
            },
            {
                "index": 122,
                "date": "2022-01-28",
                "press_title": "Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis",
                "release_url": "http://lilly.mediaroom.com/2022-01-28-Updates-on-OLUMIANT-R-baricitinib-Phase-3-lupus-program-and-FDA-review-for-atopic-dermatitis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT® (baricitinib) in adults with active systemic lupus...",
                "1d_change": 3.2193699462,
                "index_price": 3.972049275,
                "norm_price": -0.7526793288
            },
            {
                "index": 123,
                "date": "2022-01-20",
                "press_title": "Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2022-01-20-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-and-Full-Year-2021-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2021 financial results on Thursday, Feb. 3, 2022. Lilly will also conduct a conference call on that day with the...",
                "1d_change": -1.0367838561,
                "index_price": -3.3972759574,
                "norm_price": 2.3604921013
            },
            {
                "index": 124,
                "date": "2022-01-06",
                "press_title": "Lilly to Participate in the J.P. Morgan Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2022-01-06-Lilly-to-Participate-in-the-J-P-Morgan-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, Jan. 11, 2022. David A. Ricks, Lilly's chairman and CEO, will...",
                "1d_change": -0.2312216269,
                "index_price": -0.3498021675,
                "norm_price": 0.1185805405
            },
            {
                "index": 125,
                "date": "2022-01-06",
                "press_title": "Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications",
                "release_url": "http://lilly.mediaroom.com/2022-01-06-Lilly-and-Entos-Pharmaceuticals-Enter-into-Research-and-Collaboration-Agreement-to-Support-the-Development-of-Innovative-Therapies-in-Multiple-Neurologic-Indications",
                "content": "Eli Lilly and Company (NYSE: LLY) has acquired exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products...",
                "1d_change": -0.2312216269,
                "index_price": -0.3498021675,
                "norm_price": 0.1185805405
            },
            {
                "index": 126,
                "date": "2021-12-21",
                "press_title": "Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study",
                "release_url": "http://lilly.mediaroom.com/2021-12-21-Lillys-lebrikizumab-demonstrated-significant-skin-improvement-and-itch-relief-when-combined-with-topical-corticosteroids-in-people-with-atopic-dermatitis-in-third-Phase-3-study",
                "content": "Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and...",
                "1d_change": 0.9380868131,
                "index_price": 2.1632875208,
                "norm_price": -1.2252007077
            },
            {
                "index": 127,
                "date": "2021-12-15",
                "press_title": "Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting",
                "release_url": "http://lilly.mediaroom.com/2021-12-15-Lilly-Highlights-Innovation-based-Growth-Strategy-and-Pipeline-Developments-Announces-2022-Financial-Guidance-at-Investment-Community-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) is providing extensive updates across its research and development (R&D) programs to highlight the company's strong pipeline and potential for future growth. At...",
                "1d_change": 6.0815711732,
                "index_price": 0.6899172886,
                "norm_price": 5.3916538846
            },
            {
                "index": 128,
                "date": "2021-12-14",
                "press_title": "Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022",
                "release_url": "http://lilly.mediaroom.com/2021-12-14-Mirikizumab-Demonstrates-Superiority-over-Placebo-in-Phase-3-Maintenance-Study-in-Ulcerative-Colitis,-Supporting-Regulatory-Submissions-in-2022",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints at one year in LUCENT-2, a Phase 3 maintenance...",
                "1d_change": 10.0043647601,
                "index_price": 1.4195751859,
                "norm_price": 8.5847895741
            },
            {
                "index": 129,
                "date": "2021-12-13",
                "press_title": "Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend",
                "release_url": "http://lilly.mediaroom.com/2021-12-13-Lilly-Announces-15-Percent-Dividend-Increase,-First-Quarter-2022-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15 percent increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of $0.98 per share...",
                "1d_change": 1.5518430746,
                "index_price": -1.6445507857,
                "norm_price": 3.1963938603
            },
            {
                "index": 130,
                "date": "2021-12-13",
                "press_title": "Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform",
                "release_url": "http://lilly.mediaroom.com/2021-12-13-Lilly-and-Foghorn-Announce-Strategic-Collaboration-for-Novel-Oncology-Targets-Using-Foghorns-Proprietary-Gene-Traffic-Control-R-Platform",
                "content": "Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today announced a strategic collaboration to create...",
                "1d_change": 1.5518430746,
                "index_price": -1.6445507857,
                "norm_price": 3.1963938603
            },
            {
                "index": 131,
                "date": "2021-12-12",
                "press_title": "Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2021-12-12-Loxo-Oncology-at-Lilly-Announces-Updated-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-for-Pirtobrutinib-at-the-American-Society-of-Hematology-Annual-Meeting",
                "content": "Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in...",
                "1d_change": 1.5518430746,
                "index_price": -1.6445507857,
                "norm_price": 3.1963938603
            },
            {
                "index": 132,
                "date": "2021-12-10",
                "press_title": "Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders",
                "release_url": "http://lilly.mediaroom.com/2021-12-10-Lilly-and-Regor-Therapeutics-Group-Enter-into-Strategic-Collaboration-to-Discover-and-Develop-Novel-Therapies-for-Metabolic-Disorders",
                "content": "Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies...",
                "1d_change": 2.9493454656,
                "index_price": -0.3998723705,
                "norm_price": 3.3492178361
            },
            {
                "index": 133,
                "date": "2021-12-09",
                "press_title": "New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients",
                "release_url": "http://lilly.mediaroom.com/2021-12-09-New-Lilly-Study-Reveals-Underappreciation-of-Bowel-Urgency-as-a-Symptom-of-Ulcerative-Colitis-and-Highlights-Communication-Gap-Between-Healthcare-Providers-and-Patients",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced results from the CONFIDE Study (Communicating Needs and Features of IBD Experiences) that show bowel urgency – defined as the sudden or...",
                "1d_change": -0.1433720599,
                "index_price": 0.4460935956,
                "norm_price": -0.5894656555
            },
            {
                "index": 134,
                "date": "2021-12-03",
                "press_title": "Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12",
                "release_url": "http://lilly.mediaroom.com/2021-12-03-Lillys-bamlanivimab-with-etesevimab-authorized-as-the-first-and-only-neutralizing-antibody-therapy-for-emergency-use-in-COVID-19-patients-under-the-age-of-12",
                "content": "The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include certain high-risk pediatric patients...",
                "1d_change": -2.3545630446,
                "index_price": 0.0474704745,
                "norm_price": -2.4020335192
            },
            {
                "index": 135,
                "date": "2021-12-01",
                "press_title": "Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting",
                "release_url": "http://lilly.mediaroom.com/2021-12-01-Lilly-to-Announce-Initial-2022-Financial-Guidance-Provide-R-D-Overview-at-Investment-Community-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that it will host a meeting for the investment community on Wednesday, Dec. 15, 2021, from 9 a.m. to 4 p.m., Eastern time. Earlier that day, the...",
                "1d_change": -0.6293430291,
                "index_price": -0.5619218722,
                "norm_price": -0.0674211569
            },
            {
                "index": 136,
                "date": "2021-11-18",
                "press_title": "Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients",
                "release_url": "http://lilly.mediaroom.com/2021-11-18-Emgality-R-Versus-Nurtec-R-ODT-Head-to-Head-Migraine-Preventive-Treatment-Study-Now-Enrolling-Patients",
                "content": "Today, Eli Lilly and Company (NYSE: LLY) announced that enrollment is now open for the CHALLENGE-MIG clinical trial, the first and only head-to-head trial comparing two anti-calcitonin...",
                "1d_change": -0.4986607863,
                "index_price": -0.0587543089,
                "norm_price": -0.4399064774
            },
            {
                "index": 137,
                "date": "2021-11-17",
                "press_title": "Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference",
                "release_url": "http://lilly.mediaroom.com/2021-11-17-Lilly-to-Participate-in-Fourth-Annual-Evercore-ISI-HealthCONx-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the fourth annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and...",
                "1d_change": 1.7296149944,
                "index_price": 0.0646192622,
                "norm_price": 1.6649957322
            },
            {
                "index": 138,
                "date": "2021-11-11",
                "press_title": "US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction",
                "release_url": "http://lilly.mediaroom.com/2021-11-11-US-FDA-accepts-supplemental-New-Drug-Application-and-grants-Priority-Review-for-Jardiance-R-for-adults-with-heart-failure-independent-of-left-ventricular-ejection-fraction",
                "content": "The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance® (empagliflozin) 10 mg, which is being investigated...",
                "1d_change": -0.7013350427,
                "index_price": 0.5009761245,
                "norm_price": -1.2023111672
            },
            {
                "index": 139,
                "date": "2021-11-11",
                "press_title": "Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care",
                "release_url": "http://lilly.mediaroom.com/2021-11-11-Lilly-announces-winners-of-inaugural-Leonard-Award,-a-global-program-celebrating-100-years-of-innovation-in-diabetes-care",
                "content": "Today Eli Lilly and Company (NYSE: LLY) announced the five winners of the inaugural Leonard Award, which commemorates the 100th anniversary of the discovery of insulin by recognizing diverse...",
                "1d_change": -0.7013350427,
                "index_price": 0.5009761245,
                "norm_price": -1.2023111672
            },
            {
                "index": 140,
                "date": "2021-11-09",
                "press_title": "Lilly to Participate in Wolfe Research Virtual Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2021-11-09-Lilly-to-Participate-in-Wolfe-Research-Virtual-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Thursday, Nov. 18, 2021. Jacob Van Naarden, CEO of Loxo Oncology at Lilly and president,...",
                "1d_change": 1.5567663373,
                "index_price": -1.302858142,
                "norm_price": 2.8596244793
            },
            {
                "index": 141,
                "date": "2021-11-09",
                "press_title": "OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis",
                "release_url": "http://lilly.mediaroom.com/2021-11-09-OLUMIANT-R-Long-Term-Safety-Profile-Established-Up-to-9-3-Years-in-Integrated-Analysis-of-More-Than-3,700-Patients-with-Rheumatoid-Arthritis",
                "content": "OLUMIANT® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received OLUMIANT for 14,744 patient years...",
                "1d_change": 1.5567663373,
                "index_price": -1.302858142,
                "norm_price": 2.8596244793
            },
            {
                "index": 142,
                "date": "2021-11-05",
                "press_title": "Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status",
                "release_url": "http://lilly.mediaroom.com/2021-11-05-Jardiance-R-shows-consistent-cardio-renal-benefits-in-adults-with-heart-failure-with-left-ventricular-ejection-fraction-over-40-regardless-of-chronic-kidney-disease-status",
                "content": "Jardiance® (empagliflozin) reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and slowed kidney function decline in adults with heart...",
                "1d_change": -3.2472301021,
                "index_price": 0.0519052595,
                "norm_price": -3.2991353616
            },
            {
                "index": 143,
                "date": "2021-11-04",
                "press_title": "Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2021-11-04-Loxo-Oncology-at-Lilly-Announces-Details-of-Presentations-at-the-2021-American-Society-of-Hematology-ASH-Annual-Meeting",
                "content": "Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the pirtobrutinib development program...",
                "1d_change": -0.181125291,
                "index_price": 0.7365490153,
                "norm_price": -0.9176743063
            },
            {
                "index": 144,
                "date": "2021-11-02",
                "press_title": "Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19",
                "release_url": "http://lilly.mediaroom.com/2021-11-02-Lilly-to-supply-614,000-additional-doses-of-bamlanivimab-and-etesevimab-to-the-U-S-Government-for-the-treatment-or-post-exposure-prevention-of-COVID-19",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is...",
                "1d_change": 5.6373383052,
                "index_price": 1.0133949764,
                "norm_price": 4.6239433288
            },
            {
                "index": 145,
                "date": "2021-11-01",
                "press_title": "Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference",
                "release_url": "http://lilly.mediaroom.com/2021-11-01-Lilly-to-Participate-in-Bernsteins-Second-Annual-Operational-Decisions-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's Second Annual Operational Decisions Conference on Thursday, Nov. 4, 2021. Jake Van Naarden, CEO of Loxo Oncology at Lilly and...",
                "1d_change": 0.6774270409,
                "index_price": 0.4325480349,
                "norm_price": 0.244879006
            },
            {
                "index": 146,
                "date": "2021-10-28",
                "press_title": "Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology",
                "release_url": "http://lilly.mediaroom.com/2021-10-28-Additional-Verzenio-R-abemaciclib-Phase-3-monarchE-Trial-Data-Published-in-the-Annals-of-Oncology",
                "content": "Today, overall survival (OS) data from Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib) Phase 3 monarchE study were published in a Letter to the Editor in the Annals of Oncology. These...",
                "1d_change": 1.8056231785,
                "index_price": 0.9237031503,
                "norm_price": 0.8819200282
            },
            {
                "index": 147,
                "date": "2021-10-26",
                "press_title": "Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential",
                "release_url": "http://lilly.mediaroom.com/2021-10-26-Lilly-Reports-Robust-Third-Quarter-2021-Financial-Results-as-Pipeline-Success-Strengthens-Future-Growth-Potential",
                "content": "Eli Lilly and Company (NYSE: LLY) announced financial results for the third quarter of 2021 today. \"Lilly demonstrated strong performance again this quarter. Revenue attributable to our newer...",
                "1d_change": 2.2664673193,
                "index_price": -0.5934020973,
                "norm_price": 2.8598694166
            },
            {
                "index": 148,
                "date": "2021-10-19",
                "press_title": "Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk",
                "release_url": "http://lilly.mediaroom.com/2021-10-19-Tirzepatide-results-published-in-The-Lancet-show-superior-A1C-and-body-weight-reductions-compared-to-insulin-glargine-in-adults-with-type-2-diabetes-with-increased-cardiovascular-risk",
                "content": "Adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated...",
                "1d_change": 1.9120315482,
                "index_price": 0.8564477713,
                "norm_price": 1.0555837768
            },
            {
                "index": 149,
                "date": "2021-10-18",
                "press_title": "Lilly Declares Fourth-Quarter 2021 Dividend",
                "release_url": "http://lilly.mediaroom.com/2021-10-18-Lilly-Declares-Fourth-Quarter-2021-Dividend",
                "content": "error_http",
                "1d_change": 1.7993308815,
                "index_price": 1.2370408511,
                "norm_price": 0.5622900304
            },
            {
                "index": 150,
                "date": "2021-10-14",
                "press_title": "Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology",
                "release_url": "http://lilly.mediaroom.com/2021-10-14-Lilly-Announces-Updated-Verzenio-R-abemaciclib-Phase-3-monarchE-Trial-Data-Presented-at-ESMO-Virtual-Plenary-and-Simultaneously-Published-in-the-Annals-of-Oncology",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of Verzenio® (abemaciclib) in combination with standard...",
                "1d_change": 0.3657359535,
                "index_price": 1.8924874249,
                "norm_price": -1.5267514714
            },
            {
                "index": 151,
                "date": "2021-10-13",
                "press_title": "FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer",
                "release_url": "http://lilly.mediaroom.com/2021-10-13-FDA-Approves-Verzenio-R-abemaciclib-as-the-First-and-Only-CDK4-6-Inhibitor-for-Certain-People-with-HR-HER2-High-Risk-Early-Breast-Cancer",
                "content": "The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),...",
                "1d_change": 1.1069365118,
                "index_price": 1.8081411237,
                "norm_price": -0.7012046119
            },
            {
                "index": 152,
                "date": "2021-10-12",
                "press_title": "Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2021-10-12-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2021-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2021 financial results on Tuesday, October 26, 2021. Lilly will also conduct a conference call on that day with the investment...",
                "1d_change": 0.735928509,
                "index_price": -0.1033561141,
                "norm_price": 0.8392846231
            },
            {
                "index": 153,
                "date": "2021-10-07",
                "press_title": "Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics",
                "release_url": "http://lilly.mediaroom.com/2021-10-07-Loxo-Oncology-at-Lilly-Announces-Details-of-Presentations-at-2021-AACR-NCI-EORTC-Virtual-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics",
                "content": "Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that preclinical characterization data for two new agents, LOXO-783 and LOXO-435,...",
                "1d_change": 2.0603552477,
                "index_price": 0.1732925155,
                "norm_price": 1.8870627321
            },
            {
                "index": 154,
                "date": "2021-10-04",
                "press_title": "Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals",
                "release_url": "http://lilly.mediaroom.com/2021-10-04-Ready-for-the-Challenge-Boehringer-Ingelheim-and-Eli-Lilly-and-Company-Launch-First-Ever-Online-Game-on-Cardio-Renal-Metabolic-Conditions-for-Healthcare-Professionals",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the launch of CRMSynced™, an educational initiative that uses gamification to encourage healthcare professionals (HCPs)...",
                "1d_change": 1.3553879933,
                "index_price": -0.0717862345,
                "norm_price": 1.4271742278
            },
            {
                "index": 155,
                "date": "2021-10-01",
                "press_title": "At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study",
                "release_url": "http://lilly.mediaroom.com/2021-10-01-At-Week-104,-75-of-Patients-with-Ulcerative-Colitis-Taking-Mirikizumab-Maintained-Symptomatic-Remission-in-Phase-2-Study",
                "content": "Patients taking mirikizumab for their moderately to severely active ulcerative colitis (UC), were in symptomatic remission for up to two years as demonstrated in new results from Eli Lilly and...",
                "1d_change": -2.7351627337,
                "index_price": -0.3883350959,
                "norm_price": -2.3468276378
            },
            {
                "index": 156,
                "date": "2021-09-30",
                "press_title": "OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata",
                "release_url": "http://lilly.mediaroom.com/2021-09-30-OLUMIANT-R-Significantly-Improved-Hair-Regrowth-to-At-Least-80-Scalp-Coverage-as-Early-as-24-Weeks-Across-First-Completed-Phase-3-Studies-for-Alopecia-Areata",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIANT®...",
                "1d_change": -1.3894436122,
                "index_price": -0.3128243645,
                "norm_price": -1.0766192477
            },
            {
                "index": 157,
                "date": "2021-09-30",
                "press_title": "Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study",
                "release_url": "http://lilly.mediaroom.com/2021-09-30-Lillys-tirzepatide-led-to-greater-improvements-in-liver-fat-content-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-SURPASS-3-MRI-sub-study",
                "content": "Tirzepatide led to greater improvements in liver fat content and abdominal adipose tissue compared to titrated insulin degludec in adults with type 2 diabetes in an MRI sub-study of Eli Lilly and...",
                "1d_change": -1.3894436122,
                "index_price": -0.3128243645,
                "norm_price": -1.0766192477
            },
            {
                "index": 158,
                "date": "2021-09-30",
                "press_title": "Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study",
                "release_url": "http://lilly.mediaroom.com/2021-09-30-Lillys-tirzepatide-led-to-greater-time-in-range-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-SURPASS-3-CGM-sub-study",
                "content": "All three tirzepatide doses led to more time in tight target range (71-140 mg/dL), improved glycemic variability and numerically less time in hypoglycemia compared to titrated insulin degludec in...",
                "1d_change": -1.3894436122,
                "index_price": -0.3128243645,
                "norm_price": -1.0766192477
            },
            {
                "index": 159,
                "date": "2021-09-29",
                "press_title": "Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women",
                "release_url": "http://lilly.mediaroom.com/2021-09-29-Lilly-and-Susan-G-Komen-R-Partner-to-Address-Disparities-in-Breast-Cancer-Outcomes-Experienced-By-Black-Women",
                "content": "Today, Eli Lilly and Company (NYSE: LLY) and Susan G. Komen®, the world's leading breast cancer organization, launched a new multiyear program to address breast cancer health disparities...",
                "1d_change": 2.4410395101,
                "index_price": -1.2738156045,
                "norm_price": 3.7148551146
            },
            {
                "index": 160,
                "date": "2021-09-28",
                "press_title": "FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy",
                "release_url": "http://lilly.mediaroom.com/2021-09-28-FDA-Expands-Lillys-ERBITUX-R-cetuximab-Label-with-Combination-of-BRAFTOVI-R-encorafenib-for-the-Treatment-of-BRAF-V600E-Mutation-Positive-Metastatic-Colorectal-Cancer-CRC-after-Prior-Therapy",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new indication for ERBITUX® (cetuximab injection) in combination with...",
                "1d_change": 1.7233899166,
                "index_price": -1.3781541444,
                "norm_price": 3.101544061
            },
            {
                "index": 161,
                "date": "2021-09-28",
                "press_title": "Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options",
                "release_url": "http://lilly.mediaroom.com/2021-09-28-Lilly-again-reduces-list-price-of-Insulin-Lispro-Injection-as-latest-change-to-affordability-options",
                "content": "Eli Lilly and Company (NYSE: LLY) will lower the list price of Insulin Lispro Injection in the U.S. by an additional 40 percent effective January 1, 2022, effectively bringing the list price down...",
                "1d_change": 1.7233899166,
                "index_price": -1.3781541444,
                "norm_price": 3.101544061
            },
            {
                "index": 162,
                "date": "2021-09-27",
                "press_title": "New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary",
                "release_url": "http://lilly.mediaroom.com/2021-09-27-New-Data-from-Verzenio-R-abemaciclib-monarchE-Study-to-Be-Featured-in-ESMO-Virtual-Plenary",
                "content": "New data from Eli Lilly and Company's (NYSE: LLY) monarchE study for an investigational use of Verzenio® (abemaciclib), in combination with endocrine therapy, in patients with hormone...",
                "1d_change": -3.7770754157,
                "index_price": -2.0560037675,
                "norm_price": -1.7210716482
            },
            {
                "index": 163,
                "date": "2021-09-24",
                "press_title": "Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency",
                "release_url": "http://lilly.mediaroom.com/2021-09-24-Eli-Lilly-and-Company-Issues-Voluntary-Nationwide-Recall-of-One-Lot-of-GLUCAGON-R-Emergency-Kit-Due-to-Loss-of-Potency",
                "content": "Eli Lilly and Company (NYSE: LLY) is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for Injection, 1 mg per vial; Diluent for...",
                "1d_change": -2.8136061665,
                "index_price": 0.1141053086,
                "norm_price": -2.9277114751
            },
            {
                "index": 164,
                "date": "2021-09-21",
                "press_title": "Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities",
                "release_url": "http://lilly.mediaroom.com/2021-09-21-Lilly-Announces-the-Pricing-Terms-of-Its-Cash-Tender-Offer-for-Up-to-1-5-Billion-Combined-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for specified series of its outstanding debt securities. Holders of notes subject...",
                "1d_change": -1.6469598487,
                "index_price": 0.4820672473,
                "norm_price": -2.1290270959
            },
            {
                "index": 165,
                "date": "2021-09-21",
                "press_title": "Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19",
                "release_url": "http://lilly.mediaroom.com/2021-09-21-Lilly-announces-procurement-agreement-with-European-Commission-to-supply-bamlanivimab-and-etesevimab-together-for-the-treatment-of-confirmed-COVID-19",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of bamlanivimab and etesevimab for the treatment of...",
                "1d_change": -1.6469598487,
                "index_price": 0.4820672473,
                "norm_price": -2.1290270959
            },
            {
                "index": 166,
                "date": "2021-09-21",
                "press_title": "Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059",
                "release_url": "http://lilly.mediaroom.com/2021-09-21-Lilly-Announces-the-Early-Tender-Results-of-Its-Pending-Cash-Tender-Offer-for-Up-to-1-5-Billion-Combined-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities-and-Removal-of-the-Note-Caps-for-Its-3-950-Notes-due-2049-and-Its-4-150-Notes",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today the early tender results of its previously announced cash tender offer for specified series of its outstanding debt securities. Lilly also...",
                "1d_change": -1.6469598487,
                "index_price": 0.4820672473,
                "norm_price": -2.1290270959
            },
            {
                "index": 167,
                "date": "2021-09-16",
                "press_title": "Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19",
                "release_url": "http://lilly.mediaroom.com/2021-09-16-Emergency-Use-Authorization-for-Lillys-bamlanivimab-and-etesevimab-administered-together-expanded-to-include-post-exposure-prophylaxis-for-COVID-19",
                "content": "The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure...",
                "1d_change": -1.7296690865,
                "index_price": -0.9948050197,
                "norm_price": -0.7348640667
            },
            {
                "index": 168,
                "date": "2021-09-15",
                "press_title": "Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19",
                "release_url": "http://lilly.mediaroom.com/2021-09-15-Lilly-to-supply-388,000-doses-of-etesevimab-to-U-S-government-for-treatment-of-COVID-19",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. As...",
                "1d_change": -1.099381759,
                "index_price": 0.5869743643,
                "norm_price": -1.6863561233
            },
            {
                "index": 169,
                "date": "2021-09-13",
                "press_title": "Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2021-09-13-Lilly-to-Participate-in-the-2021-Cantor-Virtual-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021. Patrik Jonsson, senior vice president, president of Lilly...",
                "1d_change": -2.9816798958,
                "index_price": -0.7148300222,
                "norm_price": -2.2668498736
            },
            {
                "index": 170,
                "date": "2021-09-13",
                "press_title": "Lilly to Present New Data from Oncology Portfolio at ESMO Congress",
                "release_url": "http://lilly.mediaroom.com/2021-09-13-Lilly-to-Present-New-Data-from-Oncology-Portfolio-at-ESMO-Congress",
                "content": "New data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), Retevmo® (selpercatinib) and CYRAMZA® (ramucirumab) will be presented at the European Society for...",
                "1d_change": -2.9816798958,
                "index_price": -0.7148300222,
                "norm_price": -2.2668498736
            },
            {
                "index": 171,
                "date": "2021-09-09",
                "press_title": "Lilly Prices First Sustainability Bond to Advance Global ESG Strategy",
                "release_url": "http://lilly.mediaroom.com/2021-09-09-Lilly-Prices-First-Sustainability-Bond-to-Advance-Global-ESG-Strategy",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the pricing of its first sustainability bond to advance its global environmental, social and governance (ESG) strategy to increase access to...",
                "1d_change": -5.757830659,
                "index_price": -1.2210152213,
                "norm_price": -4.5368154377
            },
            {
                "index": 172,
                "date": "2021-09-09",
                "press_title": "FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction",
                "release_url": "http://lilly.mediaroom.com/2021-09-09-FDA-grants-Jardiance-R-Breakthrough-Therapy-designation-for-heart-failure-with-preserved-ejection-fraction",
                "content": "The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Jardiance® (empagliflozin) as an investigational treatment for adults with heart failure with preserved...",
                "1d_change": -5.757830659,
                "index_price": -1.2210152213,
                "norm_price": -4.5368154377
            },
            {
                "index": 173,
                "date": "2021-09-07",
                "press_title": "Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to \"Type 1 Diabetes Camps Initiative\"",
                "release_url": "http://lilly.mediaroom.com/2021-09-07-Lilly-Diabetes-joins-The-Leona-M-and-Harry-B-Helmsley-Charitable-Trust-to-pledge-significant-funding-to-Type-1-Diabetes-Camps-Initiative",
                "content": "Lilly Diabetes will commit nearly $1 million over the next three years in a joint effort with The Leona M. and Harry B. Helmsley Charitable Trust to promote greater access to care and resources...",
                "1d_change": -1.6324002243,
                "index_price": -0.4720808367,
                "norm_price": -1.1603193877
            },
            {
                "index": 174,
                "date": "2021-09-07",
                "press_title": "Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities",
                "release_url": "http://lilly.mediaroom.com/2021-09-07-Lilly-Announces-Cash-Tender-Offer-for-Up-to-1-5-Billion-Combined-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $1.5 billion combined aggregate principal amount (the \"Tender Cap\") of specified series of its...",
                "1d_change": -1.6324002243,
                "index_price": -0.4720808367,
                "norm_price": -1.1603193877
            },
            {
                "index": 175,
                "date": "2021-09-03",
                "press_title": "Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2021-09-03-Lilly-to-Participate-in-the-Morgan-Stanley-19th-Annual-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021. Michael Mason, senior vice president, president of...",
                "1d_change": -2.3665528245,
                "index_price": -0.2741162627,
                "norm_price": -2.0924365619
            },
            {
                "index": 176,
                "date": "2021-08-31",
                "press_title": "Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference",
                "release_url": "http://lilly.mediaroom.com/2021-08-31-Lilly-to-Participate-in-Citis-16th-Annual-BioPharma-Virtual-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in Citi's 16th Annual BioPharma Virtual Conference on September 8 and 9, 2021. Anat Ashkenazi, senior vice president and chief financial officer,...",
                "1d_change": -2.1134428649,
                "index_price": -0.1251114908,
                "norm_price": -1.9883313741
            },
            {
                "index": 177,
                "date": "2021-08-27",
                "press_title": "Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction",
                "release_url": "http://lilly.mediaroom.com/2021-08-27-Landmark-trial-demonstrates-Jardiance-R-empagliflozin-is-the-first-therapy-to-show-statistically-significant-improvement-in-heart-failure-outcomes-in-adults-with-preserved-ejection-fraction",
                "content": "error_http",
                "1d_change": -0.0800522434,
                "index_price": 1.2076060258,
                "norm_price": -1.2876582692
            },
            {
                "index": 178,
                "date": "2021-08-25",
                "press_title": "Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders",
                "release_url": "http://lilly.mediaroom.com/2021-08-25-Lilly-and-Lycia-Therapeutics-Enter-into-Strategic-Collaboration-to-Discover-and-Develop-Novel-Lysosomal-Targeting-Chimera-LYTAC-Degraders",
                "content": "Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and...",
                "1d_change": -0.5586791533,
                "index_price": -0.4574987766,
                "norm_price": -0.1011803767
            },
            {
                "index": 179,
                "date": "2021-08-25",
                "press_title": "Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors",
                "release_url": "http://lilly.mediaroom.com/2021-08-25-Lilly-Announces-that-Professor-Carolyn-Bertozzi-has-Resigned-from-its-Board-of-Directors",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) announced today that Carolyn R. Bertozzi, Ph.D., has resigned from her role as an independent director of Lilly's board. Her resignation...",
                "1d_change": -0.5586791533,
                "index_price": -0.4574987766,
                "norm_price": -0.1011803767
            },
            {
                "index": 180,
                "date": "2021-08-18",
                "press_title": "US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction",
                "release_url": "http://lilly.mediaroom.com/2021-08-18-US-FDA-approves-Jardiance-R-empagliflozin-to-treat-adults-living-with-heart-failure-with-reduced-ejection-fraction",
                "content": "Jardiance® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart...",
                "1d_change": -0.5954164047,
                "index_price": -0.7975881401,
                "norm_price": 0.2021717354
            },
            {
                "index": 181,
                "date": "2021-08-17",
                "press_title": "Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units",
                "release_url": "http://lilly.mediaroom.com/2021-08-17-Lilly-Announces-Leadership-Changes-and-Formation-of-Neuroscience-and-Immunology-Business-Units",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced executive leadership changes and the creation of neuroscience and immunology business units. These changes will increase Lilly's focus on...",
                "1d_change": -0.983173749,
                "index_price": -1.4055977788,
                "norm_price": 0.4224240298
            },
            {
                "index": 182,
                "date": "2021-08-16",
                "press_title": "FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps",
                "release_url": "http://lilly.mediaroom.com/2021-08-16-FDA-approves-Lyumjev-R-insulin-lispro-aabc-injection-100-units-mL-for-use-in-insulin-pumps",
                "content": "The U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly and Company's (NYSE: LLY) rapid-acting insulin, Lyumjev® (insulin lispro-aabc injection) 100 units/mL...",
                "1d_change": 2.8711913483,
                "index_price": -0.3050714911,
                "norm_price": 3.1762628393
            },
            {
                "index": 183,
                "date": "2021-08-16",
                "press_title": "Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials",
                "release_url": "http://lilly.mediaroom.com/2021-08-16-Lillys-lebrikizumab-significantly-improved-skin-clearance-and-itch-in-people-with-moderate-to-severe-atopic-dermatitis-in-two-Phase-3-trials",
                "content": "Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in Eli Lilly...",
                "1d_change": 2.8711913483,
                "index_price": -0.3050714911,
                "norm_price": 3.1762628393
            },
            {
                "index": 184,
                "date": "2021-08-03",
                "press_title": "Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance",
                "release_url": "http://lilly.mediaroom.com/2021-08-03-Lilly-Delivers-Strong-Second-Quarter-2021-Financial-Results,-Updates-2021-Financial-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2021. \"We delivered strong performance this quarter, with volume-driven growth across our core...",
                "1d_change": 6.7512462238,
                "index_price": 0.2253165478,
                "norm_price": 6.525929676
            },
            {
                "index": 185,
                "date": "2021-08-03",
                "press_title": "Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation",
                "release_url": "http://lilly.mediaroom.com/2021-08-03-Lilly-and-Incytes-baricitinib-reduced-deaths-among-patients-with-COVID-19-receiving-invasive-mechanical-ventilation",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with...",
                "1d_change": 6.7512462238,
                "index_price": 0.2253165478,
                "norm_price": 6.525929676
            },
            {
                "index": 186,
                "date": "2021-07-29",
                "press_title": "Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline",
                "release_url": "http://lilly.mediaroom.com/2021-07-29-Lilly-releases-donanemab-data-that-demonstrated-relationship-between-reduction-of-amyloid-plaque-and-slowing-of-cognitive-decline",
                "content": "Today at the Alzheimer's Association International Conference© (AAIC© 2021), Eli Lilly and Company (NYSE: LLY) presented two new exploratory analyses of data from the Phase 2 TRAILBLAZER-ALZ...",
                "1d_change": -1.6427014149,
                "index_price": -0.1895241367,
                "norm_price": -1.4531772783
            },
            {
                "index": 187,
                "date": "2021-07-29",
                "press_title": "FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen",
                "release_url": "http://lilly.mediaroom.com/2021-07-29-FDA-broadens-existing-emergency-use-of-Lilly-and-Incytes-baricitinib-in-patients-hospitalized-with-COVID-19-requiring-oxygen",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today the U.S. Food and Drug Administration (FDA) has broadened the Emergency Use Authorization (EUA) for baricitinib to allow...",
                "1d_change": -1.6427014149,
                "index_price": -0.1895241367,
                "norm_price": -1.4531772783
            },
            {
                "index": 188,
                "date": "2021-07-29",
                "press_title": "Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses",
                "release_url": "http://lilly.mediaroom.com/2021-07-29-Lilly-and-Kumquat-Biosciences-Announce-Collaboration-to-Discover-and-Develop-Novel-Small-Molecules-that-Stimulate-Tumor-Specific-Immune-Responses",
                "content": "Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery,...",
                "1d_change": -1.6427014149,
                "index_price": -0.1895241367,
                "norm_price": -1.4531772783
            },
            {
                "index": 189,
                "date": "2021-07-22",
                "press_title": "Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2021-07-22-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2021-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2021 financial results on Tuesday, August 3, 2021. Lilly will also conduct a conference call on that day with the investment...",
                "1d_change": 2.8138440276,
                "index_price": 1.1451138672,
                "norm_price": 1.6687301603
            },
            {
                "index": 190,
                "date": "2021-07-16",
                "press_title": "Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis",
                "release_url": "http://lilly.mediaroom.com/2021-07-16-Lilly-and-Incyte-provide-update-on-supplemental-New-Drug-Application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) action date for...",
                "1d_change": 0.7004391167,
                "index_price": -2.5581822526,
                "norm_price": 3.2586213693
            },
            {
                "index": 191,
                "date": "2021-07-15",
                "press_title": "Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab",
                "release_url": "http://lilly.mediaroom.com/2021-07-15-Lilly-and-Banner-Alzheimers-Institute-collaborate-on-planned-Phase-3-prevention-trial-of-donanemab",
                "content": "Eli Lilly and Company (NYSE: LLY) and Banner Alzheimer's Institute today announced a strategic research collaboration as part of the planned Phase 3, randomized, placebo-controlled study...",
                "1d_change": -1.0969587959,
                "index_price": -0.9673749473,
                "norm_price": -0.1295838486
            },
            {
                "index": 192,
                "date": "2021-07-14",
                "press_title": "Lilly Announces Acquisition of Protomer Technologies",
                "release_url": "http://lilly.mediaroom.com/2021-07-14-Lilly-Announces-Acquisition-of-Protomer-Technologies",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the acquisition of Protomer Technologies (\"Protomer\"), a private biotech company. Protomer's proprietary peptide- and protein-engineering platform...",
                "1d_change": -1.8663288709,
                "index_price": -0.4605491044,
                "norm_price": -1.4057797665
            },
            {
                "index": 193,
                "date": "2021-07-09",
                "press_title": "Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study",
                "release_url": "http://lilly.mediaroom.com/2021-07-09-Mirikizumab-Up-Regulates-Genes-Associated-with-Mucosal-Healing-in-Ulcerative-Colitis-for-Up-to-One-Year-in-Phase-2-Study",
                "content": "Eli Lilly and Company (NYSE: LLY) announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment...",
                "1d_change": -0.4914994039,
                "index_price": 1.2600835527,
                "norm_price": -1.7515829566
            },
            {
                "index": 194,
                "date": "2021-07-06",
                "press_title": "Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction",
                "release_url": "http://lilly.mediaroom.com/2021-07-06-Breakthrough-results-for-Jardiance-R-empagliflozin-confirm-EMPEROR-Preserved-as-first-and-only-successful-trial-for-heart-failure-with-preserved-ejection-fraction",
                "content": "The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance® (empagliflozin) as the first and only therapy to significantly reduce the risk of the composite of...",
                "1d_change": 0.9286783037,
                "index_price": 0.0383173958,
                "norm_price": 0.8903609079
            },
            {
                "index": 195,
                "date": "2021-06-29",
                "press_title": "Lilly Declares Third-Quarter 2021 Dividend",
                "release_url": "http://lilly.mediaroom.com/2021-06-29-Lilly-Declares-Third-Quarter-2021-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) (the \"Board\") has declared a dividend for the third quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is...",
                "1d_change": 0.5533240807,
                "index_price": 0.0998263889,
                "norm_price": 0.4534976918
            },
            {
                "index": 196,
                "date": "2021-06-26",
                "press_title": "Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2021-06-26-Lillys-SURPASS-1-results-published-in-The-Lancet-show-tirzepatides-superior-A1C-and-body-weight-reductions-versus-placebo-in-adults-with-type-2-diabetes",
                "content": "Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of treatment in Eli Lilly and Company's (NYSE: LLY)...",
                "1d_change": 0.1613132421,
                "index_price": 0.1607694361,
                "norm_price": 0.000543806
            },
            {
                "index": 197,
                "date": "2021-06-25",
                "press_title": "Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2021-06-25-Lillys-SURPASS-2-results-published-in-The-New-England-Journal-of-Medicine-show-tirzepatide-achieved-superior-A1C-and-body-weight-reductions-compared-to-injectable-semaglutide-in-adults-with-type-2-diabetes",
                "content": "Tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company's (NYSE: LLY) SURPASS-2 clinical...",
                "1d_change": -2.1470561338,
                "index_price": 0.3766286958,
                "norm_price": -2.5236848296
            },
            {
                "index": 198,
                "date": "2021-06-24",
                "press_title": "Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin",
                "release_url": "http://lilly.mediaroom.com/2021-06-24-Lilly-announces-call-for-Leonard-Award-nominations-as-part-of-global-initiative-celebrating-100-years-of-insulin",
                "content": "In honor of the 100th anniversary of the discovery of insulin, Eli Lilly and Company (NYSE: LLY) today launched the Leonard Award to recognize diverse champions dedicated to advancing diabetes...",
                "1d_change": -2.0415191287,
                "index_price": 0.5543481063,
                "norm_price": -2.595867235
            },
            {
                "index": 199,
                "date": "2021-06-24",
                "press_title": "Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease",
                "release_url": "http://lilly.mediaroom.com/2021-06-24-Lillys-donanemab-receives-U-S-FDAs-Breakthrough-Therapy-designation-for-treatment-of-Alzheimers-disease",
                "content": "The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY) investigational antibody therapy for Alzheimer's disease...",
                "1d_change": -2.0415191287,
                "index_price": 0.5543481063,
                "norm_price": -2.595867235
            },
            {
                "index": 200,
                "date": "2021-06-17",
                "press_title": "Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine",
                "release_url": "http://lilly.mediaroom.com/2021-06-17-Lilly-Launches-Think-Talk-Treat-Migraine-TM-to-Help-Improve-Diagnosis-and-Treatment-of-Migraine",
                "content": "Based on results from a large population-based survey, it is estimated that approximately half of people with migraine hesitate to seek care for a variety of reasons, and even fewer receive a...",
                "1d_change": -0.7870001979,
                "index_price": -1.2941453599,
                "norm_price": 0.507145162
            },
            {
                "index": 201,
                "date": "2021-06-15",
                "press_title": "Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine",
                "release_url": "http://lilly.mediaroom.com/2021-06-15-Lilly-Announces-Head-to-Head-Study-Comparing-Once-Monthly-Emgality-R-with-Every-Other-Day-Nurtec-R-ODT-for-the-Preventive-Treatment-of-Migraine",
                "content": "To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) compared to oral CGRP receptor antagonists in the...",
                "1d_change": -2.4189219862,
                "index_price": -0.747675933,
                "norm_price": -1.6712460532
            },
            {
                "index": 202,
                "date": "2021-06-14",
                "press_title": "Lilly to Participate in Guggenheim Biopharma Strategy Series",
                "release_url": "http://lilly.mediaroom.com/2021-06-14-Lilly-to-Participate-in-Guggenheim-Biopharma-Strategy-Series",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation – on Friday, June...",
                "1d_change": -0.3176256643,
                "index_price": -0.0405081467,
                "norm_price": -0.2771175176
            },
            {
                "index": 203,
                "date": "2021-06-11",
                "press_title": "Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA",
                "release_url": "http://lilly.mediaroom.com/2021-06-11-Lilly-Announces-Webcast-to-Provide-Diabetes-Portfolio-Update-at-ADA",
                "content": "Eli Lilly and Company (NYSE: LLY) will host a webcast on Thursday, July 1, 2021 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's Virtual...",
                "1d_change": -0.4113340376,
                "index_price": 0.2878864501,
                "norm_price": -0.6992204877
            },
            {
                "index": 204,
                "date": "2021-06-04",
                "press_title": "Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2021-06-04-Lilly-Announces-New-Clinical-Data-from-Verzenio-and-Oral-SERD-Programs-at-the-American-Society-of-Clinical-Oncology-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced new data for the investigational use of Verzenio® (abemaciclib) in high risk early breast cancer, and for its oral selective estrogen receptor...",
                "1d_change": 8.8666358063,
                "index_price": 0.4843278808,
                "norm_price": 8.3823079255
            },
            {
                "index": 205,
                "date": "2021-06-03",
                "press_title": "Lilly to Participate in Goldman Sachs Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2021-06-03-Lilly-to-Participate-in-Goldman-Sachs-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs Healthcare Conference on June 9 and 10, 2021. Anne White, senior vice president and president, Lilly Oncology and Jake Van...",
                "1d_change": 1.499843205,
                "index_price": 0.9092425499,
                "norm_price": 0.5906006551
            },
            {
                "index": 206,
                "date": "2021-06-03",
                "press_title": "Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021",
                "release_url": "http://lilly.mediaroom.com/2021-06-03-Lilly-Reveals-Critical-Barriers-to-Optimal-Migraine-Care-and-Insights-From-Novel-Clinical-and-Patient-Centric-Real-World-Evidence,-Supporting-Lillys-Preventive-and-Acute-Treatment-Portfolio-at-AHS-2021",
                "content": "To improve the understanding and advance the treatment of migraine, Eli Lilly and Company (NYSE: LLY) presented data on unmet needs in migraine from the OVERCOME (U.S.) study and on its portfolio...",
                "1d_change": 1.499843205,
                "index_price": 0.9092425499,
                "norm_price": 0.5906006551
            },
            {
                "index": 207,
                "date": "2021-06-01",
                "press_title": "OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses",
                "release_url": "http://lilly.mediaroom.com/2021-06-01-OLUMIANT-R-Improved-Pain,-Physical-Function-and-Morning-Joint-Stiffness-in-Rheumatoid-Arthritis-in-Phase-3-Post-Hoc-Analyses",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present data from post-hoc analyses that suggested OLUMIANT® (baricitinib) 4 mg tablet reduced pain and duration of morning joint...",
                "1d_change": -0.5975909632,
                "index_price": -0.1996117532,
                "norm_price": -0.3979792099
            },
            {
                "index": 208,
                "date": "2021-06-01",
                "press_title": "Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study",
                "release_url": "http://lilly.mediaroom.com/2021-06-01-Taltz-R-Showed-Consistent,-Long-Term-Improvement-in-Key-Signs-and-Symptoms-of-Axial-Spondyloarthritis-Through-Two-Years-in-Phase-3-Study",
                "content": "Eli Lilly and Company (NYSE: LLY) will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety profile of Taltz® (ixekizumab) among patients with axial...",
                "1d_change": -0.5975909632,
                "index_price": -0.1996117532,
                "norm_price": -0.3979792099
            },
            {
                "index": 209,
                "date": "2021-05-22",
                "press_title": "Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial",
                "release_url": "http://lilly.mediaroom.com/2021-05-22-Mirikizumab-Improves-Fatigue-in-Patients-with-Crohns-Disease-in-Phase-2-Trial",
                "content": "In a pre-specified analysis of the Phase 2 SERENITY study, Eli Lilly and Company's (NYSE: LLY) mirikizumab improved fatigue in patients with moderately to severely active Crohn's disease (CD) at...",
                "1d_change": -0.893487174,
                "index_price": 0.4290632589,
                "norm_price": -1.3225504329
            },
            {
                "index": 210,
                "date": "2021-05-20",
                "press_title": "Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial",
                "release_url": "http://lilly.mediaroom.com/2021-05-20-Lillys-tirzepatide-achieves-all-primary-and-key-secondary-study-outcomes-against-insulin-glargine-in-adults-with-type-2-diabetes-and-increased-cardiovascular-risk-in-SURPASS-4-trial",
                "content": "Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes who have increased cardiovascular (CV) risk compared to titrated...",
                "1d_change": 1.3608151642,
                "index_price": 0.8154665834,
                "norm_price": 0.5453485808
            },
            {
                "index": 211,
                "date": "2021-05-19",
                "press_title": "Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2021-05-19-Lilly-Announces-Details-of-Presentations-at-2021-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting",
                "content": "New data from across Eli Lilly and Company's (NYSE: LLY) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 4-8, 2021. The data...",
                "1d_change": 2.9669880071,
                "index_price": 1.4587201179,
                "norm_price": 1.5082678893
            },
            {
                "index": 212,
                "date": "2021-05-18",
                "press_title": "U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/index.php?s=9042&item=138226",
                "content": "SAN FRANCISCO and SUZHOU, China, May 18, 2021 — Innovent Biologics, Inc. (HKEX: 01801) and Eli Lilly and Company (NYSE: LLY) today jointly announced that the U.S. Food and Drug Administration...",
                "1d_change": 0.7683922464,
                "index_price": -1.2211776299,
                "norm_price": 1.9895698763
            },
            {
                "index": 213,
                "date": "2021-05-13",
                "press_title": "Lilly to Participate in UBS Global Healthcare Virtual Conference",
                "release_url": "http://lilly.mediaroom.com/2021-05-13-Lilly-to-Participate-in-UBS-Global-Healthcare-Virtual-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021. Anat Ashkenazi, senior vice president and chief financial officer,...",
                "1d_change": 2.0182602385,
                "index_price": 2.3685591267,
                "norm_price": -0.3502988882
            },
            {
                "index": 214,
                "date": "2021-05-11",
                "press_title": "Lilly and MiNA Therapeutics Announce saRNA Research Collaboration",
                "release_url": "http://lilly.mediaroom.com/2021-05-11-Lilly-and-MiNA-Therapeutics-Announce-saRNA-Research-Collaboration",
                "content": "Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research collaboration to develop novel drug candidates using...",
                "1d_change": -0.098324756,
                "index_price": -2.1486326457,
                "norm_price": 2.0503078897
            },
            {
                "index": 215,
                "date": "2021-05-06",
                "press_title": "Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes",
                "release_url": "http://lilly.mediaroom.com/2021-05-06-Lilly-collaborates-internationally-with-leading-diabetes-technology-companies-to-integrate-connected-insulin-pen-solutions-for-people-with-diabetes",
                "content": "With a goal of integrating data and technology to help streamline diabetes management, Eli Lilly and Company (NYSE: LLY) signed strategic international agreements with four companies – DexCom,...",
                "1d_change": 1.9803667669,
                "index_price": 1.4993138845,
                "norm_price": 0.4810528824
            },
            {
                "index": 216,
                "date": "2021-05-05",
                "press_title": "Lilly to Participate in Bank of America Securities 2021 Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2021-05-05-Lilly-to-Participate-in-Bank-of-America-Securities-2021-Health-Care-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2021 Health Care Conference on Tuesday, May 11, 2021. Michael Mason, senior vice president, president of Lilly...",
                "1d_change": 2.7025495038,
                "index_price": 0.584537819,
                "norm_price": 2.1180116849
            },
            {
                "index": 217,
                "date": "2021-05-04",
                "press_title": "Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries",
                "release_url": "http://lilly.mediaroom.com/2021-05-04-Lilly-plans-donation-of-COVID-19-therapies-to-Direct-Relief-for-use-in-low-and-lower-middle-income-countries",
                "content": "Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income...",
                "1d_change": 2.7384413949,
                "index_price": -0.2747438146,
                "norm_price": 3.0131852095
            },
            {
                "index": 218,
                "date": "2021-05-04",
                "press_title": "Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe",
                "release_url": "http://lilly.mediaroom.com/2021-05-04-Lilly-Outlines-Robust-Plans-to-Strengthen-ESG-Commitments-Across-the-Globe",
                "content": "Eli Lilly and Company (NYSE: LLY) will outline its newly updated Environmental, Social and Governance (ESG) strategy, highlighting its commitments in key areas during the company's Sustainability...",
                "1d_change": 2.7384413949,
                "index_price": -0.2747438146,
                "norm_price": 3.0131852095
            },
            {
                "index": 219,
                "date": "2021-05-04",
                "press_title": "Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements",
                "release_url": "http://lilly.mediaroom.com/2021-05-04-Lilly-accelerating-baricitinibs-availability-in-India-following-receipt-of-permission-for-restricted-emergency-use-as-a-COVID-19-therapy-via-donations-and-licensing-agreements",
                "content": "Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack...",
                "1d_change": 2.7384413949,
                "index_price": -0.2747438146,
                "norm_price": 3.0131852095
            },
            {
                "index": 220,
                "date": "2021-05-03",
                "press_title": "Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization",
                "release_url": "http://lilly.mediaroom.com/2021-05-03-Lilly-Declares-Second-Quarter-2021-Dividend-and-Announces-Additional-Share-Repurchase-Authorization",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) (the \"Board\") has declared a dividend for the second quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is...",
                "1d_change": 2.7683378201,
                "index_price": -0.6559916822,
                "norm_price": 3.4243295023
            },
            {
                "index": 221,
                "date": "2021-05-03",
                "press_title": "Lilly to Commit $5 Million to Direct Relief's Fund for Health Equity",
                "release_url": "http://lilly.mediaroom.com/2021-05-03-Lilly-to-Commit-5-Million-to-Direct-Reliefs-Fund-for-Health-Equity",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced its support of Direct Relief's Fund for Health Equity (the Fund) with a $5 million commitment over the next five years. The Fund launched in March...",
                "1d_change": 2.7683378201,
                "index_price": -0.6559916822,
                "norm_price": 3.4243295023
            },
            {
                "index": 222,
                "date": "2021-04-27",
                "press_title": "Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance",
                "release_url": "http://lilly.mediaroom.com/2021-04-27-Lilly-Delivers-First-Quarter-2021-Financial-Results,-Adjusts-2021-Financial-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2021. $ in millions, except per share data First Quarter % 2021 2020 Change Revenue $ 6,805.6 $ 5,859.8 16%",
                "1d_change": -1.9108132321,
                "index_price": -0.1211954543,
                "norm_price": -1.7896177777
            },
            {
                "index": 223,
                "date": "2021-04-23",
                "press_title": "OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses",
                "release_url": "http://lilly.mediaroom.com/2021-04-23-OLUMIANT-R-Showed-Significant-Improvements-in-the-Severity-and-Extent-of-Atopic-Dermatitis-and-Other-Patient-Reported-Outcomes-in-Phase-3-Study-Analyses",
                "content": "Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) and Incyte's (NASDAQ:INCY) OLUMIANT®...",
                "1d_change": 0.1015046192,
                "index_price": 1.1663028323,
                "norm_price": -1.0647982131
            },
            {
                "index": 224,
                "date": "2021-04-23",
                "press_title": "Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis",
                "release_url": "http://lilly.mediaroom.com/2021-04-23-Taltz-R-Delivers-More-Cumulative-Days-with-Completely-Clear-Skin-for-Adults-with-Psoriasis-Compared-to-Seven-Other-Biologics-in-Novel-Network-Meta-Analysis",
                "content": "Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's (NYSE: LLY) Taltz® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to...",
                "1d_change": 0.1015046192,
                "index_price": 1.1663028323,
                "norm_price": -1.0647982131
            },
            {
                "index": 225,
                "date": "2021-04-20",
                "press_title": "Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study",
                "release_url": "http://lilly.mediaroom.com/2021-04-20-Lilly-and-Incytes-Baricitinib-Improved-Hair-Regrowth-for-Alopecia-Areata-Patients-in-Second-Phase-3-Study",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today results from a second Phase 3 trial (BRAVE-AA1) evaluating the efficacy and safety of once-daily baricitinib 2-mg and...",
                "1d_change": 0.2828056094,
                "index_price": 0.3412008942,
                "norm_price": -0.0583952849
            },
            {
                "index": 226,
                "date": "2021-04-16",
                "press_title": "Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.",
                "release_url": "http://lilly.mediaroom.com/2021-04-16-Lilly-requests-revocation-of-emergency-use-authorization-for-bamlanivimab-alone-to-complete-transition-to-bamlanivimab-and-etesevimab-together-for-treatment-of-COVID-19-in-the-U-S",
                "content": "Eli Lilly and Company (NYSE: LLY) has requested the U.S. Food and Drug Administration (FDA) revoke the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg alone. Lilly made this...",
                "1d_change": 1.1917309885,
                "index_price": -0.2613425947,
                "norm_price": 1.4530735831
            },
            {
                "index": 227,
                "date": "2021-04-13",
                "press_title": "Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer",
                "release_url": "http://lilly.mediaroom.com/2021-04-13-Diogo-Rau-to-join-Lilly-as-Senior-Vice-President-and-Chief-Information-and-Digital-Officer",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Diogo Rau will join the company on May 17, 2021 as senior vice-president and chief information and digital officer. Rau succeeds Aarti Shah,...",
                "1d_change": 0.9945278689,
                "index_price": -0.1318882332,
                "norm_price": 1.1264161021
            },
            {
                "index": 228,
                "date": "2021-04-12",
                "press_title": "Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together",
                "release_url": "http://lilly.mediaroom.com/2021-04-12-Lilly-modified-COVID-19-purchase-agreement-for-bamlanivimab-alone-with-the-U-S-government-and-is-focusing-on-supply-of-bamlanivimab-and-etesevimab-together",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced changes to the purchase agreements with the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment...",
                "1d_change": -0.4930776082,
                "index_price": 0.4075701228,
                "norm_price": -0.900647731
            },
            {
                "index": 229,
                "date": "2021-04-11",
                "press_title": "Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2021-04-11-Lilly-Presents-New-Data-on-Retevmo-R-selpercatinib-in-Advanced-RET-Fusion-Positive-Gastrointestinal-and-Other-Cancers-at-2021-American-Association-for-Cancer-Research-AACR-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo® (selpercatinib) demonstrated encouraging antitumor...",
                "1d_change": -0.4930776082,
                "index_price": 0.4075701228,
                "norm_price": -0.900647731
            },
            {
                "index": 230,
                "date": "2021-04-08",
                "press_title": "Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients",
                "release_url": "http://lilly.mediaroom.com/2021-04-08-Lilly-and-Incyte-announce-results-from-the-Phase-3-COV-BARRIER-study-of-baricitinib-in-hospitalized-COVID-19-patients",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo...",
                "1d_change": 0.8347255851,
                "index_price": 0.9409478627,
                "norm_price": -0.1062222776
            },
            {
                "index": 231,
                "date": "2021-04-06",
                "press_title": "Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis",
                "release_url": "http://lilly.mediaroom.com/2021-04-06-Lilly-and-Incyte-communicate-review-extension-of-supplemental-New-Drug-Application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application...",
                "1d_change": -1.2999109149,
                "index_price": 0.1073513858,
                "norm_price": -1.4072623007
            },
            {
                "index": 232,
                "date": "2021-04-06",
                "press_title": "Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2021-04-06-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2021-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2021 financial results on Tuesday, April 27, 2021. Lilly will also conduct a conference call on that day with the investment...",
                "1d_change": -1.2999109149,
                "index_price": 0.1073513858,
                "norm_price": -1.4072623007
            },
            {
                "index": 233,
                "date": "2021-04-01",
                "press_title": "Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts",
                "release_url": "http://lilly.mediaroom.com/2021-04-01-Lilly-to-Host-Sustainability-Webcast-to-Provide-Overview-of-Environmental-Social-and-Governance-ESG-Efforts",
                "content": "Eli Lilly and Company (NYSE: LLY) will host a webcast for the investment community, media and the general public on May 4, 2021 to provide an overview of the company's strong commitment to...",
                "1d_change": -1.0438518583,
                "index_price": 2.0875861568,
                "norm_price": -3.1314380151
            },
            {
                "index": 234,
                "date": "2021-03-31",
                "press_title": "Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care",
                "release_url": "http://lilly.mediaroom.com/2021-03-31-Survey-reveals-healthcare-professionals-believe-greater-collaboration-is-needed-to-improve-patient-outcomes-in-diabetes-care",
                "content": "Approximately 9 in 10 specialists agree that people with type 2 diabetes whose healthcare professionals (HCPs) collaborate tend to have better outcomes than those whose HCPs do not, while the top...",
                "1d_change": -0.1781495986,
                "index_price": 1.3090004317,
                "norm_price": -1.4871500303
            },
            {
                "index": 235,
                "date": "2021-03-29",
                "press_title": "Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19",
                "release_url": "http://lilly.mediaroom.com/2021-03-29-Lilly-Vir-Biotechnology-and-GSK-Announce-Positive-Topline-Data-from-the-Phase-2-BLAZE-4-Trial-Evaluating-Bamlanivimab-with-VIR-7831-in-Low-Risk-Adults-with-COVID-19",
                "content": "Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying...",
                "1d_change": 0.452813119,
                "index_price": -0.2718169439,
                "norm_price": 0.7246300629
            },
            {
                "index": 236,
                "date": "2021-03-25",
                "press_title": "Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain",
                "release_url": "http://lilly.mediaroom.com/index.php?s=9042&item=138180",
                "content": "NEW YORK AND INDIANAPOLIS, March 25, 2021—Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis...",
                "1d_change": 2.3258316021,
                "index_price": 2.3952444871,
                "norm_price": -0.0694128849
            },
            {
                "index": 237,
                "date": "2021-03-17",
                "press_title": "Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021",
                "release_url": "http://lilly.mediaroom.com/2021-03-17-Lilly-Presents-Patient-Reported-Outcomes-from-the-Positive-Phase-3-monarchE-Trial-for-Verzenio-R-at-St-Gallen-Virtual-Congress-2021",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy...",
                "1d_change": -3.1533812544,
                "index_price": -0.8711647613,
                "norm_price": -2.2822164931
            },
            {
                "index": 238,
                "date": "2021-03-16",
                "press_title": "Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study",
                "release_url": "http://lilly.mediaroom.com/2021-03-16-Lillys-Mirikizumab-Helps-Patients-Achieve-Clinical-Remission-and-Improves-Symptoms-in-Adults-with-Ulcerative-Colitis-in-12-Week-Phase-3-Induction-Study",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety...",
                "1d_change": -2.575905051,
                "index_price": 0.0133370226,
                "norm_price": -2.5892420736
            },
            {
                "index": 239,
                "date": "2021-03-13",
                "press_title": "Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM",
                "release_url": "http://lilly.mediaroom.com/2021-03-13-Lillys-donanemab-slowed-Alzheimers-disease-progression-in-Phase-2-trial-full-data-presented-at-AD-PD-TM-2021-and-published-in-NEJM",
                "content": "Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer's & Parkinson Diseases™ 2021 (AD/PD™ 2021) held virtually...",
                "1d_change": -1.1052838861,
                "index_price": 0.4983963044,
                "norm_price": -1.6036801905
            },
            {
                "index": 240,
                "date": "2021-03-10",
                "press_title": "Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)",
                "release_url": "http://lilly.mediaroom.com/2021-03-10-Lilly-Announces-Details-of-Presentations-at-2021-American-Association-for-Cancer-Research-AACR",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR)...",
                "1d_change": -0.8186704736,
                "index_price": 1.2019804485,
                "norm_price": -2.0206509221
            },
            {
                "index": 241,
                "date": "2021-03-10",
                "press_title": "Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19",
                "release_url": "http://lilly.mediaroom.com/2021-03-10-Lillys-bamlanivimab-and-etesevimab-together-reduced-hospitalizations-and-death-in-Phase-3-trial-for-early-COVID-19",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and etesevimab...",
                "1d_change": -0.8186704736,
                "index_price": 1.2019804485,
                "norm_price": -2.0206509221
            },
            {
                "index": 242,
                "date": "2021-03-09",
                "press_title": "Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research",
                "release_url": "http://lilly.mediaroom.com/2021-03-09-Data-from-Lilly-at-International-Conference-on-Alzheimers-Parkinson-Diseases-2021-TM-AD-PD-TM-2021-to-Showcase-Clinical-Advances-in-Alzheimers-Disease-Research",
                "content": "New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer's & Parkinson Diseases™ 2021 (AD/PD™ 2021), March...",
                "1d_change": -1.4066602219,
                "index_price": 1.2024214119,
                "norm_price": -2.6090816337
            },
            {
                "index": 243,
                "date": "2021-03-09",
                "press_title": "Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations",
                "release_url": "http://lilly.mediaroom.com/2021-03-09-Lilly-Announces-Leadership-Transitions-in-Manufacturing-and-Ethics-and-Compliance-Organizations",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of two executive committee members and the naming of their successors in the company's manufacturing operations and ethics...",
                "1d_change": -1.4066602219,
                "index_price": 1.2024214119,
                "norm_price": -2.6090816337
            },
            {
                "index": 244,
                "date": "2021-03-08",
                "press_title": "Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes",
                "release_url": "http://lilly.mediaroom.com/2021-03-08-Lilly-and-Biolojic-Design-Announce-Research-Collaboration-to-Discover-and-Develop-Antibody-Therapies-for-Diabetes",
                "content": "Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd. (\"Biolojic\"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and...",
                "1d_change": -0.4318092056,
                "index_price": 0.8012006197,
                "norm_price": -1.2330098254
            },
            {
                "index": 245,
                "date": "2021-03-08",
                "press_title": "Lilly to Participate in Barclays Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2021-03-08-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 9, 2021. Patrik Jonsson, senior vice president, president of Lilly USA and chief...",
                "1d_change": -0.4318092056,
                "index_price": 0.8012006197,
                "norm_price": -1.2330098254
            },
            {
                "index": 246,
                "date": "2021-03-05",
                "press_title": "EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union",
                "release_url": "http://lilly.mediaroom.com/2021-03-05-EMA-issues-advice-on-Lillys-bamlanivimab-LY-CoV555-alone-and-administered-together-with-etesevimab-LY-CoV016-for-the-treatment-of-confirmed-COVID-19-in-the-European-Union",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for...",
                "1d_change": 2.902950902,
                "index_price": 0.726707023,
                "norm_price": 2.176243879
            },
            {
                "index": 247,
                "date": "2021-03-05",
                "press_title": "Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet",
                "release_url": "http://lilly.mediaroom.com/2021-03-05-Loxo-Oncology-at-Lilly-Announces-Publication-of-Pirtobrutinib-LOXO-305-Phase-1-2-Data-in-The-Lancet",
                "content": "Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data from the pirtobrutinib (previously referred to as...",
                "1d_change": 2.902950902,
                "index_price": 0.726707023,
                "norm_price": 2.176243879
            },
            {
                "index": 248,
                "date": "2021-03-04",
                "press_title": "Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2021-03-04-Tirzepatide-achieved-superior-A1C-and-body-weight-reductions-across-all-three-doses-compared-to-injectable-semaglutide-in-adults-with-type-2-diabetes",
                "content": "Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes in Eli Lilly and Company's...",
                "1d_change": 1.5126632635,
                "index_price": 0.6093253009,
                "norm_price": 0.9033379626
            },
            {
                "index": 249,
                "date": "2021-03-03",
                "press_title": "Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial",
                "release_url": "http://lilly.mediaroom.com/2021-03-03-Baricitinib-is-First-JAK-Inhibitor-to-Demonstrate-Hair-Regrowth-in-Phase-3-Alopecia-Areata-AA-Trial",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and...",
                "1d_change": -1.4111877197,
                "index_price": -2.5347162184,
                "norm_price": 1.1235284987
            },
            {
                "index": 250,
                "date": "2021-02-26",
                "press_title": "Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19",
                "release_url": "http://lilly.mediaroom.com/2021-02-26-Lilly-announces-additional-doses-of-neutralizing-antibody-therapy-purchased-by-U-S-government-to-treat-COVID-19",
                "content": "The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced....",
                "1d_change": -0.1114006954,
                "index_price": 1.5931066825,
                "norm_price": -1.704507378
            },
            {
                "index": 251,
                "date": "2021-02-25",
                "press_title": "Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions",
                "release_url": "http://lilly.mediaroom.com/2021-02-25-Welldoc-and-Lilly-collaborate-to-integrate-BlueStar-R-app-capabilities-into-Lillys-connected-insulin-solutions",
                "content": "Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly's connected insulin solutions, currently in...",
                "1d_change": 0.6442391118,
                "index_price": -2.745894262,
                "norm_price": 3.3901333738
            },
            {
                "index": 252,
                "date": "2021-02-24",
                "press_title": "Lilly to Participate in Cowen Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2021-02-24-Lilly-to-Participate-in-Cowen-Health-Care-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41st Annual Health Care Conference on Thursday, March 4, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific...",
                "1d_change": 1.0548555533,
                "index_price": -1.1586819668,
                "norm_price": 2.2135375202
            },
            {
                "index": 253,
                "date": "2021-02-18",
                "press_title": "Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases",
                "release_url": "http://lilly.mediaroom.com/2021-02-18-Lilly-and-Rigel-Enter-Strategic-Collaboration-to-Develop-RIPK1-Inhibitors-for-the-Potential-Treatment-of-Immunological-and-Neurodegenerative-Diseases",
                "content": "Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize...",
                "1d_change": -2.1799657717,
                "index_price": -0.234216171,
                "norm_price": -1.9457496007
            },
            {
                "index": 254,
                "date": "2021-02-17",
                "press_title": "Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program",
                "release_url": "http://lilly.mediaroom.com/2021-02-17-Tirzepatide-significantly-reduced-A1C-and-body-weight-in-people-with-type-2-diabetes-in-two-phase-3-trials-from-Lillys-SURPASS-program",
                "content": "Tirzepatide led to significant A1C and body weight reductions from baseline in adults with type 2 diabetes in Eli Lilly and Company's (NYSE: LLY) SURPASS-3 and SURPASS-5 phase 3 clinical trials...",
                "1d_change": -1.9341775978,
                "index_price": -0.1157400116,
                "norm_price": -1.8184375862
            },
            {
                "index": 255,
                "date": "2021-02-17",
                "press_title": "Kimberly H. Johnson Elected to Lilly Board of Directors",
                "release_url": "http://lilly.mediaroom.com/2021-02-17-Kimberly-H-Johnson-Elected-to-Lilly-Board-of-Directors",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Kimberly H. Johnson as a new member, effective February 16, 2021. As a member of Lilly's board, she will serve on both the...",
                "1d_change": -1.9341775978,
                "index_price": -0.1157400116,
                "norm_price": -1.8184375862
            },
            {
                "index": 256,
                "date": "2021-02-11",
                "press_title": "Lilly To Participate in SVB Leerink Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2021-02-11-Lilly-To-Participate-in-SVB-Leerink-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Ilya Yuffa, Lilly senior vice president and president...",
                "1d_change": 2.1322910285,
                "index_price": 0.4683855571,
                "norm_price": 1.6639054714
            },
            {
                "index": 257,
                "date": "2021-02-09",
                "press_title": "Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19",
                "release_url": "http://lilly.mediaroom.com/2021-02-09-Lillys-bamlanivimab-LY-CoV555-administered-with-etesevimab-LY-CoV016-receives-FDA-emergency-use-authorization-for-COVID-19",
                "content": "The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and...",
                "1d_change": 0.31314786,
                "index_price": -0.0156042498,
                "norm_price": 0.3287521097
            },
            {
                "index": 258,
                "date": "2021-02-09",
                "press_title": "Lilly Appoints Anat Ashkenazi Chief Financial Officer",
                "release_url": "http://lilly.mediaroom.com/2021-02-09-Lilly-Appoints-Anat-Ashkenazi-Chief-Financial-Officer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the appointment of Anat Ashkenazi as senior vice president and chief financial officer. Ms. Ashkenazi, who most recently served in the role of...",
                "1d_change": 0.31314786,
                "index_price": -0.0156042498,
                "norm_price": 0.3287521097
            },
            {
                "index": 259,
                "date": "2021-02-04",
                "press_title": "Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference",
                "release_url": "http://lilly.mediaroom.com/2021-02-04-Lilly-Announces-Webcast-to-Provide-Alzheimers-Disease-Update-at-AD-PD-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, March 15, 2021 to provide an update on its Alzheimer's disease program and discuss results from the Phase 2 TRAILBLAZER-ALZ...",
                "1d_change": 2.458254395,
                "index_price": 1.2907733296,
                "norm_price": 1.1674810654
            },
            {
                "index": 260,
                "date": "2021-02-03",
                "press_title": "Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day",
                "release_url": "http://lilly.mediaroom.com/2021-02-03-Lilly-to-Participate-in-Guggenheim-Healthcare-Talks-2021-Oncology-Day",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021. Anne White, senior vice president and president, Lilly...",
                "1d_change": 1.8897022724,
                "index_price": 0.8128120892,
                "norm_price": 1.0768901832
            },
            {
                "index": 261,
                "date": "2021-02-01",
                "press_title": "Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients",
                "release_url": "http://lilly.mediaroom.com/2021-02-01-Lilly-Partners-with-Area-Health-Systems-to-Help-Enable-Access-to-Important-Antibody-Infusion-Therapies-for-COVID-19-Patients",
                "content": "Eli Lilly and Company (NYSE: LLY) has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that are intended to...",
                "1d_change": -6.0235139286,
                "index_price": 2.4864722216,
                "norm_price": -8.5099861502
            },
            {
                "index": 262,
                "date": "2021-01-29",
                "press_title": "Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results",
                "release_url": "http://lilly.mediaroom.com/2021-01-29-Lilly-Reports-Strong-Fourth-Quarter-and-Full-Year-2020-Financial-Results",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2020. $ in millions, except per share data Fourth Quarter % Full Year % 2020 2019 Change...",
                "1d_change": -4.3418168141,
                "index_price": -0.1110253504,
                "norm_price": -4.2307914637
            },
            {
                "index": 263,
                "date": "2021-01-28",
                "press_title": "Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate",
                "release_url": "http://lilly.mediaroom.com/2021-01-28-Lilly-and-Asahi-Kasei-Pharma-Announce-License-Agreement-for-Chronic-Pain-Drug-Candidate",
                "content": "Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780...",
                "1d_change": -0.0144450828,
                "index_price": -1.1175909439,
                "norm_price": 1.1031458611
            },
            {
                "index": 264,
                "date": "2021-01-27",
                "press_title": "Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19",
                "release_url": "http://lilly.mediaroom.com/2021-01-27-Lilly-Vir-Biotechnology-and-GSK-announce-first-patient-dosed-in-expanded-BLAZE-4-trial-evaluating-bamlanivimab-LY-CoV555-with-VIR-7831-GSK4182136-for-COVID-19",
                "content": "Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies...",
                "1d_change": -0.4521187719,
                "index_price": -1.3056571256,
                "norm_price": 0.8535383537
            },
            {
                "index": 265,
                "date": "2021-01-26",
                "press_title": "New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death  by 70 percent",
                "release_url": "http://lilly.mediaroom.com/2021-01-26-New-data-show-treatment-with-Lillys-neutralizing-antibodies-bamlanivimab-LY-CoV555-and-etesevimab-LY-CoV016-together-reduced-risk-of-COVID-19-hospitalizations-and-death-by-70-percent",
                "content": "Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, \"events\") in high-risk patients...",
                "1d_change": -2.3991850136,
                "index_price": -2.9911175791,
                "norm_price": 0.5919325655
            },
            {
                "index": 266,
                "date": "2021-01-22",
                "press_title": "Lilly Completes Acquisition of Prevail Therapeutics",
                "release_url": "http://lilly.mediaroom.com/2021-01-22-Lilly-Completes-Acquisition-of-Prevail-Therapeutics",
                "content": "Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug...",
                "1d_change": 4.8551878431,
                "index_price": 0.2884326464,
                "norm_price": 4.5667551967
            },
            {
                "index": 267,
                "date": "2021-01-21",
                "press_title": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents",
                "release_url": "http://lilly.mediaroom.com/2021-01-21-Lillys-neutralizing-antibody-bamlanivimab-LY-CoV555-prevented-COVID-19-at-nursing-homes-in-the-BLAZE-2-trial-reducing-risk-by-up-to-80-percent-for-residents",
                "content": "Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The...",
                "1d_change": 1.1836685151,
                "index_price": -0.4162466544,
                "norm_price": 1.5999151696
            },
            {
                "index": 268,
                "date": "2021-01-19",
                "press_title": "Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies",
                "release_url": "http://lilly.mediaroom.com/2021-01-19-Lilly-and-Merus-NV-Announce-Collaboration-to-Discover-Novel-T-Cell-Re-Directing-Bispecific-Antibodies",
                "content": "Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific...",
                "1d_change": 2.6135294876,
                "index_price": 1.8165352511,
                "norm_price": 0.7969942365
            },
            {
                "index": 269,
                "date": "2021-01-15",
                "press_title": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2021-01-15-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2020-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021. Lilly will also conduct a conference call on that day with the...",
                "1d_change": 5.8847206455,
                "index_price": 0.2679698091,
                "norm_price": 5.6167508364
            },
            {
                "index": 270,
                "date": "2021-01-15",
                "press_title": "Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund",
                "release_url": "http://lilly.mediaroom.com/2021-01-15-Lilly-Announces-30-Million-Limited-Partner-Investment-in-Unseen-Capital-Health-Fund",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced a $30 million limited partner investment in Unseen Capital Health Fund LP, a newly-formed venture fund created by racially diverse and...",
                "1d_change": 5.8847206455,
                "index_price": 0.2679698091,
                "norm_price": 5.6167508364
            },
            {
                "index": 271,
                "date": "2021-01-14",
                "press_title": "Gabrielle Sulzberger Elected to Lilly Board of Directors",
                "release_url": "http://lilly.mediaroom.com/2021-01-14-Gabrielle-Sulzberger-Elected-to-Lilly-Board-of-Directors",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Gabrielle Sulzberger as a new member, effective January 25, 2021. As a member of Lilly's board, she will serve on both the...",
                "1d_change": 2.8830388308,
                "index_price": -1.2400976705,
                "norm_price": 4.1231365013
            },
            {
                "index": 272,
                "date": "2021-01-11",
                "press_title": "US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction",
                "release_url": "http://lilly.mediaroom.com/2021-01-11-US-FDA-accepts-supplemental-New-Drug-Application-for-Jardiance-R-empagliflozin-for-adults-with-heart-failure-with-reduced-ejection-fraction",
                "content": "error_http",
                "1d_change": -3.4675616107,
                "index_price": -0.0512984408,
                "norm_price": -3.4162631699
            },
            {
                "index": 273,
                "date": "2021-01-11",
                "press_title": "Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial",
                "release_url": "http://lilly.mediaroom.com/2021-01-11-Lillys-Donanemab-Slows-Clinical-Decline-of-Alzheimers-Disease-in-Positive-Phase-2-Trial",
                "content": "Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in...",
                "1d_change": -3.4675616107,
                "index_price": -0.0512984408,
                "norm_price": -3.4162631699
            },
            {
                "index": 274,
                "date": "2021-01-04",
                "press_title": "Lilly to Participate in J.P. Morgan Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2021-01-04-Lilly-to-Participate-in-J-P-Morgan-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. David A. Ricks, Lilly's chairman and chief executive officer,...",
                "1d_change": -1.6233694174,
                "index_price": -1.0129170109,
                "norm_price": -0.6104524065
            },
            {
                "index": 275,
                "date": "2020-12-18",
                "press_title": "Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico",
                "release_url": "http://lilly.mediaroom.com/2020-12-18-Lilly-to-begin-pragmatic-study-of-neutralizing-antibody-bamlanivimab-LY-CoV555-for-COVID-19-in-New-Mexico",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local...",
                "1d_change": -2.2159114379,
                "index_price": -0.7434523964,
                "norm_price": -1.4724590415
            },
            {
                "index": 276,
                "date": "2020-12-15",
                "press_title": "Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance",
                "release_url": "http://lilly.mediaroom.com/2020-12-15-Lilly-Announces-2021-Financial-Guidance-Updates-2020-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced its 2021 financial guidance, highlighted by volume-based revenue growth, increased investment in research and development, operating margin...",
                "1d_change": 7.3350873606,
                "index_price": 0.9391627647,
                "norm_price": 6.3959245959
            },
            {
                "index": 277,
                "date": "2020-12-15",
                "press_title": "Lilly Announces Agreement to Acquire Prevail Therapeutics",
                "release_url": "http://lilly.mediaroom.com/2020-12-15-Lilly-Announces-Agreement-to-Acquire-Prevail-Therapeutics",
                "content": "Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of...",
                "1d_change": 7.3350873606,
                "index_price": 0.9391627647,
                "norm_price": 6.3959245959
            },
            {
                "index": 278,
                "date": "2020-12-14",
                "press_title": "Lilly Announces 15 Percent Dividend Increase",
                "release_url": "http://lilly.mediaroom.com/2020-12-14-Lilly-Announces-15-Percent-Dividend-Increase",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter of 2021 will be $0.85 per share on...",
                "1d_change": 4.0255695355,
                "index_price": 0.5237371379,
                "norm_price": 3.5018323976
            },
            {
                "index": 279,
                "date": "2020-12-14",
                "press_title": "Lilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study",
                "release_url": "http://lilly.mediaroom.com/2020-12-14-Lilly-announces-opening-of-patient-enrollment-for-New-IDEAS-Imaging-Dementia-Evidence-for-Amyloid-Scanning-study",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that qualified physicians may now enroll patients in the study New IDEAS: Imaging Dementia—Evidence for Amyloid Scanning at New IDEAS-Study.org....",
                "1d_change": 4.0255695355,
                "index_price": 0.5237371379,
                "norm_price": 3.5018323976
            },
            {
                "index": 280,
                "date": "2020-12-11",
                "press_title": "Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine",
                "release_url": "http://lilly.mediaroom.com/2020-12-11-Data-from-ACTT-2-Trial-of-Baricitinib-in-Hospitalized-COVID-19-Patients-Supportive-of-the-EUA-Published-in-New-England-Journal-of-Medicine",
                "content": "error_http",
                "1d_change": -1.1462243035,
                "index_price": -0.2355068256,
                "norm_price": -0.9107174778
            },
            {
                "index": 281,
                "date": "2020-12-09",
                "press_title": "Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio®",
                "release_url": "http://lilly.mediaroom.com/2020-12-09-Lilly-Presents-Positive-Primary-Outcome-Data-from-monarchE-that-Builds-on-Previous-Definitive-Analysis-for-Verzenio-R",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced additional data from a pre-planned primary outcome analysis from the Phase 3 monarchE trial that showed Verzenio® (abemaciclib) in combination...",
                "1d_change": 3.9813577055,
                "index_price": -1.032684,
                "norm_price": 5.0140417055
            },
            {
                "index": 282,
                "date": "2020-12-09",
                "press_title": "Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2020-12-09-Lillys-tirzepatide-significantly-reduced-A1C-and-body-weight-in-people-with-type-2-diabetes",
                "content": "Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company's (NYSE: LLY)...",
                "1d_change": 3.9813577055,
                "index_price": -1.032684,
                "norm_price": 5.0140417055
            },
            {
                "index": 283,
                "date": "2020-12-08",
                "press_title": "Lilly Confirms Date and Conference Call for 2021 Financial Guidance Announcement",
                "release_url": "http://lilly.mediaroom.com/2020-12-08-Lilly-Confirms-Date-and-Conference-Call-for-2021-Financial-Guidance-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2021 on Tuesday, December 15, 2020. Lilly will also conduct a conference call on that day with the investment community...",
                "1d_change": 6.9747039384,
                "index_price": -0.2785320347,
                "norm_price": 7.2532359731
            },
            {
                "index": 284,
                "date": "2020-12-07",
                "press_title": "Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2020-12-07-Loxo-Oncology-at-Lilly-Announces-Updated-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-for-LOXO-305-in-Chronic-Lymphocytic-Leukemia-and-Small-Lymphocytic-Lymphoma-at-the-American-Society-of-Hematology-Annual-Meeting",
                "content": "Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced clinical data from the LOXO-305 global Phase 1/2 BRUIN clinical trial in chronic...",
                "1d_change": 1.3395598241,
                "index_price": 0.203120252,
                "norm_price": 1.1364395721
            },
            {
                "index": 285,
                "date": "2020-12-05",
                "press_title": "Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2020-12-05-Loxo-Oncology-at-Lilly-Announces-Updated-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-for-LOXO-305-in-Mantle-Cell-Lymphoma-and-Non-Hodgkin-Lymphomas-at-the-American-Society-of-Hematology-ASH-Annual-Meeting",
                "content": "Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced clinical data from the LOXO-305 global Phase 1/2 BRUIN clinical trial in mantle cell...",
                "1d_change": 1.3395598241,
                "index_price": 0.203120252,
                "norm_price": 1.1364395721
            },
            {
                "index": 286,
                "date": "2020-12-04",
                "press_title": "Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19",
                "release_url": "http://lilly.mediaroom.com/2020-12-04-Lilly-and-UnitedHealth-Group-partner-on-pragmatic-study-of-neutralizing-antibody-bamlanivimab-LY-CoV555-for-COVID-19",
                "content": "error_http",
                "1d_change": 2.272417908,
                "index_price": 0.5693458151,
                "norm_price": 1.7030720929
            },
            {
                "index": 287,
                "date": "2020-12-02",
                "press_title": "Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19",
                "release_url": "http://lilly.mediaroom.com/2020-12-02-Lilly-announces-650-000-additional-doses-of-neutralizing-antibody-bamlanivimab-LY-CoV555-purchased-by-U-S-government-to-treat-COVID-19",
                "content": "The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY) neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. The purchase agreement is for $812.5...",
                "1d_change": -0.8673917587,
                "index_price": 0.3529023626,
                "norm_price": -1.2202941213
            },
            {
                "index": 288,
                "date": "2020-11-24",
                "press_title": "Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference",
                "release_url": "http://lilly.mediaroom.com/2020-11-24-Lilly-to-Participate-in-Evercore-ISI-3rd-Annual-HealthCONx-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020. Michael Mason, Lilly senior vice president and president of...",
                "1d_change": 0.9395316129,
                "index_price": 0.9678587125,
                "norm_price": -0.0283270996
            },
            {
                "index": 289,
                "date": "2020-11-20",
                "press_title": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19",
                "release_url": "http://lilly.mediaroom.com/2020-11-20-Lillys-neutralizing-antibody-bamlanivimab-LY-CoV555-receives-interim-authorization-from-Health-Canada-as-a-treatment-for-COVID-19",
                "content": "Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab (LY-CoV555)...",
                "1d_change": 0.376649622,
                "index_price": -0.0480762374,
                "norm_price": 0.4247258594
            },
            {
                "index": 290,
                "date": "2020-11-20",
                "press_title": "Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement",
                "release_url": "http://lilly.mediaroom.com/2020-11-20-Lilly-and-Precision-BioSciences-Announce-Genome-Editing-Research-Collaboration-and-License-Agreement",
                "content": "Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS®...",
                "1d_change": 0.376649622,
                "index_price": -0.0480762374,
                "norm_price": 0.4247258594
            },
            {
                "index": 291,
                "date": "2020-11-19",
                "press_title": "Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19",
                "release_url": "http://lilly.mediaroom.com/2020-11-19-Baricitinib-Receives-Emergency-Use-Authorization-from-the-FDA-for-the-Treatment-of-Hospitalized-Patients-with-COVID-19",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the distribution and...",
                "1d_change": 3.6015983479,
                "index_price": -0.0525608433,
                "norm_price": 3.6541591912
            },
            {
                "index": 292,
                "date": "2020-11-19",
                "press_title": "Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes",
                "release_url": "http://lilly.mediaroom.com/2020-11-19-Lilly-and-Ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-with-diabetes",
                "content": "Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly's connected diabetes...",
                "1d_change": 3.6015983479,
                "index_price": -0.0525608433,
                "norm_price": 3.6541591912
            },
            {
                "index": 293,
                "date": "2020-11-18",
                "press_title": "Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial",
                "release_url": "http://lilly.mediaroom.com/2020-11-18-Jardiance-R-reduced-the-risk-of-first-plus-recurrent-cardiovascular-events-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease-in-new-analysis-from-the-EMPA-REG-OUTCOME-R-trial",
                "content": "Jardiance® (empagliflozin) reduced the risk of total (first plus recurrent) cardiovascular events compared with placebo, when both were given on top of standard of care, in adults with type 2...",
                "1d_change": 1.0529581711,
                "index_price": -0.8436925325,
                "norm_price": 1.8966507036
            },
            {
                "index": 294,
                "date": "2020-11-12",
                "press_title": "Lilly to Participate in Wolfe Research Virtual Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2020-11-12-Lilly-to-Participate-in-Wolfe-Research-Virtual-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Wednesday, November 18, 2020. Joshua Smiley, senior vice president and Lilly's chief...",
                "1d_change": -0.3862975242,
                "index_price": 0.6270304194,
                "norm_price": -1.0133279436
            },
            {
                "index": 295,
                "date": "2020-11-12",
                "press_title": "Lilly to Participate in Bernstein Operational Decisions Conference",
                "release_url": "http://lilly.mediaroom.com/2020-11-12-Lilly-to-Participate-in-Bernstein-Operational-Decisions-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Bernstein Operational Decisions Conference on Monday, November 16, 2020. Andrew Adams, Ph.D., vice president of new therapeutic modalities...",
                "1d_change": -0.3862975242,
                "index_price": 0.6270304194,
                "norm_price": -1.0133279436
            },
            {
                "index": 296,
                "date": "2020-11-11",
                "press_title": "Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program",
                "release_url": "http://lilly.mediaroom.com/2020-11-11-Lilly-Announces-Webcast-to-Provide-an-Overview-of-Tirzepatide-Phase-3-clinical-program",
                "content": "Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Friday, November 20, 2020 to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in preparation for...",
                "1d_change": -4.2364260374,
                "index_price": -0.7410202647,
                "norm_price": -3.4954057727
            },
            {
                "index": 297,
                "date": "2020-11-09",
                "press_title": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19",
                "release_url": "http://lilly.mediaroom.com/2020-11-09-Lillys-neutralizing-antibody-bamlanivimab-LY-CoV555-receives-FDA-emergency-use-authorization-for-the-treatment-of-recently-diagnosed-COVID-19",
                "content": "The U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlanivimab (LY-CoV555)...",
                "1d_change": 2.7428988719,
                "index_price": -1.0579521103,
                "norm_price": 3.8008509821
            },
            {
                "index": 298,
                "date": "2020-11-05",
                "press_title": "Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2020-11-05-Loxo-Oncology-at-Lilly-Announces-Details-of-LOXO-305-Presentations-at-the-2020-American-Society-of-Hematology-ASH-Annual-Meeting",
                "content": "Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the LOXO-305 development program at...",
                "1d_change": -3.4608225609,
                "index_price": 0.6753200387,
                "norm_price": -4.1361425996
            },
            {
                "index": 299,
                "date": "2020-11-05",
                "press_title": "Aarti Shah to Retire as Lilly Chief Information and Digital Officer",
                "release_url": "http://lilly.mediaroom.com/2020-11-05-Aarti-Shah-to-Retire-as-Lilly-Chief-Information-and-Digital-Officer",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Aarti Shah, Ph.D., senior vice president and chief information and digital officer, will retire in the first half of 2021 after 27 years of...",
                "1d_change": -3.4608225609,
                "index_price": 0.6753200387,
                "norm_price": -4.1361425996
            },
            {
                "index": 300,
                "date": "2020-11-02",
                "press_title": "ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis",
                "release_url": "http://lilly.mediaroom.com/2020-11-02-ACR-2020-Lilly-and-Incyte-Highlight-Positive-Data-for-Olumiant-R-in-Rheumatoid-Arthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today positive data for Olumiant® (baricitinib) will be presented at ACR Convergence 2020, the American College of...",
                "1d_change": -1.1910224447,
                "index_price": 2.165523835,
                "norm_price": -3.3565462798
            },
            {
                "index": 301,
                "date": "2020-10-31",
                "press_title": "EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis",
                "release_url": "http://lilly.mediaroom.com/2020-10-31-EADV-2020-Lilly-and-Incyte-Showcase-New-Data-for-Baricitinib-for-the-Treatment-of-Moderate-to-Severe-Atopic-Dermatitis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib will be presented at the 29th annual European Academy of Dermatology and Venereology (EADV)...",
                "1d_change": -1.1910224447,
                "index_price": 2.165523835,
                "norm_price": -3.3565462798
            },
            {
                "index": 302,
                "date": "2020-10-30",
                "press_title": "Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata",
                "release_url": "http://lilly.mediaroom.com/2020-10-30-Fall-Clinical-Dermatology-2020-Lilly-and-Incyte-Showcase-Positive-New-Data-for-Baricitinib-in-Adult-Patients-with-Alopecia-Areata",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT®) will be presented at the annual Fall Clinical Dermatology meeting...",
                "1d_change": -0.0987677337,
                "index_price": 0.5029817292,
                "norm_price": -0.6017494629
            },
            {
                "index": 303,
                "date": "2020-10-29",
                "press_title": "New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis",
                "release_url": "http://lilly.mediaroom.com/2020-10-29-New-Data-at-EADV-2020-Confirm-Taltz-R-ixekizumab-Demonstrates-Sustained-Long-Term-Efficacy-in-Patients-with-Psoriasis-and-Psoriatic-Arthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today it will share new Taltz® (ixekizumab) data from multiple long-term and post-hoc analyses that indicate sustained efficacy in patients with...",
                "1d_change": -1.1804094774,
                "index_price": -0.2204908018,
                "norm_price": -0.9599186755
            },
            {
                "index": 304,
                "date": "2020-10-28",
                "press_title": "Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine",
                "release_url": "http://lilly.mediaroom.com/2020-10-28-Data-for-Lillys-bamlanivimab-LY-CoV555-in-COVID-19-outpatients-published-in-New-England-Journal-of-Medicine",
                "content": "The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab...",
                "1d_change": 1.5767471781,
                "index_price": -0.9779092537,
                "norm_price": 2.5546564318
            },
            {
                "index": 305,
                "date": "2020-10-28",
                "press_title": "Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19",
                "release_url": "http://lilly.mediaroom.com/2020-10-28-Lilly-announces-agreement-with-U-S-government-to-supply-300-000-vials-of-investigational-neutralizing-antibody-bamlanivimab-LY-CoV555-in-an-effort-to-fight-COVID-19",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing...",
                "1d_change": 1.5767471781,
                "index_price": -0.9779092537,
                "norm_price": 2.5546564318
            },
            {
                "index": 306,
                "date": "2020-10-27",
                "press_title": "Lilly Reports Third-Quarter Financial Results, Updates Guidance",
                "release_url": "http://lilly.mediaroom.com/2020-10-27-Lilly-Reports-Third-Quarter-Financial-Results-Updates-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2020. $ in millions, except per share data Third Quarter % 2020 2019 Change Revenue $ 5,740.6 $ 5,476.6...",
                "1d_change": -1.3022441895,
                "index_price": -4.0390908021,
                "norm_price": 2.7368466126
            },
            {
                "index": 307,
                "date": "2020-10-23",
                "press_title": "New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status",
                "release_url": "http://lilly.mediaroom.com/2020-10-23-New-Jardiance-R-findings-showed-improved-cardio-renal-outcomes-in-adults-with-heart-failure-with-reduced-ejection-fraction-regardless-of-chronic-kidney-disease-status",
                "content": "Findings from a new exploratory sub-analysis of the EMPEROR-Reduced phase III trial showed that Jardiance® (empagliflozin) reduced the risk of adverse cardiovascular and kidney events in adults...",
                "1d_change": -0.3810929019,
                "index_price": -1.87975584,
                "norm_price": 1.498662938
            },
            {
                "index": 308,
                "date": "2020-10-19",
                "press_title": "Lilly Declares Fourth-Quarter 2020 Dividend",
                "release_url": "http://lilly.mediaroom.com/2020-10-19-Lilly-Declares-Fourth-Quarter-2020-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable December...",
                "1d_change": -2.3748464997,
                "index_price": -1.4678487303,
                "norm_price": -0.9069977694
            },
            {
                "index": 309,
                "date": "2020-10-15",
                "press_title": "Lilly Announces Agreement to Acquire Disarm Therapeutics",
                "release_url": "http://lilly.mediaroom.com/2020-10-15-Lilly-Announces-Agreement-to-Acquire-Disarm-Therapeutics",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying...",
                "1d_change": -0.2669049774,
                "index_price": 0.8637120677,
                "norm_price": -1.130617045
            },
            {
                "index": 310,
                "date": "2020-10-12",
                "press_title": "Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial",
                "release_url": "http://lilly.mediaroom.com/2020-10-12-Mirikizumab-Shows-Continued-Symptom-Improvement-and-Reduction-of-Intestinal-Inflammation-in-Patients-with-Crohns-Disease-in-52-Week-Phase-2-Trial",
                "content": "Eli Lilly and Company (NYSE:LLY) announced today new efficacy and safety data from the Phase 2 SERENITY study evaluating mirikizumab in patients with moderately to severely active Crohn's disease,...",
                "1d_change": -4.4976221773,
                "index_price": 0.3391272702,
                "norm_price": -4.8367494475
            },
            {
                "index": 311,
                "date": "2020-10-09",
                "press_title": "Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment",
                "release_url": "http://lilly.mediaroom.com/2020-10-09-Lillys-OVERCOME-Study-Reveals-Nearly-80-of-People-Reported-Improvement-in-Their-Migraine-Since-Starting-a-CGRP-Monoclonal-Antibody-for-Preventive-Treatment",
                "content": "Nearly 80% of people taking calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) for the preventive treatment of migraine reported their migraine as \"better\" overall since starting...",
                "1d_change": 0.258944319,
                "index_price": 2.1093777254,
                "norm_price": -1.8504334064
            },
            {
                "index": 312,
                "date": "2020-10-08",
                "press_title": "Lilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2020-10-08-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2020-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2020 financial results on Tuesday, October 27, 2020. Lilly will also conduct a conference call on that day with the investment...",
                "1d_change": 2.8556733275,
                "index_price": 1.2326183187,
                "norm_price": 1.6230550089
            },
            {
                "index": 313,
                "date": "2020-10-08",
                "press_title": "Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen",
                "release_url": "http://lilly.mediaroom.com/2020-10-08-Baricitinib-has-Significant-Effect-on-Recovery-Time-Most-Impactful-in-COVID-19-Patients-Requiring-Oxygen",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes...",
                "1d_change": 2.8556733275,
                "index_price": 1.2326183187,
                "norm_price": 1.6230550089
            },
            {
                "index": 314,
                "date": "2020-10-08",
                "press_title": "Indy Racial Equity Pledge Launches to Drive Accountability, Action and Progress on Racial Equity",
                "release_url": "http://lilly.mediaroom.com/2020-10-08-Indy-Racial-Equity-Pledge-Launches-to-Drive-Accountability-Action-and-Progress-on-Racial-Equity",
                "content": "A local coalition of corporate and civic organizations has launched the Indy Racial Equity Pledge to hold their organizations accountable for driving measurable progress in advancing racial equity...",
                "1d_change": 2.8556733275,
                "index_price": 1.2326183187,
                "norm_price": 1.6230550089
            },
            {
                "index": 315,
                "date": "2020-10-08",
                "press_title": "Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries",
                "release_url": "http://lilly.mediaroom.com/2020-10-08-Lilly-Announces-Arrangement-for-Supply-of-Potential-COVID-19-Antibody-Therapy-for-Low-and-Middle-Income-Countries",
                "content": "Eli Lilly and Company (NYSE: LLY) and the Bill & Melinda Gates Foundation, as part of the COVID-19 Therapeutics Accelerator, have entered into an agreement to facilitate access to future Lilly...",
                "1d_change": 2.8556733275,
                "index_price": 1.2326183187,
                "norm_price": 1.6230550089
            },
            {
                "index": 316,
                "date": "2020-10-07",
                "press_title": "Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs",
                "release_url": "http://lilly.mediaroom.com/2020-10-07-Lilly-provides-comprehensive-update-on-progress-of-SARS-CoV-2-neutralizing-antibody-programs",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed...",
                "1d_change": 3.2443217776,
                "index_price": 1.8065880278,
                "norm_price": 1.4377337498
            },
            {
                "index": 317,
                "date": "2020-10-07",
                "press_title": "Lilly and Dexcom team up on new program to help improve diabetes management",
                "release_url": "http://lilly.mediaroom.com/2020-10-07-Lilly-and-Dexcom-team-up-on-new-program-to-help-improve-diabetes-management",
                "content": "Eli Lilly and Company (NYSE: LLY) and DexCom, Inc. (NASDAQ: DXCM) announced today a joint program for U.S. healthcare providers (HCPs) about Lilly's new rapid-acting mealtime insulin Lyumjev™...",
                "1d_change": 3.2443217776,
                "index_price": 1.8065880278,
                "norm_price": 1.4377337498
            },
            {
                "index": 318,
                "date": "2020-10-06",
                "press_title": "REYVOW® (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study",
                "release_url": "http://lilly.mediaroom.com/2020-10-06-REYVOW-R-lasmiditan-C-V-Demonstrated-Superior-Pain-Freedom-At-2-Hours-in-At-Least-2-of-3-Migraine-Attacks-in-New-Phase-3-Consistency-of-Effect-Study",
                "content": "Adults who took REYVOW® (lasmiditan) C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 7.2 times greater odds, respectively, of achieving superior pain freedom at 2 hours...",
                "1d_change": 1.3627898969,
                "index_price": 0.3129153123,
                "norm_price": 1.0498745846
            },
            {
                "index": 319,
                "date": "2020-09-20",
                "press_title": "Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer",
                "release_url": "http://lilly.mediaroom.com/2020-09-20-Verzenio-R-Significantly-Reduced-the-Risk-of-Cancer-Recurrence-by-25-for-People-with-HR-HER2-High-Risk-Early-Breast-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence...",
                "1d_change": -2.2087289671,
                "index_price": 0.9048217767,
                "norm_price": -3.1135507438
            },
            {
                "index": 320,
                "date": "2020-09-18",
                "press_title": "CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis",
                "release_url": "http://lilly.mediaroom.com/2020-09-18-CHMP-Recommends-Approval-of-Lillys-Baricitinib-for-the-Treatment-of-Adults-with-Moderate-to-Severe-Atopic-Dermatitis",
                "content": "Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive...",
                "1d_change": -0.568863122,
                "index_price": -2.3260721491,
                "norm_price": 1.7572090271
            },
            {
                "index": 321,
                "date": "2020-09-17",
                "press_title": "Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies",
                "release_url": "http://lilly.mediaroom.com/2020-09-17-Lilly-and-Amgen-Announce-Manufacturing-Collaboration-for-COVID-19-Antibody-Therapies",
                "content": "Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly's potential...",
                "1d_change": 2.6204737509,
                "index_price": -0.8251358488,
                "norm_price": 3.4456095997
            },
            {
                "index": 322,
                "date": "2020-09-16",
                "press_title": "Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting",
                "release_url": "http://lilly.mediaroom.com/2020-09-16-Lilly-announces-proof-of-concept-data-for-neutralizing-antibody-LY-CoV555-in-the-COVID-19-outpatient-setting",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization for patients treated with...",
                "1d_change": 0.4919033874,
                "index_price": -1.6151268702,
                "norm_price": 2.1070302576
            },
            {
                "index": 323,
                "date": "2020-09-15",
                "press_title": "Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care",
                "release_url": "http://lilly.mediaroom.com/2020-09-15-Lilly-Launches-Digital-Health-Open-Innovation-Challenge-to-Help-Transform-Atopic-Dermatitis-Care",
                "content": "Eli Lilly and Company (NYSE: LLY) has launched an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions that can help make life...",
                "1d_change": 0.6624429356,
                "index_price": -0.6569208681,
                "norm_price": 1.3193638037
            },
            {
                "index": 324,
                "date": "2020-09-15",
                "press_title": "US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack",
                "release_url": "http://lilly.mediaroom.com/2020-09-15-US-FDA-grants-Fast-Track-designation-to-Jardiance-R-empagliflozin-to-improve-outcomes-following-a-heart-attack",
                "content": "The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of Jardiance® (empagliflozin) to prevent hospitalization for heart failure and reduce the risk...",
                "1d_change": 0.6624429356,
                "index_price": -0.6569208681,
                "norm_price": 1.3193638037
            },
            {
                "index": 325,
                "date": "2020-09-14",
                "press_title": "Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial",
                "release_url": "http://lilly.mediaroom.com/2020-09-14-Baricitinib-in-Combination-with-Remdesivir-Reduces-Time-to-Recovery-in-Hospitalized-Patients-with-COVID-19-in-NIAID-Sponsored-ACTT-2-Trial",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy...",
                "1d_change": 0.6596415869,
                "index_price": 1.1066650923,
                "norm_price": -0.4470235054
            },
            {
                "index": 326,
                "date": "2020-09-11",
                "press_title": "Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2020-09-11-Lilly-to-Participate-in-Cantor-Fitzgerald-Virtual-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020. Joshua Smiley, senior vice president and Lilly's...",
                "1d_change": 0.96644231,
                "index_price": 0.9114740046,
                "norm_price": 0.0549683054
            },
            {
                "index": 327,
                "date": "2020-09-11",
                "press_title": "Lilly to Participate in Morgan Stanley Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2020-09-11-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2020. Joshua Smiley, senior vice president and Lilly's chief...",
                "1d_change": 0.96644231,
                "index_price": 0.9114740046,
                "norm_price": 0.0549683054
            },
            {
                "index": 328,
                "date": "2020-09-11",
                "press_title": "REYVOW® (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study",
                "release_url": "http://lilly.mediaroom.com/2020-09-11-REYVOW-TM-lasmiditan-C-V-Demonstrated-Pain-Freedom-from-Migraine-Attacks-At-60-Minutes-and-Up-to-48-Hours-in-New-Phase-3-Study",
                "content": "Adults who took REYVOW™ (lasmiditan) C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 4.6 times greater odds, respectively, of achieving pain freedom at 2 hours compared...",
                "1d_change": 0.96644231,
                "index_price": 0.9114740046,
                "norm_price": 0.0549683054
            },
            {
                "index": 329,
                "date": "2020-09-10",
                "press_title": "Lilly Announces Webcast to Discuss ESMO 2020 Presentations",
                "release_url": "http://lilly.mediaroom.com/2020-09-10-Lilly-Announces-Webcast-to-Discuss-ESMO-2020-Presentations",
                "content": "Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 21, 2020 to discuss the company's presentations at the 2020 European Society for Medical Oncology (ESMO) Virtual...",
                "1d_change": -1.2087228959,
                "index_price": -2.1427935156,
                "norm_price": 0.9340706197
            },
            {
                "index": 330,
                "date": "2020-09-10",
                "press_title": "Lilly commits Insulin Value Program, featuring $35 copay card, to suite of affordability solutions for people with diabetes",
                "release_url": "http://lilly.mediaroom.com/2020-09-10-Lilly-commits-Insulin-Value-Program-featuring-35-copay-card-to-suite-of-affordability-solutions-for-people-with-diabetes",
                "content": "Eli Lilly and Company (NYSE: LLY), which introduced the Lilly Insulin Value Program $35 copay card in April 2020 to help people struggling financially during the COVID-19 crisis, today announced...",
                "1d_change": -1.2087228959,
                "index_price": -2.1427935156,
                "norm_price": 0.9340706197
            },
            {
                "index": 331,
                "date": "2020-09-10",
                "press_title": "Lilly Oncology to Showcase New Data from Robust Cancer Research Pipeline at ESMO Virtual Congress 2020",
                "release_url": "http://lilly.mediaroom.com/2020-09-10-Lilly-Oncology-to-Showcase-New-Data-from-Robust-Cancer-Research-Pipeline-at-ESMO-Virtual-Congress-2020",
                "content": "Data from 20 studies across Eli Lilly and Company's (NYSE: LLY) oncology product portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress, September 19-21,...",
                "1d_change": -1.2087228959,
                "index_price": -2.1427935156,
                "norm_price": 0.9340706197
            },
            {
                "index": 332,
                "date": "2020-09-09",
                "press_title": "Lilly Announces Leadership Changes",
                "release_url": "http://lilly.mediaroom.com/2020-09-09-Lilly-Announces-Leadership-Changes",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Patrik Jonsson, senior vice president and president of Lilly Bio-Medicines, is being named to the new role of senior vice president,...",
                "1d_change": -3.0091603925,
                "index_price": -0.9172921424,
                "norm_price": -2.0918682501
            },
            {
                "index": 333,
                "date": "2020-09-03",
                "press_title": "FDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2020-09-03-FDA-approves-additional-doses-of-Trulicity-R-dulaglutide-for-the-treatment-of-type-2-diabetes",
                "content": "The U.S. Food and Drug Administration (FDA) today approved two additional doses of Eli Lilly and Company's (NYSE: LLY) Trulicity® (dulaglutide). The approval expands the label of once-weekly...",
                "1d_change": -0.8481705535,
                "index_price": -4.0204738563,
                "norm_price": 3.1723033029
            },
            {
                "index": 334,
                "date": "2020-08-29",
                "press_title": "Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction",
                "release_url": "http://lilly.mediaroom.com/2020-08-29-Jardiance-R-reduced-the-combined-relative-risk-of-cardiovascular-death-and-hospitalization-for-heart-failure-by-25-in-adults-with-and-without-diabetes-who-had-heart-failure-with-reduced-ejection-fraction",
                "content": "Full results from the EMPEROR-Reduced phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, showed that Jardiance® (empagliflozin) was associated...",
                "1d_change": -0.0339404842,
                "index_price": 0.4797732223,
                "norm_price": -0.5137137065
            },
            {
                "index": 335,
                "date": "2020-08-27",
                "press_title": "New England Journal of Medicine Publishes Phase 1/2 Data for Retevmo™ (selpercatinib) in Advanced RET-Driven Lung and Thyroid Cancers",
                "release_url": "http://lilly.mediaroom.com/2020-08-27-New-England-Journal-of-Medicine-Publishes-Phase-1-2-Data-for-Retevmo-TM-selpercatinib-in-Advanced-RET-Driven-Lung-and-Thyroid-Cancers",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine (NEJM) published Phase 1/2 study results of the registrational trial for Retevmo™ (selpercatinib), the...",
                "1d_change": -2.1989828281,
                "index_price": 0.6519399068,
                "norm_price": -2.8509227349
            },
            {
                "index": 336,
                "date": "2020-08-18",
                "press_title": "Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement",
                "release_url": "http://lilly.mediaroom.com/2020-08-18-Lilly-and-Innovent-Announce-Global-Expansion-of-TYVYT-Licensing-Agreement",
                "content": "Eli Lilly and Company (NYSE: LLY) and Innovent Biologics, Inc. (HKEX: 01801) today announced a global expansion of their strategic alliance for TYVYT® (sintilimab injection), an anti-PD-1...",
                "1d_change": 0.0919194336,
                "index_price": -0.3611994919,
                "norm_price": 0.4531189255
            },
            {
                "index": 337,
                "date": "2020-08-03",
                "press_title": "Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)",
                "release_url": "http://lilly.mediaroom.com/2020-08-03-Lilly-Initiates-Phase-3-Trial-of-LY-CoV555-for-Prevention-of-COVID-19-at-Long-Term-Care-Facilities-in-Partnership-with-the-National-Institute-of-Allergy-and-Infectious-Diseases-NIAID",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the initiation of BLAZE-2, a Phase 3 trial studying LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at...",
                "1d_change": 1.3238625526,
                "index_price": 0.5519414714,
                "norm_price": 0.7719210812
            },
            {
                "index": 338,
                "date": "2020-07-30",
                "press_title": "Lilly Reports Second-Quarter Financial Results, Raises EPS Guidance",
                "release_url": "http://lilly.mediaroom.com/2020-07-30-Lilly-Reports-Second-Quarter-Financial-Results-Raises-EPS-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2020. $ in millions, except per share data Second Quarter % 2020 2019 Change Revenue $ 5,499.4 $...",
                "1d_change": -5.4294789261,
                "index_price": 1.2032608407,
                "norm_price": -6.6327397668
            },
            {
                "index": 339,
                "date": "2020-07-30",
                "press_title": "Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes",
                "release_url": "http://lilly.mediaroom.com/2020-07-30-Jardiance-R-meets-primary-endpoint-in-reducing-risk-of-cardiovascular-death-or-hospitalization-for-heart-failure-in-phase-III-trial-in-adults-with-and-without-diabetes",
                "content": "Positive top-line results from the EMPEROR-Reduced phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, were announced today by Boehringer...",
                "1d_change": -5.4294789261,
                "index_price": 1.2032608407,
                "norm_price": -6.6327397668
            },
            {
                "index": 340,
                "date": "2020-07-28",
                "press_title": "Lilly's P-tau217 Blood Test Shows High Accuracy in Diagnosis of Alzheimer's Disease in Data Published in JAMA",
                "release_url": "http://lilly.mediaroom.com/2020-07-28-Lillys-P-tau217-Blood-Test-Shows-High-Accuracy-in-Diagnosis-of-Alzheimers-Disease-in-Data-Published-in-JAMA",
                "content": "A new study on Lilly's blood test for Alzheimer's disease (AD), P-tau217 (phosphorylated tau at threonine-217), was published today in JAMA. The results showed that P-tau217 distinguished AD from...",
                "1d_change": 0.0494665501,
                "index_price": 0.7417636142,
                "norm_price": -0.6922970641
            },
            {
                "index": 341,
                "date": "2020-07-21",
                "press_title": "Data from Lilly at Alzheimer's Association International Conference 2020® (AAIC® 2020) to Showcase Clinical Advances in Alzheimer's Research",
                "release_url": "http://lilly.mediaroom.com/2020-07-21-Data-from-Lilly-at-Alzheimers-Association-International-Conference-2020-R-AAIC-R-2020-to-Showcase-Clinical-Advances-in-Alzheimers-Research",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that new results from 17 research studies will be presented at the upcoming Alzheimer's Association International Conference® 2020 (AAIC® 2020)...",
                "1d_change": -1.2315080705,
                "index_price": 0.2289363299,
                "norm_price": -1.4604444004
            },
            {
                "index": 342,
                "date": "2020-07-17",
                "press_title": "Lilly Confirms Date and Conference Call for Second-Quarter 2020 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2020-07-17-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2020-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2020 financial results on Thursday, July 30, 2020. Lilly will also conduct a conference call on that day with the investment...",
                "1d_change": 0.5986685476,
                "index_price": 0.8496766817,
                "norm_price": -0.2510081341
            },
            {
                "index": 343,
                "date": "2020-07-17",
                "press_title": "Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis",
                "release_url": "http://lilly.mediaroom.com/2020-07-17-Lillys-Mirikizumab-Superior-to-Cosentyx-R-secukinumab-in-a-Phase-3-Study-for-Patients-with-Moderate-to-Severe-Plaque-Psoriasis",
                "content": "Eli Lilly and Company (NYSE:LLY) announced today that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints...",
                "1d_change": 0.5986685476,
                "index_price": 0.8496766817,
                "norm_price": -0.2510081341
            },
            {
                "index": 344,
                "date": "2020-07-15",
                "press_title": "Lilly Declares Third-Quarter 2020 Dividend",
                "release_url": "http://lilly.mediaroom.com/2020-07-15-Lilly-Declares-Third-Quarter-2020-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable September...",
                "1d_change": -0.1151498659,
                "index_price": -0.3237345755,
                "norm_price": 0.2085847096
            },
            {
                "index": 345,
                "date": "2020-06-25",
                "press_title": "Central Indiana Racial Equity Fund Launches with more than $2.2 Million in Initial Commitments",
                "release_url": "http://lilly.mediaroom.com/2020-06-25-Central-Indiana-Racial-Equity-Fund-Launches-with-more-than-2-2-Million-in-Initial-Commitments",
                "content": "INDIANAPOLIS, June 25, 2020 – A coalition of local stakeholders has established the Central Indiana Racial Equity Fund with an initial investment of more than $2.2 million to advance effective...",
                "1d_change": 3.1873800848,
                "index_price": -1.2479037643,
                "norm_price": 4.4352838491
            },
            {
                "index": 346,
                "date": "2020-06-24",
                "press_title": "Lilly launches program about what people with diabetes should “Know Before the Low”",
                "release_url": "http://lilly.mediaroom.com/2020-06-24-Lilly-launches-program-about-what-people-with-diabetes-should-Know-Before-the-Low",
                "content": "INDIANAPOLIS, June 24, 2020 -- About 34 million Americans live with diabetes, and some are at risk of low blood sugar and very low blood sugar emergencies (severe hypoglycemia).[1] That is why Eli...",
                "1d_change": 2.6464236734,
                "index_price": -0.9935887514,
                "norm_price": 3.6400124248
            },
            {
                "index": 347,
                "date": "2020-06-19",
                "press_title": "Full results from EMPERIAL exercise ability trials presented",
                "release_url": "http://lilly.mediaroom.com/2020-06-19-Full-results-from-EMPERIAL-exercise-ability-trials-presented",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to exercise ability and symptom improvement...",
                "1d_change": -1.1093835564,
                "index_price": -0.7194014763,
                "norm_price": -0.3899820801
            },
            {
                "index": 348,
                "date": "2020-06-17",
                "press_title": "Emgality® Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine",
                "release_url": "http://lilly.mediaroom.com/2020-06-17-Emgality-R-Demonstrates-Reduction-in-Frequency-Duration-and-Pain-Severity-in-Patients-with-Episodic-and-Chronic-Migraine",
                "content": "Emgality® (galcanezumab-gnlm) reduces total pain burden in a recent analysis of patients with episodic and chronic migraine. Total pain burden is a patient-centric measure that combines the...",
                "1d_change": -1.9618622715,
                "index_price": -0.6673362887,
                "norm_price": -1.2945259829
            },
            {
                "index": 349,
                "date": "2020-06-16",
                "press_title": "Lilly's OVERCOME Study Reveals Less than 30 Percent of People Living with Migraine Take Recommended Prescription Medications",
                "release_url": "http://lilly.mediaroom.com/2020-06-16-Lillys-OVERCOME-Study-Reveals-Less-than-30-Percent-of-People-Living-with-Migraine-Take-Recommended-Prescription-Medications",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that less than 30 percent of people with migraine are taking a recommended prescription medication, highlighting the need for improvement in...",
                "1d_change": 2.2816716277,
                "index_price": -0.5623917154,
                "norm_price": 2.8440633431
            },
            {
                "index": 350,
                "date": "2020-06-16",
                "press_title": "Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer",
                "release_url": "http://lilly.mediaroom.com/2020-06-16-Verzenio-R-abemaciclib-Significantly-Reduced-the-Risk-of-Cancer-Returning-in-People-with-High-Risk-HR-HER2-Early-Breast-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) has met the primary endpoint of invasive disease-free...",
                "1d_change": 2.2816716277,
                "index_price": -0.5623917154,
                "norm_price": 2.8440633431
            },
            {
                "index": 351,
                "date": "2020-06-15",
                "press_title": "Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients",
                "release_url": "http://lilly.mediaroom.com/2020-06-15-Lilly-Begins-a-Phase-3-Clinical-Trial-with-Baricitinib-for-Hospitalized-COVID-19-Patients",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of...",
                "1d_change": 13.2612612986,
                "index_price": 4.1917081382,
                "norm_price": 9.0695531603
            },
            {
                "index": 352,
                "date": "2020-06-13",
                "press_title": "Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections",
                "release_url": "http://lilly.mediaroom.com/2020-06-13-Once-weekly-Trulicity-R-dulaglutide-demonstrates-significantly-higher-adherence-and-more-persistence-compared-to-once-weekly-semaglutide-and-exenatide-injections",
                "content": "New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people with...",
                "1d_change": 13.2612612986,
                "index_price": 4.1917081382,
                "norm_price": 9.0695531603
            },
            {
                "index": 353,
                "date": "2020-06-13",
                "press_title": "Eli Lilly and Company Foundation Pledges $25 Million to Combat Racial Injustice",
                "release_url": "http://lilly.mediaroom.com/2020-06-13-Eli-Lilly-and-Company-Foundation-Pledges-25-Million-to-Combat-Racial-Injustice",
                "content": "Eli Lilly and Company (NYSE: LLY) and the Lilly Foundation announced today a pledge of $25 million and 25,000 volunteer hours over five years to decrease the burden of racial injustice and its...",
                "1d_change": 13.2612612986,
                "index_price": 4.1917081382,
                "norm_price": 9.0695531603
            },
            {
                "index": 354,
                "date": "2020-06-12",
                "press_title": "Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life",
                "release_url": "http://lilly.mediaroom.com/2020-06-12-Lilly-and-Dermira-Present-New-Lebrikizumab-Phase-2b-Clinical-Data-Showing-Patients-with-Atopic-Dermatitis-Had-Clinically-Meaningful-Improvements-in-Itch-Sleep-and-Quality-of-Life",
                "content": "Eli Lilly and Company (NYSE: LLY) and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from the Phase 2b clinical trial of lebrikizumab in patients with...",
                "1d_change": -2.8405836483,
                "index_price": -0.145110727,
                "norm_price": -2.6954729212
            },
            {
                "index": 355,
                "date": "2020-06-12",
                "press_title": "Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD)",
                "release_url": "http://lilly.mediaroom.com/2020-06-12-Lilly-Highlights-the-Evolution-of-Its-Dermatology-Portfolio-at-Annual-American-Academy-of-Dermatology-Meeting-AAD",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz® (ixekizumab), Olumiant® (baricitinib), mirikizumab and lebrikizumab at the virtual American Academy of...",
                "1d_change": -2.8405836483,
                "index_price": -0.145110727,
                "norm_price": -2.6954729212
            },
            {
                "index": 356,
                "date": "2020-06-12",
                "press_title": "Lilly Partners with Indianapolis Recorder Newspaper, Radio One and WISH-TV for a Day of Solidarity Virtual Event",
                "release_url": "http://lilly.mediaroom.com/2020-06-12-Lilly-Partners-with-Indianapolis-Recorder-Newspaper-Radio-One-and-WISH-TV-for-a-Day-of-Solidarity-Virtual-Event",
                "content": "What: Eli Lilly and Company, Indianapolis Recorder Newspaper, Radio One and WISH-TV invite people and organizations to come together to acknowledge the trauma of racial injustice, understand its...",
                "1d_change": -2.8405836483,
                "index_price": -0.145110727,
                "norm_price": -2.6954729212
            },
            {
                "index": 357,
                "date": "2020-06-09",
                "press_title": "First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial",
                "release_url": "http://lilly.mediaroom.com/2020-06-09-First-patient-dose-delivered-for-Lillys-tirzepatide-cardiovascular-outcomes-trial",
                "content": "The first patient dose has been delivered in SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide, Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1...",
                "1d_change": 0.8278050777,
                "index_price": -0.7266194136,
                "norm_price": 1.5544244913
            },
            {
                "index": 358,
                "date": "2020-06-08",
                "press_title": "Lilly to Participate in Goldman Sachs Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2020-06-08-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020. Joshua Smiley, senior vice president and Lilly's chief...",
                "1d_change": 1.5959277139,
                "index_price": 0.2263673982,
                "norm_price": 1.3695603158
            },
            {
                "index": 359,
                "date": "2020-06-08",
                "press_title": "Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment",
                "release_url": "http://lilly.mediaroom.com/2020-06-08-Lilly-Announces-Start-of-a-Phase-1-Study-for-its-Second-Potential-COVID-19-Antibody-Treatment",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today its partner Junshi Biosciences (HKEX: 1877) has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment...",
                "1d_change": 1.5959277139,
                "index_price": 0.2263673982,
                "norm_price": 1.3695603158
            },
            {
                "index": 360,
                "date": "2020-06-03",
                "press_title": "EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus",
                "release_url": "http://lilly.mediaroom.com/2020-06-03-EULAR-2020-Lilly-Shares-New-Data-for-Olumiant-R-in-Rheumatoid-Arthritis-and-Systemic-Lupus-Erythematosus",
                "content": "Eli Lilly and Company (NYSE: LLY) will present new data for Olumiant® (baricitinib) at the virtual European Congress of Rheumatology (EULAR 2020) taking place June 3-6, 2020. Highlights from...",
                "1d_change": -1.7450628918,
                "index_price": 0.4321556024,
                "norm_price": -2.1772184942
            },
            {
                "index": 361,
                "date": "2020-06-03",
                "press_title": "EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis",
                "release_url": "http://lilly.mediaroom.com/2020-06-03-EULAR-2020-Lillys-Taltz-R-ixekizumab-Continues-to-Show-Robust-and-Consistent-Efficacy-in-Psoriatic-Arthritis",
                "content": "Taltz® (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data to be presented virtually on June 5 at the European...",
                "1d_change": -1.7450628918,
                "index_price": 0.4321556024,
                "norm_price": -2.1772184942
            },
            {
                "index": 362,
                "date": "2020-06-01",
                "press_title": "Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)",
                "release_url": "http://lilly.mediaroom.com/2020-06-01-Lillys-Taltz-R-ixekizumab-is-the-First-IL-17A-Antagonist-to-Receive-U-S-FDA-Approval-for-the-Treatment-of-Non-Radiographic-Axial-Spondyloarthritis-nr-axSpA",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz® (ixekizumab) injection 80...",
                "1d_change": -0.3964652007,
                "index_price": 1.3645730075,
                "norm_price": -1.7610382082
            },
            {
                "index": 363,
                "date": "2020-06-01",
                "press_title": "Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans",
                "release_url": "http://lilly.mediaroom.com/2020-06-01-Lilly-Begins-Worlds-First-Study-of-a-Potential-COVID-19-Antibody-Treatment-in-Humans",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This investigational medicine,...",
                "1d_change": -0.3964652007,
                "index_price": 1.3645730075,
                "norm_price": -1.7610382082
            },
            {
                "index": 364,
                "date": "2020-05-29",
                "press_title": "Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/2020-05-29-Lillys-CYRAMZA-R-ramucirumab-Receives-FDA-Approval-as-First-Line-Treatment-for-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib,...",
                "1d_change": 0.5181973291,
                "index_price": 1.0000902825,
                "norm_price": -0.4818929534
            },
            {
                "index": 365,
                "date": "2020-05-28",
                "press_title": "Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease",
                "release_url": "http://lilly.mediaroom.com/2020-05-28-Lilly-Receives-U-S-FDA-Approval-of-TAUVID-TM-flortaucipir-F-18-injection-for-Use-in-Patients-Being-Evaluated-for-Alzheimers-Disease",
                "content": "TAUVID™, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau...",
                "1d_change": 3.6090339534,
                "index_price": -0.0755523841,
                "norm_price": 3.6845863375
            },
            {
                "index": 366,
                "date": "2020-05-26",
                "press_title": "Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model",
                "release_url": "http://lilly.mediaroom.com/2020-05-26-Statement-from-Lilly-Chairman-and-CEO-Dave-Ricks-on-New-Part-D-Senior-Savings-Model",
                "content": "President Donald J. Trump and Seema Verma, Administrator for the Centers for Medicare & Medicaid Services, today announced details of the new Part D Senior Savings Model that will allow people in...",
                "1d_change": -3.7131221516,
                "index_price": 1.0556137558,
                "norm_price": -4.7687359074
            },
            {
                "index": 367,
                "date": "2020-05-26",
                "press_title": "Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction",
                "release_url": "http://lilly.mediaroom.com/2020-05-26-Boehringer-Ingelheim-and-Lilly-to-collaborate-with-Duke-Clinical-Research-Institute-on-a-pragmatic-trial-examining-Jardiances-R-effects-following-an-acute-myocardial-infarction",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI...",
                "1d_change": -3.7131221516,
                "index_price": 1.0556137558,
                "norm_price": -4.7687359074
            },
            {
                "index": 368,
                "date": "2020-05-26",
                "press_title": "Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure",
                "release_url": "http://lilly.mediaroom.com/2020-05-26-Emgality-R-Shows-Improvement-in-Work-Productivity-and-Health-and-Well-Being-Between-Attacks-in-Patients-with-Migraine-and-a-History-of-Preventive-Treatment-Failure",
                "content": "Emgality® (galcanezumab-gnlm) significantly improved work productivity and reduced interictal burden, defined as health and well-being between migraine attacks, in an analysis of the 3-month...",
                "1d_change": -3.7131221516,
                "index_price": 1.0556137558,
                "norm_price": -4.7687359074
            },
            {
                "index": 369,
                "date": "2020-05-19",
                "press_title": "Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Disease",
                "release_url": "http://lilly.mediaroom.com/2020-05-19-Results-of-GERAS-US-Study-Demonstrate-Societal-Cost-Burden-for-Patients-and-Caregivers-During-Early-Stages-of-Alzheimers-Disease",
                "content": "Eli Lilly and Company (NYSE: LLY) announced baseline results from the GERAS-US Study examining the societal costs associated with mild cognitive impairment (MCI), mild dementia (MILD), and caring...",
                "1d_change": -2.429298559,
                "index_price": 0.7746648685,
                "norm_price": -3.2039634275
            },
            {
                "index": 370,
                "date": "2020-05-13",
                "press_title": "Lilly Oncology Showcases Innovation in Cancer Research at ASCO 2020",
                "release_url": "http://lilly.mediaroom.com/2020-05-13-Lilly-Oncology-Showcases-Innovation-in-Cancer-Research-at-ASCO-2020",
                "content": "Data from 23 studies across Eli Lilly and Company's (NYSE: LLY) oncology product portfolio will be presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO), held...",
                "1d_change": 1.3169496515,
                "index_price": -0.4683648527,
                "norm_price": 1.7853145041
            },
            {
                "index": 371,
                "date": "2020-05-08",
                "press_title": "Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers",
                "release_url": "http://lilly.mediaroom.com/2020-05-08-Lilly-Receives-U-S-FDA-Approval-for-Retevmo-TM-selpercatinib-the-First-Therapy-Specifically-for-Patients-with-Advanced-RET-Driven-Lung-and-Thyroid-Cancers",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules), the first therapy specifically...",
                "1d_change": 2.7436207445,
                "index_price": 0.728958317,
                "norm_price": 2.0146624276
            },
            {
                "index": 372,
                "date": "2020-05-08",
                "press_title": "Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2020-05-08-Higher-investigational-doses-of-Trulicity-R-dulaglutide-meaningfully-reduced-A1C-and-body-weight-in-people-with-type-2-diabetes",
                "content": "New 36-week data showed higher investigational doses of Trulicity (3 mg and 4.5 mg) were well-tolerated and led to A1C reductions up to 1.9 percent and weight reductions up to 10.4 pounds in...",
                "1d_change": 2.7436207445,
                "index_price": 0.728958317,
                "norm_price": 2.0146624276
            },
            {
                "index": 373,
                "date": "2020-05-05",
                "press_title": "Lilly to Participate in UBS Virtual Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2020-05-05-Lilly-to-Participate-in-UBS-Virtual-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020. Michael Mason, Lilly senior vice president and president of Lilly...",
                "1d_change": 1.8381374464,
                "index_price": -0.7182915967,
                "norm_price": 2.5564290431
            },
            {
                "index": 374,
                "date": "2020-05-04",
                "press_title": "Lilly Declares Second-Quarter 2020 Dividend",
                "release_url": "http://lilly.mediaroom.com/2020-05-04-Lilly-Declares-Second-Quarter-2020-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable June 10,...",
                "1d_change": 2.0520677169,
                "index_price": 1.8626825986,
                "norm_price": 0.1893851183
            },
            {
                "index": 375,
                "date": "2020-05-04",
                "press_title": "Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19",
                "release_url": "http://lilly.mediaroom.com/2020-05-04-Lilly-and-Junshi-Biosciences-to-Co-develop-Antibody-Therapies-for-the-Prevention-and-Treatment-of-COVID-19",
                "content": "Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and...",
                "1d_change": 2.0520677169,
                "index_price": 1.8626825986,
                "norm_price": 0.1893851183
            },
            {
                "index": 376,
                "date": "2020-04-30",
                "press_title": "Lilly to Participate in Bank of America Securities Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2020-04-30-Lilly-to-Participate-in-Bank-of-America-Securities-Health-Care-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2020 Health Care Conference on Wednesday, May 13, 2020. Patrik Jonsson, Lilly senior vice president and...",
                "1d_change": -1.0219339806,
                "index_price": -3.5397463023,
                "norm_price": 2.5178123217
            },
            {
                "index": 377,
                "date": "2020-04-23",
                "press_title": "Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance",
                "release_url": "http://lilly.mediaroom.com/2020-04-23-Lilly-Reports-Strong-First-Quarter-Financial-Results-Adjusts-EPS-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2020. $ in millions, except per share data First Quarter % 2020 2019 Change Revenue $ 5,859.8 $ 5,092.2 15%",
                "1d_change": 3.5291209522,
                "index_price": 0.9278280156,
                "norm_price": 2.6012929366
            },
            {
                "index": 378,
                "date": "2020-04-16",
                "press_title": "Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available",
                "release_url": "http://lilly.mediaroom.com/2020-04-16-Lower-priced-versions-of-Humalog-R-Mix75-25-TM-KwikPen-R-and-Humalog-R-Junior-KwikPen-R-now-available",
                "content": "Non-branded versions of Humalog® Mix75/25™ KwikPen® (insulin lispro protamine and insulin lispro injectable suspension, 100 units/mL) and Humalog® Junior KwikPen® (insulin lispro injection,...",
                "1d_change": 2.79738978,
                "index_price": 2.6167472298,
                "norm_price": 0.1806425502
            },
            {
                "index": 379,
                "date": "2020-04-10",
                "press_title": "Lilly Begins Clinical Testing of Therapies for COVID-19",
                "release_url": "http://lilly.mediaroom.com/2020-04-10-Lilly-Begins-Clinical-Testing-of-Therapies-for-COVID-19",
                "content": "error_http",
                "1d_change": 4.0632591414,
                "index_price": 2.2346716635,
                "norm_price": 1.8285874779
            },
            {
                "index": 380,
                "date": "2020-04-08",
                "press_title": "Lilly Confirms Date and Conference Call for First-Quarter 2020 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2020-04-08-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2020-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2020 financial results on Thursday, April 23, 2020. Lilly will also conduct a conference call on that day with the investment...",
                "1d_change": 2.5252176382,
                "index_price": 3.7572340076,
                "norm_price": -1.2320163694
            },
            {
                "index": 381,
                "date": "2020-04-07",
                "press_title": "Eli Lilly and Company to Hold 2020 Annual Meeting of Shareholders Virtually",
                "release_url": "http://lilly.mediaroom.com/2020-04-07-Eli-Lilly-and-Company-to-Hold-2020-Annual-Meeting-of-Shareholders-Virtually",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that due to the public health impact of the coronavirus outbreak, and to support the health and well-being of its employees, shareholders, and...",
                "1d_change": 2.1132618148,
                "index_price": 0.4120058402,
                "norm_price": 1.7012559746
            },
            {
                "index": 382,
                "date": "2020-04-07",
                "press_title": "New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.",
                "release_url": "http://lilly.mediaroom.com/2020-04-07-New-35-Co-Pay-Now-Available-Through-Lilly-Insulin-Value-Program-in-Response-to-COVID-19-Crisis-in-U-S",
                "content": "In response to the crisis caused by COVID-19, Eli Lilly and Company (NYSE: LLY) is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance and those without...",
                "1d_change": 2.1132618148,
                "index_price": 0.4120058402,
                "norm_price": 1.7012559746
            },
            {
                "index": 383,
                "date": "2020-04-01",
                "press_title": "Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic",
                "release_url": "http://lilly.mediaroom.com/2020-04-01-Medical-Professionals-Across-Merck-Co-Inc-Pfizer-Inc-and-Eli-Lilly-and-Company-Activate-to-Support-Health-Systems-First-Responders-and-Patients-Amid-COVID-19-Pandemic",
                "content": "KENILWORTH, N.J., NEW YORK, N.Y., and INDIANAPOLIS, Ind., April 1, 2020 – Merck & Co., Inc., (NYSE: MRK), Pfizer Inc. (NYSE: PFE), and Eli Lilly and Company (NYSE: LLY) today announced medical...",
                "1d_change": 5.7532709162,
                "index_price": 1.1405210073,
                "norm_price": 4.6127499089
            },
            {
                "index": 384,
                "date": "2020-04-01",
                "press_title": "Governor Holcomb and Mayor Hogsett announce coalition to flatten the COVID-19 curve across state, public invited to make commitment",
                "release_url": "http://lilly.mediaroom.com/2020-04-01-Governor-Holcomb-and-Mayor-Hogsett-announce-coalition-to-flatten-the-COVID-19-curve-across-state-public-invited-to-make-commitment",
                "content": "INDIANAPOLIS, April 1, 2020 – Governor Eric J. Holcomb and Mayor Joe Hogsett – and a coalition of statewide business and community partners including Eli Lilly and Company – announced a...",
                "1d_change": 5.7532709162,
                "index_price": 1.1405210073,
                "norm_price": 4.6127499089
            },
            {
                "index": 385,
                "date": "2020-03-31",
                "press_title": "Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines",
                "release_url": "http://lilly.mediaroom.com/2020-03-31-Lilly-and-Sitryx-Announce-Licensing-and-Research-Collaboration-to-Discover-and-Develop-New-Immunometabolic-Medicines",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop...",
                "1d_change": -0.395836244,
                "index_price": -5.8364679784,
                "norm_price": 5.4406317344
            },
            {
                "index": 386,
                "date": "2020-03-30",
                "press_title": "Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis",
                "release_url": "http://lilly.mediaroom.com/2020-03-30-Lillys-Taltz-R-ixekizumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Pediatric-Patients-with-Moderate-to-Severe-Plaque-Psoriasis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz® (ixekizumab) injection,...",
                "1d_change": 3.4962193616,
                "index_price": 0.9908769496,
                "norm_price": 2.505342412
            },
            {
                "index": 387,
                "date": "2020-03-24",
                "press_title": "Updates from Lilly about insulin supply and affordability",
                "release_url": "http://lilly.mediaroom.com/2020-03-24-Updates-from-Lilly-about-insulin-supply-and-affordability",
                "content": "To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY) today is providing updates related to insulin supply and affordability:",
                "1d_change": -1.0661050678,
                "index_price": 5.2965839682,
                "norm_price": -6.3626890361
            },
            {
                "index": 388,
                "date": "2020-03-23",
                "press_title": "Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic",
                "release_url": "http://lilly.mediaroom.com/2020-03-23-Lilly-Provides-Update-on-Clinical-Trial-Activities-During-COVID-19-Pandemic",
                "content": "Eli Lilly and Company (NYSE: LLY) today provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company will delay most new study starts and pause...",
                "1d_change": 1.5786620762,
                "index_price": 6.3996319331,
                "norm_price": -4.8209698568
            },
            {
                "index": 389,
                "date": "2020-03-22",
                "press_title": "Lilly to Provide Drive-Through COVID-19 Testing for Indianapolis Health Care Workers",
                "release_url": "http://lilly.mediaroom.com/2020-03-22-Lilly-to-Provide-Drive-Through-COVID-19-Testing-for-Indianapolis-Health-Care-Workers",
                "content": "Eli Lilly and Company (NYSE:LLY) will offer drive-through testing for SARS-CoV-2, the virus that causes COVID-19, to Indianapolis area health care workers beginning Monday, March 23, as a service...",
                "1d_change": 1.5786620762,
                "index_price": 6.3996319331,
                "norm_price": -4.8209698568
            },
            {
                "index": 390,
                "date": "2020-03-20",
                "press_title": "US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes",
                "release_url": "http://lilly.mediaroom.com/2020-03-20-US-FDA-issues-complete-response-letter-for-empagliflozin-2-5-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes",
                "content": "The U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental New Drug Application (sNDA) of the investigational medicine empagliflozin 2.5 mg as an...",
                "1d_change": -11.0121790982,
                "index_price": -8.6949158646,
                "norm_price": -2.3172632336
            },
            {
                "index": 391,
                "date": "2020-03-20",
                "press_title": "Kathryn Beiser to join Lilly as Vice President, Global Communications",
                "release_url": "http://lilly.mediaroom.com/2020-03-20-Kathryn-Beiser-to-join-Lilly-as-Vice-President-Global-Communications",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Kathryn Beiser will join the company on April 6, 2020 as vice president, global communications. In this role, Beiser will oversee all aspects...",
                "1d_change": -11.0121790982,
                "index_price": -8.6949158646,
                "norm_price": -2.3172632336
            },
            {
                "index": 392,
                "date": "2020-03-18",
                "press_title": "Lilly, Indiana State Department of Health Partner to Accelerate COVID-19 Testing Using Lilly Research Laboratories",
                "release_url": "http://lilly.mediaroom.com/2020-03-18-Lilly-Indiana-State-Department-of-Health-Partner-to-Accelerate-COVID-19-Testing-Using-Lilly-Research-Laboratories",
                "content": "Eli Lilly and Company (NYSE:LLY) announced today its scientists are partnering with the Indiana State Department of Health (ISDH), with support from the Food and Drug Administration (FDA), to...",
                "1d_change": -2.4419703025,
                "index_price": -1.1251855711,
                "norm_price": -1.3167847314
            },
            {
                "index": 393,
                "date": "2020-03-16",
                "press_title": "Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata",
                "release_url": "http://lilly.mediaroom.com/2020-03-16-Lilly-Receives-FDA-Breakthrough-Therapy-Designation-for-Baricitinib-for-the-Treatment-of-Alopecia-Areata",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib...",
                "1d_change": 8.5195490357,
                "index_price": 0.8144842417,
                "norm_price": 7.705064794
            },
            {
                "index": 394,
                "date": "2020-03-12",
                "press_title": "AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19",
                "release_url": "http://lilly.mediaroom.com/2020-03-12-AbCellera-and-Lilly-to-Co-develop-Antibody-Therapies-for-the-Treatment-of-COVID-19",
                "content": "AbCellera and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused...",
                "1d_change": 6.1562724592,
                "index_price": 2.9568174168,
                "norm_price": 3.1994550424
            },
            {
                "index": 395,
                "date": "2020-03-12",
                "press_title": "US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease",
                "release_url": "http://lilly.mediaroom.com/2020-03-12-US-FDA-grants-Fast-Track-designation-to-Jardiance-R-for-the-treatment-of-chronic-kidney-disease",
                "content": "error_http",
                "1d_change": 6.1562724592,
                "index_price": 2.9568174168,
                "norm_price": 3.1994550424
            },
            {
                "index": 396,
                "date": "2020-03-11",
                "press_title": "Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in Medicare Part D",
                "release_url": "http://lilly.mediaroom.com/2020-03-11-Lilly-to-Participate-in-New-Model-Designed-to-Make-Insulins-More-Affordable-for-Seniors-in-Medicare-Part-D",
                "content": "Eli Lilly and Company (NYSE: LLY) is proud to announce its planned participation in the new Part D Senior Savings Model, announced today by the Centers for Medicare & Medicaid Services (CMS), that...",
                "1d_change": -10.6649812276,
                "index_price": -13.9060976206,
                "norm_price": 3.241116393
            },
            {
                "index": 397,
                "date": "2020-03-09",
                "press_title": "Lilly to Participate in Barclays Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2020-03-09-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference",
                "content": "error_http",
                "1d_change": 5.0782435303,
                "index_price": 0.6363159087,
                "norm_price": 4.4419276216
            },
            {
                "index": 398,
                "date": "2020-03-03",
                "press_title": "Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines",
                "release_url": "http://lilly.mediaroom.com/2020-03-03-Lilly-Statement-on-Novel-Coronavirus-and-the-Reliable-Supply-of-the-Companys-Medicines",
                "content": "Eli Lilly and Company (NYSE: LLY) issued the following statement today regarding the novel coronavirus: Among the concerns raised due to the impact of the novel coronavirus is whether patients can...",
                "1d_change": 5.0577167527,
                "index_price": 1.0753630848,
                "norm_price": 3.982353668
            },
            {
                "index": 399,
                "date": "2020-03-02",
                "press_title": "U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis",
                "release_url": "http://lilly.mediaroom.com/2020-03-02-U-S-FDA-Accepts-Regulatory-Submission-for-Tanezumab-a-Potential-First-in-Class-Treatment-for-Patients-with-Chronic-Pain-Due-to-Moderate-to-Severe-Osteoarthritis",
                "content": "Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab...",
                "1d_change": 1.9722312194,
                "index_price": 0.9685815186,
                "norm_price": 1.0036497008
            },
            {
                "index": 400,
                "date": "2020-02-28",
                "press_title": "Eli Lilly and Company Statement on ICER Final Report for Acute Treatments for Migraine: Effectiveness and Value",
                "release_url": "http://lilly.mediaroom.com/2020-02-28-Eli-Lilly-and-Company-Statement-on-ICER-Final-Report-for-Acute-Treatments-for-Migraine-Effectiveness-and-Value",
                "content": "INDIANAPOLIS, February 28, 2020 – Eli Lilly and Company shared the following statement in response to the Institute for Clinical and Economic Review (ICER) Final Report on Acute Treatments for...",
                "1d_change": 4.8629900826,
                "index_price": 5.6089701809,
                "norm_price": -0.7459800982
            },
            {
                "index": 401,
                "date": "2020-02-26",
                "press_title": "FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/2020-02-26-FDA-Advisory-Committee-Votes-in-Favor-of-Lillys-CYRAMZA-R-ramucirumab-as-First-Line-Treatment-for-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 6-5 that CYRAMZA® (ramucirumab) plus erlotinib...",
                "1d_change": -5.2945175515,
                "index_price": -5.4096299148,
                "norm_price": 0.1151123633
            },
            {
                "index": 402,
                "date": "2020-02-21",
                "press_title": "Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease",
                "release_url": "http://lilly.mediaroom.com/2020-02-21-Trulicity-R-dulaglutide-is-the-first-and-only-type-2-diabetes-medicine-approved-to-reduce-cardiovascular-events-in-adults-with-and-without-established-cardiovascular-disease",
                "content": "The U.S. Food and Drug Administration (FDA) has approved Trulicity® (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have...",
                "1d_change": -2.3090516132,
                "index_price": -4.1728053934,
                "norm_price": 1.8637537802
            },
            {
                "index": 403,
                "date": "2020-02-21",
                "press_title": "Lilly to Participate in Cowen Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2020-02-21-Lilly-to-Participate-in-Cowen-Health-Care-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3, 2020. Joshua Smiley, senior vice president and Lilly's chief...",
                "1d_change": -2.3090516132,
                "index_price": -4.1728053934,
                "norm_price": 1.8637537802
            },
            {
                "index": 404,
                "date": "2020-02-21",
                "press_title": "Lilly To Participate in SVB Leerink Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2020-02-21-Lilly-To-Participate-in-SVB-Leerink-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Thursday, February 27, 2020. Patrik Jonsson, Lilly senior vice president and...",
                "1d_change": -2.3090516132,
                "index_price": -4.1728053934,
                "norm_price": 1.8637537802
            },
            {
                "index": 405,
                "date": "2020-02-20",
                "press_title": "Lilly Completes Acquisition of Dermira",
                "release_url": "http://lilly.mediaroom.com/2020-02-20-Lilly-Completes-Acquisition-of-Dermira",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Dermira, Inc. (NASDAQ: DERM). The acquisition expands Lilly's immunology pipeline with the...",
                "1d_change": 0.2886165526,
                "index_price": -1.2793034581,
                "norm_price": 1.5679200107
            },
            {
                "index": 406,
                "date": "2020-02-10",
                "press_title": "Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study",
                "release_url": "http://lilly.mediaroom.com/2020-02-10-Lilly-Announces-Topline-Results-for-Solanezumab-from-the-Dominantly-Inherited-Alzheimer-Network-Trials-Unit-DIAN-TU-Study",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the analysis performed by Washington University School of Medicine in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study...",
                "1d_change": 1.906421338,
                "index_price": 1.1754886666,
                "norm_price": 0.7309326714
            },
            {
                "index": 407,
                "date": "2020-02-07",
                "press_title": "Lilly to Participate in Guggenheim Healthcare Talks Idea Forum",
                "release_url": "http://lilly.mediaroom.com/2020-02-07-Lilly-to-Participate-in-Guggenheim-Healthcare-Talks-Idea-Forum",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 13, 2020. Jacob Van Naarden, chief operating officer for Loxo Oncology at...",
                "1d_change": -1.1751741053,
                "index_price": 0.493723271,
                "norm_price": -1.6688973763
            },
            {
                "index": 408,
                "date": "2020-01-31",
                "press_title": "Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription",
                "release_url": "http://lilly.mediaroom.com/2020-01-31-Lillys-REYVOW-TM-lasmiditan-C-V-the-First-and-Only-Medicine-in-a-New-Class-of-Acute-Treatment-for-Migraine-ditan-Now-Available-for-Prescription",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that REYVOW™ (lasmiditan) C-V 50 mg and 100 mg tablets, an oral medication for the acute treatment of migraine with or without aura in adults,...",
                "1d_change": -1.3120893622,
                "index_price": -1.0283465599,
                "norm_price": -0.2837428024
            },
            {
                "index": 409,
                "date": "2020-01-31",
                "press_title": "CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes",
                "release_url": "http://lilly.mediaroom.com/2020-01-31-CHMP-Recommends-Approval-of-Lillys-New-Fast-Acting-Mealtime-Insulin-to-Improve-Glycemic-Control-in-Adults-with-Diabetes",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Lilly's new...",
                "1d_change": -1.3120893622,
                "index_price": -1.0283465599,
                "norm_price": -0.2837428024
            },
            {
                "index": 410,
                "date": "2020-01-30",
                "press_title": "Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition",
                "release_url": "http://lilly.mediaroom.com/2020-01-30-Lilly-Reports-Strong-Fourth-Quarter-and-Full-Year-2019-Financial-Results-Updates-2020-Guidance-for-Pending-Dermira-Acquisition",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2019. $ in millions, except per share data Fourth Quarter % Full Year % 2019 2018 Change...",
                "1d_change": 1.0455747292,
                "index_price": -0.9589130265,
                "norm_price": 2.0044877558
            },
            {
                "index": 411,
                "date": "2020-01-30",
                "press_title": "Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis",
                "release_url": "http://lilly.mediaroom.com/2020-01-30-Lilly-and-Incyte-Announce-Positive-Top-Line-Results-from-the-North-American-BREEZE-AD5-Phase-3-Study-of-Oral-Selective-JAK-Inhibitor-Baricitinib-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized, placebo-controlled...",
                "1d_change": 1.0455747292,
                "index_price": -0.9589130265,
                "norm_price": 2.0044877558
            },
            {
                "index": 412,
                "date": "2020-01-29",
                "press_title": "Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application",
                "release_url": "http://lilly.mediaroom.com/2020-01-29-Lilly-Receives-FDA-Priority-Review-for-the-Selpercatinib-New-Drug-Application",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib (LOXO-292), for...",
                "1d_change": 2.214882251,
                "index_price": -0.1766336644,
                "norm_price": 2.3915159153
            },
            {
                "index": 413,
                "date": "2020-01-28",
                "press_title": "Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities",
                "release_url": "http://lilly.mediaroom.com/2020-01-28-Lilly-plans-donation-of-200-000-insulin-KwikPens-over-next-three-years-to-support-lower-income-communities",
                "content": "Starting this month, Eli Lilly and Company (NYSE: LLY) will donate at least 200,000 KwikPens® to three relief organizations – Americares, Direct Relief and Dispensary of Hope – to stock...",
                "1d_change": 0.8790938478,
                "index_price": 0.5514084813,
                "norm_price": 0.3276853666
            },
            {
                "index": 414,
                "date": "2020-01-27",
                "press_title": "US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2020-01-27-US-FDA-approves-only-triple-combination-tablet-with-Jardiance-R-for-adults-with-type-2-diabetes",
                "content": "error_http",
                "1d_change": 1.3786971722,
                "index_price": 0.8876052491,
                "norm_price": 0.4910919232
            },
            {
                "index": 415,
                "date": "2020-01-27",
                "press_title": "Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine",
                "release_url": "http://lilly.mediaroom.com/2020-01-27-Lilly-and-Incyte-Announce-Top-Line-Results-from-Phase-3-Study-BREEZE-AD4-of-Oral-Selective-JAK-Inhibitor-Baricitinib-in-Combination-with-Topical-Corticosteroids-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis-Not-Controlled-with-Cyclospor",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD4, an investigational Phase 3, randomized, placebo-controlled...",
                "1d_change": 1.3786971722,
                "index_price": 0.8876052491,
                "norm_price": 0.4910919232
            },
            {
                "index": 416,
                "date": "2020-01-24",
                "press_title": "Anat Hakim to join Lilly as General Counsel",
                "release_url": "http://lilly.mediaroom.com/2020-01-24-Anat-Hakim-to-join-Lilly-as-General-Counsel",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Anat Hakim will join the company on February 3, 2020 as senior vice-president and general counsel. Hakim succeeds Michael J. Harrington who...",
                "1d_change": -2.5594670222,
                "index_price": -2.7583361258,
                "norm_price": 0.1988691036
            },
            {
                "index": 417,
                "date": "2020-01-21",
                "press_title": "Governor Cooper Announces over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant",
                "release_url": "http://lilly.mediaroom.com/2020-01-21-Governor-Cooper-Announces-over-460-Jobs-in-Durham-as-Eli-Lilly-and-Company-Selects-North-Carolina-for-Major-Pharmaceutical-Plant",
                "content": "Eli Lilly and Company (NYSE: LLY), a global healthcare and biopharmaceutical company, will invest over $470 million and create more than 460 new jobs in Durham, Governor Roy Cooper announced...",
                "1d_change": 1.4551818333,
                "index_price": 0.0216744398,
                "norm_price": 1.4335073935
            },
            {
                "index": 418,
                "date": "2020-01-16",
                "press_title": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2020-01-16-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2019-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2019 financial results on Thursday, January 30, 2020. Lilly will also conduct a conference call on that day with...",
                "1d_change": -1.6120103758,
                "index_price": 0.8003960075,
                "norm_price": -2.4124063834
            },
            {
                "index": 419,
                "date": "2020-01-15",
                "press_title": "Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease",
                "release_url": "http://lilly.mediaroom.com/2020-01-15-Lilly-Anna-Kaiser-Launch-30-Day-Thriver-Challenge-to-Increase-Awareness-of-Daily-Stress-of-Living-with-Metastatic-Breast-Cancer-Elevate-Support-for-Women-and-Men-Living-with-the-Disease",
                "content": "- An estimated 113 people die every day in the U.S. from metastatic breast cancer (MBC).1 This devastating statistic adds to the emotional and mental weight of living with incurable cancer. - The...",
                "1d_change": 0.6010354456,
                "index_price": 1.0413631909,
                "norm_price": -0.4403277453
            },
            {
                "index": 420,
                "date": "2020-01-14",
                "press_title": "Lilly expands insulin affordability options with lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen®",
                "release_url": "http://lilly.mediaroom.com/2020-01-14-Lilly-expands-insulin-affordability-options-with-lower-priced-versions-of-Humalog-R-Mix75-25-TM-KwikPen-R-and-Humalog-R-Junior-KwikPen-R",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced plans to add two more cost-saving options to its suite of solutions for people who use Lilly insulin by introducing lower-priced versions of...",
                "1d_change": 1.5023514631,
                "index_price": 0.1197809059,
                "norm_price": 1.3825705572
            },
            {
                "index": 421,
                "date": "2020-01-13",
                "press_title": "Tyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC",
                "release_url": "http://lilly.mediaroom.com/2020-01-13-Tyvyt-R-Sintilimab-Injection-Combined-with-ALIMTA-R-Pemetrexed-and-Platinum-Met-Predefined-Primary-Endpoint-in-Phase-3-ORIENT-11-Study-as-First-Line-Therapy-in-Nonsquamous-NSCLC",
                "content": "Today, Eli Lilly and Company (NYSE: LLY) jointly announced with Innovent Biologics, Inc. the results of a Phase 3 study in China; the ORIENT-11 trial of Tyvyt® (sintilimab injection) in...",
                "1d_change": 1.741908263,
                "index_price": 0.3661124191,
                "norm_price": 1.3757958439
            },
            {
                "index": 422,
                "date": "2020-01-10",
                "press_title": "Lilly Announces Agreement to Acquire Dermira",
                "release_url": "http://lilly.mediaroom.com/2020-01-10-Lilly-Announces-Agreement-to-Acquire-Dermira",
                "content": "Eli Lilly and Company (NYSE: LLY) and Dermira, Inc. (NASDAQ: DERM) today announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an...",
                "1d_change": 2.2743865741,
                "index_price": 0.1922011734,
                "norm_price": 2.0821854007
            },
            {
                "index": 423,
                "date": "2020-01-09",
                "press_title": "Eli Lilly and Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab",
                "release_url": "http://lilly.mediaroom.com/2020-01-09-Eli-Lilly-and-Company-in-Collaboration-with-Strateos-Inc-Launch-Remote-Controlled-Robotic-Cloud-Lab",
                "content": "Eli Lilly and Company (NYSE: LLY) and Strateos, Inc. today unveiled a new robotic laboratory in San Diego, California designed to accelerate the drug discovery process. The Lilly Life Sciences...",
                "1d_change": 2.499991062,
                "index_price": -0.0208226261,
                "norm_price": 2.5208136881
            },
            {
                "index": 424,
                "date": "2020-01-02",
                "press_title": "Lilly to Participate in J.P. Morgan Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2020-01-02-Lilly-to-Participate-in-J-P-Morgan-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020. David A. Ricks, Lilly's chairman and chief executive officer,...",
                "1d_change": -1.23747e-05,
                "index_price": -0.3035635013,
                "norm_price": 0.3035511266
            },
            {
                "index": 425,
                "date": "2019-12-30",
                "press_title": "U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit",
                "release_url": "http://lilly.mediaroom.com/2019-12-30-U-S-District-Court-Rules-in-Favor-of-Lilly-in-Alimta-Vitamin-Regimen-Patent-Lawsuit",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana ruled in favor of Lilly that the Alimta® (pemetrexed for injection) vitamin...",
                "1d_change": -0.0684711304,
                "index_price": -0.2881675171,
                "norm_price": 0.2196963867
            },
            {
                "index": 426,
                "date": "2019-12-30",
                "press_title": "Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer",
                "release_url": "http://lilly.mediaroom.com/2019-12-30-Lilly-Opens-Phase-3-Clinical-Trial-in-RET-Mutant-Medullary-Thyroid-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as LOXO-292, for treatment-naïve RET-mutant medullary...",
                "1d_change": -0.0684711304,
                "index_price": -0.2881675171,
                "norm_price": 0.2196963867
            },
            {
                "index": 427,
                "date": "2019-12-19",
                "press_title": "Lilly Launches Campaign to Increase Awareness of Insulin Cost-Saving Options",
                "release_url": "http://lilly.mediaroom.com/2019-12-19-Lilly-Launches-Campaign-to-Increase-Awareness-of-Insulin-Cost-Saving-Options",
                "content": "In an open letter published today in several top U.S. newspapers, Eli Lilly and Company (NYSE: LLY) Chairman and CEO Dave Ricks encouraged anyone who needs help affording their monthly...",
                "1d_change": 2.5296139653,
                "index_price": 0.8971725808,
                "norm_price": 1.6324413845
            },
            {
                "index": 428,
                "date": "2019-12-18",
                "press_title": "Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm)",
                "release_url": "http://lilly.mediaroom.com/2019-12-18-Lilly-Announces-the-Launch-of-TRIUMPH-the-First-Long-Term-Real-World-Evidence-Study-of-Emgality-R-galcanezumab-gnlm",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today the launch of TRIUMPH, a long-term, real-world evidence study of Emgality® (galcanezumab-gnlm). The objective of the TRIUMPH study (Preventive...",
                "1d_change": 2.2697901479,
                "index_price": 0.316972951,
                "norm_price": 1.952817197
            },
            {
                "index": 429,
                "date": "2019-12-17",
                "press_title": "Lilly Announces 2020 Financial Guidance, Updates 2019 Guidance",
                "release_url": "http://lilly.mediaroom.com/2019-12-17-Lilly-Announces-2020-Financial-Guidance-Updates-2019-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced its 2020 financial guidance, highlighted by volume-based revenue growth and improving productivity, which are expected to result in operating...",
                "1d_change": 4.232306353,
                "index_price": -0.1334949237,
                "norm_price": 4.3658012767
            },
            {
                "index": 430,
                "date": "2019-12-16",
                "press_title": "Lilly Announces 15 Percent Dividend Increase",
                "release_url": "http://lilly.mediaroom.com/2019-12-16-Lilly-Announces-15-Percent-Dividend-Increase",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter of 2020 will be $0.74 per share on...",
                "1d_change": 1.8032394308,
                "index_price": 0.278467689,
                "norm_price": 1.5247717418
            },
            {
                "index": 431,
                "date": "2019-12-16",
                "press_title": "Lilly to Integrate Dexcom CGM into Personalized Diabetes Management System",
                "release_url": "http://lilly.mediaroom.com/2019-12-16-Lilly-to-Integrate-Dexcom-CGM-into-Personalized-Diabetes-Management-System",
                "content": "Eli Lilly and Company (NYSE: LLY) has announced a global commercialization agreement to integrate DexCom, Inc. (NASDAQ: DXCM) products into Lilly's personalized diabetes management system,...",
                "1d_change": 1.8032394308,
                "index_price": 0.278467689,
                "norm_price": 1.5247717418
            },
            {
                "index": 432,
                "date": "2019-12-13",
                "press_title": "Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure",
                "release_url": "http://lilly.mediaroom.com/2019-12-13-Boehringer-Ingelheim-and-Lilly-provide-update-on-Jardiance-R-phase-III-exercise-ability-studies-in-chronic-heart-failure",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance®...",
                "1d_change": 0.7081835611,
                "index_price": 0.7770777925,
                "norm_price": -0.0688942314
            },
            {
                "index": 433,
                "date": "2019-12-13",
                "press_title": "CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/2019-12-13-CHMP-Issues-Positive-Opinion-to-Expand-CYRAMZA-R-ramucirumab-Label-to-Include-Results-from-RELAY-Study-in-Patients-with-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending a new...",
                "1d_change": 0.7081835611,
                "index_price": 0.7770777925,
                "norm_price": -0.0688942314
            },
            {
                "index": 434,
                "date": "2019-12-11",
                "press_title": "Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/2019-12-11-Lilly-Opens-First-Ever-Randomized-Phase-3-Clinical-Trial-in-Treatment-Naive-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-431 clinical trial [NCT04194944] for selpercatinib, also known as LOXO-292, for treatment-naïve RET fusion-positive...",
                "1d_change": 0.9367101278,
                "index_price": 1.0358006183,
                "norm_price": -0.0990904905
            },
            {
                "index": 435,
                "date": "2019-12-08",
                "press_title": "Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2019-12-08-Lilly-Presents-Interim-Clinical-Data-from-LOXO-305-Dose-Escalation-Trial-in-B-Cell-Leukemias-and-Lymphomas-at-the-American-Society-Hematology-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced interim clinical data from the LOXO-305 global Phase 1/2 BRUIN dose escalation trial. LOXO-305 is an investigational, highly selective,...",
                "1d_change": 0.9283153711,
                "index_price": -0.2981653056,
                "norm_price": 1.2264806767
            },
            {
                "index": 436,
                "date": "2019-12-05",
                "press_title": "Lilly Announces New Leadership and Strategy in Oncology Research and Development",
                "release_url": "http://lilly.mediaroom.com/2019-12-05-Lilly-Announces-New-Leadership-and-Strategy-in-Oncology-Research-and-Development",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced new leadership and strategic direction in oncology R&D, combining the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology,...",
                "1d_change": 1.0364440107,
                "index_price": 0.8487195094,
                "norm_price": 0.1877245013
            },
            {
                "index": 437,
                "date": "2019-12-02",
                "press_title": "Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference",
                "release_url": "http://lilly.mediaroom.com/2019-12-02-Lilly-to-Participate-in-Evercore-ISI-2nd-Annual-HealthCONx-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific...",
                "1d_change": 0.07651901,
                "index_price": -1.6374675832,
                "norm_price": 1.7139865932
            },
            {
                "index": 438,
                "date": "2019-12-02",
                "press_title": "Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco",
                "release_url": "http://lilly.mediaroom.com/2019-12-02-Eli-Lilly-and-Company-Unveils-Shared-Innovation-Laboratory-in-South-San-Francisco",
                "content": "Eli Lilly and Company (NYSE: LLY) today unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with...",
                "1d_change": 0.07651901,
                "index_price": -1.6374675832,
                "norm_price": 1.7139865932
            },
            {
                "index": 439,
                "date": "2019-12-02",
                "press_title": "Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD)",
                "release_url": "http://lilly.mediaroom.com/2019-12-02-Lilly-Names-HealthVoyager-as-Winner-of-Digital-Health-Innovation-Challenge-for-Inflammatory-Bowel-Disease-IBD",
                "content": "Eli Lilly and Company's (NYSE: LLY) first digital health open innovation challenge, \"Transforming IBD Care: Better Disease Monitoring, Management, and Care for People with Inflammatory Bowel...",
                "1d_change": 0.07651901,
                "index_price": -1.6374675832,
                "norm_price": 1.7139865932
            },
            {
                "index": 440,
                "date": "2019-11-20",
                "press_title": "Lilly announces $400 million capital investment in manufacturing facilities in Indianapolis",
                "release_url": "http://lilly.mediaroom.com/2019-11-20-Lilly-announces-400-million-capital-investment-in-manufacturing-facilities-in-Indianapolis",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus in Indianapolis. The plans are driven by...",
                "1d_change": -0.183014051,
                "index_price": -0.3582964262,
                "norm_price": 0.1752823753
            },
            {
                "index": 441,
                "date": "2019-11-19",
                "press_title": "Lilly Confirms Date and Conference Call for 2020 Financial Guidance Announcement",
                "release_url": "http://lilly.mediaroom.com/2019-11-19-Lilly-Confirms-Date-and-Conference-Call-for-2020-Financial-Guidance-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2020 on Tuesday, December 17, 2019. Lilly will also conduct a conference call on that day with the investment community...",
                "1d_change": 0.5060840008,
                "index_price": -0.6109131362,
                "norm_price": 1.116997137
            },
            {
                "index": 442,
                "date": "2019-11-17",
                "press_title": "Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists",
                "release_url": "http://lilly.mediaroom.com/2019-11-17-Interim-analysis-from-EMPRISE-real-world-study-shows-Jardiance-R-decreased-risk-of-hospitalization-for-heart-failure-compared-with-DPP-4-inhibitors-and-GLP-1-receptor-agonists",
                "content": "A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that Jardiance® (empagliflozin) was...",
                "1d_change": 1.8071059918,
                "index_price": 0.0727528406,
                "norm_price": 1.7343531512
            },
            {
                "index": 443,
                "date": "2019-11-13",
                "press_title": "Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes",
                "release_url": "http://lilly.mediaroom.com/2019-11-13-Boehringer-Ingelheim-and-Lilly-announce-outcome-of-FDA-Advisory-Committee-meeting-for-empagliflozin-2-5-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes",
                "content": "The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to...",
                "1d_change": -0.7492003064,
                "index_price": 0.4020484089,
                "norm_price": -1.1512487152
            },
            {
                "index": 444,
                "date": "2019-11-12",
                "press_title": "Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized",
                "release_url": "http://lilly.mediaroom.com/2019-11-12-Boehringer-Ingelheim-and-Lilly-initiate-first-ever-study-to-assess-Jardiance-R-in-people-hospitalized-for-acute-heart-failure-who-have-been-stabilized",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth phase III study in the Jardiance® (empagliflozin) heart failure program. The study...",
                "1d_change": 0.017742089,
                "index_price": 0.1538444786,
                "norm_price": -0.1361023896
            },
            {
                "index": 445,
                "date": "2019-11-12",
                "press_title": "ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis",
                "release_url": "http://lilly.mediaroom.com/2019-11-12-ACR-2019-Lilly-Presents-52-Week-Head-to-Head-SPIRIT-H2H-Data-from-Taltz-R-ixekizumab-Versus-Humira-R-adalimumab-Trial-in-Psoriatic-Arthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of Taltz® (ixekizumab) versus Humira® (adalimumab) in biologic-naïve...",
                "1d_change": 0.017742089,
                "index_price": 0.1538444786,
                "norm_price": -0.1361023896
            },
            {
                "index": 446,
                "date": "2019-11-12",
                "press_title": "ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis",
                "release_url": "http://lilly.mediaroom.com/2019-11-12-ACR-2019-Lilly-Presents-Positive-New-Data-from-COAST-X-a-Phase-3-Study-of-Taltz-R-ixekizumab-in-Patients-with-Non-Radiographic-Axial-Spondyloarthritis",
                "content": "error_http",
                "1d_change": 0.017742089,
                "index_price": 0.1538444786,
                "norm_price": -0.1361023896
            },
            {
                "index": 447,
                "date": "2019-11-08",
                "press_title": "Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2019-11-08-Lilly-Reinforces-its-Commitment-to-Rheumatology-through-Data-Showcased-at-the-ACR-ARP-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz® (ixekizumab) and Olumiant® (baricitinib) at the American College of Rheumatology (ACR)/Association of...",
                "1d_change": 0.1329790173,
                "index_price": 0.1865886326,
                "norm_price": -0.0536096153
            },
            {
                "index": 448,
                "date": "2019-11-07",
                "press_title": "Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities",
                "release_url": "http://lilly.mediaroom.com/2019-11-07-Lilly-Announces-the-Pricing-Terms-of-its-Cash-Tender-Offer-for-Up-to-2-000-006-000-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for up to $2,000,006,000 aggregate principal amount of its outstanding debt...",
                "1d_change": -0.6165788922,
                "index_price": 0.1959231071,
                "norm_price": -0.8125019992
            },
            {
                "index": 449,
                "date": "2019-11-07",
                "press_title": "Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities",
                "release_url": "http://lilly.mediaroom.com/2019-11-07-Lilly-Announces-the-Early-Tender-Results-and-Upsizing-of-Its-Pending-Cash-Tender-Offer-to-Up-to-2-000-006-000-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today the early tender results for its previously announced cash tender offer of its outstanding debt securities. Lilly also announced that it had...",
                "1d_change": -0.6165788922,
                "index_price": 0.1959231071,
                "norm_price": -0.8125019992
            },
            {
                "index": 450,
                "date": "2019-11-06",
                "press_title": "Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019",
                "release_url": "http://lilly.mediaroom.com/2019-11-06-Eli-Lilly-and-Company-to-Present-Multiple-Abstracts-for-LOXO-305-at-ASH-2019",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that multiple abstracts from its LOXO-305 program have been accepted for presentation at the 61st American Society of Hematology Annual Meeting...",
                "1d_change": 1.0641022317,
                "index_price": 0.3267178644,
                "norm_price": 0.7373843673
            },
            {
                "index": 451,
                "date": "2019-11-04",
                "press_title": "Lilly to Participate in Credit Suisse 28th Annual Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2019-11-04-Lilly-to-Participate-in-Credit-Suisse-28th-Annual-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Credit Suisse 28th Annual Healthcare Conference on Wednesday, November 13, 2019. Anne White, president of Lilly Oncology, Kimberly...",
                "1d_change": -1.7887495259,
                "index_price": -0.1411505677,
                "norm_price": -1.6475989582
            },
            {
                "index": 452,
                "date": "2019-11-04",
                "press_title": "Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®",
                "release_url": "http://lilly.mediaroom.com/2019-11-04-Boehringer-Ingelheim-and-Lilly-modernise-alliance-to-focus-full-expertise-on-Jardiance-R",
                "content": "- Alliance to focus combined expertise and investment to maximise Jardiance® for people with type 2 diabetes, heart failure, and chronic kidney disease - Alliance to continue to include three...",
                "1d_change": -1.7887495259,
                "index_price": -0.1411505677,
                "norm_price": -1.6475989582
            },
            {
                "index": 453,
                "date": "2019-10-24",
                "press_title": "Lilly Announces Cash Tender Offer for Up to $2.0 Billion Aggregate Principal Amount of Its Outstanding Debt Securities",
                "release_url": "http://lilly.mediaroom.com/2019-10-24-Lilly-Announces-Cash-Tender-Offer-for-Up-to-2-0-Billion-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $2.0 billion aggregate principal amount (the \"tender cap\") of specified series of its...",
                "1d_change": 2.4500946002,
                "index_price": 0.2570683498,
                "norm_price": 2.1930262505
            },
            {
                "index": 454,
                "date": "2019-10-23",
                "press_title": "Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance",
                "release_url": "http://lilly.mediaroom.com/2019-10-23-Lilly-Reports-Strong-Third-Quarter-2019-Financial-Results-Raises-2019-EPS-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2019. $ in millions, except per share data Third Quarter % 2019 2018 Change Revenue $ 5,476.6 $ 5,306.9...",
                "1d_change": 1.7062158845,
                "index_price": 0.5408126488,
                "norm_price": 1.1654032357
            },
            {
                "index": 455,
                "date": "2019-10-23",
                "press_title": "Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to Retire at End of Year; Mike Mason to Succeed Conterno",
                "release_url": "http://lilly.mediaroom.com/2019-10-23-Enrique-Conterno-Senior-Vice-President-and-President-of-Lilly-Diabetes-and-Lilly-USA-to-Retire-at-End-of-Year-Mike-Mason-to-Succeed-Conterno",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27...",
                "1d_change": 1.7062158845,
                "index_price": 0.5408126488,
                "norm_price": 1.1654032357
            },
            {
                "index": 456,
                "date": "2019-10-21",
                "press_title": "Lilly Declares Fourth-Quarter 2019 Dividend",
                "release_url": "http://lilly.mediaroom.com/2019-10-21-Lilly-Declares-Fourth-Quarter-2019-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2019 of $0.645 per share on outstanding common stock. The dividend is payable December...",
                "1d_change": 0.8831175382,
                "index_price": -0.0163548689,
                "norm_price": 0.8994724071
            },
            {
                "index": 457,
                "date": "2019-10-16",
                "press_title": "Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival",
                "release_url": "http://lilly.mediaroom.com/2019-10-16-Lilly-Announces-Phase-3-Study-in-Patients-with-Metastatic-Pancreatic-Cancer-Did-Not-Meet-Primary-Endpoint-of-Overall-Survival",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in...",
                "1d_change": -0.663825232,
                "index_price": 0.2758558237,
                "norm_price": -0.9396810556
            },
            {
                "index": 458,
                "date": "2019-10-12",
                "press_title": "Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress",
                "release_url": "http://lilly.mediaroom.com/2019-10-12-Lilly-Presents-Positive-Results-for-Taltz-R-ixekizumab-in-Pediatric-Patients-with-Moderate-to-Severe-Plaque-Psoriasis-at-the-28th-Annual-European-Academy-of-Dermatology-and-Venereology-EADV-Congress",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe...",
                "1d_change": 1.0756757658,
                "index_price": 0.9970982791,
                "norm_price": 0.0785774867
            },
            {
                "index": 459,
                "date": "2019-10-11",
                "press_title": "Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval",
                "release_url": "http://lilly.mediaroom.com/2019-10-11-Lillys-REYVOW-TM-lasmiditan-The-First-and-Only-Medicine-in-a-New-Class-of-Acute-Treatment-for-Migraine-Receives-FDA-Approval",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication for the acute treatment of migraine, with...",
                "1d_change": 0.1390181063,
                "index_price": 0.1038327153,
                "norm_price": 0.035185391
            },
            {
                "index": 460,
                "date": "2019-10-08",
                "press_title": "Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress",
                "release_url": "http://lilly.mediaroom.com/2019-10-08-Lilly-to-Unveil-New-Data-for-the-Treatments-of-Complex-Dermatological-Conditions-at-the-28th-Annual-European-Academy-of-Dermatology-and-Venereology-EADV-Congress",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 28th annual European Academy of...",
                "1d_change": 0.382125451,
                "index_price": -0.0342536149,
                "norm_price": 0.4163790659
            },
            {
                "index": 461,
                "date": "2019-10-07",
                "press_title": "Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology",
                "release_url": "http://lilly.mediaroom.com/2019-10-07-Lillys-CYRAMZA-R-ramucirumab-Phase-3-Data-in-First-Line-EGFR-Mutated-Non-Small-Cell-Lung-Cancer-Published-in-The-Lancet-Oncology",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that results from the global Phase 3 RELAY trial of CYRAMZA® (ramucirumab) in previously untreated patients with metastatic EGFR-mutated...",
                "1d_change": -1.0448677215,
                "index_price": -1.7687127415,
                "norm_price": 0.72384502
            },
            {
                "index": 462,
                "date": "2019-10-03",
                "press_title": "Lilly Announces Voluntary Delisting from Euronext Paris",
                "release_url": "http://lilly.mediaroom.com/2019-10-03-Lilly-Announces-Voluntary-Delisting-from-Euronext-Paris",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that it has requested the delisting of its shares (ISIN US5324571083) (\"Lilly Shares\") from Euronext Paris due to the very low trading volume,...",
                "1d_change": 1.0258850509,
                "index_price": 2.2571104682,
                "norm_price": -1.2312254173
            },
            {
                "index": 463,
                "date": "2019-10-03",
                "press_title": "New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis",
                "release_url": "http://lilly.mediaroom.com/2019-10-03-New-Head-to-Head-Data-Show-Taltz-R-ixekizumab-Superiority-versus-TREMFYA-R-guselkumab-in-People-with-Moderate-to-Severe-Plaque-Psoriasis",
                "content": "Eli Lilly and Company (NYSE: LLY) today presented detailed data at the 5th Annual Maui Derm NP+PA Fall meeting from the Phase 4 IXORA-R study, the first head-to-head (H2H) study between an IL-17A...",
                "1d_change": 1.0258850509,
                "index_price": 2.2571104682,
                "norm_price": -1.2312254173
            },
            {
                "index": 464,
                "date": "2019-10-02",
                "press_title": "Lilly Confirms Date and Conference Call for Third-Quarter 2019 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2019-10-02-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2019-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2019 financial results on Wednesday, October 23, 2019. Lilly will also conduct a conference call on that day with the investment...",
                "1d_change": -2.833467734,
                "index_price": -0.4861540991,
                "norm_price": -2.3473136349
            },
            {
                "index": 465,
                "date": "2019-09-29",
                "press_title": "Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers",
                "release_url": "http://lilly.mediaroom.com/2019-09-29-Lilly-Announces-Positive-Registrational-Data-for-Selpercatinib-LOXO-292-in-Heavily-Pretreated-RET-Altered-Thyroid-Cancers",
                "content": "Eli Lilly and Company (NYSE: LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib1 monotherapy, also known as LOXO-292, for the...",
                "1d_change": -1.2977555667,
                "index_price": -0.9121696577,
                "norm_price": -0.385585909
            },
            {
                "index": 466,
                "date": "2019-09-23",
                "press_title": "Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019",
                "release_url": "http://lilly.mediaroom.com/2019-09-23-Lilly-Oncology-to-Present-Robust-Data-across-Its-Growing-Portfolio-at-ESMO-2019",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced data from a number of studies across the company's oncology product portfolio will be presented at the European Society for Medical Oncology...",
                "1d_change": -2.4282533962,
                "index_price": -0.5696724124,
                "norm_price": -1.8585809837
            },
            {
                "index": 467,
                "date": "2019-09-20",
                "press_title": "CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial",
                "release_url": "http://lilly.mediaroom.com/2019-09-20-CHMP-Issues-Positive-Opinion-to-Expand-Trulicity-R-dulaglutide-Label-to-Include-Results-from-REWIND-Cardiovascular-Outcomes-Trial",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending an update to the...",
                "1d_change": -1.5326660119,
                "index_price": -0.556187033,
                "norm_price": -0.9764789789
            },
            {
                "index": 468,
                "date": "2019-09-19",
                "press_title": "Lilly Announces Webcast to Discuss ESMO 2019 Presentations",
                "release_url": "http://lilly.mediaroom.com/2019-09-19-Lilly-Announces-Webcast-to-Discuss-ESMO-2019-Presentations",
                "content": "Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Wednesday, October 2, 2019 to discuss the company's presentations at the 2019 European Society for Medical Oncology (ESMO) Congress in...",
                "1d_change": 2.8409078201,
                "index_price": -0.6112837816,
                "norm_price": 3.4521916017
            },
            {
                "index": 469,
                "date": "2019-09-09",
                "press_title": "Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/2019-09-09-Lilly-Announces-Positive-Results-for-Selpercatinib-LOXO-292-Demonstrating-a-68-Percent-Objective-Response-Rate-and-Sustained-Durability-in-Heavily-Pretreated-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known as LOXO-292, for...",
                "1d_change": -3.0783054126,
                "index_price": -0.3034191357,
                "norm_price": -2.7748862768
            },
            {
                "index": 470,
                "date": "2019-09-05",
                "press_title": "Lilly's Pain Clinical Trial Protocol Selected for FDA Complex Innovative Trial Designs Pilot Meeting Program",
                "release_url": "http://lilly.mediaroom.com/2019-09-05-Lillys-Pain-Clinical-Trial-Protocol-Selected-for-FDA-Complex-Innovative-Trial-Designs-Pilot-Meeting-Program",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has accepted its application to enter the Complex Innovative Trial Designs (CID) Pilot Meeting...",
                "1d_change": 0.0789201483,
                "index_price": 0.6079767255,
                "norm_price": -0.5290565771
            },
            {
                "index": 471,
                "date": "2019-09-04",
                "press_title": "Lilly to Participate in Morgan Stanley Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2019-09-04-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and...",
                "1d_change": 0.1919679037,
                "index_price": 1.7248010123,
                "norm_price": -1.5328331086
            },
            {
                "index": 472,
                "date": "2019-08-26",
                "press_title": "Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)",
                "release_url": "http://lilly.mediaroom.com/2019-08-26-Lilly-Receives-U-S-FDA-Approval-for-Taltz-R-ixekizumab-for-the-Treatment-of-Active-Ankylosing-Spondylitis-Radiographic-Axial-Spondyloarthritis",
                "content": "error_http",
                "1d_change": 0.1083809199,
                "index_price": 0.0857380213,
                "norm_price": 0.0226428985
            },
            {
                "index": 473,
                "date": "2019-08-23",
                "press_title": "Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis",
                "release_url": "http://lilly.mediaroom.com/2019-08-23-Lilly-Announces-Top-Line-Phase-3-Results-for-Oral-JAK-Inhibitor-Baricitinib-in-Combination-with-Topical-Corticosteroids-in-Adult-Patients-with-Moderate-to-Severe-Atopic-Dermatitis",
                "content": "Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD...",
                "1d_change": 0.2862802989,
                "index_price": -1.1357147728,
                "norm_price": 1.4219950717
            },
            {
                "index": 474,
                "date": "2019-08-22",
                "press_title": "Arbitration panel rules in favor of Lilly in complaint filed by Adocia",
                "release_url": "http://lilly.mediaroom.com/2019-08-22-Arbitration-panel-rules-in-favor-of-Lilly-in-complaint-filed-by-Adocia",
                "content": "A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY) in a claim filed by Adocia S.A. over the companies' prior collaboration on a rapid-acting insulin. The...",
                "1d_change": -1.7624054393,
                "index_price": -2.9443832806,
                "norm_price": 1.1819778413
            },
            {
                "index": 475,
                "date": "2019-08-19",
                "press_title": "Lilly Announces Webcast to Discuss World Conference on Lung Cancer Presentation",
                "release_url": "http://lilly.mediaroom.com/2019-08-19-Lilly-Announces-Webcast-to-Discuss-World-Conference-on-Lung-Cancer-Presentation",
                "content": "Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at the 20th meeting of the International...",
                "1d_change": -0.0360304816,
                "index_price": -0.4471617288,
                "norm_price": 0.4111312472
            },
            {
                "index": 476,
                "date": "2019-08-14",
                "press_title": "Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health",
                "release_url": "http://lilly.mediaroom.com/2019-08-14-Lilly-Launches-Open-Innovation-Challenge-to-Help-Transform-Inflammatory-Bowel-Disease-IBD-Care-through-Digital-Health",
                "content": "Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering digital health solutions aimed at...",
                "1d_change": -4.2002921654,
                "index_price": -1.6347030163,
                "norm_price": -2.5655891492
            },
            {
                "index": 477,
                "date": "2019-08-13",
                "press_title": "Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis",
                "release_url": "http://lilly.mediaroom.com/2019-08-13-Lilly-Announces-Superiority-of-Taltz-R-ixekizumab-versus-TREMFYA-R-guselkumab-in-Delivering-Total-Skin-Clearance-at-Week-12-in-Topline-Results-from-Head-to-Head-IXORA-R-Trial-in-People-Living-with-Moderate-to-Severe-Plaque-Psoriasis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy...",
                "1d_change": -2.3638464621,
                "index_price": -1.4123731489,
                "norm_price": -0.9514733132
            },
            {
                "index": 478,
                "date": "2019-08-09",
                "press_title": "U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit",
                "release_url": "http://lilly.mediaroom.com/2019-08-09-U-S-Court-of-Appeals-Rules-in-Favor-of-Lilly-in-Alimta-Alternate-Salt-Form-Patent-Lawsuit",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lilly, confirming that the Alimta® (pemetrexed for injection) vitamin...",
                "1d_change": 0.3169141124,
                "index_price": -1.6585166477,
                "norm_price": 1.9754307601
            },
            {
                "index": 479,
                "date": "2019-08-08",
                "press_title": "Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia",
                "release_url": "http://lilly.mediaroom.com/2019-08-08-Lilly-Evidation-Health-and-Apple-Study-Shows-Personal-Digital-Devices-May-Help-in-the-Identification-of-Mild-Cognitive-Impairment-and-Mild-Alzheimers-Disease-Dementia",
                "content": "Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL) showed that an iPhone, Apple Watch, iPad and the Beddit...",
                "1d_change": 1.5909121023,
                "index_price": 0.7688466297,
                "norm_price": 0.8220654726
            },
            {
                "index": 480,
                "date": "2019-08-07",
                "press_title": "Lilly Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services",
                "release_url": "http://lilly.mediaroom.com/2019-08-07-Lilly-Announces-Leadership-Changes-in-Corporate-Business-Development-Oncology-R-D-and-Managed-Healthcare-Services",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations. Darren...",
                "1d_change": 3.1587264259,
                "index_price": 2.7038035993,
                "norm_price": 0.4549228266
            },
            {
                "index": 481,
                "date": "2019-08-05",
                "press_title": "Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments",
                "release_url": "http://lilly.mediaroom.com/2019-08-05-Lilly-Announces-Positive-Results-for-Emgality-R-galcanezumab-gnlm-from-the-CONQUER-Study-in-Patients-who-Failed-Previous-Migraine-Preventive-Treatments",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety...",
                "1d_change": 0.0179664167,
                "index_price": -0.5656262893,
                "norm_price": 0.5835927061
            },
            {
                "index": 482,
                "date": "2019-07-30",
                "press_title": "Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance",
                "release_url": "http://lilly.mediaroom.com/2019-07-30-Lilly-Reports-Second-Quarter-2019-Financial-Results-Raises-2019-EPS-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2019. $ in millions, except per share data Second Quarter % 2019 2018 Change Revenue $ 5,636.7 $...",
                "1d_change": 0.5966098773,
                "index_price": -0.915320542,
                "norm_price": 1.5119304193
            },
            {
                "index": 483,
                "date": "2019-07-30",
                "press_title": "Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2",
                "release_url": "http://lilly.mediaroom.com/2019-07-30-Lillys-Verzenio-R-abemaciclib-Significantly-Extended-Life-in-Women-with-HR-HER2-Advanced-Breast-Cancer-in-MONARCH-2",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall survival in the Phase 3 MONARCH 2 clinical trial....",
                "1d_change": 0.5966098773,
                "index_price": -0.915320542,
                "norm_price": 1.5119304193
            },
            {
                "index": 484,
                "date": "2019-07-24",
                "press_title": "BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA",
                "release_url": "http://lilly.mediaroom.com/2019-07-24-BAQSIMI-TM-glucagon-Nasal-Powder-3-mg-the-First-and-Only-Nasally-Administered-Glucagon-to-Treat-Severe-Hypoglycemia-in-Adults-and-Children-with-Diabetes-Ages-Four-Years-and-Older-Approved-by-FDA",
                "content": "The U.S. Food and Drug Administration (FDA) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above, Eli...",
                "1d_change": -0.4915643918,
                "index_price": 0.1631305194,
                "norm_price": -0.6546949112
            },
            {
                "index": 485,
                "date": "2019-07-13",
                "press_title": "Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study",
                "release_url": "http://lilly.mediaroom.com/2019-07-13-Lilly-Presents-New-Findings-on-Stigma-Faced-by-People-with-Migraine-Based-on-Interim-Results-from-the-OVERCOME-Observational-Study",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the presentation of data about personal attitudes toward migraine among people without the disease.1 These data are from the OVERCOME...",
                "1d_change": 0.4778417635,
                "index_price": -0.4580501454,
                "norm_price": 0.9358919089
            },
            {
                "index": 486,
                "date": "2019-07-12",
                "press_title": "Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine",
                "release_url": "http://lilly.mediaroom.com/2019-07-12-Lillys-OVERCOME-Observational-Study-Reveals-Inconsistent-and-Sub-Optimal-Treatment-Landscape-for-Migraine",
                "content": "Eli Lilly and Company (NYSE: LLY) announced the upcoming presentation of data highlighting inconsistent and sub-optimal treatment patterns that people living with migraine experience across the...",
                "1d_change": -0.9219095855,
                "index_price": 0.3629347188,
                "norm_price": -1.2848443043
            },
            {
                "index": 487,
                "date": "2019-07-12",
                "press_title": "AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine",
                "release_url": "http://lilly.mediaroom.com/2019-07-12-AHS-2019-Post-Hoc-Analyses-of-Phase-3-Pivotal-Studies-of-Emgality-R-galcanezumab-gnlm-Show-Improvements-in-Daily-Functioning-and-Reductions-in-Disability-in-Patients-with-Chronic-and-Episodic-Migraine",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the presentation of post-hoc analyses showing improvements in daily functioning and reductions in disability in patients with chronic and episodic...",
                "1d_change": -0.9219095855,
                "index_price": 0.3629347188,
                "norm_price": -1.2848443043
            },
            {
                "index": 488,
                "date": "2019-07-11",
                "press_title": "Lilly Announces Changes in Senior Leadership",
                "release_url": "http://lilly.mediaroom.com/2019-07-11-Lilly-Announces-Changes-in-Senior-Leadership",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced several changes to the company's executive committee. Mike Harrington, senior vice president and general counsel, will retire at the end of the...",
                "1d_change": -2.9919700338,
                "index_price": 0.469508365,
                "norm_price": -3.4614783988
            },
            {
                "index": 489,
                "date": "2019-07-11",
                "press_title": "New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache",
                "release_url": "http://lilly.mediaroom.com/2019-07-11-New-England-Journal-of-Medicine-Publishes-Positive-Phase-3-Data-for-Emgality-R-galcanezumab-gnlm-in-Episodic-Cluster-Headache",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine published positive Phase 3 study results of Emgality® (galcanezumab-gnlm) for the treatment of episodic...",
                "1d_change": -2.9919700338,
                "index_price": 0.469508365,
                "norm_price": -3.4614783988
            },
            {
                "index": 490,
                "date": "2019-07-10",
                "press_title": "Lilly Announces Upcoming Presentation of New Data Indicating Rise in Opioid Use for Migraine Treatment",
                "release_url": "http://lilly.mediaroom.com/2019-07-10-Lilly-Announces-Upcoming-Presentation-of-New-Data-Indicating-Rise-in-Opioid-Use-for-Migraine-Treatment",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of data indicating rising rates of opioid use for the treatment of migraine based on results from the OVERCOME...",
                "1d_change": -3.1415117348,
                "index_price": 0.3536727299,
                "norm_price": -3.4951844647
            },
            {
                "index": 491,
                "date": "2019-07-09",
                "press_title": "Lilly Confirms Date and Conference Call for Second-Quarter 2019 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2019-07-09-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2019-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2019 financial results on Tuesday, July 30, 2019. Lilly will also conduct a conference call on that day with the investment...",
                "1d_change": 2.3400176499,
                "index_price": 0.9204612053,
                "norm_price": 1.4195564445
            },
            {
                "index": 492,
                "date": "2019-06-26",
                "press_title": "Lilly's AWARD-11 trial studying higher investigational doses of Trulicity® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2019-06-26-Lillys-AWARD-11-trial-studying-higher-investigational-doses-of-Trulicity-R-dulaglutide-demonstrated-superiority-in-A1C-reduction-in-people-with-type-2-diabetes",
                "content": "Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity® (dulaglutide) met its primary efficacy endpoint of superiority, significantly reducing A1C from...",
                "1d_change": -2.9963084818,
                "index_price": -0.0393223239,
                "norm_price": -2.9569861579
            },
            {
                "index": 493,
                "date": "2019-06-26",
                "press_title": "U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure",
                "release_url": "http://lilly.mediaroom.com/2019-06-26-U-S-FDA-Grants-Fast-Track-Designation-to-Empagliflozin-for-the-Treatment-of-Chronic-Heart-Failure",
                "content": "The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization for heart failure in...",
                "1d_change": -2.9963084818,
                "index_price": -0.0393223239,
                "norm_price": -2.9569861579
            },
            {
                "index": 494,
                "date": "2019-06-19",
                "press_title": "Lilly Declares Third-Quarter 2019 Dividend",
                "release_url": "http://lilly.mediaroom.com/2019-06-19-Lilly-Declares-Third-Quarter-2019-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2019 of $0.645 per share on outstanding common stock. The dividend is payable September...",
                "1d_change": 0.4672786915,
                "index_price": 1.1383830231,
                "norm_price": -0.6711043315
            },
            {
                "index": 495,
                "date": "2019-06-14",
                "press_title": "Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology",
                "release_url": "http://lilly.mediaroom.com/2019-06-14-Lilly-Presents-Positive-Results-for-Taltz-R-ixekizumab-vs-Humira-R-adalimumab-in-a-Head-to-Head-SPIRIT-H2H-Superiority-Study-in-Patients-with-Active-Psoriatic-Arthritis-at-the-European-Congress-of-Rheumatology",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis...",
                "1d_change": 1.1199270427,
                "index_price": 0.0986221123,
                "norm_price": 1.0213049304
            },
            {
                "index": 496,
                "date": "2019-06-11",
                "press_title": "Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology",
                "release_url": "http://lilly.mediaroom.com/2019-06-11-Lilly-to-Present-5-Year-Sustained-Efficacy-and-Safety-Results-for-Taltz-R-ixekizumab-in-Patients-with-Plaque-Psoriasis-at-the-World-Congress-of-Dermatology",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz® (ixekizumab). Patients with moderate- to severe plaque psoriasis who...",
                "1d_change": 0.3991720864,
                "index_price": -0.8135844674,
                "norm_price": 1.2127565538
            },
            {
                "index": 497,
                "date": "2019-06-10",
                "press_title": "Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®",
                "release_url": "http://lilly.mediaroom.com/2019-06-10-Detailed-findings-from-CAROLINA-R-outcome-trial-support-long-term-cardiovascular-safety-profile-of-Tradjenta-R",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced detailed findings from the CAROLINA® trial demonstrating that Tradjenta® (linagliptin) did not increase cardiovascular risk...",
                "1d_change": -3.3776011166,
                "index_price": -0.0038155962,
                "norm_price": -3.3737855204
            },
            {
                "index": 498,
                "date": "2019-06-10",
                "press_title": "New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria",
                "release_url": "http://lilly.mediaroom.com/2019-06-10-New-analysis-shows-cardiorenal-risk-reductions-of-Jardiance-R-are-consistent-in-adults-with-type-2-diabetes-cardiovascular-disease-and-kidney-disease-without-overt-proteinuria",
                "content": "A new post-hoc analysis of data from the EMPA-REG OUTCOME® trial indicates a consistent effect of Jardiance® (empagliflozin) on reducing cardiovascular and renal risk in adults with type 2...",
                "1d_change": -3.3776011166,
                "index_price": -0.0038155962,
                "norm_price": -3.3737855204
            },
            {
                "index": 499,
                "date": "2019-06-09",
                "press_title": "Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2019-06-09-Trulicity-R-dulaglutide-significantly-reduced-major-cardiovascular-events-for-broad-range-of-people-with-type-2-diabetes",
                "content": "Detailed results from REWIND, the Trulicity® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major cardiovascular events (MACE), a composite endpoint of...",
                "1d_change": -3.3776011166,
                "index_price": -0.0038155962,
                "norm_price": -3.3737855204
            },
            {
                "index": 500,
                "date": "2019-06-09",
                "press_title": "Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions",
                "release_url": "http://lilly.mediaroom.com/2019-06-09-Lillys-ultra-rapid-lispro-provided-similar-A1C-reductions-compared-to-Humalog-R-insulin-lispro-with-superior-post-meal-blood-glucose-reductions",
                "content": "Two phase 3 studies show that Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) provided non-inferior A1C reductions compared to Humalog® (insulin lispro) at 26 weeks in people with...",
                "1d_change": -3.3776011166,
                "index_price": -0.0038155962,
                "norm_price": -3.3737855204
            },
            {
                "index": 501,
                "date": "2019-06-08",
                "press_title": "Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions®",
                "release_url": "http://lilly.mediaroom.com/2019-06-08-Lillys-tirzepatide-demonstrates-benefits-in-data-presented-at-the-American-Diabetes-Associations-R-79-Scientific-Sessions-R",
                "content": "Results from several studies of Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight...",
                "1d_change": -3.3776011166,
                "index_price": -0.0038155962,
                "norm_price": -3.3737855204
            },
            {
                "index": 502,
                "date": "2019-06-06",
                "press_title": "Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology",
                "release_url": "http://lilly.mediaroom.com/2019-06-06-Lilly-to-Present-New-Data-and-Commitment-to-Patient-Centered-Solutions-at-the-Annual-European-Congress-of-Rheumatology",
                "content": "Eli Lilly and Company (NYSE: LLY) will present data for Taltz® (ixekizumab) and Olumiant® (baricitinib) at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid from June 12-15,...",
                "1d_change": 0.7013150039,
                "index_price": 1.560207868,
                "norm_price": -0.8588928641
            },
            {
                "index": 503,
                "date": "2019-06-05",
                "press_title": "Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology",
                "release_url": "http://lilly.mediaroom.com/2019-06-05-Lilly-to-Showcase-Scientific-Innovation-within-Dermatology-Portfolio-at-24th-World-Congress-of-Dermatology",
                "content": "Eli Lilly and Company (NYSE: LLY) will present data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 24th World Congress of Dermatology (WCD) taking place June 10-15, 2019...",
                "1d_change": -0.4510683461,
                "index_price": 0.8932650521,
                "norm_price": -1.3443333982
            },
            {
                "index": 504,
                "date": "2019-06-04",
                "press_title": "FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks",
                "release_url": "http://lilly.mediaroom.com/2019-06-04-FDA-Approves-Emgality-R-galcanezumab-gnlm-as-the-First-and-Only-Medication-for-the-Treatment-of-Episodic-Cluster-Headache-that-Reduces-the-Frequency-of-Attacks",
                "content": "INDIANAPOLIS, June 04, 2019 – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality® (galcanezumab-gnlm) injection (300 mg)...",
                "1d_change": -0.9058514304,
                "index_price": 2.2472272158,
                "norm_price": -3.1530786463
            },
            {
                "index": 505,
                "date": "2019-06-04",
                "press_title": "U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2019-06-04-U-S-FDA-Accepts-New-Drug-Application-for-Triple-Combination-Tablet-for-Adults-with-Type-2-Diabetes",
                "content": "The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended...",
                "1d_change": -0.9058514304,
                "index_price": 2.2472272158,
                "norm_price": -3.1530786463
            },
            {
                "index": 506,
                "date": "2019-05-31",
                "press_title": "Hurricane Season is Almost Here. Are You Ready?",
                "release_url": "http://lilly.mediaroom.com/2019-05-31-Hurricane-Season-is-Almost-Here-Are-You-Ready",
                "content": "The 2019 Atlantic hurricane season begins June 1. With natural disasters and extreme weather on the rise, it's critical to be prepared and ready to respond. That's why Eli Lilly and Company (NYSE:...",
                "1d_change": 1.2246437827,
                "index_price": -0.7906848934,
                "norm_price": 2.0153286761
            },
            {
                "index": 507,
                "date": "2019-05-30",
                "press_title": "Lilly to Participate in Goldman Sachs Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2019-05-30-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019. Joshua Smiley, senior vice president and Lilly's chief...",
                "1d_change": 0.3881218869,
                "index_price": -1.2674099427,
                "norm_price": 1.6555318297
            },
            {
                "index": 508,
                "date": "2019-05-29",
                "press_title": "Lilly Announces Webcast to Discuss ADA Presentations and Diabetes Portfolio",
                "release_url": "http://lilly.mediaroom.com/2019-05-29-Lilly-Announces-Webcast-to-Discuss-ADA-Presentations-and-Diabetes-Portfolio",
                "content": "Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 10, 2019 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's 79th...",
                "1d_change": 0.2502265327,
                "index_price": -0.0498373,
                "norm_price": 0.3000638327
            },
            {
                "index": 509,
                "date": "2019-05-28",
                "press_title": "Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics",
                "release_url": "http://lilly.mediaroom.com/2019-05-28-Lilly-Announces-Licensing-Agreement-for-Non-Opioid-Pain-Asset-from-Centrexion-Therapeutics",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on...",
                "1d_change": -1.3854134917,
                "index_price": -1.6891725333,
                "norm_price": 0.3037590416
            },
            {
                "index": 510,
                "date": "2019-05-22",
                "press_title": "Lilly's Lower-Priced Insulin Now Available",
                "release_url": "http://lilly.mediaroom.com/2019-05-22-Lillys-Lower-Priced-Insulin-Now-Available",
                "content": "Eli Lilly and Company's (NYSE: LLY) Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin and need a lower-cost option. Lilly's Insulin...",
                "1d_change": 0.5907003668,
                "index_price": -1.1983413344,
                "norm_price": 1.7890417012
            },
            {
                "index": 511,
                "date": "2019-05-21",
                "press_title": "Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions",
                "release_url": "http://lilly.mediaroom.com/2019-05-21-Lillys-Mirikizumab-Met-Primary-Endpoint-and-Key-Secondary-Endpoints-in-Phase-2-Study-Including-Reductions-of-Gastrointestinal-Lesions",
                "content": "In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company (NYSE: LLY) announced new safety and efficacy data for mirikizumab...",
                "1d_change": 0.7967439072,
                "index_price": 0.0787740649,
                "norm_price": 0.7179698423
            },
            {
                "index": 512,
                "date": "2019-05-16",
                "press_title": "Lilly to Participate in UBS Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2019-05-16-Lilly-to-Participate-in-UBS-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 21, 2019. Christi Shaw, president of Lilly Bio-Medicines, will participate in a fireside chat at...",
                "1d_change": 1.2412725732,
                "index_price": 0.1304403322,
                "norm_price": 1.1108322411
            },
            {
                "index": 513,
                "date": "2019-05-15",
                "press_title": "Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer",
                "release_url": "http://lilly.mediaroom.com/2019-05-15-Data-Presentations-at-ASCO-2019-Highlight-Lillys-Targeted-Approach-to-Developing-Treatments-for-Patients-Living-with-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that data from a number of studies across the company's oncology product portfolio will be presented at the 55th Annual Meeting of the American...",
                "1d_change": 1.8186787258,
                "index_price": 1.944852597,
                "norm_price": -0.1261738711
            },
            {
                "index": 514,
                "date": "2019-05-15",
                "press_title": "Lilly to Participate in Bank of America Merrill Lynch Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2019-05-15-Lilly-to-Participate-in-Bank-of-America-Merrill-Lynch-Health-Care-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019. Enrique Conterno, senior vice president of Lilly and...",
                "1d_change": 1.8186787258,
                "index_price": 1.944852597,
                "norm_price": -0.1261738711
            },
            {
                "index": 515,
                "date": "2019-05-13",
                "press_title": "Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma",
                "release_url": "http://lilly.mediaroom.com/2019-05-13-Lillys-CYRAMZA-R-ramucirumab-Becomes-First-FDA-Approved-Biomarker-Driven-Therapy-in-Patients-with-Hepatocellular-Carcinoma",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), as a single agent, for the...",
                "1d_change": 0.0695871212,
                "index_price": -0.2039235494,
                "norm_price": 0.2735106706
            },
            {
                "index": 516,
                "date": "2019-05-08",
                "press_title": "AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience",
                "release_url": "http://lilly.mediaroom.com/2019-05-08-AAN-2019-Two-New-Analyses-of-Lasmiditan-Phase-3-Studies-Measured-Onset-of-Effect-and-the-Effect-of-Lasmiditan-in-Patients-with-Prior-Triptan-Experience",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced new data and post-hoc analyses for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, being...",
                "1d_change": -0.0431705751,
                "index_price": -0.3096831739,
                "norm_price": 0.2665125988
            },
            {
                "index": 517,
                "date": "2019-05-06",
                "press_title": "Lilly Declares Second-Quarter 2019 Dividend",
                "release_url": "http://lilly.mediaroom.com/2019-05-06-Lilly-Declares-Second-Quarter-2019-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2019 of $0.645 per share on outstanding common stock. The dividend is payable June 10,...",
                "1d_change": -0.7656235936,
                "index_price": -0.8612833803,
                "norm_price": 0.0956597867
            },
            {
                "index": 518,
                "date": "2019-05-06",
                "press_title": "AAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups",
                "release_url": "http://lilly.mediaroom.com/2019-05-06-AAN-2019-Pooled-Analyses-of-Two-Emgality-R-galcanezumab-gnlm-Phase-3-Studies-Show-Reduction-in-Monthly-Migraine-Headache-Days-in-Low-and-High-Frequency-Episodic-Migraine-Subgroups",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase 3 EVOLVE-1 and EVOLVE-2 studies. These analyses...",
                "1d_change": -0.7656235936,
                "index_price": -0.8612833803,
                "norm_price": 0.0956597867
            },
            {
                "index": 519,
                "date": "2019-05-02",
                "press_title": "Lilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio",
                "release_url": "http://lilly.mediaroom.com/2019-05-02-Lilly-to-Present-New-Data-at-AAN-2019-on-Emgality-R-galcanezumab-gnlm-and-Lasmiditan-Reinforcing-Breadth-of-Headache-Disorders-Portfolio",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today it will present 19 scientific abstracts for Emgality® (galcanezumab-gnlm) and lasmiditan at the 71st Annual Meeting of the American Academy of...",
                "1d_change": -1.3087025093,
                "index_price": 0.7971096714,
                "norm_price": -2.1058121807
            },
            {
                "index": 520,
                "date": "2019-04-30",
                "press_title": "Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance to Reflect Disposition of Elanco Animal Health",
                "release_url": "http://lilly.mediaroom.com/2019-04-30-Lilly-Reports-Solid-First-Quarter-2019-Financial-Results-Updates-2019-Guidance-to-Reflect-Disposition-of-Elanco-Animal-Health",
                "content": "INDIANAPOLIS, April 30, 2019 PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2019. $ in millions, except per share data First Quarter % 2019",
                "1d_change": 1.3284989994,
                "index_price": -0.4586576804,
                "norm_price": 1.7871566798
            },
            {
                "index": 521,
                "date": "2019-04-26",
                "press_title": "U.S. Court of Appeals Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit",
                "release_url": "http://lilly.mediaroom.com/2019-04-26-U-S-Court-of-Appeals-Rules-in-Favor-of-Lilly-in-Alimta-Vitamin-Regimen-Patent-Lawsuit",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in the company's favor regarding patentability of the vitamin regimen for...",
                "1d_change": 0.6438114714,
                "index_price": 0.5851102616,
                "norm_price": 0.0587012098
            },
            {
                "index": 522,
                "date": "2019-04-25",
                "press_title": "Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market",
                "release_url": "http://lilly.mediaroom.com/2019-04-25-Lilly-to-Establish-an-Access-Program-for-Patients-as-it-Prepares-to-Withdraw-Lartruvo-from-the-Global-Market",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the company has been working to facilitate the withdrawal of Lartruvo® (olaratumab) from the market for the treatment of advanced soft...",
                "1d_change": 1.7685820899,
                "index_price": 0.3704196434,
                "norm_price": 1.3981624465
            },
            {
                "index": 523,
                "date": "2019-04-22",
                "press_title": "Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China",
                "release_url": "http://lilly.mediaroom.com/2019-04-22-Lilly-Announces-Sale-of-Legacy-Antibiotics-Brands-and-Manufacturing-Facility-in-China",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor® and Vancocin®, as well as a...",
                "1d_change": 2.0852840406,
                "index_price": 1.1896288333,
                "norm_price": 0.8956552073
            },
            {
                "index": 524,
                "date": "2019-04-22",
                "press_title": "Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis",
                "release_url": "http://lilly.mediaroom.com/2019-04-22-Lilly-Announces-Positive-Top-Line-Results-for-COAST-X-a-52-Week-Placebo-Controlled-Study-of-Taltz-R-ixekizumab-in-Patients-with-Non-Radiographic-Axial-Spondyloarthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of...",
                "1d_change": 2.0852840406,
                "index_price": 1.1896288333,
                "norm_price": 0.8956552073
            },
            {
                "index": 525,
                "date": "2019-04-22",
                "press_title": "Lilly and Avidity Biosciences Announce Licensing and Research Collaboration",
                "release_url": "http://lilly.mediaroom.com/2019-04-22-Lilly-and-Avidity-Biosciences-Announce-Licensing-and-Research-Collaboration",
                "content": "Eli Lilly and Company (NYSE: LLY) and Avidity Biosciences, Inc. today announced a global licensing and research collaboration focused on the discovery, development and commercialization of...",
                "1d_change": 2.0852840406,
                "index_price": 1.1896288333,
                "norm_price": 0.8956552073
            },
            {
                "index": 526,
                "date": "2019-04-18",
                "press_title": "Pfizer and Lilly Announce Top-Line Results from Long-Term Phase 3 Study of Tanezumab in Patients with Osteoarthritis",
                "release_url": "http://lilly.mediaroom.com/2019-04-18-Pfizer-and-Lilly-Announce-Top-Line-Results-from-Long-Term-Phase-3-Study-of-Tanezumab-in-Patients-with-Osteoarthritis",
                "content": "NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE)and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The...",
                "1d_change": -0.6581616311,
                "index_price": 0.1086638494,
                "norm_price": -0.7668254805
            },
            {
                "index": 527,
                "date": "2019-03-26",
                "press_title": "Lilly and ImmuNext Announce Licensing and Research Collaboration",
                "release_url": "http://lilly.mediaroom.com/2019-03-26-Lilly-and-ImmuNext-Announce-Licensing-and-Research-Collaboration",
                "content": "error_http",
                "1d_change": -1.1415825455,
                "index_price": -0.2598514498,
                "norm_price": -0.8817310957
            },
            {
                "index": 528,
                "date": "2019-03-21",
                "press_title": "Survey Reveals Genital Psoriasis May Reduce Patients’ Self-Confidence and Hinder Them from Having Close Relationships",
                "release_url": "http://lilly.mediaroom.com/2019-03-21-Survey-Reveals-Genital-Psoriasis-May-Reduce-Patients-Self-Confidence-and-Hinder-Them-from-Having-Close-Relationships",
                "content": "INDIANAPOLIS, March 21, 2019 – Eli Lilly and Company (NYSE:LLY) announced today findings from a quantitative opinion survey, which found that people with genital psoriasis can experience reduced...",
                "1d_change": 1.1067851493,
                "index_price": -0.6787568163,
                "norm_price": 1.7855419657
            },
            {
                "index": 529,
                "date": "2019-03-20",
                "press_title": "NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology",
                "release_url": "http://lilly.mediaroom.com/2019-03-20-NCCN-Announces-Six-Quality-Improvement-Projects-in-Gastric-Cancer-Care-Approved-for-Collaboration-with-Lilly-Oncology",
                "content": "PLYMOUTH MEETING, PA and INDIANAPOLIS, IN [March 20, 2019] — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) and Eli Lilly and Company (NYSE: LLY) today...",
                "1d_change": 0.6001094369,
                "index_price": 0.8245458964,
                "norm_price": -0.2244364595
            },
            {
                "index": 530,
                "date": "2019-03-13",
                "press_title": "Lilly Announces Final Results of Elanco Exchange Offer",
                "release_url": "http://lilly.mediaroom.com/2019-03-13-Lilly-Announces-Final-Results-of-Elanco-Exchange-Offer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the final results of its offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated...",
                "1d_change": -1.2349623319,
                "index_price": 0.3097743702,
                "norm_price": -1.5447367021
            },
            {
                "index": 531,
                "date": "2019-03-12",
                "press_title": "Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/2019-03-12-Lillys-CYRAMZA-R-ramucirumab-Phase-3-RELAY-Trial-Met-Primary-Endpoint-Significantly-Improving-Progression-Free-Survival-in-First-Line-Treatment-of-Patients-with-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RELAY study of CYRAMZA® (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically...",
                "1d_change": 0.6516025656,
                "index_price": 0.8388653765,
                "norm_price": -0.1872628108
            },
            {
                "index": 532,
                "date": "2019-03-11",
                "press_title": "Lilly Announces Preliminary Results of Elanco Exchange Offer",
                "release_url": "http://lilly.mediaroom.com/2019-03-11-Lilly-Announces-Preliminary-Results-of-Elanco-Exchange-Offer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that, based on preliminary results, its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of...",
                "1d_change": 0.5667991484,
                "index_price": 1.5729750029,
                "norm_price": -1.0061758546
            },
            {
                "index": 533,
                "date": "2019-03-08",
                "press_title": "Lilly to Participate in Barclays Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2019-03-08-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and...",
                "1d_change": -2.3238978696,
                "index_price": 1.8866097382,
                "norm_price": -4.2105076079
            },
            {
                "index": 534,
                "date": "2019-03-07",
                "press_title": "Lilly to Participate in Cowen Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2019-03-07-Lilly-to-Participate-in-Cowen-Health-Care-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019. Joshua Smiley, senior vice president and Lilly's chief...",
                "1d_change": 0.228879547,
                "index_price": -0.855244684,
                "norm_price": 1.084124231
            },
            {
                "index": 535,
                "date": "2019-03-07",
                "press_title": "Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer",
                "release_url": "http://lilly.mediaroom.com/2019-03-07-Lilly-Announces-Final-Exchange-Ratio-of-4-5121-for-Elanco-Exchange-Offer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the final exchange ratio for its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco...",
                "1d_change": 0.228879547,
                "index_price": -0.855244684,
                "norm_price": 1.084124231
            },
            {
                "index": 536,
                "date": "2019-03-05",
                "press_title": "Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults",
                "release_url": "http://lilly.mediaroom.com/2019-03-05-Lilly-Receives-FDA-Priority-Review-Designation-for-Emgality-R-galcanezumab-gnlm-Injection-for-the-Preventive-Treatment-of-Episodic-Cluster-Headache-in-Adults",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental Biologics License Application (sBLA) for...",
                "1d_change": -1.3577620302,
                "index_price": -0.8284458079,
                "norm_price": -0.5293162223
            },
            {
                "index": 537,
                "date": "2019-03-04",
                "press_title": "Lilly to Introduce Lower-Priced Insulin",
                "release_url": "http://lilly.mediaroom.com/2019-03-04-Lilly-to-Introduce-Lower-Priced-Insulin",
                "content": "Reinforcing our commitment to lower out-of-pocket costs for people who need insulin, Eli Lilly and Company (NYSE: LLY) today announced we will introduce a lower-priced version of Humalog®...",
                "1d_change": -1.5720820854,
                "index_price": -0.8861404015,
                "norm_price": -0.685941684
            },
            {
                "index": 538,
                "date": "2019-03-01",
                "press_title": "Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2019-03-01-Lilly-to-Present-Data-Demonstrating-Continued-Scientific-Advancements-in-Broad-Dermatology-Portfolio-at-AAD-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) announced that it will present data for Taltz® (ixekizumab) and mirikizumab at the American Academy of Dermatology (AAD) annual meeting taking place March 1-5,...",
                "1d_change": 0.1647572216,
                "index_price": -0.1937085586,
                "norm_price": 0.3584657802
            },
            {
                "index": 539,
                "date": "2019-02-19",
                "press_title": "Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain",
                "release_url": "http://lilly.mediaroom.com/2019-02-19-Pfizer-and-Lilly-Announce-Top-line-Results-From-Phase-3-Study-of-Tanezumab-in-Chronic-Low-Back-Pain",
                "content": "Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low...",
                "1d_change": 1.1006176275,
                "index_price": 0.5537372839,
                "norm_price": 0.5468803436
            },
            {
                "index": 540,
                "date": "2019-02-15",
                "press_title": "Lilly Completes Acquisition of Loxo Oncology",
                "release_url": "http://lilly.mediaroom.com/2019-02-15-Lilly-Completes-Acquisition-of-Loxo-Oncology",
                "content": "Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc. (NASDAQ:LOXO). The acquisition broadens the scope of Lilly's oncology portfolio...",
                "1d_change": 0.7778465761,
                "index_price": 0.7022195968,
                "norm_price": 0.0756269794
            },
            {
                "index": 541,
                "date": "2019-02-14",
                "press_title": "Lilly To Participate in Leerink Partners Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2019-02-14-Lilly-To-Participate-in-Leerink-Partners-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019. Christi Shaw, president of Lilly Bio-Medicines, will...",
                "1d_change": 2.8902718686,
                "index_price": 1.1565101789,
                "norm_price": 1.7337616896
            },
            {
                "index": 542,
                "date": "2019-02-14",
                "press_title": "Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride",
                "release_url": "http://lilly.mediaroom.com/2019-02-14-Boehringer-Ingelheim-and-Lilly-announce-the-CAROLINA-R-cardiovascular-outcome-trial-of-Tradjenta-R-met-its-primary-endpoint-of-non-inferiority-compared-with-glimepiride",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary...",
                "1d_change": 2.8902718686,
                "index_price": 1.1565101789,
                "norm_price": 1.7337616896
            },
            {
                "index": 543,
                "date": "2019-02-08",
                "press_title": "Lilly to Participate in Guggenheim Healthcare Talks Idea Forum",
                "release_url": "http://lilly.mediaroom.com/2019-02-08-Lilly-to-Participate-in-Guggenheim-Healthcare-Talks-Idea-Forum",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019. Anne White, president of Lilly Oncology, and Levi Garraway, M.D.,...",
                "1d_change": 0.2372859745,
                "index_price": 0.6435877589,
                "norm_price": -0.4063017845
            },
            {
                "index": 544,
                "date": "2019-02-08",
                "press_title": "Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health",
                "release_url": "http://lilly.mediaroom.com/2019-02-08-Lilly-Will-Initiate-Divestiture-of-its-Remaining-Interest-in-Elanco-Animal-Health",
                "content": "Eli Lilly and Company (NYSE: LLY) announced it will initiate an exchange offer today to divest its remaining interest in Elanco Animal Health (NYSE: ELAN). Elanco completed its initial public...",
                "1d_change": 0.2372859745,
                "index_price": 0.6435877589,
                "norm_price": -0.4063017845
            },
            {
                "index": 545,
                "date": "2019-02-06",
                "press_title": "Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology",
                "release_url": "http://lilly.mediaroom.com/2019-02-06-Lilly-Reports-Strong-Fourth-Quarter-and-Full-Year-2018-Financial-Results-Lowers-2019-EPS-Guidance-to-Reflect-the-Pending-Acquisition-of-Loxo-Oncology",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2018. $ in millions, except per share data Fourth Quarter % Full Year % 2018 2017 Change...",
                "1d_change": -0.995753853,
                "index_price": -1.071672714,
                "norm_price": 0.075918861
            },
            {
                "index": 546,
                "date": "2019-02-04",
                "press_title": "Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis",
                "release_url": "http://lilly.mediaroom.com/2019-02-04-Lilly-Announces-Top-Line-Phase-3-Results-for-Baricitinib-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the...",
                "1d_change": -0.6476868935,
                "index_price": 1.1400066294,
                "norm_price": -1.787693523
            },
            {
                "index": 547,
                "date": "2019-02-01",
                "press_title": "Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction",
                "release_url": "http://lilly.mediaroom.com/2019-02-01-Lilly-and-Loxo-Oncology-Announce-Expiration-of-HSR-Act-Waiting-Period-in-Connection-with-Proposed-Transaction",
                "content": "Eli Lilly and Company (NYSE: LLY) (\"Lilly\") and Loxo Oncology, Inc. (NASDAQ: LOXO) (\"Loxo Oncology\") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust...",
                "1d_change": -0.1248042894,
                "index_price": 0.8275641722,
                "norm_price": -0.9523684615
            },
            {
                "index": 548,
                "date": "2019-01-31",
                "press_title": "FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/2019-01-31-FDA-Expands-Lillys-ALIMTA-R-pemetrexed-Label-with-Combination-of-KEYTRUDA-R-pembrolizumab-and-Platinum-Chemotherapy-for-the-First-Line-Treatment-of-Metastatic-Nonsquamous-Non-Small-Cell-Lung-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new indication for ALIMTA® (pemetrexed for injection) in combination...",
                "1d_change": 3.2674317604,
                "index_price": 0.7773805882,
                "norm_price": 2.4900511721
            },
            {
                "index": 549,
                "date": "2019-01-30",
                "press_title": "Lilly Revises Date for Fourth-Quarter 2018 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2019-01-30-Lilly-Revises-Date-for-Fourth-Quarter-2018-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) has revised the date for its fourth-quarter and full-year 2018 financial results announcement. The company will now announce results on Wednesday, February 6,...",
                "1d_change": 3.6125285725,
                "index_price": 1.8667940774,
                "norm_price": 1.7457344952
            },
            {
                "index": 550,
                "date": "2019-01-29",
                "press_title": "Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain",
                "release_url": "http://lilly.mediaroom.com/2019-01-29-Pfizer-and-Lilly-Announce-Top-Line-Results-From-Second-Phase-3-Study-of-Tanezumab-in-Osteoarthritis-Pain",
                "content": "NEW YORK, NY and INDIANAPOLIS, IN – Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg...",
                "1d_change": 2.1806135685,
                "index_price": 1.3487311162,
                "norm_price": 0.8318824522
            },
            {
                "index": 551,
                "date": "2019-01-23",
                "press_title": "Government Employees Affected by Federal Shutdown Encouraged to Contact Lilly Diabetes Solution Center to Access Insulin",
                "release_url": "http://lilly.mediaroom.com/2019-01-23-Government-Employees-Affected-by-Federal-Shutdown-Encouraged-to-Contact-Lilly-Diabetes-Solution-Center-to-Access-Insulin",
                "content": "Eli Lilly and Company (NYSE: LLY) is encouraging government employees affected by the partial government shutdown to call the Lilly Diabetes Solution Center and check whether they are receiving...",
                "1d_change": -1.8436331067,
                "index_price": -0.0435184973,
                "norm_price": -1.8001146094
            },
            {
                "index": 552,
                "date": "2019-01-21",
                "press_title": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2018 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2019-01-21-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2018-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2018 financial results on Wednesday, February 13, 2019. Lilly will also conduct a conference call on that day with...",
                "1d_change": 2.609638181,
                "index_price": -0.7268705042,
                "norm_price": 3.3365086852
            },
            {
                "index": 553,
                "date": "2019-01-18",
                "press_title": "Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients",
                "release_url": "http://lilly.mediaroom.com/2019-01-18-Lilly-Phase-3-REACH-2-Trial-Data-Published-in-The-Lancet-Oncology-Shows-Improvement-in-Overall-Survival-with-CYRAMZA-R-ramucirumab-in-Second-Line-AFP-High-Hepatocellular-Carcinoma-Patients",
                "content": "Eli Lilly and Company (NYSE: LLY) announced that results from the global Phase 3 REACH-2 study of CYRAMZA® (ramucirumab) as a single agent in the second-line treatment of people with AFP-High...",
                "1d_change": 1.2895881015,
                "index_price": -0.6977142265,
                "norm_price": 1.987302328
            },
            {
                "index": 554,
                "date": "2019-01-18",
                "press_title": "Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®",
                "release_url": "http://lilly.mediaroom.com/2019-01-18-Lilly-Reports-Results-of-Phase-3-Soft-Tissue-Sarcoma-Study-of-LARTRUVO-R",
                "content": "Eli Lilly and Company (NYSE: LLY) today reported that the results of ANNOUNCE, the Phase 3 study of LARTRUVO® (olaratumab), in combination with doxorubicin in patients with advanced or metastatic...",
                "1d_change": 1.2895881015,
                "index_price": -0.6977142265,
                "norm_price": 1.987302328
            },
            {
                "index": 555,
                "date": "2019-01-07",
                "press_title": "Lilly Announces Agreement To Acquire Loxo Oncology",
                "release_url": "http://lilly.mediaroom.com/2019-01-07-Lilly-Announces-Agreement-To-Acquire-Loxo-Oncology",
                "content": "Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines through the addition of a marketed therapy and a pipeline of highly selective potential medicines for...",
                "1d_change": 3.4124076963,
                "index_price": 1.5071339069,
                "norm_price": 1.9052737894
            },
            {
                "index": 556,
                "date": "2019-01-03",
                "press_title": "Lilly to Participate in J.P. Morgan Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2019-01-03-Lilly-to-Participate-in-J-P-Morgan-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019. David A. Ricks, Lilly's chairman and chief executive officer,...",
                "1d_change": -0.0523318939,
                "index_price": 1.5806069835,
                "norm_price": -1.6329388773
            },
            {
                "index": 557,
                "date": "2018-12-19",
                "press_title": "Lilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting",
                "release_url": "http://lilly.mediaroom.com/2018-12-19-Lilly-Announces-Financial-Guidance-Reviews-Commercial-Performance-and-Highlights-Promising-Pipeline-Opportunities-at-Investment-Community-Meeting",
                "content": "2019 revenue is expected to be between $25.3 billion and $25.8 billion, representing mid-single-digit growth driven by volume from newer medicines, including Trulicity, Taltz, Basaglar, Jardiance,...",
                "1d_change": -2.0587330449,
                "index_price": -3.2272628687,
                "norm_price": 1.1685298237
            },
            {
                "index": 558,
                "date": "2018-12-19",
                "press_title": "Lilly Announces 15 Percent Dividend Increase",
                "release_url": "http://lilly.mediaroom.com/2018-12-19-Lilly-Announces-15-Percent-Dividend-Increase",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter of 2019 will be $0.645 per share on...",
                "1d_change": -2.0587330449,
                "index_price": -3.2272628687,
                "norm_price": 1.1685298237
            },
            {
                "index": 559,
                "date": "2018-12-18",
                "press_title": "Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies",
                "release_url": "http://lilly.mediaroom.com/2018-12-18-Lilly-and-Aduro-Biotech-Announce-Research-Collaboration-and-License-Agreement-to-Develop-Novel-Immunotherapies",
                "content": "Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program...",
                "1d_change": -0.2932909648,
                "index_price": -2.1117186645,
                "norm_price": 1.8184276997
            },
            {
                "index": 560,
                "date": "2018-12-18",
                "press_title": "Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis",
                "release_url": "http://lilly.mediaroom.com/2018-12-18-Lilly-announces-publication-of-analyses-showing-benefit-of-the-addition-of-Verzenio-R-abemaciclib-in-multiple-subgroups-of-patients-with-advanced-breast-cancer-identified-as-having-a-more-concerning-prognosis",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced npj Breast Cancer published results from exploratory subgroup analyses of the MONARCH 2 and MONARCH 3 trials reinforcing the clinical benefit of...",
                "1d_change": -0.2932909648,
                "index_price": -2.1117186645,
                "norm_price": 1.8184276997
            },
            {
                "index": 561,
                "date": "2018-12-17",
                "press_title": "Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis",
                "release_url": "http://lilly.mediaroom.com/2018-12-17-Lilly-Announces-Positive-Top-Line-Results-for-Taltz-R-ixekizumab-vs-Humira-R-adalimumab-in-a-Head-to-Head-SPIRIT-H2H-Superiority-Study-in-Patients-with-Active-Psoriatic-Arthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety...",
                "1d_change": -4.4225239968,
                "index_price": -1.7512681619,
                "norm_price": -2.6712558349
            },
            {
                "index": 562,
                "date": "2018-12-14",
                "press_title": "Lilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences",
                "release_url": "http://lilly.mediaroom.com/2018-12-14-Lilly-to-Acquire-Pre-Clinical-Pain-Program-from-Hydra-Biosciences",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced an agreement with Hydra Biosciences to acquire all assets related to Hydra's pre-clinical program of TRPA1 antagonists, part of the Transient...",
                "1d_change": -5.4725086598,
                "index_price": -3.2891581169,
                "norm_price": -2.1833505429
            },
            {
                "index": 563,
                "date": "2018-12-14",
                "press_title": "Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors",
                "release_url": "http://lilly.mediaroom.com/2018-12-14-Lilly-and-Evidation-Health-Expand-Collaboration-to-Analyze-Data-from-Smartphones-and-Connected-Sensors",
                "content": "Eli Lilly and Company (NYSE: LLY) and Evidation Health, a health and measurement company that helps innovative life sciences and health care companies understand how everyday behavior and health...",
                "1d_change": -5.4725086598,
                "index_price": -3.2891581169,
                "norm_price": -2.1833505429
            },
            {
                "index": 564,
                "date": "2018-12-13",
                "press_title": "FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)",
                "release_url": "http://lilly.mediaroom.com/2018-12-13-FDA-Grants-Fast-Track-Designation-to-the-Baricitinib-Development-Program-for-the-Treatment-of-Systemic-Lupus-Erythematosus-SLE",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to baricitinib, which is...",
                "1d_change": -2.4032868366,
                "index_price": -2.259658882,
                "norm_price": -0.1436279546
            },
            {
                "index": 565,
                "date": "2018-12-13",
                "press_title": "Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease",
                "release_url": "http://lilly.mediaroom.com/2018-12-13-Boehringer-Ingelheim-and-Lilly-Partner-with-Duke-Clinical-Research-Institute-to-Advance-Multidisciplinary-Care-for-People-with-Type-2-Diabetes-and-Cardiovascular-Disease",
                "content": "The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2 diabetes and cardiovascular disease through evaluation of a multidisciplinary...",
                "1d_change": -2.4032868366,
                "index_price": -2.259658882,
                "norm_price": -0.1436279546
            },
            {
                "index": 566,
                "date": "2018-12-12",
                "press_title": "Lilly and AC Immune Announce License and Collaboration Agreement",
                "release_url": "http://lilly.mediaroom.com/2018-12-12-Lilly-and-AC-Immune-Announce-License-and-Collaboration-Agreement",
                "content": "Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial...",
                "1d_change": -0.5398010918,
                "index_price": -0.2901273436,
                "norm_price": -0.2496737482
            },
            {
                "index": 567,
                "date": "2018-12-03",
                "press_title": "NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment",
                "release_url": "http://lilly.mediaroom.com/2018-12-03-NCCN-Oncology-Research-Program-Awarded-2-Million-from-Lilly-to-Study-Mechanisms-of-Resistance-to-CDK4-6-Inhibitors-in-Breast-Cancer-Treatment",
                "content": "The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces plans to solicit and oversee research projects that evaluate cyclin dependent kinase (CDK)4 & 6...",
                "1d_change": -1.8194198155,
                "index_price": -3.3495529523,
                "norm_price": 1.5301331368
            },
            {
                "index": 568,
                "date": "2018-11-29",
                "press_title": "Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS",
                "release_url": "http://lilly.mediaroom.com/2018-11-29-Lilly-to-Present-Clinical-Data-for-Verzenio-R-abemaciclib-and-Real-World-Evidence-across-HR-HER2-Metastatic-Breast-Cancer-at-2018-SABCS",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of clinical data at the 2018 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 4-8, 2018 on...",
                "1d_change": 2.8152410057,
                "index_price": 0.8405261933,
                "norm_price": 1.9747148125
            },
            {
                "index": 569,
                "date": "2018-11-27",
                "press_title": "Lilly to Announce 2019 Financial Guidance, Highlight Late-Stage Pipeline Opportunities and Discuss Commercial Performance at Upcoming Investment Community Meeting",
                "release_url": "http://lilly.mediaroom.com/2018-11-27-Lilly-to-Announce-2019-Financial-Guidance-Highlight-Late-Stage-Pipeline-Opportunities-and-Discuss-Commercial-Performance-at-Upcoming-Investment-Community-Meeting",
                "content": "Eli Lilly and Company (NYSE:LLY) today announced that it will host a meeting for the investment community on Wednesday, December 19, 2018, from 9:00 a.m. (EST) until approximately 12:00 p.m....",
                "1d_change": 2.81311658,
                "index_price": 2.9171342531,
                "norm_price": -0.1040176731
            },
            {
                "index": 570,
                "date": "2018-11-26",
                "press_title": "Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway",
                "release_url": "http://lilly.mediaroom.com/2018-11-26-Jardiance-R-Recommended-as-Preferred-SGLT2-Inhibitor-for-Adults-with-Type-2-Diabetes-and-Established-Cardiovascular-Disease-in-American-College-of-Cardiology-Expert-Consensus-Decision-Pathway",
                "content": "A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends Jardiance® (empagliflozin) as the preferred SGLT2 inhibitor for its proven benefit in...",
                "1d_change": 2.5914989312,
                "index_price": 1.2005186886,
                "norm_price": 1.3909802426
            },
            {
                "index": 571,
                "date": "2018-11-14",
                "press_title": "Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache",
                "release_url": "http://lilly.mediaroom.com/2018-11-14-Lilly-Submits-New-Drug-Application-to-the-FDA-for-Lasmiditan-for-Acute-Treatment-of-Migraine-Receives-Breakthrough-Therapy-Designation-for-Emgality-TM-galcanezumab-gnlm-for-Prevention-of-Episodic-Cluster-Headache",
                "content": "Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute treatment of migraine...",
                "1d_change": -0.1425775373,
                "index_price": -0.2820288371,
                "norm_price": 0.1394512998
            },
            {
                "index": 572,
                "date": "2018-11-08",
                "press_title": "Lilly to Participate in Credit Suisse 27th Annual Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2018-11-08-Lilly-to-Participate-in-Credit-Suisse-27th-Annual-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13, 2018. Enrique Conterno, senior vice president of Lilly and...",
                "1d_change": 2.4240416564,
                "index_price": -0.9122539278,
                "norm_price": 3.3362955842
            },
            {
                "index": 573,
                "date": "2018-11-06",
                "press_title": "Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance",
                "release_url": "http://lilly.mediaroom.com/2018-11-06-Lilly-Delivers-Solid-Third-Quarter-2018-Results-Revises-EPS-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2018. $ in millions, except per share data Third Quarter % 2018 2017 Change Revenue $ 6,061.9 $ 5,658.0...",
                "1d_change": 0.6562275717,
                "index_price": 2.6827627632,
                "norm_price": -2.0265351914
            },
            {
                "index": 574,
                "date": "2018-11-05",
                "press_title": "Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines",
                "release_url": "http://lilly.mediaroom.com/2018-11-05-Lilly-and-NextCure-Announce-Collaboration-to-Discover-and-Develop-Novel-Immuno-Oncology-Medicines",
                "content": "Eli Lilly and Company (NYSE: LLY) and NextCure, Inc. today announced a multi-year collaboration focused on the discovery and development of immuno-oncology therapies. The collaboration seeks to...",
                "1d_change": -4.2776383267,
                "index_price": 1.0553570016,
                "norm_price": -5.3329953283
            },
            {
                "index": 575,
                "date": "2018-11-05",
                "press_title": "Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2018-11-05-Trulicity-R-dulaglutide-demonstrates-superiority-in-reduction-of-cardiovascular-events-for-broad-range-of-people-with-type-2-diabetes",
                "content": "INDIANAPOLIS, November 5, 2018 – Trulicity® (dulaglutide) significantly reduced major adverse cardiovascular events (MACE), a composite endpoint of cardiovascular (CV) death, non-fatal...",
                "1d_change": -4.2776383267,
                "index_price": 1.0553570016,
                "norm_price": -5.3329953283
            },
            {
                "index": 576,
                "date": "2018-11-05",
                "press_title": "Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease",
                "release_url": "http://lilly.mediaroom.com/2018-11-05-Initial-results-from-EMPRISE-real-world-evidence-study-show-Jardiance-R-was-associated-with-reduced-risk-for-hospitalization-for-heart-failure-compared-with-DPP-4-inhibitors-in-people-with-type-2-diabetes-with-and-without-cardiovascular-disease",
                "content": "Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study showed Jardiance® was associated with a 44 percent relative risk reduction in...",
                "1d_change": -4.2776383267,
                "index_price": 1.0553570016,
                "norm_price": -5.3329953283
            },
            {
                "index": 577,
                "date": "2018-10-29",
                "press_title": "Lilly and Dicerna Announce RNAi Licensing and Research Collaboration",
                "release_url": "http://lilly.mediaroom.com/2018-10-29-Lilly-and-Dicerna-Announce-RNAi-Licensing-and-Research-Collaboration",
                "content": "Eli Lilly and Company (NYSE: LLY) and Dicerna Pharmaceuticals (NASDAQ: DRNA) today announced a global licensing and research collaboration focused on the discovery, development and...",
                "1d_change": 0.8214693314,
                "index_price": -0.0007462651,
                "norm_price": 0.8222155965
            },
            {
                "index": 578,
                "date": "2018-10-23",
                "press_title": "Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients",
                "release_url": "http://lilly.mediaroom.com/2018-10-23-Complete-Results-from-First-Study-in-Ongoing-Phase-3-Program-for-Tanezumab-Demonstrated-Significant-Improvement-in-Pain-and-Function-in-Osteoarthritis-Patients",
                "content": "NEW YORK, NY, and INDIANAPOLIS, IN, October 23, 2018 – Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced complete results from a Phase 3 study evaluating the efficacy...",
                "1d_change": -4.1196394941,
                "index_price": -2.4445589117,
                "norm_price": -1.6750805824
            },
            {
                "index": 579,
                "date": "2018-10-22",
                "press_title": "ACR 2018: Lilly Announces Positive Results for Two Phase 3 Studies of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)",
                "release_url": "http://lilly.mediaroom.com/2018-10-22-ACR-2018-Lilly-Announces-Positive-Results-for-Two-Phase-3-Studies-of-Taltz-R-ixekizumab-in-Ankylosing-Spondylitis-Radiographic-Axial-Spondyloarthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from two Phase 3 studies, COAST-V and COAST-W, in adults with ankylosing spondylitis (AS), also...",
                "1d_change": -1.4584590293,
                "index_price": -1.2131981622,
                "norm_price": -0.2452608671
            },
            {
                "index": 580,
                "date": "2018-10-21",
                "press_title": "ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis",
                "release_url": "http://lilly.mediaroom.com/2018-10-21-ACR-2018-Lilly-Shares-Updated-Safety-Analysis-of-OLUMIANT-R-baricitinib-in-Patients-with-Moderately-to-Severely-Active-Rheumatoid-Arthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today findings from an updated integrated safety analysis of OLUMIANT® (baricitinib) based on an ongoing...",
                "1d_change": -1.4584590293,
                "index_price": -1.2131981622,
                "norm_price": -0.2452608671
            },
            {
                "index": 581,
                "date": "2018-10-16",
                "press_title": "Karen Walker Elected to Lilly Board of Directors",
                "release_url": "http://lilly.mediaroom.com/2018-10-16-Karen-Walker-Elected-to-Lilly-Board-of-Directors",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Karen Walker as a new member, effective December 1, 2018. As a member of Lilly's board, she will serve on both the Audit...",
                "1d_change": 2.4210039599,
                "index_price": 1.5007746909,
                "norm_price": 0.9202292689
            },
            {
                "index": 582,
                "date": "2018-10-15",
                "press_title": "Lilly Declares Fourth-Quarter 2018 Dividend",
                "release_url": "http://lilly.mediaroom.com/2018-10-15-Lilly-Declares-Fourth-Quarter-2018-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2018 of $0.5625 per share on outstanding common stock. The dividend is payable...",
                "1d_change": 0.477341683,
                "index_price": 1.6402547059,
                "norm_price": -1.1629130229
            },
            {
                "index": 583,
                "date": "2018-10-15",
                "press_title": "New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2018-10-15-New-Data-Showcasing-Lillys-Growing-Commitment-in-Rheumatology-to-be-Featured-at-the-ACR-ARHP-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz® (ixekizumab) and Olumiant® (baricitinib) at the American College of Rheumatology (ACR)/Association of...",
                "1d_change": 0.477341683,
                "index_price": 1.6402547059,
                "norm_price": -1.1629130229
            },
            {
                "index": 584,
                "date": "2018-10-12",
                "press_title": "Lilly and Metastatic Breast Cancer Advocates Launch Thriver Movement to Elevate Understanding of the Daily Impact of the Disease, Encourage Public to do More for MBC",
                "release_url": "http://lilly.mediaroom.com/2018-10-12-Lilly-and-Metastatic-Breast-Cancer-Advocates-Launch-Thriver-Movement-to-Elevate-Understanding-of-the-Daily-Impact-of-the-Disease-Encourage-Public-to-do-More-for-MBC",
                "content": "- National survey uncovers majority of people living with MBC say the daily stress and anxiety they experience associated with the disease can impact everything from relationships to careers, with...",
                "1d_change": 1.4644803844,
                "index_price": -0.7179755532,
                "norm_price": 2.1824559376
            },
            {
                "index": 585,
                "date": "2018-10-10",
                "press_title": "New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease",
                "release_url": "http://lilly.mediaroom.com/2018-10-10-New-analysis-estimates-the-positive-impact-of-Jardiance-R-on-life-expectancy-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease",
                "content": "Novel results based on data from the landmark EMPA-REG OUTCOME® trial were published in the journal Circulation which suggest that treatment with Jardiance® positively impacts life expectancy in...",
                "1d_change": -6.5332188695,
                "index_price": -5.333945869,
                "norm_price": -1.1992730005
            },
            {
                "index": 586,
                "date": "2018-10-08",
                "press_title": "Lilly to Present New Data From Oncology Portfolio at ESMO 2018 Congress, Showcasing Patient-Centric Advances in Cancer Care",
                "release_url": "http://lilly.mediaroom.com/2018-10-08-Lilly-to-Present-New-Data-From-Oncology-Portfolio-at-ESMO-2018-Congress-Showcasing-Patient-Centric-Advances-in-Cancer-Care",
                "content": "Eli Lilly and Company (NYSE: LLY) will present new data from its clinical development program at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany, October 19-23....",
                "1d_change": 0.5197199945,
                "index_price": 0.0975599585,
                "norm_price": 0.422160036
            },
            {
                "index": 587,
                "date": "2018-10-04",
                "press_title": "Boehringer Ingelheim and Lilly present full results of Tradjenta®'s CARMELINA® cardiovascular outcome trial",
                "release_url": "http://lilly.mediaroom.com/2018-10-04-Boehringer-Ingelheim-and-Lilly-present-full-results-of-Tradjenta-R-s-CARMELINA-R-cardiovascular-outcome-trial",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Tradjenta® on...",
                "1d_change": 1.2171730737,
                "index_price": -1.1706535796,
                "norm_price": 2.3878266533
            },
            {
                "index": 588,
                "date": "2018-10-04",
                "press_title": "Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes",
                "release_url": "http://lilly.mediaroom.com/2018-10-04-Boehringer-Ingelheim-and-Lilly-present-full-results-from-EASE-Phase-III-program-for-empagliflozin-as-adjunct-to-insulin-in-type-1-diabetes",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today that empagliflozin met the primary efficacy endpoint, defined as a change from baseline in A1C versus placebo after 26...",
                "1d_change": 1.2171730737,
                "index_price": -1.1706535796,
                "norm_price": 2.3878266533
            },
            {
                "index": 589,
                "date": "2018-10-04",
                "press_title": "Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2018-10-04-Lillys-Investigational-Dual-GIP-and-GLP-1-Receptor-Agonist-Shows-Significant-Reduction-in-HbA1c-and-Body-Weight-in-People-With-Type-2-Diabetes",
                "content": "Results from a phase 2b clinical trial of Eli Lilly and Company's (NYSE: LLY) dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA, LY3298176) showed strong and clinically meaningful blood sugar...",
                "1d_change": 1.2171730737,
                "index_price": -1.1706535796,
                "norm_price": 2.3878266533
            },
            {
                "index": 590,
                "date": "2018-10-03",
                "press_title": "Lilly Confirms Date and Conference Call for Third-Quarter 2018 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2018-10-03-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2018-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2018 on Tuesday, November 6, 2018. Lilly will also conduct a conference call on that day with the...",
                "1d_change": 4.0003603397,
                "index_price": -1.0366600911,
                "norm_price": 5.0370204308
            },
            {
                "index": 591,
                "date": "2018-10-02",
                "press_title": "Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2018-10-02-Results-from-Two-Phase-3-Studies-Show-Lillys-Ultra-Rapid-Lispro-URLi-Met-Primary-Efficacy-Endpoint-in-People-with-Type-1-and-Type-2-Diabetes",
                "content": "Readouts from two phase 3 clinical trials demonstrated that Eli Lilly and Company's (NYSE: LLY) Ultra Rapid Lispro (URLi) met the primary efficacy endpoint of non-inferior A1C reduction from...",
                "1d_change": 1.0311079049,
                "index_price": 0.0584500115,
                "norm_price": 0.9726578934
            },
            {
                "index": 592,
                "date": "2018-09-27",
                "press_title": "Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults",
                "release_url": "http://lilly.mediaroom.com/2018-09-27-Lillys-Emgality-TM-galcanezumab-gnlm-Receives-U-S-FDA-Approval-for-the-Preventive-Treatment-of-Migraine-in-Adults",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of...",
                "1d_change": 0.7641428544,
                "index_price": 0.0799620499,
                "norm_price": 0.6841808046
            },
            {
                "index": 593,
                "date": "2018-09-26",
                "press_title": "Chugai and Lilly Enter into a License Agreement for Oral GLP-1 Agonist, OWL833",
                "release_url": "http://lilly.mediaroom.com/2018-09-26-Chugai-and-Lilly-Enter-into-a-License-Agreement-for-Oral-GLP-1-Agonist-OWL833",
                "content": "TOKYO / INDIANAPOLIS, IN – Chugai Pharmaceutical Co., Ltd (TOKYO: 4519, Chugai) and Eli Lilly and Company (NYSE: LLY, Lilly) today announced they have entered into a license agreement for...",
                "1d_change": 0.590500666,
                "index_price": -0.1022642577,
                "norm_price": 0.6927649237
            },
            {
                "index": 594,
                "date": "2018-09-21",
                "press_title": "Lilly Receives Positive CHMP Opinion for Emgality™ (galcanezumab) for the Prophylaxis of Migraine in Adults",
                "release_url": "http://lilly.mediaroom.com/2018-09-21-Lilly-Receives-Positive-CHMP-Opinion-for-Emgality-TM-galcanezumab-for-the-Prophylaxis-of-Migraine-in-Adults",
                "content": "Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality™...",
                "1d_change": -0.6061522051,
                "index_price": -0.5956727609,
                "norm_price": -0.0104794442
            },
            {
                "index": 595,
                "date": "2018-09-13",
                "press_title": "New Lilly Diabetes Center of Excellence Established at the Indiana Biosciences Research Institute",
                "release_url": "http://lilly.mediaroom.com/2018-09-13-New-Lilly-Diabetes-Center-of-Excellence-Established-at-the-Indiana-Bioscience-Research-Institute",
                "content": "Eli Lilly and Company (NYSE: LLY) and the Indiana Bioscience Research Institute (IBRI), in collaboration with Indiana University School of Medicine, have created the Lilly Diabetes Center of...",
                "1d_change": -0.3687299864,
                "index_price": 0.279860201,
                "norm_price": -0.6485901874
            },
            {
                "index": 596,
                "date": "2018-09-12",
                "press_title": "NCCN and Lilly Support Quality Improvements for Gastric Cancer Care",
                "release_url": "http://lilly.mediaroom.com/2018-09-12-NCCN-and-Lilly-Support-Quality-Improvements-for-Gastric-Cancer-Care",
                "content": "FORT WASHINGTON, PA and INDIANAPOLIS, [September 12, 2018] — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) and Eli Lilly and Company (NYSE: LLY) are...",
                "1d_change": 0.7224546533,
                "index_price": 0.5471387088,
                "norm_price": 0.1753159446
            },
            {
                "index": 597,
                "date": "2018-09-10",
                "press_title": "Lilly to Showcase New Data at the 27th European Academy of Dermatology and Venereology (EADV) Congress, Furthering Innovation for Patients with Complex Dermatological Conditions",
                "release_url": "http://lilly.mediaroom.com/2018-09-10-Lilly-to-Showcase-New-Data-at-the-27th-European-Academy-of-Dermatology-and-Venereology-EADV-Congress-Furthering-Innovation-for-Patients-with-Complex-Dermatological-Conditions",
                "content": "Eli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 27th annual European Academy of Dermatology and...",
                "1d_change": -1.7606852369,
                "index_price": 0.2250778334,
                "norm_price": -1.9857630702
            },
            {
                "index": 598,
                "date": "2018-09-10",
                "press_title": "Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz® and Tremfya® in Patients with Moderate-to-Severe Plaque Psoriasis",
                "release_url": "http://lilly.mediaroom.com/2018-09-10-Lilly-Announces-Initiation-of-IXORA-R-Head-to-Head-Trial-Comparing-Taltz-R-and-Tremfya-R-in-Patients-with-Moderate-to-Severe-Plaque-Psoriasis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today the initiation of the IXORA-R head-to-head (H2H) clinical trial, designed to evaluate superiority between Taltz® (ixekizumab) and Tremfya®...",
                "1d_change": -1.7606852369,
                "index_price": 0.2250778334,
                "norm_price": -1.9857630702
            },
            {
                "index": 599,
                "date": "2018-09-06",
                "press_title": "Lilly Announces Webcast to Discuss EASD Presentations",
                "release_url": "http://lilly.mediaroom.com/2018-09-06-Lilly-Announces-Webcast-to-Discuss-EASD-Presentations",
                "content": "Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Thursday, October 4, 2018 to discuss the company's presentations at the 54th annual meeting of the European Association for the Study of...",
                "1d_change": 1.2706766202,
                "index_price": -0.5905937062,
                "norm_price": 1.8612703264
            },
            {
                "index": 600,
                "date": "2018-09-05",
                "press_title": "Lilly Announces Positive Phase 3 Results in Study of Flortaucipir PET Imaging Agent",
                "release_url": "http://lilly.mediaroom.com/2018-09-05-Lilly-Announces-Positive-Phase-3-Results-in-Study-of-Flortaucipir-PET-Imaging-Agent",
                "content": "Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced that a Phase 3 study of flortaucipir F 18, a Positron Emission Tomography...",
                "1d_change": 0.4935134502,
                "index_price": -0.470458777,
                "norm_price": 0.9639722273
            },
            {
                "index": 601,
                "date": "2018-08-30",
                "press_title": "Anne White Promoted to President of Lilly Oncology",
                "release_url": "http://lilly.mediaroom.com/2018-08-30-Anne-White-Promoted-to-President-of-Lilly-Oncology",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that Anne White has been promoted to senior vice president of Lilly and president of Lilly Oncology effective September 1, 2018. She will become a...",
                "1d_change": 0.4448736578,
                "index_price": -0.2557253379,
                "norm_price": 0.7005989957
            },
            {
                "index": 602,
                "date": "2018-08-27",
                "press_title": "Lilly to Participate in Morgan Stanley Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2018-08-27-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018. Joshua Smiley, senior vice president and Lilly's chief financial...",
                "1d_change": -0.92222705,
                "index_price": 0.4427951503,
                "norm_price": -1.3650222003
            },
            {
                "index": 603,
                "date": "2018-08-14",
                "press_title": "Elanco Animal Health Announces Pricing of $2.0 Billion of Senior Notes",
                "release_url": "http://lilly.mediaroom.com/2018-08-14-Elanco-Animal-Health-Announces-Pricing-of-2-0-Billion-of-Senior-Notes",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health Incorporated, has priced a private offering of $2.0 billion of senior notes (the \"Offering\"), consisting...",
                "1d_change": 1.5097538524,
                "index_price": -0.3374207513,
                "norm_price": 1.8471746037
            },
            {
                "index": 604,
                "date": "2018-08-02",
                "press_title": "Elanco Animal Health Files IPO Registration Statement",
                "release_url": "http://lilly.mediaroom.com/2018-08-02-Elanco-Animal-Health-Files-IPO-Registration-Statement",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for an...",
                "1d_change": 2.6148433237,
                "index_price": 1.4037043258,
                "norm_price": 1.211138998
            },
            {
                "index": 605,
                "date": "2018-08-01",
                "press_title": "Lilly Diabetes Solution Center Now Open to Help People with Insulin Affordability",
                "release_url": "http://lilly.mediaroom.com/2018-08-01-Lilly-Diabetes-Solution-Center-Now-Open-to-Help-People-with-Insulin-Affordability",
                "content": "The Lilly Diabetes Solution Center, a new patient-focused helpline with representatives who will identify personalized solutions to address insulin affordability, is now available to residents in...",
                "1d_change": 0.7338926171,
                "index_price": 0.2139928584,
                "norm_price": 0.5198997587
            },
            {
                "index": 606,
                "date": "2018-07-30",
                "press_title": "Lilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute",
                "release_url": "http://lilly.mediaroom.com/2018-07-30-Lilly-Announces-Extension-of-Cancer-Research-Collaboration-with-Dana-Farber-Cancer-Institute",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced a three-year extension of its cancer research collaboration with Dana-Farber Cancer Institute. Since 2015, scientists from Lilly and Dana-Farber...",
                "1d_change": 2.4592964984,
                "index_price": -0.0962244975,
                "norm_price": 2.5555209959
            },
            {
                "index": 607,
                "date": "2018-07-24",
                "press_title": "Lilly Delivers Strong Second-Quarter 2018 Results, Revises EPS Guidance",
                "release_url": "http://lilly.mediaroom.com/2018-07-24-Lilly-Delivers-Strong-Second-Quarter-2018-Results-Revises-EPS-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2018. $ in millions, except per share data Second Quarter % 2018 2017 Change Revenue $ 6,355.2 $...",
                "1d_change": 5.5688066306,
                "index_price": 0.8921121444,
                "norm_price": 4.6766944861
            },
            {
                "index": 608,
                "date": "2018-07-24",
                "press_title": "Lilly to Separate Elanco Animal Health with Initial Public Offering",
                "release_url": "http://lilly.mediaroom.com/2018-07-24-Lilly-to-Separate-Elanco-Animal-Health-with-Initial-Public-Offering",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the company has completed its strategic review of Elanco Animal Health, and will file a registration statement in the coming weeks with the...",
                "1d_change": 5.5688066306,
                "index_price": 0.8921121444,
                "norm_price": 4.6766944861
            },
            {
                "index": 609,
                "date": "2018-07-20",
                "press_title": "Highlights from Lilly's Alzheimer's Disease Pipeline at the Alzheimer's Association International Conference® 2018 (AAIC® 2018)",
                "release_url": "http://lilly.mediaroom.com/2018-07-20-Highlights-from-Lillys-Alzheimers-Disease-Pipeline-at-the-Alzheimers-Association-International-Conference-R-2018-AAIC-R-2018",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company's Alzheimer's disease pipeline will be presented at the Alzheimer's Association...",
                "1d_change": -0.1575299123,
                "index_price": 0.0865674731,
                "norm_price": -0.2440973854
            },
            {
                "index": 610,
                "date": "2018-07-19",
                "press_title": "Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)",
                "release_url": "http://lilly.mediaroom.com/2018-07-19-Study-Published-in-The-Lancet-Shows-Benefit-of-Baricitinib-4-mg-for-the-Treatment-of-Systemic-Lupus-Erythematosus-SLE",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 study for baricitinib were published by...",
                "1d_change": -1.5372310682,
                "index_price": -0.2691112185,
                "norm_price": -1.2681198497
            },
            {
                "index": 611,
                "date": "2018-07-19",
                "press_title": "Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint",
                "release_url": "http://lilly.mediaroom.com/2018-07-19-Boehringer-Ingelheim-and-Lilly-announce-Tradjentas-CARMELINA-R-cardiovascular-outcome-trial-meets-primary-endpoint",
                "content": "CARMELINA® (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first...",
                "1d_change": -1.5372310682,
                "index_price": -0.2691112185,
                "norm_price": -1.2681198497
            },
            {
                "index": 612,
                "date": "2018-07-19",
                "press_title": "Lilly's Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease",
                "release_url": "http://lilly.mediaroom.com/2018-07-19-Lillys-Once-Weekly-Trulicity-R-dulaglutide-Label-Updated-to-Include-Data-Showing-Benefits-for-Adults-with-Type-2-Diabetes-and-Chronic-Kidney-Disease",
                "content": "The U.S. label for Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity® (dulaglutide) is updated to show the medicine's safety and efficacy in people with type 2 diabetes who have moderate...",
                "1d_change": -1.5372310682,
                "index_price": -0.2691112185,
                "norm_price": -1.2681198497
            },
            {
                "index": 613,
                "date": "2018-07-18",
                "press_title": "Pfizer and Lilly Announce Positive Top-Line Results from Phase 3 Trial of Tanezumab for the Treatment of Osteoarthritis (OA) Pain",
                "release_url": "http://lilly.mediaroom.com/2018-07-18-Pfizer-and-Lilly-Announce-Positive-Top-Line-Results-from-Phase-3-Trial-of-Tanezumab-for-the-Treatment-of-Osteoarthritis-OA-Pain",
                "content": "Pfizer and Lilly Announce Positive Top-Line Results from Phase 3 Trial of Tanezumab for the Treatment of Osteoarthritis (OA) Pain",
                "1d_change": -0.1900915269,
                "index_price": -0.2446115852,
                "norm_price": 0.0545200583
            },
            {
                "index": 614,
                "date": "2018-07-12",
                "press_title": "New Lilly Diabetes helpline to Assist People Seeking Solutions to Insulin Affordability",
                "release_url": "http://lilly.mediaroom.com/2018-07-12-New-Lilly-Diabetes-helpline-to-Assist-People-Seeking-Solutions-to-Insulin-Affordability",
                "content": "Starting August 1, a new dedicated helpline called the Lilly Diabetes Solution Center will assist people who need help paying for their insulin – such as those with lower incomes, the uninsured,...",
                "1d_change": 1.7946639617,
                "index_price": 0.6486310203,
                "norm_price": 1.1460329413
            },
            {
                "index": 615,
                "date": "2018-06-29",
                "press_title": "Lilly Announces Initiation of the Observational Survey of the Epidemiology, Treatment and Care of Migraine (OVERCOME) to Advance Understanding of Burden, Impact and Epidemiology of Migraine",
                "release_url": "http://lilly.mediaroom.com/2018-06-29-Lilly-Announces-Initiation-of-the-Observational-Survey-of-the-Epidemiology-Treatment-and-Care-of-Migraine-OVERCOME-to-Advance-Understanding-of-Burden-Impact-and-Epidemiology-of-Migraine",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today initiation of the ObserVational Survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME) study, which aims to be the largest study of...",
                "1d_change": 0.0232915354,
                "index_price": -0.0154003132,
                "norm_price": 0.0386918486
            },
            {
                "index": 616,
                "date": "2018-06-28",
                "press_title": "Lilly Confirms Date and Conference Call for Second-Quarter 2018 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2018-06-28-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2018-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2018 on Tuesday, July 24, 2018. Lilly will also conduct a conference call on that day with the...",
                "1d_change": 0.5625319112,
                "index_price": 0.7239696926,
                "norm_price": -0.1614377814
            },
            {
                "index": 617,
                "date": "2018-06-28",
                "press_title": "Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients",
                "release_url": "http://lilly.mediaroom.com/2018-06-28-Lilly-Announces-Positive-Top-Line-Results-for-Second-Phase-3-Study-of-Taltz-R-ixekizumab-in-Ankylosing-Spondylitis-Radiographic-Axial-Spondyloarthritis-for-TNF-Inhibitor-Experienced-Patients",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study evaluating the safety and efficacy of Taltz...",
                "1d_change": 0.5625319112,
                "index_price": 0.7239696926,
                "norm_price": -0.1614377814
            },
            {
                "index": 618,
                "date": "2018-06-27",
                "press_title": "AHS 2018: Lilly's Emgality™ (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX®* (onabotulinumtoxinA)",
                "release_url": "http://lilly.mediaroom.com/2018-06-27-AHS-2018-Lillys-Emgality-TM-galcanezumab-gnlm-Significantly-Reduced-Monthly-Migraine-Headache-Days-in-Patients-with-Migraine-Who-Previously-Failed-BOTOX-R-onabotulinumtoxinA",
                "content": "error_http",
                "1d_change": 0.6784343356,
                "index_price": -0.446925878,
                "norm_price": 1.1253602135
            },
            {
                "index": 619,
                "date": "2018-06-27",
                "press_title": "AHS 2018: Lilly Highlights Positive Phase 3 Results from the Largest Controlled Preventive Trial in Episodic Cluster Headache",
                "release_url": "http://lilly.mediaroom.com/2018-06-27-AHS-2018-Lilly-Highlights-Positive-Phase-3-Results-from-the-Largest-Controlled-Preventive-Trial-in-Episodic-Cluster-Headache",
                "content": "Eli Lilly and Company (NYSE:LLY) announced today full results from a positive Phase 3 study of patients with episodic cluster headache treated with Emgality™ (galcanezumab-gnlm). Detailed...",
                "1d_change": 0.6784343356,
                "index_price": -0.446925878,
                "norm_price": 1.1253602135
            },
            {
                "index": 620,
                "date": "2018-06-25",
                "press_title": "Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes",
                "release_url": "http://lilly.mediaroom.com/2018-06-25-Boehringer-Ingelheim-and-Lilly-announce-positive-top-line-Phase-III-data-results-for-empagliflozin-as-adjunct-to-insulin-in-type-1-diabetes",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomized controlled trials in the EASE Phase III program, investigating the use of empagliflozin in...",
                "1d_change": -1.0456994809,
                "index_price": -0.730056715,
                "norm_price": -0.3156427659
            },
            {
                "index": 621,
                "date": "2018-06-25",
                "press_title": "First-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2018-06-25-First-ever-Study-of-Lillys-Humulin-R-R-U-500-Administered-in-an-Insulin-Pump-Shows-Improved-A1C-in-People-with-Type-2-Diabetes",
                "content": "Eli Lilly and Company's (NYSE: LLY) Humulin® R U-500 administered via an investigational insulin pump (Omnipod® U-500™ Insulin Management System) provided greater A1C reduction with less daily...",
                "1d_change": -1.0456994809,
                "index_price": -0.730056715,
                "norm_price": -0.3156427659
            },
            {
                "index": 622,
                "date": "2018-06-25",
                "press_title": "Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache",
                "release_url": "http://lilly.mediaroom.com/2018-06-25-Lilly-to-Present-Phase-3-Data-at-AHS-2018-Highlighting-Innovative-Potential-Treatments-for-Migraine-and-Cluster-Headache",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migraine and cluster headache, at the...",
                "1d_change": -1.0456994809,
                "index_price": -0.730056715,
                "norm_price": -0.3156427659
            },
            {
                "index": 623,
                "date": "2018-06-24",
                "press_title": "Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW",
                "release_url": "http://lilly.mediaroom.com/2018-06-24-Real-World-Data-Show-Advantages-in-People-Treated-with-Lillys-Once-Weekly-Trulicity-R-dulaglutide-Compared-to-Those-Treated-with-Liraglutide-and-Exenatide-QW",
                "content": "People with type 2 diabetes new to treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) had better blood sugar control, were more likely to adhere to treatment and stayed on...",
                "1d_change": -1.0456994809,
                "index_price": -0.730056715,
                "norm_price": -0.3156427659
            },
            {
                "index": 624,
                "date": "2018-06-23",
                "press_title": "New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce Potential of Lilly's Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2018-06-23-New-Data-Presented-at-the-American-Diabetes-Association-78th-Scientific-Sessions-R-Reinforce-Potential-of-Lillys-Ultra-Rapid-Lispro-in-People-with-Type-1-and-Type-2-Diabetes",
                "content": "Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from...",
                "1d_change": -1.0456994809,
                "index_price": -0.730056715,
                "norm_price": -0.3156427659
            },
            {
                "index": 625,
                "date": "2018-06-23",
                "press_title": "Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors",
                "release_url": "http://lilly.mediaroom.com/2018-06-23-Jardiance-R-reduced-risk-of-kidney-disease-progression-in-adults-with-type-2-diabetes-and-established-cardiovascular-CV-disease-independent-of-control-of-conventional-CV-risk-factors",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced findings from two new analyses of the landmark EMPA-REG OUTCOME® trial, presented at the 78th American Diabetes...",
                "1d_change": -1.0456994809,
                "index_price": -0.730056715,
                "norm_price": -0.3156427659
            },
            {
                "index": 626,
                "date": "2018-06-23",
                "press_title": "Investigational Doses of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2018-06-23-Investigational-Doses-of-Lillys-Once-Weekly-Trulicity-R-dulaglutide-Show-Promise-in-Delivering-Powerful-Efficacy-in-People-with-Type-2-Diabetes",
                "content": "Two investigational doses of Lilly's dulaglutide (4.5 mg and 3.0 mg), as well as Trulicity® (dulaglutide) 1.5 mg, provided significantly better blood sugar control with weight benefits compared...",
                "1d_change": -1.0456994809,
                "index_price": -0.730056715,
                "norm_price": -0.3156427659
            },
            {
                "index": 627,
                "date": "2018-06-22",
                "press_title": "U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit",
                "release_url": "http://lilly.mediaroom.com/2018-06-22-U-S-District-Court-Rules-in-Favor-of-Lilly-in-Alimta-Vitamin-Regimen-Patent-Lawsuit",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana ruled in favor of Lilly that the Alimta® (pemetrexed for injection) vitamin...",
                "1d_change": -0.2914678885,
                "index_price": -1.6090851396,
                "norm_price": 1.3176172511
            },
            {
                "index": 628,
                "date": "2018-06-22",
                "press_title": "Lilly Completes Acquisition of ARMO BioSciences",
                "release_url": "http://lilly.mediaroom.com/2018-06-22-Lilly-Completes-Acquisition-of-ARMO-BioSciences",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (NASDAQ: ARMO). Lilly's tender offer for all outstanding shares of common...",
                "1d_change": -0.2914678885,
                "index_price": -1.6090851396,
                "norm_price": 1.3176172511
            },
            {
                "index": 629,
                "date": "2018-06-18",
                "press_title": "Lilly Declares Third-Quarter 2018 Dividend",
                "release_url": "http://lilly.mediaroom.com/2018-06-18-Lilly-Declares-Third-Quarter-2018-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2018 of $0.5625 per share on outstanding common stock. The dividend is payable...",
                "1d_change": 0.9675289742,
                "index_price": -0.1158315592,
                "norm_price": 1.0833605333
            },
            {
                "index": 630,
                "date": "2018-06-12",
                "press_title": "Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease",
                "release_url": "http://lilly.mediaroom.com/2018-06-12-Update-on-Phase-3-Clinical-Trials-of-Lanabecestat-for-Alzheimers-Disease",
                "content": "Eli Lilly and Company (NYSE: LLY) and AstraZeneca are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment...",
                "1d_change": -0.0466814294,
                "index_price": -0.3592054872,
                "norm_price": 0.3125240578
            },
            {
                "index": 631,
                "date": "2018-06-11",
                "press_title": "Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology",
                "release_url": "http://lilly.mediaroom.com/2018-06-11-Lilly-to-Unveil-New-Data-at-the-Annual-European-Congress-of-Rheumatology-Furthering-Commitment-to-Scientific-Discovery-in-Immunology",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today it will present new data from its immunology portfolio, including cornerstone treatments OLUMIANT® (baricitinib) and Taltz® (ixekizumab), at the...",
                "1d_change": -0.9591750417,
                "index_price": 0.2393442698,
                "norm_price": -1.1985193114
            },
            {
                "index": 632,
                "date": "2018-06-05",
                "press_title": "Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer by TRC Capital Corp.",
                "release_url": "http://lilly.mediaroom.com/2018-06-05-Lilly-Recommends-Shareholders-Reject-Below-Market-Mini-Tender-Offer-by-TRC-Capital-Corp",
                "content": "Eli Lilly and Company (NYSE: LLY) has learned of an unsolicited mini-tender offer by TRC Capital Corp. for the purchase of up to 1.5 million shares of Lilly common stock at $81.00 per share. Lilly...",
                "1d_change": 0.7913478369,
                "index_price": 0.8617287095,
                "norm_price": -0.0703808726
            },
            {
                "index": 633,
                "date": "2018-06-05",
                "press_title": "DDW 2018: Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial",
                "release_url": "http://lilly.mediaroom.com/2018-06-05-DDW-2018-Patients-with-Moderate-to-Severe-Ulcerative-Colitis-Achieved-Clinical-and-Endoscopic-Remission-with-Mirikizumab-in-Phase-2-Trial",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today new safety and efficacy data from a Phase 2 study evaluating mirikizumab in patients with moderate-to-severe ulcerative colitis (UC). The results...",
                "1d_change": 0.7913478369,
                "index_price": 0.8617287095,
                "norm_price": -0.0703808726
            },
            {
                "index": 634,
                "date": "2018-06-05",
                "press_title": "FDA Expands Lilly's ALIMTA® (pemetrexed) Label to Include Combination with KEYTRUDA® (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression",
                "release_url": "http://lilly.mediaroom.com/2018-06-05-FDA-Expands-Lillys-ALIMTA-R-pemetrexed-Label-to-Include-Combination-with-KEYTRUDA-R-pembrolizumab-and-Carboplatin-as-First-Line-Treatment-for-Metastatic-Nonsquamous-Non-Small-Cell-Lung-Cancer-Irrespective-of-PD-L1-Expression",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new indication for ALIMTA® (pemetrexed for injection) in combination...",
                "1d_change": 0.7913478369,
                "index_price": 0.8617287095,
                "norm_price": -0.0703808726
            },
            {
                "index": 635,
                "date": "2018-06-01",
                "press_title": "FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis",
                "release_url": "http://lilly.mediaroom.com/2018-06-01-FDA-Approves-OLUMIANT-R-baricitinib-2-mg-Tablets-for-the-Treatment-of-Adults-with-Moderately-to-Severely-Active-Rheumatoid-Arthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved the 2-mg dose of OLUMIANT® (baricitinib), a...",
                "1d_change": -0.1528234497,
                "index_price": 1.025536877,
                "norm_price": -1.1783603268
            },
            {
                "index": 636,
                "date": "2018-06-01",
                "press_title": "Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to-Severe Ulcerative Colitis",
                "release_url": "http://lilly.mediaroom.com/2018-06-01-Lilly-to-Showcase-New-Data-at-Digestive-Disease-Week-2018-for-Mirikizumab-in-Moderate-to-Severe-Ulcerative-Colitis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced that it will present new data evaluating mirikizumab for the treatment of moderate-to-severe ulcerative colitis (UC) at Digestive Disease Week (DDW),...",
                "1d_change": -0.1528234497,
                "index_price": 1.025536877,
                "norm_price": -1.1783603268
            },
            {
                "index": 637,
                "date": "2018-05-31",
                "press_title": "Lilly to Participate in Goldman Sachs Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2018-05-31-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018. David A. Ricks, Lilly's chairman and chief executive...",
                "1d_change": 1.1432180575,
                "index_price": 0.4987945723,
                "norm_price": 0.6444234852
            },
            {
                "index": 638,
                "date": "2018-05-30",
                "press_title": "Lilly to Participate in Jefferies Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2018-05-30-Lilly-to-Participate-in-Jefferies-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the Jefferies Global Healthcare Conference on Wednesday, June 6, 2018. Joshua Smiley, senior vice president and Lilly's chief financial officer, will...",
                "1d_change": 2.4929417872,
                "index_price": 0.1049835273,
                "norm_price": 2.3879582598
            },
            {
                "index": 639,
                "date": "2018-05-23",
                "press_title": "Sue Mahony to Retire as President of Lilly Oncology",
                "release_url": "http://lilly.mediaroom.com/2018-05-23-Sue-Mahony-to-Retire-as-President-of-Lilly-Oncology",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Sue Mahony, Ph.D., senior vice president of Lilly and president of Lilly Oncology, will retire at the end of August after 18 years of service...",
                "1d_change": 1.209055508,
                "index_price": 0.5051774807,
                "norm_price": 0.7038780273
            },
            {
                "index": 640,
                "date": "2018-05-22",
                "press_title": "Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area",
                "release_url": "http://lilly.mediaroom.com/2018-05-22-Lillys-Taltz-R-ixekizumab-Receives-the-First-U-S-FDA-Approval-for-Label-Update-to-Include-Data-for-Psoriasis-Involving-the-Genital-Area",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz® (ixekizumab) injection 80 mg/mL to include data in...",
                "1d_change": 0.6531061476,
                "index_price": -0.1847608105,
                "norm_price": 0.8378669581
            },
            {
                "index": 641,
                "date": "2018-05-16",
                "press_title": "Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care",
                "release_url": "http://lilly.mediaroom.com/2018-05-16-Lilly-Data-at-ASCO-Illustrate-Patient-Driven-Advances-in-Cancer-Care",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company's oncology product and pipeline portfolio will be presented at the 54th Annual...",
                "1d_change": -0.1714078674,
                "index_price": 0.2760811413,
                "norm_price": -0.4474890087
            },
            {
                "index": 642,
                "date": "2018-05-15",
                "press_title": "Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache",
                "release_url": "http://lilly.mediaroom.com/2018-05-15-Lillys-Galcanezumab-Meets-Primary-Endpoint-in-Phase-3-Study-Evaluating-Galcanezumab-for-the-Prevention-of-Episodic-Cluster-Headache",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant...",
                "1d_change": -1.1992135443,
                "index_price": 0.1421461877,
                "norm_price": -1.341359732
            },
            {
                "index": 643,
                "date": "2018-05-14",
                "press_title": "Lilly to Acquire AurKa Pharma",
                "release_url": "http://lilly.mediaroom.com/2018-05-14-Lilly-to-Acquire-AurKa-Pharma",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire AurKa Pharma, Inc., a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase...",
                "1d_change": -0.4743948131,
                "index_price": -0.9965155182,
                "norm_price": 0.5221207051
            },
            {
                "index": 644,
                "date": "2018-05-11",
                "press_title": "Lilly to Participate in UBS Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2018-05-11-Lilly-to-Participate-in-UBS-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 22, 2018. Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and...",
                "1d_change": 2.3113015953,
                "index_price": 0.2721457205,
                "norm_price": 2.0391558748
            },
            {
                "index": 645,
                "date": "2018-05-10",
                "press_title": "Lilly Announces Agreement To Acquire ARMO BioSciences",
                "release_url": "http://lilly.mediaroom.com/2018-05-10-Lilly-Announces-Agreement-To-Acquire-ARMO-BioSciences",
                "content": "Eli Lilly and Company (NYSE: LLY) and ARMO BioSciences, Inc. (NASDAQ: ARMO) today announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an...",
                "1d_change": 3.6264169191,
                "index_price": 0.8321950719,
                "norm_price": 2.7942218472
            },
            {
                "index": 646,
                "date": "2018-05-07",
                "press_title": "Lilly Declares Second-Quarter 2018 Dividend",
                "release_url": "http://lilly.mediaroom.com/2018-05-07-Lilly-Declares-Second-Quarter-2018-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2018 of $0.5625 per share on outstanding common stock. The dividend is payable June 8,...",
                "1d_change": 0.5958518075,
                "index_price": -0.315135418,
                "norm_price": 0.9109872255
            },
            {
                "index": 647,
                "date": "2018-05-01",
                "press_title": "Lilly and Local Partners Launch Diabetes Prevention and Management Pilot in Three Underserved Neighborhoods in Indianapolis",
                "release_url": "http://lilly.mediaroom.com/2018-05-01-Lilly-and-Local-Partners-Launch-Diabetes-Prevention-and-Management-Pilot-in-Three-Underserved-Neighborhoods-in-Indianapolis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Indiana University's Richard M. Fairbanks School of Public Health at IUPUI announced today the launch of a new neighborhood-based, data-driven pilot in...",
                "1d_change": -2.3468100923,
                "index_price": -0.2765915034,
                "norm_price": -2.0702185888
            },
            {
                "index": 648,
                "date": "2018-04-30",
                "press_title": "Leena Gandhi, M.D., Ph.D., to Lead Lilly Oncology Immuno-Oncology Medical Development",
                "release_url": "http://lilly.mediaroom.com/2018-04-30-Leena-Gandhi-M-D-Ph-D-to-Lead-Lilly-Oncology-Immuno-Oncology-Medical-Development",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that Leena Gandhi, M.D., Ph.D., a prestigious thoracic oncologist with a focus on immunotherapy and early drug development, will join Lilly...",
                "1d_change": -5.0841173369,
                "index_price": -1.0437682849,
                "norm_price": -4.040349052
            },
            {
                "index": 649,
                "date": "2018-04-27",
                "press_title": "Lilly to Participate in Bank of America Merrill Lynch Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2018-04-27-Lilly-to-Participate-in-Bank-of-America-Merrill-Lynch-Health-Care-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018. Christi Shaw, senior vice president and president of...",
                "1d_change": -1.7638809921,
                "index_price": -1.035475968,
                "norm_price": -0.7284050241
            },
            {
                "index": 650,
                "date": "2018-04-25",
                "press_title": "Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease",
                "release_url": "http://lilly.mediaroom.com/2018-04-25-Lilly-and-Chinas-NCCD-announce-collaboration-to-advance-scientific-understanding-and-care-for-people-living-with-diabetes-and-cardiovascular-disease",
                "content": "Today, Eli Lilly and Company (NYSE: LLY) and China's National Center for Cardiovascular Diseases (NCCD) announced plans to collaborate across four strategic initiatives to advance the scientific...",
                "1d_change": 2.7619368667,
                "index_price": 1.2006276945,
                "norm_price": 1.5613091722
            },
            {
                "index": 651,
                "date": "2018-04-24",
                "press_title": "Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance",
                "release_url": "http://lilly.mediaroom.com/2018-04-24-Lilly-Reports-Strong-First-Quarter-2018-Results-Raises-EPS-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2018. $ in millions, except per share data First Quarter % 2018 2017 Change Revenue $ 5,700.0 $ 5,228.3...",
                "1d_change": -0.0369401466,
                "index_price": -1.5685439121,
                "norm_price": 1.5316037655
            },
            {
                "index": 652,
                "date": "2018-04-24",
                "press_title": "AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies",
                "release_url": "http://lilly.mediaroom.com/2018-04-24-AAN-2018-Lillys-Galcanezumab-Significantly-Reduced-Monthly-Migraine-Headache-Days-in-Patients-with-Migraine-Who-Previously-Failed-to-Respond-to-Multiple-Preventive-Therapies",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc subgroup analysis which demonstrated efficacy of galcanezumab in patients with episodic and chronic migraine who...",
                "1d_change": -0.0369401466,
                "index_price": -1.5685439121,
                "norm_price": 1.5316037655
            },
            {
                "index": 653,
                "date": "2018-04-23",
                "press_title": "FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis",
                "release_url": "http://lilly.mediaroom.com/2018-04-23-FDA-Advisory-Committee-Recommends-the-Approval-of-Baricitinib-2mg-but-not-4mg-for-the-Treatment-of-Moderately-to-Severely-Active-Rheumatoid-Arthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the...",
                "1d_change": 0.8240688045,
                "index_price": -1.550158009,
                "norm_price": 2.3742268135
            },
            {
                "index": 654,
                "date": "2018-04-20",
                "press_title": "Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer",
                "release_url": "http://lilly.mediaroom.com/2018-04-20-Lilly-Reports-Additional-Top-Line-Results-from-CYRAMZA-R-ramucirumab-Phase-3-RANGE-Study-in-Advanced-or-Metastatic-Urothelial-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced additional results from its global, randomized, double-blind, placebo-controlled Phase 3 RANGE trial evaluating CYRAMZA® (ramucirumab) in...",
                "1d_change": 0.6982162125,
                "index_price": -0.8339925329,
                "norm_price": 1.5322087454
            },
            {
                "index": 655,
                "date": "2018-04-20",
                "press_title": "Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine",
                "release_url": "http://lilly.mediaroom.com/2018-04-20-Lilly-to-Present-Phase-3-Data-at-AAN-2018-Reinforcing-Commitment-to-New-Innovative-Therapies-in-Migraine",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational treatments for migraine, at the American Academy of Neurology...",
                "1d_change": 0.6982162125,
                "index_price": -0.8339925329,
                "norm_price": 1.5322087454
            },
            {
                "index": 656,
                "date": "2018-04-16",
                "press_title": "Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease",
                "release_url": "http://lilly.mediaroom.com/2018-04-16-Boehringer-Ingelheim-and-Lilly-announce-an-academic-collaboration-with-University-of-Oxford-to-investigate-the-effects-of-Jardiance-R-in-adults-with-chronic-kidney-disease",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance® on the progression of...",
                "1d_change": -0.6756307221,
                "index_price": 1.340893085,
                "norm_price": -2.0165238071
            },
            {
                "index": 657,
                "date": "2018-04-04",
                "press_title": "Lilly Confirms Date and Conference Call for First-Quarter 2018 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2018-04-04-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2018-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2018 on Tuesday, April 24, 2018. Lilly will also conduct a conference call on that day with the...",
                "1d_change": 2.2895216061,
                "index_price": 2.9592482548,
                "norm_price": -0.6697266487
            },
            {
                "index": 658,
                "date": "2018-04-04",
                "press_title": "Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2018-04-04-Lilly-and-Sigilon-Therapeutics-Announce-Strategic-Collaboration-to-Develop-Encapsulated-Cell-Therapies-for-the-Treatment-of-Type-1-Diabetes",
                "content": "Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics today announced a global collaboration to develop encapsulated cell therapies for the potential treatment of type 1 diabetes. Sigilon is...",
                "1d_change": 2.2895216061,
                "index_price": 2.9592482548,
                "norm_price": -0.6697266487
            },
            {
                "index": 659,
                "date": "2018-04-04",
                "press_title": "Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint",
                "release_url": "http://lilly.mediaroom.com/2018-04-04-Lilly-Announces-CYRAMZA-R-ramucirumab-Phase-3-REACH-2-Study-in-Second-Line-Hepatocellular-Carcinoma-Patients-Met-Overall-Survival-Endpoint",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 REACH-2 study of CYRAMZA® (ramucirumab) as a single agent in the second-line treatment of people with...",
                "1d_change": 2.2895216061,
                "index_price": 2.9592482548,
                "norm_price": -0.6697266487
            },
            {
                "index": 660,
                "date": "2018-03-09",
                "press_title": "Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology",
                "release_url": "http://lilly.mediaroom.com/2018-03-09-Maura-Dickler-M-D-to-become-Vice-President-of-Late-Phase-Development-at-Lilly-Oncology",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that Maura Dickler, M.D., a prestigious breast cancer researcher, will join Lilly Oncology as Vice President of Late Phase Development on May 7, 2018.",
                "1d_change": -0.3036284394,
                "index_price": 1.0819220563,
                "norm_price": -1.3855504957
            },
            {
                "index": 661,
                "date": "2018-03-08",
                "press_title": "EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research",
                "release_url": "http://lilly.mediaroom.com/2018-03-08-EFSD-JDRF-and-Lilly-Extend-Collaboration-Supporting-Type-1-Diabetes-Research",
                "content": "The European Foundation for the Study of Diabetes (EFSD), JDRF and Eli Lilly and Company (NYSE: LLY) have agreed to extend their collaboration for the European Programme in Type 1 Diabetes...",
                "1d_change": 2.4620038059,
                "index_price": 1.9314091173,
                "norm_price": 0.5305946886
            },
            {
                "index": 662,
                "date": "2018-03-06",
                "press_title": "Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials",
                "release_url": "http://lilly.mediaroom.com/2018-03-06-Boehringer-Ingelheim-and-Lilly-expand-heart-failure-program-for-Jardiance-R-with-new-exercise-capacity-trials",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to expand their clinical trial program for Jardiance® in chronic heart failure with the EMPERIAL clinical trials....",
                "1d_change": -0.5423560985,
                "index_price": -0.123950519,
                "norm_price": -0.4184055795
            },
            {
                "index": 663,
                "date": "2018-02-26",
                "press_title": "Lilly Receives Additional FDA Approval for Verzenio (abemaciclib), as Initial Treatment for Advanced Breast Cancer",
                "release_url": "http://lilly.mediaroom.com/2018-02-26-Lilly-Receives-Additional-FDA-Approval-for-Verzenio-abemaciclib-as-Initial-Treatment-for-Advanced-Breast-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial...",
                "1d_change": -0.368436804,
                "index_price": -0.4769953413,
                "norm_price": 0.1085585373
            },
            {
                "index": 664,
                "date": "2018-02-26",
                "press_title": "New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2018-02-26-New-Data-Show-Lillys-Trulicity-R-dulaglutide-in-Combination-with-an-SGLT-2-Inhibitor-Improves-Blood-Sugar-Control-in-People-with-Type-2-Diabetes",
                "content": "Trulicity® (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sodium-glucose co-transporter-2 (SGLT-2)...",
                "1d_change": -0.368436804,
                "index_price": -0.4769953413,
                "norm_price": 0.1085585373
            },
            {
                "index": 665,
                "date": "2018-02-21",
                "press_title": "Lilly to Participate in Barclays Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2018-02-21-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Barclays Global Healthcare Conference on Wednesday, March 14, 2018. Joshua Smiley, senior vice president and Lilly's chief financial...",
                "1d_change": -0.5181899603,
                "index_price": -0.6128074601,
                "norm_price": 0.0946174998
            },
            {
                "index": 666,
                "date": "2018-02-20",
                "press_title": "Lilly to Participate in Cowen Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2018-02-20-Lilly-to-Participate-in-Cowen-Health-Care-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018. Sue Mahony, Ph.D., senior vice president and president of...",
                "1d_change": -0.8123755366,
                "index_price": -0.8018239713,
                "norm_price": -0.0105515653
            },
            {
                "index": 667,
                "date": "2018-02-20",
                "press_title": "Survey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month",
                "release_url": "http://lilly.mediaroom.com/2018-02-20-Survey-Reveals-Many-People-with-Migraine-Live-with-Pain-Nearly-Half-of-Every-Month",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today findings from a Lilly-sponsored, quantitative opinion survey, which found among those surveyed, people diagnosed with migraine experienced on...",
                "1d_change": -0.8123755366,
                "index_price": -0.8018239713,
                "norm_price": -0.0105515653
            },
            {
                "index": 668,
                "date": "2018-02-19",
                "press_title": "AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity",
                "release_url": "http://lilly.mediaroom.com/2018-02-19-AAD-2018-Treatment-with-Lillys-Taltz-R-ixekizumab-Resulted-in-Improvement-in-Impact-of-Genital-Psoriasis-on-Sexual-Activity",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe genital psoriasis treated with Taltz® (ixekizumab) reported a greater decrease in the impact of their...",
                "1d_change": -0.8123755366,
                "index_price": -0.8018239713,
                "norm_price": -0.0105515653
            },
            {
                "index": 669,
                "date": "2018-02-14",
                "press_title": "Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2018-02-14-Lilly-to-Showcase-New-Data-for-Taltz-R-ixekizumab-and-Other-Products-Across-Immunology-Pipeline-at-AAD-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz® (ixekizumab), baricitinib and mirikizumab at the American Academy of Dermatology (AAD) annual meeting taking place",
                "1d_change": 3.3452997385,
                "index_price": 2.9287489625,
                "norm_price": 0.416550776
            },
            {
                "index": 670,
                "date": "2018-02-13",
                "press_title": "Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)",
                "release_url": "http://lilly.mediaroom.com/2018-02-13-Lilly-Announces-Positive-Top-Line-Phase-3-Results-for-Taltz-R-ixekizumab-in-Ankylosing-Spondylitis-Radiographic-Axial-Spondyloarthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and efficacy of Taltz...",
                "1d_change": 2.0402149433,
                "index_price": 1.9402387713,
                "norm_price": 0.099976172
            },
            {
                "index": 671,
                "date": "2018-01-31",
                "press_title": "Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance",
                "release_url": "http://lilly.mediaroom.com/2018-01-31-Lilly-Reports-Strong-Fourth-Quarter-and-Full-Year-2017-Revenue-Growth-Increases-2018-EPS-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2017. $ in millions, except per share data Fourth Quarter % Full Year % 2017 2016 Change...",
                "1d_change": -4.9630223505,
                "index_price": -0.3695962308,
                "norm_price": -4.5934261197
            },
            {
                "index": 672,
                "date": "2018-01-26",
                "press_title": "Lilly To Present At Leerink Partners Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2018-01-26-Lilly-To-Present-At-Leerink-Partners-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 15, 2018. Jan Lundberg, Ph.D., executive vice president for science and...",
                "1d_change": 3.2420140708,
                "index_price": 0.2120198059,
                "norm_price": 3.0299942649
            },
            {
                "index": 673,
                "date": "2018-01-08",
                "press_title": "Livongo and Lilly Collaborate on Real-World Diabetes Research",
                "release_url": "http://lilly.mediaroom.com/2018-01-08-Livongo-and-Lilly-Collaborate-on-Real-World-Diabetes-Research",
                "content": "Eli Lilly and Company (NYSE: LLY) and Livongo Health, a leading consumer digital health company focused on empowering all people with chronic conditions to live better and healthier lives, today...",
                "1d_change": -0.732034284,
                "index_price": 0.3133118306,
                "norm_price": -1.0453461147
            },
            {
                "index": 674,
                "date": "2018-01-05",
                "press_title": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2018-01-05-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2017-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2017 financial results on Wednesday, January 31, 2018. Lilly will also conduct a conference call on that day with...",
                "1d_change": 0.0464082203,
                "index_price": 0.5961285232,
                "norm_price": -0.5497203029
            },
            {
                "index": 675,
                "date": "2018-01-02",
                "press_title": "Lilly to Present at J.P. Morgan Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2018-01-02-Lilly-to-Present-at-J-P-Morgan-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018. David A. Ricks, Lilly's chairman and chief executive officer, will...",
                "1d_change": 0.7987177731,
                "index_price": 1.0810699908,
                "norm_price": -0.2823522176
            },
            {
                "index": 676,
                "date": "2017-12-18",
                "press_title": "Lilly to Participate in Goldman Sachs Healthcare CEOs Unscripted Conference",
                "release_url": "http://lilly.mediaroom.com/2017-12-18-Lilly-to-Participate-in-Goldman-Sachs-Healthcare-CEOs-Unscripted-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 4, 2018. David A. Ricks, Lilly's chairman and chief executive...",
                "1d_change": -0.0576685326,
                "index_price": -0.1659519301,
                "norm_price": 0.1082833975
            },
            {
                "index": 677,
                "date": "2017-12-14",
                "press_title": "Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin",
                "release_url": "http://lilly.mediaroom.com/2017-12-14-Rimidi-and-Lilly-Collaborate-to-Personalize-Solutions-for-People-Using-Insulin",
                "content": "Rimidi, a digital health company that provides software and clinical analytics for chronic disease management, and Eli Lilly and Company (NYSE: LLY), a leader in diabetes care for more than 90...",
                "1d_change": -1.9413112757,
                "index_price": 0.3714741027,
                "norm_price": -2.3127853784
            },
            {
                "index": 678,
                "date": "2017-12-13",
                "press_title": "Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020",
                "release_url": "http://lilly.mediaroom.com/2017-12-13-Lilly-Announces-2018-Financial-Guidance-and-Enhances-Outlook-Through-2020",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced its 2018 financial guidance, including low-single-digit revenue growth driven by volume from recently launched pharmaceutical products. The...",
                "1d_change": 0.1040469063,
                "index_price": -0.5874818748,
                "norm_price": 0.6915287811
            },
            {
                "index": 679,
                "date": "2017-12-11",
                "press_title": "Lilly Announces 8 Percent Dividend Increase",
                "release_url": "http://lilly.mediaroom.com/2017-12-11-Lilly-Announces-8-Percent-Dividend-Increase",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) today announced an 8 percent increase in its quarterly dividend. The dividend for the first quarter of 2018 will be $0.5625 per share on...",
                "1d_change": 0.1153230682,
                "index_price": 0.447435186,
                "norm_price": -0.3321121178
            },
            {
                "index": 680,
                "date": "2017-12-11",
                "press_title": "FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults",
                "release_url": "http://lilly.mediaroom.com/2017-12-11-FDA-Accepts-Biologics-License-Application-BLA-to-Review-Galcanezumab-for-the-Prevention-of-Migraine-in-Adults",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) to review galcanezumab for the prevention of...",
                "1d_change": 0.1153230682,
                "index_price": 0.447435186,
                "norm_price": -0.3321121178
            },
            {
                "index": 681,
                "date": "2017-12-11",
                "press_title": "Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology",
                "release_url": "http://lilly.mediaroom.com/2017-12-11-Kimberly-Blackwell-M-D-to-become-Vice-President-of-Early-Phase-Development-and-Immuno-oncology-at-Lilly-Oncology",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that Kimberly Blackwell, M.D., one of the nation's leading breast cancer researchers, will join Lilly Oncology as vice president of early phase...",
                "1d_change": 0.1153230682,
                "index_price": 0.447435186,
                "norm_price": -0.3321121178
            },
            {
                "index": 682,
                "date": "2017-12-08",
                "press_title": "Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer",
                "release_url": "http://lilly.mediaroom.com/2017-12-08-Lilly-Reports-Top-Line-Results-from-CYRAMZA-R-ramucirumab-Phase-3-Study-in-First-Line-Advanced-Gastric-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 RAINFALL study of CYRAMZA® (ramucirumab) in combination with cisplatin and capecitabine or 5-FU...",
                "1d_change": 1.1653214153,
                "index_price": 0.5180481636,
                "norm_price": 0.6472732517
            },
            {
                "index": 683,
                "date": "2017-12-05",
                "press_title": "Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System",
                "release_url": "http://lilly.mediaroom.com/2017-12-05-Lilly-Initiates-Clinical-Trial-to-Evaluate-the-Functionality-and-Safety-of-its-Automated-Insulin-Delivery-System",
                "content": "Yesterday marked dosing of the first patient with type 1 diabetes in a feasibility study to evaluate the functionality and safety of an automated insulin delivery (AID) system in development by...",
                "1d_change": -0.3164490377,
                "index_price": -0.3997310922,
                "norm_price": 0.0832820544
            },
            {
                "index": 684,
                "date": "2017-12-01",
                "press_title": "Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis",
                "release_url": "http://lilly.mediaroom.com/2017-12-01-Lillys-Taltz-R-ixekizumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Active-Psoriatic-Arthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults with active...",
                "1d_change": 0.7011312124,
                "index_price": -0.2144453511,
                "norm_price": 0.9155765635
            },
            {
                "index": 685,
                "date": "2017-11-20",
                "press_title": "Lilly Confirms Date and Conference Call for 2018 Financial Guidance Announcement",
                "release_url": "http://lilly.mediaroom.com/2017-11-20-Lilly-Confirms-Date-and-Conference-Call-for-2018-Financial-Guidance-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2018 on Wednesday, December 13, 2017. Lilly will also conduct a conference call on that day with the investment community...",
                "1d_change": 0.5029167551,
                "index_price": 0.7518204423,
                "norm_price": -0.2489036872
            },
            {
                "index": 686,
                "date": "2017-11-17",
                "press_title": "Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference",
                "release_url": "http://lilly.mediaroom.com/2017-11-17-Lilly-to-Participate-in-Evercore-ISI-2017-Biopharma-Catalyst-Deep-Dive-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017. Dan Skovronsky, M.D., Ph.D., senior vice...",
                "1d_change": 0.2164172227,
                "index_price": -0.0309839459,
                "norm_price": 0.2474011686
            },
            {
                "index": 687,
                "date": "2017-11-13",
                "press_title": "Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease",
                "release_url": "http://lilly.mediaroom.com/2017-11-13-Jardiance-R-reduced-risk-of-cardiovascular-death-in-adults-with-type-2-diabetes-and-peripheral-artery-disease",
                "content": "New data presented today showed that Jardiance® reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery...",
                "1d_change": -0.3843841427,
                "index_price": 0.09074082,
                "norm_price": -0.4751249626
            },
            {
                "index": 688,
                "date": "2017-11-13",
                "press_title": "Lilly Appoints Philip Johnson to Senior Vice President and Treasurer",
                "release_url": "http://lilly.mediaroom.com/2017-11-13-Lilly-Appoints-Philip-Johnson-to-Senior-Vice-President-and-Treasurer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced Philip Johnson has been appointed to senior vice president, Finance, and treasurer effective January 1, 2018. Johnson currently serves as vice...",
                "1d_change": -0.3843841427,
                "index_price": 0.09074082,
                "norm_price": -0.4751249626
            },
            {
                "index": 689,
                "date": "2017-11-09",
                "press_title": "New Data on FORTEO® (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis",
                "release_url": "http://lilly.mediaroom.com/2017-11-09-New-Data-on-FORTEO-R-teriparatide-rDNA-origin-injection-Showed-Reduced-Risk-for-New-Vertebral-and-Clinical-Fractures-in-Postmenopausal-Women-with-Severe-Osteoporosis",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced new data showing that treatment with FORTEO® for 24 months was associated with significantly fewer vertebral and clinical fractures (a composite...",
                "1d_change": -0.6363517502,
                "index_price": -0.0658308926,
                "norm_price": -0.5705208576
            },
            {
                "index": 690,
                "date": "2017-11-08",
                "press_title": "ACR/ARHP 2017: Long-Term Use of Lilly's Taltz® (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors",
                "release_url": "http://lilly.mediaroom.com/2017-11-08-ACR-ARHP-2017-Long-Term-Use-of-Lillys-Taltz-R-ixekizumab-Shows-Efficacy-Improvements-in-Psoriatic-Arthritis-for-Patients-with-Prior-Inadequate-Response-or-Intolerance-to-TNF-Inhibitors",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today patients with active psoriatic arthritis (PsA) treated with Taltz® (ixekizumab), who were previously intolerant or had inadequate responses to...",
                "1d_change": 1.1787011794,
                "index_price": -0.1582377125,
                "norm_price": 1.3369388919
            },
            {
                "index": 691,
                "date": "2017-11-05",
                "press_title": "ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo",
                "release_url": "http://lilly.mediaroom.com/2017-11-05-ACR-ARHP-2017-New-Analysis-Shows-Rheumatoid-Arthritis-Patients-Treated-with-Baricitinib-Reported-Greater-Improvements-in-Pain-Compared-to-Adalimumab-or-Placebo",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that patients with moderate-to-severe rheumatoid arthritis (RA) treated with baricitinib reported greater...",
                "1d_change": -0.0119827836,
                "index_price": 0.1223605752,
                "norm_price": -0.1343433588
            },
            {
                "index": 692,
                "date": "2017-10-30",
                "press_title": "Lilly to Present New Data on Immunology Portfolio at ACR/ARHP Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2017-10-30-Lilly-to-Present-New-Data-on-Immunology-Portfolio-at-ACR-ARHP-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) announced that it will present new data for baricitinib and Taltz® (ixekizumab) at the American College of Rheumatology (ACR)/Association of Rheumatology Health...",
                "1d_change": -2.2211167095,
                "index_price": -0.0966888868,
                "norm_price": -2.1244278228
            },
            {
                "index": 693,
                "date": "2017-10-25",
                "press_title": "Lilly To Participate In Credit Suisse 26th Annual Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2017-10-25-Lilly-To-Participate-In-Credit-Suisse-26th-Annual-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Credit Suisse 26th Annual Healthcare Conference on Tuesday, November 7, 2017. Jan Lundberg, Ph.D., executive vice president for science...",
                "1d_change": -2.0793650107,
                "index_price": -0.2390297384,
                "norm_price": -1.8403352724
            },
            {
                "index": 694,
                "date": "2017-10-24",
                "press_title": "Lilly Reports Third-Quarter Results, Announces Strategic Review of Elanco Animal Health",
                "release_url": "http://lilly.mediaroom.com/2017-10-24-Lilly-Reports-Third-Quarter-Results-Announces-Strategic-Review-of-Elanco-Animal-Health",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2017. $ in millions, except per share data Third Quarter % 2017 2016 Change Revenue $ 5,658.0 $ 5,191.7...",
                "1d_change": -3.0288739684,
                "index_price": -0.4501108736,
                "norm_price": -2.5787630947
            },
            {
                "index": 695,
                "date": "2017-10-23",
                "press_title": "Lilly announces $72 million investment in diabetes manufacturing in Indianapolis",
                "release_url": "http://lilly.mediaroom.com/2017-10-23-Lilly-announces-72-million-investment-in-diabetes-manufacturing-in-Indianapolis",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. The investment will be used to replace an...",
                "1d_change": -2.7004730286,
                "index_price": -0.3483745751,
                "norm_price": -2.3520984535
            },
            {
                "index": 696,
                "date": "2017-10-18",
                "press_title": "Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines",
                "release_url": "http://lilly.mediaroom.com/2017-10-18-Lilly-and-CureVac-Announce-Global-Collaboration-to-Develop-mRNA-Cancer-Vaccines",
                "content": "Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine...",
                "1d_change": 0.0347375839,
                "index_price": -0.0300542329,
                "norm_price": 0.0647918169
            },
            {
                "index": 697,
                "date": "2017-10-16",
                "press_title": "Lilly Declares Fourth-Quarter 2017 Dividend",
                "release_url": "http://lilly.mediaroom.com/2017-10-16-Lilly-Declares-Fourth-Quarter-2017-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable December...",
                "1d_change": -0.4880321205,
                "index_price": 0.148085416,
                "norm_price": -0.6361175365
            },
            {
                "index": 698,
                "date": "2017-10-16",
                "press_title": "Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis",
                "release_url": "http://lilly.mediaroom.com/2017-10-16-Rapidly-Progressing-Advanced-Non-Small-Cell-Lung-Cancer-Patients-Shown-to-Benefit-in-New-CYRAMZA-R-ramucirumab-Phase-3-Subgroup-Analysis",
                "content": "New subgroup analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 REVEL trial of CYRAMZA® (ramucirumab) in advanced non-small cell lung cancer (NSCLC) was presented today at the 18th World...",
                "1d_change": -0.4880321205,
                "index_price": 0.148085416,
                "norm_price": -0.6361175365
            },
            {
                "index": 699,
                "date": "2017-10-12",
                "press_title": "FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer",
                "release_url": "http://lilly.mediaroom.com/2017-10-12-FDA-Grants-Priority-Review-for-Potential-New-Indication-for-Lillys-Verzenio-TM-abemaciclib-as-Initial-Treatment-of-Advanced-Breast-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its New Drug Application (NDA) for Verzenio™...",
                "1d_change": 0.5199411534,
                "index_price": 0.0113599592,
                "norm_price": 0.5085811942
            },
            {
                "index": 700,
                "date": "2017-10-10",
                "press_title": "Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/2017-10-10-Lilly-Reports-Topline-Results-from-Phase-3-JUNIPER-Trial-Evaluating-Verzenio-TM-abemaciclib-in-KRAS-Mutated-Advanced-Non-Small-Cell-Lung-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 JUNIPER study evaluating Verzenio™ (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, as monotherapy in...",
                "1d_change": 0.790148481,
                "index_price": 0.2054601533,
                "norm_price": 0.5846883278
            },
            {
                "index": 701,
                "date": "2017-10-06",
                "press_title": "Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer",
                "release_url": "http://lilly.mediaroom.com/2017-10-06-Lilly-MONARCH-3-Study-Published-in-Journal-of-Clinical-Oncology-Demonstrates-Benefit-of-Verzenio-TM-abemaciclib-Plus-NSAI-in-Advanced-Breast-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study evaluating VerzenioTM (abemaciclib), a cyclin-dependent...",
                "1d_change": -0.2986589688,
                "index_price": -0.1064930644,
                "norm_price": -0.1921659044
            },
            {
                "index": 702,
                "date": "2017-10-05",
                "press_title": "U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent",
                "release_url": "http://lilly.mediaroom.com/2017-10-05-U-S-Patent-and-Trademark-Office-Rules-In-Lillys-Favor-On-Alimta-Vitamin-Regimen-Patent",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) has ruled in the company's favor regarding patentability of...",
                "1d_change": 0.3559728645,
                "index_price": 0.3322429989,
                "norm_price": 0.0237298656
            },
            {
                "index": 703,
                "date": "2017-10-05",
                "press_title": "Additional Delivery of Insulin Ready for Distribution in Puerto Rico",
                "release_url": "http://lilly.mediaroom.com/2017-10-05-Additional-Delivery-of-Insulin-Ready-for-Distribution-in-Puerto-Rico",
                "content": "Today, a new shipment of commercial medicines, including more than 36,000 vials and pens of insulin, arrived in Puerto Rico. The delivery by Eli Lilly and Company (NYSE: LLY) includes 3,000 vials...",
                "1d_change": 0.3559728645,
                "index_price": 0.3322429989,
                "norm_price": 0.0237298656
            },
            {
                "index": 704,
                "date": "2017-10-04",
                "press_title": "Lilly Receives U.S. FDA Approval of Verzenio™ (abemaciclib)",
                "release_url": "http://lilly.mediaroom.com/2017-10-04-Lilly-Receives-U-S-FDA-Approval-of-Verzenio-TM-abemaciclib",
                "content": "INDIANAPOLIS, October 4, 2017 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with fulvestrant...",
                "1d_change": 1.3120803219,
                "index_price": 0.7284317198,
                "norm_price": 0.583648602
            },
            {
                "index": 705,
                "date": "2017-10-04",
                "press_title": "Humalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes",
                "release_url": "http://lilly.mediaroom.com/2017-10-04-Humalog-R-Junior-KwikPen-R-Now-Available-in-the-U-S-for-People-with-Diabetes",
                "content": "Humalog® Junior KwikPen® [insulin lispro injection 100 units/mL] is now available by prescription for the treatment of diabetes in the U.S. This innovation is the latest in the treatment and...",
                "1d_change": 1.3120803219,
                "index_price": 0.7284317198,
                "norm_price": 0.583648602
            },
            {
                "index": 706,
                "date": "2017-10-02",
                "press_title": "Lilly Confirms Date and Conference Call for Third-Quarter 2017 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2017-10-02-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2017-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2017 on Tuesday, October 24, 2017. Lilly will also conduct a conference call on that day with the...",
                "1d_change": 0.7750096903,
                "index_price": 0.5279031059,
                "norm_price": 0.2471065845
            },
            {
                "index": 707,
                "date": "2017-09-29",
                "press_title": "Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing",
                "release_url": "http://lilly.mediaroom.com/2017-09-29-Lilly-Announces-Senior-Leadership-Appointments-for-Finance-Research-Development-and-Manufacturing",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced a number of leadership changes, promoting several experienced Lilly leaders to executive roles, effective in 2018. Josh Smiley has been promoted...",
                "1d_change": 1.3665398569,
                "index_price": 0.7575819005,
                "norm_price": 0.6089579564
            },
            {
                "index": 708,
                "date": "2017-09-25",
                "press_title": "Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death",
                "release_url": "http://lilly.mediaroom.com/2017-09-25-Geisinger-and-Boehringer-Ingelheim-collaborate-to-create-a-predictive-model-to-help-improve-health-outcomes-for-people-with-type-2-diabetes-at-greatest-risk-of-serious-long-term-complications-including-cardiovascular-death",
                "content": "In an effort to improve health outcomes of people with type 2 diabetes, Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company (NYSE: LLY), today...",
                "1d_change": 0.4155692895,
                "index_price": -0.1021212652,
                "norm_price": 0.5176905547
            },
            {
                "index": 709,
                "date": "2017-09-14",
                "press_title": "Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis",
                "release_url": "http://lilly.mediaroom.com/2017-09-14-Baricitinib-Meets-Primary-Endpoint-in-Phase-2-Study-of-Patients-with-Moderate-to-Severe-Atopic-Dermatitis",
                "content": "error_http",
                "1d_change": 0.1334406999,
                "index_price": 0.2267760134,
                "norm_price": -0.0933353135
            },
            {
                "index": 710,
                "date": "2017-09-12",
                "press_title": "Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control",
                "release_url": "http://lilly.mediaroom.com/2017-09-12-Jardiance-R-empagliflozin-tablets-reduced-risk-of-cardiovascular-death-in-people-with-type-2-diabetes-and-established-cardiovascular-disease-independent-of-background-blood-sugar-control",
                "content": "New analyses of the landmark EMPA-REG OUTCOME® trial showed that Jardiance® (empagliflozin) tablets reduced the risk of cardiovascular death in adults with type 2 diabetes and established...",
                "1d_change": -0.2062150597,
                "index_price": 0.2573748276,
                "norm_price": -0.4635898873
            },
            {
                "index": 711,
                "date": "2017-09-11",
                "press_title": "Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress",
                "release_url": "http://lilly.mediaroom.com/2017-09-11-Lilly-to-Present-New-Data-for-Olumiant-R-baricitinib-and-Taltz-R-ixekizumab-at-the-European-Academy-of-Dermatology-and-Venereology-EADV-Annual-Congress",
                "content": "Eli Lilly and Company (NYSE: LLY) announced that data across its immunology portfolio will be presented at the annual European Academy of Dermatology and Venereology Congress (EADV), including...",
                "1d_change": -0.9371100004,
                "index_price": 0.8796369732,
                "norm_price": -1.8167469737
            },
            {
                "index": 712,
                "date": "2017-09-10",
                "press_title": "Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer",
                "release_url": "http://lilly.mediaroom.com/2017-09-10-Lilly-Builds-Upon-Body-of-Clinical-Evidence-for-CYRAMZA-R-ramucirumab-with-Phase-3-RANGE-Data-Demonstrating-Superior-Progression-Free-Survival-in-Advanced-or-Metastatic-Urothelial-Cancer",
                "content": "At the European Society for Medical Oncology (ESMO) 2017 Congress today, Phase 3 RANGE data from Eli Lilly and Company (NYSE: LLY) were presented in the Presidential Symposium (abstract#:...",
                "1d_change": -0.9371100004,
                "index_price": 0.8796369732,
                "norm_price": -1.8167469737
            },
            {
                "index": 713,
                "date": "2017-09-09",
                "press_title": "IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine",
                "release_url": "http://lilly.mediaroom.com/2017-09-09-IHC-2017-Lillys-Lasmiditan-Significantly-Reduces-Pain-in-Patients-with-Migraine",
                "content": "Eli Lilly and Company (NYSE: LLY) will present key primary and secondary endpoint data for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, which...",
                "1d_change": -0.9371100004,
                "index_price": 0.8796369732,
                "norm_price": -1.8167469737
            },
            {
                "index": 714,
                "date": "2017-09-08",
                "press_title": "IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine",
                "release_url": "http://lilly.mediaroom.com/2017-09-08-IHC-2017-Lillys-Galcanezumab-Demonstrates-Positive-Long-Term-Safety-Results-for-up-to-12-Months-in-Patients-with-Migraine",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that treatment with self-administered galcanezumab for up to 12 months demonstrated a positive safety and tolerability profile in patients with...",
                "1d_change": 1.2344005752,
                "index_price": 1.0393473884,
                "norm_price": 0.1950531868
            },
            {
                "index": 715,
                "date": "2017-09-07",
                "press_title": "Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth",
                "release_url": "http://lilly.mediaroom.com/2017-09-07-Lilly-Takes-Steps-to-Streamline-Business-Invest-in-New-Medicines-and-Drive-Growth",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced actions to streamline operations to more efficiently focus resources on developing new medicines and to improve its cost structure. Global...",
                "1d_change": 2.7737384188,
                "index_price": -0.2693607837,
                "norm_price": 3.0430992025
            },
            {
                "index": 716,
                "date": "2017-09-06",
                "press_title": "Lilly to Present New Data for Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC)",
                "release_url": "http://lilly.mediaroom.com/2017-09-06-Lilly-to-Present-New-Data-for-Galcanezumab-and-Lasmiditan-at-the-18th-Congress-of-the-International-Headache-Society-IHC",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today it will present new data for galcanezumab and lasmiditan, two investigational treatments for migraine, at the 18th Congress of the International...",
                "1d_change": 1.6311452972,
                "index_price": 0.0515199984,
                "norm_price": 1.5796252988
            },
            {
                "index": 717,
                "date": "2017-08-30",
                "press_title": "Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018",
                "release_url": "http://lilly.mediaroom.com/2017-08-30-Lilly-to-File-Baricitinib-Resubmission-to-U-S-FDA-before-end-of-January-2018",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that, after discussions with the U.S. Food and Drug Administration (FDA) in late August, Lilly will resubmit...",
                "1d_change": 2.6940613094,
                "index_price": 1.0353344835,
                "norm_price": 1.658726826
            },
            {
                "index": 718,
                "date": "2017-08-29",
                "press_title": "New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress",
                "release_url": "http://lilly.mediaroom.com/2017-08-29-New-Phase-3-Data-for-Abemaciclib-and-Ramucirumab-Presented-at-ESMO-2017-Congress",
                "content": "Eli Lilly and Company (NYSE: LLY) will showcase new data across six different tumor types at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, September 8-12, 2017....",
                "1d_change": 2.422663678,
                "index_price": 1.0437113419,
                "norm_price": 1.3789523361
            },
            {
                "index": 719,
                "date": "2017-08-28",
                "press_title": "Lilly to Participate in Morgan Stanley Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2017-08-28-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017. Derica Rice, Lilly's executive vice president for global services and...",
                "1d_change": -0.7001772206,
                "index_price": -0.0429239589,
                "norm_price": -0.6572532616
            },
            {
                "index": 720,
                "date": "2017-08-04",
                "press_title": "Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine",
                "release_url": "http://lilly.mediaroom.com/2017-08-04-Lilly-Announces-Positive-Results-for-Second-Phase-3-Study-of-Lasmiditan-for-the-Acute-Treatment-of-Migraine",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its primary endpoint in SPARTAN, a...",
                "1d_change": 0.2071176739,
                "index_price": 0.1624415815,
                "norm_price": 0.0446760924
            },
            {
                "index": 721,
                "date": "2017-07-31",
                "press_title": "Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2017-07-31-Boehringer-Ingelheim-and-Lilly-to-support-new-American-College-of-Cardiology-program-to-highlight-the-increasingly-important-role-of-cardiologists-in-reducing-cardiovascular-risk-and-cardiovascular-death-in-people-with-type-2-diabetes",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the companies will support an American College of Cardiology (ACC) program focused on driving quality improvement in...",
                "1d_change": -1.1775704604,
                "index_price": 0.0165629347,
                "norm_price": -1.1941333951
            },
            {
                "index": 722,
                "date": "2017-07-25",
                "press_title": "Lilly Reports Second-Quarter Results",
                "release_url": "http://lilly.mediaroom.com/2017-07-25-Lilly-Reports-Second-Quarter-Results",
                "content": "error_http",
                "1d_change": -2.3216343156,
                "index_price": -0.0020100122,
                "norm_price": -2.3196243034
            },
            {
                "index": 723,
                "date": "2017-07-25",
                "press_title": "Lilly and Incyte Provide Update on Baricitinib",
                "release_url": "http://lilly.mediaroom.com/2017-07-25-Lilly-and-Incyte-Provide-Update-on-Baricitinib",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that a resubmission to the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for...",
                "1d_change": -2.3216343156,
                "index_price": -0.0020100122,
                "norm_price": -2.3196243034
            },
            {
                "index": 724,
                "date": "2017-07-24",
                "press_title": "Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy",
                "release_url": "http://lilly.mediaroom.com/2017-07-24-Lilly-and-Nektar-Therapeutics-Announce-Alliance-to-Develop-and-Commercialize-NKTR-358-A-Novel-Autoimmune-Therapy",
                "content": "Eli Lilly and Company (NYSE: LLY) and Nektar Therapeutics (NASDAQ: NKTR) have announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar....",
                "1d_change": -3.0052205926,
                "index_price": 0.2054734306,
                "norm_price": -3.2106940232
            },
            {
                "index": 725,
                "date": "2017-07-12",
                "press_title": "Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation",
                "release_url": "http://lilly.mediaroom.com/2017-07-12-Lilly-Reaches-Settlement-Agreement-in-U-S-Cialis-Patent-Litigation",
                "content": "Eli Lilly and Company (NYSE: LLY) has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S. District Court for the Eastern District of...",
                "1d_change": 1.5353534133,
                "index_price": 0.4935014989,
                "norm_price": 1.0418519145
            },
            {
                "index": 726,
                "date": "2017-07-12",
                "press_title": "Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017)",
                "release_url": "http://lilly.mediaroom.com/2017-07-12-Eli-Lilly-and-Company-to-Present-More-Than-40-Abstracts-at-the-Alzheimers-Association-International-Conference-R-2017-AAIC-R-2017",
                "content": "Data highlights include important health outcomes data emphasizing the need for timely detection and management of Alzheimer's disease INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and...",
                "1d_change": 1.5353534133,
                "index_price": 0.4935014989,
                "norm_price": 1.0418519145
            },
            {
                "index": 727,
                "date": "2017-07-10",
                "press_title": "Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment",
                "release_url": "http://lilly.mediaroom.com/2017-07-10-Renowned-Television-Personality-Don-Francisco-Introduces-New-Initiative-to-Help-Dispel-Myths-About-Diabetes-and-Insulin-Treatment",
                "content": "Popular television host and legendary entertainer, Don Francisco, is joining Lilly and Boehringer Ingelheim to launch a new awareness initiative, Basado en Hechos, to help address common...",
                "1d_change": 0.0242962711,
                "index_price": 0.0420534695,
                "norm_price": -0.0177571984
            },
            {
                "index": 728,
                "date": "2017-07-10",
                "press_title": "FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer",
                "release_url": "http://lilly.mediaroom.com/2017-07-10-FDA-Grants-Priority-Review-for-Lillys-Abemaciclib-for-the-Treatment-of-Advanced-Breast-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its New Drug Application (NDA) for abemaciclib, a cyclin-dependent kinase...",
                "1d_change": 0.0242962711,
                "index_price": 0.0420534695,
                "norm_price": -0.0177571984
            },
            {
                "index": 729,
                "date": "2017-07-07",
                "press_title": "UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents",
                "release_url": "http://lilly.mediaroom.com/2017-07-07-UK-Supreme-Court-Rules-In-Lillys-Favor-On-Alimta-Vitamin-Regimen-Patents",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the UK Supreme Court has decided in the litigation relating to alternative salt forms of Alimta® (pemetrexed disodium) that Actavis's...",
                "1d_change": 0.8021407933,
                "index_price": 0.5730304273,
                "norm_price": 0.2291103661
            },
            {
                "index": 730,
                "date": "2017-07-06",
                "press_title": "Lilly Confirms Date and Conference Call for Second-Quarter 2017 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2017-07-06-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2017-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2017 on Tuesday, July 25, 2017. Lilly will also conduct a conference call on that day with the...",
                "1d_change": -0.0364548539,
                "index_price": 0.0717468511,
                "norm_price": -0.1082017049
            },
            {
                "index": 731,
                "date": "2017-07-06",
                "press_title": "Lilly and Purdue University Announce Strategic Research Collaboration",
                "release_url": "http://lilly.mediaroom.com/2017-07-06-Lilly-and-Purdue-University-Announce-Strategic-Research-Collaboration",
                "content": "Eli Lilly and Company (NYSE: LLY) and Purdue University today announced a strategic collaboration to conduct life science research. The five-year agreement, where Lilly will provide up to $52...",
                "1d_change": -0.0364548539,
                "index_price": 0.0717468511,
                "norm_price": -0.1082017049
            },
            {
                "index": 732,
                "date": "2017-07-03",
                "press_title": "Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis",
                "release_url": "http://lilly.mediaroom.com/2017-07-03-Japan-Ministry-of-Health-Labor-and-Welfare-MHLW-Grants-Marketing-Approval-For-Olumiant-R-baricitinib-for-the-Treatment-of-Rheumatoid-Arthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant®...",
                "1d_change": -0.9926493097,
                "index_price": -0.8980140088,
                "norm_price": -0.0946353009
            },
            {
                "index": 733,
                "date": "2017-06-27",
                "press_title": "Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour",
                "release_url": "http://lilly.mediaroom.com/2017-06-27-Lilly-Diabetes-Brings-an-Extra-Splash-of-Summertime-Fun-and-Inspiration-to-Diabetes-Camps-with-Launch-of-Annual-Camp-Care-Package-Speaker-Tour",
                "content": "INDIANAPOLIS (June 27, 2017) — For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun experiences and new...",
                "1d_change": -1.299631167,
                "index_price": 0.1782222904,
                "norm_price": -1.4778534574
            },
            {
                "index": 734,
                "date": "2017-06-21",
                "press_title": "Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego",
                "release_url": "http://lilly.mediaroom.com/2017-06-21-Eli-Lilly-and-Company-Unveils-Expanded-Biotechnology-Center-in-San-Diego",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. Lilly's new space will help foster and accelerate the...",
                "1d_change": 1.4351947182,
                "index_price": -0.1975789112,
                "norm_price": 1.6327736294
            },
            {
                "index": 735,
                "date": "2017-06-19",
                "press_title": "Lilly Declares Third-Quarter 2017 Dividend",
                "release_url": "http://lilly.mediaroom.com/2017-06-19-Lilly-Declares-Third-Quarter-2017-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable September...",
                "1d_change": 0.8821763168,
                "index_price": -0.226506012,
                "norm_price": 1.1086823288
            },
            {
                "index": 736,
                "date": "2017-06-16",
                "press_title": "EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks",
                "release_url": "http://lilly.mediaroom.com/2017-06-16-EULAR-2017-Lillys-Taltz-R-ixekizumab-Demonstrated-No-Progression-or-Minimal-Progression-of-Radiographic-Disease-in-Patients-with-Psoriatic-Arthritis-Through-52-Weeks",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz® (ixekizumab) exhibited either no progression or minimal...",
                "1d_change": 0.1214281938,
                "index_price": 0.9056585824,
                "norm_price": -0.7842303886
            },
            {
                "index": 737,
                "date": "2017-06-16",
                "press_title": "New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017",
                "release_url": "http://lilly.mediaroom.com/2017-06-16-New-Safety-and-Long-Term-Efficacy-Data-from-Baricitinib-Clinical-Trials-in-Patients-with-Moderate-to-Severe-Rheumatoid-Arthritis-Presented-at-EULAR-2017",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced a new pooled analysis of data from eight Olumiant® (baricitinib) clinical trials, showing that...",
                "1d_change": 0.1214281938,
                "index_price": 0.9056585824,
                "norm_price": -0.7842303886
            },
            {
                "index": 738,
                "date": "2017-06-15",
                "press_title": "EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors",
                "release_url": "http://lilly.mediaroom.com/2017-06-15-EULAR-2017-Lillys-Taltz-R-ixekizumab-Demonstrated-Significant-Improvements-in-Disease-Signs-and-Symptoms-at-24-Weeks-Among-Patients-with-Active-Psoriatic-Arthritis-Who-Had-Prior-Inadequate-Response-or-Intolerance-to-TNF-Inhibitors",
                "content": "Taltz also demonstrated significant improvements in key secondary measures at 24 weeks INDIANAPOLIS, June 15, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients...",
                "1d_change": 0.5984471829,
                "index_price": 0.3703022883,
                "norm_price": 0.2281448946
            },
            {
                "index": 739,
                "date": "2017-06-13",
                "press_title": "Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)",
                "release_url": "http://lilly.mediaroom.com/2017-06-13-Lilly-to-Present-New-Data-on-Olumiant-R-baricitinib-in-Rheumatoid-Arthritis-and-Taltz-R-ixekizumab-in-Psoriatic-Arthritis-at-the-Annual-European-Congress-of-Rheumatology-EULAR-2017",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data on safety and long-term efficacy from the Olumiant® (baricitinib) clinical trials will be...",
                "1d_change": 0.4779470608,
                "index_price": 0.1546408271,
                "norm_price": 0.3233062337
            },
            {
                "index": 740,
                "date": "2017-06-13",
                "press_title": "U.S. FDA Approves Humalog® Junior KwikPen® for the Treatment of Diabetes",
                "release_url": "http://lilly.mediaroom.com/2017-06-13-U-S-FDA-Approves-Humalog-R-Junior-KwikPen-R-for-the-Treatment-of-Diabetes",
                "content": "INDIANAPOLIS, June 13, 2017 – The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Humalog® Junior KwikPen® for the treatment of diabetes. Humalog Junior...",
                "1d_change": 0.4779470608,
                "index_price": 0.1546408271,
                "norm_price": 0.3233062337
            },
            {
                "index": 741,
                "date": "2017-06-13",
                "press_title": "Jardiance® (empagliflozin) analysis reinforces established safety profile",
                "release_url": "http://lilly.mediaroom.com/2017-06-13-Jardiance-R-empagliflozin-analysis-reinforces-established-safety-profile",
                "content": "An analysis of pooled safety data from 19 studies, including the EMPA-REG OUTCOME® trial, involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance®...",
                "1d_change": 0.4779470608,
                "index_price": 0.1546408271,
                "norm_price": 0.3233062337
            },
            {
                "index": 742,
                "date": "2017-06-13",
                "press_title": "Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab",
                "release_url": "http://lilly.mediaroom.com/2017-06-13-Pfizer-and-Lilly-Receive-FDA-Fast-Track-Designation-for-Tanezumab",
                "content": "NEW YORK, N.Y., & INDIANAPOLIS, IN, June 13 – Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...",
                "1d_change": 0.4779470608,
                "index_price": 0.1546408271,
                "norm_price": 0.3233062337
            },
            {
                "index": 743,
                "date": "2017-06-12",
                "press_title": "Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease",
                "release_url": "http://lilly.mediaroom.com/2017-06-12-Jardiance-R-empagliflozin-tablets-to-be-studied-in-chronic-kidney-disease",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to conduct a new, large clinical outcomes trial investigating Jardiance® (empagliflozin) tablets for the treatment...",
                "1d_change": 0.3569203598,
                "index_price": 0.592956513,
                "norm_price": -0.2360361532
            },
            {
                "index": 744,
                "date": "2017-06-10",
                "press_title": "Lilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS",
                "release_url": "http://lilly.mediaroom.com/2017-06-10-Lillys-Galcanezumab-Significantly-Reduces-Number-of-Migraine-Headache-Days-for-Patients-with-Migraine-New-Results-Presented-at-AHS",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today positive results from three Phase 3 studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine,...",
                "1d_change": 0.3569203598,
                "index_price": 0.592956513,
                "norm_price": -0.2360361532
            },
            {
                "index": 745,
                "date": "2017-06-09",
                "press_title": "IDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention",
                "release_url": "http://lilly.mediaroom.com/2017-06-09-IDF-in-partnership-with-Lilly-announces-second-phase-of-BRIDGES-programme-funding-for-translational-research-in-diabetes-with-focus-on-secondary-prevention",
                "content": "More than 400 million people are living with diabetes. In a further effort to help spread lessons learned from clinical research to benefit people affected by this condition, the International...",
                "1d_change": 0.9888616338,
                "index_price": -0.2881381873,
                "norm_price": 1.2769998211
            },
            {
                "index": 746,
                "date": "2017-06-08",
                "press_title": "Lilly to Present Late-Breaking Data for Galcanezumab and Lasmiditan at the American Headache Society Annual Scientific Meeting",
                "release_url": "http://lilly.mediaroom.com/2017-06-08-Lilly-to-Present-Late-Breaking-Data-for-Galcanezumab-and-Lasmiditan-at-the-American-Headache-Society-Annual-Scientific-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) will present data from 14 abstracts, including late-breaking Phase 3 data for two investigational treatments for migraine, at the American Headache Society (AHS)...",
                "1d_change": 2.036068145,
                "index_price": -0.1028057744,
                "norm_price": 2.1388739194
            },
            {
                "index": 747,
                "date": "2017-06-08",
                "press_title": "Lilly Announces Webcast to Discuss Pain Management Portfolio",
                "release_url": "http://lilly.mediaroom.com/2017-06-08-Lilly-Announces-Webcast-to-Discuss-Pain-Management-Portfolio",
                "content": "Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 19, 2017, to discuss the company's pain management portfolio, including data from three Phase 3 studies of galcanezumab, an...",
                "1d_change": 2.036068145,
                "index_price": -0.1028057744,
                "norm_price": 2.1388739194
            },
            {
                "index": 748,
                "date": "2017-06-08",
                "press_title": "Lilly Announces Strategic Collaboration with KeyBioscience AG",
                "release_url": "http://lilly.mediaroom.com/2017-06-08-Lilly-Announces-Strategic-Collaboration-with-KeyBioscience-AG",
                "content": "Eli Lilly and Company (NYSE: LLY) and KeyBioscience AG have agreed to a new collaboration focused on the development of Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of...",
                "1d_change": 2.036068145,
                "index_price": -0.1028057744,
                "norm_price": 2.1388739194
            },
            {
                "index": 749,
                "date": "2017-06-03",
                "press_title": "Lilly Builds Upon Body of Data for Abemaciclib with Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival in Advanced Breast Cancer",
                "release_url": "http://lilly.mediaroom.com/2017-06-03-Lilly-Builds-Upon-Body-of-Data-for-Abemaciclib-with-Phase-3-MONARCH-2-Data-Demonstrating-Superior-Progression-Free-Survival-in-Advanced-Breast-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that results from the Phase 3 MONARCH 2 study showed that abemaciclib, a cyclin-dependent kinase (CDK)4 & 6 inhibitor, in combination with...",
                "1d_change": -1.1505782625,
                "index_price": -0.3498906994,
                "norm_price": -0.8006875631
            },
            {
                "index": 750,
                "date": "2017-06-01",
                "press_title": "Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at the American Diabetes Association's 77th Scientific Sessions®",
                "release_url": "http://lilly.mediaroom.com/2017-06-01-Boehringer-Ingelheim-and-Lilly-Diabetes-Alliance-to-Present-33-Abstracts-at-the-American-Diabetes-Associations-77th-Scientific-Sessions-R",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present 33 abstracts highlighting the companies' wide range of diabetes treatment options at the 77th American Diabetes...",
                "1d_change": 0.6613987754,
                "index_price": 0.9602088238,
                "norm_price": -0.2988100485
            },
            {
                "index": 751,
                "date": "2017-06-01",
                "press_title": "Derica Rice to Retire as Lilly Chief Financial Officer",
                "release_url": "http://lilly.mediaroom.com/2017-06-01-Derica-Rice-to-Retire-as-Lilly-Chief-Financial-Officer",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Derica Rice, executive vice president global services and chief financial officer, will retire at the end of December 2017 after 27 years of...",
                "1d_change": 0.6613987754,
                "index_price": 0.9602088238,
                "norm_price": -0.2988100485
            },
            {
                "index": 752,
                "date": "2017-05-31",
                "press_title": "Lilly to Participate in Goldman Sachs Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2017-05-31-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017. Sue Mahony, Ph.D., senior vice president and president...",
                "1d_change": 1.8877391832,
                "index_price": 0.5938197178,
                "norm_price": 1.2939194655
            },
            {
                "index": 753,
                "date": "2017-05-31",
                "press_title": "Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA® (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival",
                "release_url": "http://lilly.mediaroom.com/2017-05-31-Lilly-Announces-Phase-3-RANGE-Urothelial-Cancer-Trial-of-CYRAMZA-R-ramucirumab-Met-Primary-Endpoint-Improving-Progression-Free-Survival",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RANGE study of CYRAMZA® (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically...",
                "1d_change": 1.8877391832,
                "index_price": 0.5938197178,
                "norm_price": 1.2939194655
            },
            {
                "index": 754,
                "date": "2017-05-17",
                "press_title": "Lilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib and New Portfolio Data at ASCO 2017",
                "release_url": "http://lilly.mediaroom.com/2017-05-17-Lilly-to-Present-Results-from-Pivotal-Breast-Cancer-Study-of-Abemaciclib-and-New-Portfolio-Data-at-ASCO-2017",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that new research demonstrating advances in the Company's oncology pipeline and product portfolio will be presented at the 53rd Annual Meeting of...",
                "1d_change": -0.8812372686,
                "index_price": -0.7283186802,
                "norm_price": -0.1529185884
            },
            {
                "index": 755,
                "date": "2017-05-16",
                "press_title": "Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom",
                "release_url": "http://lilly.mediaroom.com/2017-05-16-Actress-Angela-Bassett-joins-For-Your-SweetHeart-TM-to-urge-people-with-diabetes-to-know-their-heart-disease-risk-in-honor-of-her-mom",
                "content": "Award-winning actress Angela Bassett, along with 11 leading patient and professional organizations, is joining For Your SweetHeart™: Where diabetes and heart disease meet — a nationwide...",
                "1d_change": -2.6746834658,
                "index_price": -2.0160973318,
                "norm_price": -0.658586134
            },
            {
                "index": 756,
                "date": "2017-05-12",
                "press_title": "Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine",
                "release_url": "http://lilly.mediaroom.com/2017-05-12-Lilly-Announces-Positive-Results-for-Three-Phase-3-Studies-of-Galcanezumab-for-the-Prevention-of-Episodic-and-Chronic-Migraine",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, met its primary endpoint in three Phase 3...",
                "1d_change": -0.0373725358,
                "index_price": 0.4112743794,
                "norm_price": -0.4486469152
            },
            {
                "index": 757,
                "date": "2017-05-10",
                "press_title": "Lilly to Participate in Bernstein Strategic Decisions Conference",
                "release_url": "http://lilly.mediaroom.com/2017-05-10-Lilly-to-Participate-in-Bernstein-Strategic-Decisions-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will attend the Bernstein Strategic Decisions Conference on Wednesday, May 31, 2017. David A. Ricks, Lilly's president and chief executive officer, will...",
                "1d_change": -0.1263390581,
                "index_price": -0.0981481145,
                "norm_price": -0.0281909436
            },
            {
                "index": 758,
                "date": "2017-05-10",
                "press_title": "Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications",
                "release_url": "http://lilly.mediaroom.com/2017-05-10-Leigh-Ann-Pusey-Joins-Lilly-as-Senior-Vice-President-of-Corporate-Affairs-and-Communications",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Leigh Ann Pusey will be joining Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017. She will be...",
                "1d_change": -0.1263390581,
                "index_price": -0.0981481145,
                "norm_price": -0.0281909436
            },
            {
                "index": 759,
                "date": "2017-05-03",
                "press_title": "Lilly to Participate in UBS Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2017-05-03-Lilly-to-Participate-in-UBS-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 23, 2017. Derica Rice, Lilly's executive vice president for global services and chief financial...",
                "1d_change": 2.1435600394,
                "index_price": 0.1263860318,
                "norm_price": 2.0171740076
            },
            {
                "index": 760,
                "date": "2017-05-02",
                "press_title": "Lilly Announces Webcast to Discuss Oncology Pipeline",
                "release_url": "http://lilly.mediaroom.com/2017-05-02-Lilly-Announces-Webcast-to-Discuss-Oncology-Pipeline",
                "content": "Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Saturday, June 3, 2017, to discuss the company's oncology pipeline, including data from the MONARCH 2 study of abemaciclib in patients...",
                "1d_change": -0.8984822594,
                "index_price": -0.1222783583,
                "norm_price": -0.776203901
            },
            {
                "index": 761,
                "date": "2017-05-01",
                "press_title": "Lilly Declares Second-Quarter 2017 Dividend",
                "release_url": "http://lilly.mediaroom.com/2017-05-01-Lilly-Declares-Second-Quarter-2017-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable June 9,...",
                "1d_change": -0.4773561589,
                "index_price": 0.1116575552,
                "norm_price": -0.5890137141
            },
            {
                "index": 762,
                "date": "2017-04-25",
                "press_title": "Lilly Reports First-Quarter 2017 Results",
                "release_url": "http://lilly.mediaroom.com/2017-04-25-Lilly-Reports-First-Quarter-2017-Results",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2017. $ in millions, except per share data First Quarter % 2017 2016 Change Revenue $ 5,228.3 $ 4,865.1 7 %",
                "1d_change": -2.1615831909,
                "index_price": 0.2487985729,
                "norm_price": -2.4103817638
            },
            {
                "index": 763,
                "date": "2017-04-24",
                "press_title": "Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis",
                "release_url": "http://lilly.mediaroom.com/2017-04-24-Lilly-Announces-Phase-3-MONARCH-3-Breast-Cancer-Study-of-Abemaciclib-Demonstrated-Superior-Progression-Free-Survival-at-Interim-Analysis",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating statistically significant...",
                "1d_change": -1.995050683,
                "index_price": 0.7652998386,
                "norm_price": -2.7603505216
            },
            {
                "index": 764,
                "date": "2017-04-20",
                "press_title": "Lilly to Present Data for Galcanezumab for the Prevention of Migraine at the American Academy of Neurology (AAN) Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2017-04-20-Lilly-to-Present-Data-for-Galcanezumab-for-the-Prevention-of-Migraine-at-the-American-Academy-of-Neurology-AAN-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take...",
                "1d_change": 0.854809598,
                "index_price": 0.2554615615,
                "norm_price": 0.5993480365
            },
            {
                "index": 765,
                "date": "2017-04-14",
                "press_title": "U.S. FDA Issues Complete Response Letter for Baricitinib",
                "release_url": "http://lilly.mediaroom.com/2017-04-14-U-S-FDA-Issues-Complete-Response-Letter-for-Baricitinib",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug...",
                "1d_change": -0.1231348734,
                "index_price": 0.408584464,
                "norm_price": -0.5317193374
            },
            {
                "index": 766,
                "date": "2017-04-11",
                "press_title": "Lilly Confirms Date and Conference Call for First-Quarter 2017 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2017-04-11-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2017-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2017 on Tuesday, April 25, 2017. Lilly will also conduct a conference call on that day with the...",
                "1d_change": 0.9043338868,
                "index_price": -0.3833799088,
                "norm_price": 1.2877137956
            },
            {
                "index": 767,
                "date": "2017-04-07",
                "press_title": "Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences",
                "release_url": "http://lilly.mediaroom.com/2017-04-07-Life-with-Type-1-Diabetes-Made-a-Little-Easier-through-Lilly-Diabetes-Scholarship-Donations-for-Camps-College-and-Conferences",
                "content": "Living with type 1 diabetes comes with many unique challenges in all stages of life. For parents of children with the condition, financial, medical and emotional worries can be overwhelming. To...",
                "1d_change": 0.1520812554,
                "index_price": 0.0241741859,
                "norm_price": 0.1279070695
            },
            {
                "index": 768,
                "date": "2017-04-04",
                "press_title": "Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students",
                "release_url": "http://lilly.mediaroom.com/2017-04-04-Lilly-and-Ohio-University-Heritage-College-of-Osteopathic-Medicine-Partner-on-Rotation-Program-for-Medical-Students",
                "content": "Students from Ohio University's Heritage College of Osteopathic Medicine will soon join Eli Lilly and Company's (NYSE: LLY) innovative rotation program for aspiring physicians. Launched in early...",
                "1d_change": 1.2845807898,
                "index_price": -0.0769272034,
                "norm_price": 1.3615079932
            },
            {
                "index": 769,
                "date": "2017-03-23",
                "press_title": "Lilly and the William Sansum Diabetes Center announce a five-year research collaboration",
                "release_url": "http://lilly.mediaroom.com/2017-03-23-Lilly-and-the-William-Sansum-Diabetes-Center-announce-a-five-year-research-collaboration",
                "content": "Eli Lilly and Company (NYSE: LLY) and the William Sansum Diabetes Center have established a research collaboration to improve the lives of Latino people affected by diabetes through enhanced...",
                "1d_change": 0.3088947916,
                "index_price": -0.0848979194,
                "norm_price": 0.393792711
            },
            {
                "index": 770,
                "date": "2017-03-20",
                "press_title": "Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival",
                "release_url": "http://lilly.mediaroom.com/2017-03-20-Lilly-Announces-Phase-3-MONARCH-2-Breast-Cancer-Study-of-Abemaciclib-Met-Primary-Endpoint-of-Progression-Free-Survival",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemaciclib, a...",
                "1d_change": -1.0390636472,
                "index_price": -1.4598838925,
                "norm_price": 0.4208202454
            },
            {
                "index": 771,
                "date": "2017-03-17",
                "press_title": "First dedicated outcome trials of empagliflozin in chronic heart failure initiated",
                "release_url": "http://lilly.mediaroom.com/2017-03-17-First-dedicated-outcome-trials-of-empagliflozin-in-chronic-heart-failure-initiated",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the EMPEROR HF clinical trial program was initiated. EMPEROR HF comprises two phase III outcome studies that will...",
                "1d_change": -0.4520604561,
                "index_price": -0.4314354241,
                "norm_price": -0.020625032
            },
            {
                "index": 772,
                "date": "2017-03-04",
                "press_title": "New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis",
                "release_url": "http://lilly.mediaroom.com/2017-03-04-New-Head-to-Head-Data-Shows-Significantly-Higher-Response-Rates-for-Lillys-Taltz-R-ixekizumab-Compared-to-Stelara-R-ustekinumab-in-Patients-with-Moderate-to-Severe-Plaque-Psoriasis",
                "content": "error_http",
                "1d_change": -0.6163822973,
                "index_price": -0.2888075106,
                "norm_price": -0.3275747866
            },
            {
                "index": 773,
                "date": "2017-03-03",
                "press_title": "Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®'",
                "release_url": "http://lilly.mediaroom.com/2017-03-03-Lilly-Diabetes-Becomes-Official-Diabetes-Health-Partner-of-NASCAR-R",
                "content": "NASCAR® and Lilly Diabetes announced today that Lilly is expanding its involvement in NASCAR with a multi-year official partnership with the sanctioning body. The new collaboration designates...",
                "1d_change": 1.3479843167,
                "index_price": -0.236173937,
                "norm_price": 1.5841582537
            },
            {
                "index": 774,
                "date": "2017-03-02",
                "press_title": "Lilly Announces Changes in Senior Management",
                "release_url": "http://lilly.mediaroom.com/2017-03-02-Lilly-Announces-Changes-in-Senior-Management",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced changes in its executive committee. Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh,...",
                "1d_change": -0.1074430901,
                "index_price": -0.4880107691,
                "norm_price": 0.380567679
            },
            {
                "index": 775,
                "date": "2017-03-01",
                "press_title": "Lilly Completes Acquisition of CoLucid Pharmaceuticals",
                "release_url": "http://lilly.mediaroom.com/2017-03-01-Lilly-Completes-Acquisition-of-CoLucid-Pharmaceuticals",
                "content": "Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD). The tender offer for all outstanding shares of common...",
                "1d_change": -0.6392610512,
                "index_price": 0.0751511017,
                "norm_price": -0.7144121529
            },
            {
                "index": 776,
                "date": "2017-02-28",
                "press_title": "Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2017-02-28-Lilly-to-Present-New-Data-for-Taltz-R-ixekizumab-in-Psoriasis-and-Psoriatic-Arthritis-at-the-American-Academy-of-Dermatology-AAD-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the...",
                "1d_change": 1.2283712691,
                "index_price": 1.2470944131,
                "norm_price": -0.018723144
            },
            {
                "index": 777,
                "date": "2017-02-15",
                "press_title": "Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo",
                "release_url": "http://lilly.mediaroom.com/2017-02-15-Additional-results-from-pivotal-RA-BEAM-study-published-in-New-England-Journal-of-Medicine-show-baricitinib-treated-patients-demonstrated-sustained-improvement-in-rheumatoid-arthritis-compared-to-adalimumab-and-placebo",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a pivotal phase 3 study of baricitinib in the treatment of...",
                "1d_change": 2.1239171308,
                "index_price": 0.4959012246,
                "norm_price": 1.6280159063
            },
            {
                "index": 778,
                "date": "2017-02-13",
                "press_title": "European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis",
                "release_url": "http://lilly.mediaroom.com/2017-02-13-European-Commission-Approves-Once-Daily-Olumiant-Tablets-for-Treatment-of-Adults-with-Moderate-to-Severe-Active-Rheumatoid-Arthritis",
                "content": "Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU INDIANAPOLIS, Feb. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation...",
                "1d_change": 1.5734006229,
                "index_price": 0.6784840259,
                "norm_price": 0.8949165971
            },
            {
                "index": 779,
                "date": "2017-02-09",
                "press_title": "Lilly To Present At Leerink Partners Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2017-02-09-Lilly-To-Present-At-Leerink-Partners-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017. Enrique Conterno, senior vice president of Lilly and president...",
                "1d_change": -0.4113469447,
                "index_price": 0.8376212455,
                "norm_price": -1.2489681902
            },
            {
                "index": 780,
                "date": "2017-02-09",
                "press_title": "Carolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors",
                "release_url": "http://lilly.mediaroom.com/2017-02-09-Carolyn-R-Bertozzi-Ph-D-Elected-to-Lilly-Board-of-Directors",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Carolyn R. Bertozzi, Ph.D., as a new member, effective Feb. 10, 2017. As a member of Lilly's board, she will serve on the...",
                "1d_change": -0.4113469447,
                "index_price": 0.8376212455,
                "norm_price": -1.2489681902
            },
            {
                "index": 781,
                "date": "2017-02-08",
                "press_title": "Lilly to Present at Cowen Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2017-02-08-Lilly-to-Present-at-Cowen-Health-Care-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017. David A. Ricks, Lilly's president and chief executive officer,...",
                "1d_change": 0.334593902,
                "index_price": 0.7938084653,
                "norm_price": -0.4592145634
            },
            {
                "index": 782,
                "date": "2017-02-08",
                "press_title": "Lilly's Trulicity® (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2017-02-08-Lillys-Trulicity-R-dulaglutide-Label-Updated-to-Include-Use-in-Combination-with-Basal-Insulin-for-Adults-with-Type-2-Diabetes",
                "content": "The label for Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity® (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2 diabetes. The U.S....",
                "1d_change": 0.334593902,
                "index_price": 0.7938084653,
                "norm_price": -0.4592145634
            },
            {
                "index": 783,
                "date": "2017-02-02",
                "press_title": "Japan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents",
                "release_url": "http://lilly.mediaroom.com/2017-02-02-Japan-IP-High-Court-Rules-In-Lillys-Favor-On-Alimta-Vitamin-Regimen-Patents",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the Japan IP High Court confirmed the decisions of the Japan Patent Office and ruled in Lilly's favor in the invalidation trials initiated by...",
                "1d_change": 0.3107719049,
                "index_price": 0.9023156921,
                "norm_price": -0.5915437872
            },
            {
                "index": 784,
                "date": "2017-01-31",
                "press_title": "Lilly Reports Fourth-Quarter and Full-Year 2016 Results",
                "release_url": "http://lilly.mediaroom.com/2017-01-31-Lilly-Reports-Fourth-Quarter-and-Full-Year-2016-Results",
                "content": "error_http",
                "1d_change": 4.3170227166,
                "index_price": 0.2425930196,
                "norm_price": 4.074429697
            },
            {
                "index": 785,
                "date": "2017-01-30",
                "press_title": "Lilly Revises Time for Conference Call for Fourth-Quarter 2016 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2017-01-30-Lilly-Revises-Time-for-Conference-Call-for-Fourth-Quarter-2016-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will host a call for investors, media and the general public at 11:30 a.m. Eastern Time on January 31, 2017 to discuss the company's fourth-quarter and full-year...",
                "1d_change": 2.518461903,
                "index_price": -0.3133084472,
                "norm_price": 2.8317703502
            },
            {
                "index": 786,
                "date": "2017-01-18",
                "press_title": "Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid",
                "release_url": "http://lilly.mediaroom.com/2017-01-18-Lilly-and-CoLucid-Pharmaceuticals-Announce-Agreement-for-Lilly-To-Acquire-CoLucid",
                "content": "Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASD: CLCD) today announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This...",
                "1d_change": -0.6246970041,
                "index_price": -0.2407551967,
                "norm_price": -0.3839418073
            },
            {
                "index": 787,
                "date": "2017-01-13",
                "press_title": "U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment",
                "release_url": "http://lilly.mediaroom.com/2017-01-13-U-S-FDA-Extends-Review-Period-for-Baricitinib-an-Investigational-Rheumatoid-Arthritis-Treatment",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application...",
                "1d_change": -0.0910768327,
                "index_price": -0.2138594855,
                "norm_price": 0.1227826528
            },
            {
                "index": 788,
                "date": "2017-01-12",
                "press_title": "U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent",
                "release_url": "http://lilly.mediaroom.com/2017-01-12-U-S-Court-of-Appeals-Rules-In-Lillys-Favor-On-Alimta-Vitamin-Regimen-Patent",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the district court's decision and ruled in the company's favor regarding...",
                "1d_change": 3.2945890128,
                "index_price": 0.1538705099,
                "norm_price": 3.1407185029
            },
            {
                "index": 789,
                "date": "2017-01-11",
                "press_title": "Lilly and Merck Expand Immuno-Oncology Collaboration",
                "release_url": "http://lilly.mediaroom.com/2017-01-11-Lilly-and-Merck-Expand-Immuno-Oncology-Collaboration",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada, through a subsidiary, to add a...",
                "1d_change": 0.8295275249,
                "index_price": 0.0810346804,
                "norm_price": 0.7484928445
            },
            {
                "index": 790,
                "date": "2017-01-05",
                "press_title": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2016 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2017-01-05-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2016-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2016 financial results on Tuesday, January 31, 2017. Lilly will also conduct a conference call on that day with the...",
                "1d_change": 0.977914595,
                "index_price": 0.3864789723,
                "norm_price": 0.5914356227
            },
            {
                "index": 791,
                "date": "2017-01-05",
                "press_title": "Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities",
                "release_url": "http://lilly.mediaroom.com/2017-01-05-Lilly-to-Adjust-Organization-and-Leadership-Structure-to-Better-Align-with-Growth-Opportunities",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced a series of changes to its organization and leadership structure to better align them with the company's growth opportunities. Explaining the need...",
                "1d_change": 0.977914595,
                "index_price": 0.3864789723,
                "norm_price": 0.5914356227
            },
            {
                "index": 792,
                "date": "2017-01-04",
                "press_title": "U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag",
                "release_url": "http://lilly.mediaroom.com/2017-01-04-U-S-FDA-approves-supplemental-New-Drug-Applications-to-include-landmark-data-in-product-labels-for-Synjardy-R-empagliflozin-metformin-hydrochloride-Synjardy-R-XR-empagliflozin-metformin-hydrochloride-extended-release-and-Glyxambi-R-empagliflozi",
                "content": "The U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications for three type 2 diabetes medicines within the empagliflozin family to include data from the landmark...",
                "1d_change": 0.8466755663,
                "index_price": 0.3261305572,
                "norm_price": 0.5205450091
            },
            {
                "index": 793,
                "date": "2017-01-03",
                "press_title": "Lilly to Present at J.P. Morgan Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2017-01-03-Lilly-to-Present-at-J-P-Morgan-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017. David A. Ricks, Lilly's president and chief executive officer,...",
                "1d_change": 1.0439331305,
                "index_price": 0.8446518393,
                "norm_price": 0.1992812912
            },
            {
                "index": 794,
                "date": "2016-12-16",
                "press_title": "Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) Tablets in Updated American Diabetes Association's 2017 Standards",
                "release_url": "http://lilly.mediaroom.com/2016-12-16-Boehringer-Ingelheim-and-Lilly-Welcome-New-Recommendation-for-Jardiance-R-empagliflozin-Tablets-in-Updated-American-Diabetes-Associations-2017-Standards",
                "content": "The American Diabetes Association's (ADA) 2017 Standards of Medical Care in Diabetes specifically include a new recommendation to consider the use of Jardiance® (empagliflozin) tablets in people...",
                "1d_change": 0.7627273596,
                "index_price": -0.1891700548,
                "norm_price": 0.9518974144
            },
            {
                "index": 795,
                "date": "2016-12-16",
                "press_title": "CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)",
                "release_url": "http://lilly.mediaroom.com/2016-12-16-CHMP-Recommends-Approval-of-Lillys-Baricitinib-for-the-Treatment-of-Adults-with-Moderate-to-Severe-Active-Rheumatoid-Arthritis-RA",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued...",
                "1d_change": 0.7627273596,
                "index_price": -0.1891700548,
                "norm_price": 0.9518974144
            },
            {
                "index": 796,
                "date": "2016-12-15",
                "press_title": "BASAGLAR® (insulin glargine injection 100 units/mL), A Long-Acting Basal Insulin, Is Now Available in U.S.",
                "release_url": "http://lilly.mediaroom.com/2016-12-15-BASAGLAR-R-insulin-glargine-injection-100-units-mL-A-Long-Acting-Basal-Insulin-Is-Now-Available-in-U-S",
                "content": "Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. announced today that BASAGLAR® (insulin glargine injection 100 units/mL) is available by prescription in the U.S....",
                "1d_change": 4.0103687757,
                "index_price": 0.1904302656,
                "norm_price": 3.8199385101
            },
            {
                "index": 797,
                "date": "2016-12-15",
                "press_title": "Lilly Provides 2017 Financial Guidance and 2016 Update, Reaffirms Financial Expectations Through the Remainder of the Decade",
                "release_url": "http://lilly.mediaroom.com/2016-12-15-Lilly-Provides-2017-Financial-Guidance-and-2016-Update-Reaffirms-Financial-Expectations-Through-the-Remainder-of-the-Decade",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced its 2017 financial guidance and highlighted key events for the upcoming year. The company reaffirmed its financial expectations through the...",
                "1d_change": 4.0103687757,
                "index_price": 0.1904302656,
                "norm_price": 3.8199385101
            },
            {
                "index": 798,
                "date": "2016-12-13",
                "press_title": "Lilly Announces Program to Provide Insulin at Discounted Prices",
                "release_url": "http://lilly.mediaroom.com/2016-12-13-Lilly-Announces-Program-to-Provide-Insulin-at-Discounted-Prices",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that people who use Lilly insulin will be able to access discounted prices for their purchases starting January 1, 2017 via mobile and web...",
                "1d_change": -0.4728628709,
                "index_price": -0.4455744041,
                "norm_price": -0.0272884668
            },
            {
                "index": 799,
                "date": "2016-12-12",
                "press_title": "Lilly Announces Dividend Increase",
                "release_url": "http://lilly.mediaroom.com/2016-12-12-Lilly-Announces-Dividend-Increase",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 2 percent increase in its quarterly dividend. The dividend for the first quarter of 2017 will be $0.52 per share on...",
                "1d_change": 0.9615204754,
                "index_price": 0.5674067554,
                "norm_price": 0.39411372
            },
            {
                "index": 800,
                "date": "2016-12-12",
                "press_title": "U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2016-12-12-U-S-FDA-approves-Synjardy-R-XR-empagliflozin-metformin-hydrochloride-extended-release-tablets-for-adults-with-type-2-diabetes",
                "content": "The U.S. Food and Drug Administration (FDA) has approved Synjardy® XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. When used along with...",
                "1d_change": 0.9615204754,
                "index_price": 0.5674067554,
                "norm_price": 0.39411372
            },
            {
                "index": 801,
                "date": "2016-12-09",
                "press_title": "Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease",
                "release_url": "http://lilly.mediaroom.com/2016-12-09-Lilly-and-AstraZeneca-to-Develop-Second-Potentially-Disease-Modifying-Treatment-for-Alzheimers-Disease",
                "content": "Eli Lilly and Company (NYSE: LLY) and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase 1 trials as...",
                "1d_change": 0.3401732154,
                "index_price": 0.3203415477,
                "norm_price": 0.0198316677
            },
            {
                "index": 802,
                "date": "2016-12-08",
                "press_title": "Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting",
                "release_url": "http://lilly.mediaroom.com/2016-12-08-Lilly-Announces-Detailed-Results-of-Solanezumab-Phase-3-EXPEDITION3-Study-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-2016-Meeting",
                "content": "Eli Lilly and Company (NYSE:LLY) today presented detailed results of its phase 3 EXPEDITION3 trial at the 9th Clinical Trials on Alzheimer's Disease (CTAD) meeting. As previously disclosed,...",
                "1d_change": 1.1790734159,
                "index_price": 0.814335116,
                "norm_price": 0.3647382999
            },
            {
                "index": 803,
                "date": "2016-12-08",
                "press_title": "Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer",
                "release_url": "http://lilly.mediaroom.com/2016-12-08-Lilly-Presents-neoMONARCH-Phase-2-Data-on-Abemaciclib-in-Early-Stage-Breast-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, met its primary endpoint of reducing expression...",
                "1d_change": 1.1790734159,
                "index_price": 0.814335116,
                "norm_price": 0.3647382999
            },
            {
                "index": 804,
                "date": "2016-12-05",
                "press_title": "U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease",
                "release_url": "http://lilly.mediaroom.com/2016-12-05-U-S-FDA-approves-Jardiance-R-empagliflozin-tablets-to-reduce-the-risk-of-cardiovascular-death-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease",
                "content": "The U.S. Food and Drug Administration (FDA) approved a new indication for Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and...",
                "1d_change": -0.5309867939,
                "index_price": 0.5234572457,
                "norm_price": -1.0544440396
            },
            {
                "index": 805,
                "date": "2016-12-02",
                "press_title": "Lilly Confirms Date and Conference Call for 2017 Financial Guidance Announcement",
                "release_url": "http://lilly.mediaroom.com/2016-12-02-Lilly-Confirms-Date-and-Conference-Call-for-2017-Financial-Guidance-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2017 and provide updated financial guidance for 2016 on Thursday, December 15, 2016. Lilly will also conduct a conference...",
                "1d_change": 1.4273076541,
                "index_price": 0.6164005239,
                "norm_price": 0.8109071302
            },
            {
                "index": 806,
                "date": "2016-11-30",
                "press_title": "Lilly Introduces Scholars Programs for Florida A&M University's and Howard University's Business Students",
                "release_url": "http://lilly.mediaroom.com/2016-11-30-Lilly-Introduces-Scholars-Programs-for-Florida-A-M-Universitys-and-Howard-Universitys-Business-Students",
                "content": "Eli Lilly and Company (NYSE:LLY) will deepen its partnership with Florida Agricultural and Mechanical University (FAMU) and Howard University with the inaugural Sybil C. Mobley Scholars Program...",
                "1d_change": -2.0161010391,
                "index_price": -0.6339290251,
                "norm_price": -1.382172014
            },
            {
                "index": 807,
                "date": "2016-11-23",
                "press_title": "Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial",
                "release_url": "http://lilly.mediaroom.com/2016-11-23-Lilly-Announces-Top-Line-Results-of-Solanezumab-Phase-3-Clinical-Trial",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia...",
                "1d_change": 4.2559692315,
                "index_price": 0.1439747978,
                "norm_price": 4.1119944338
            },
            {
                "index": 808,
                "date": "2016-11-22",
                "press_title": "Survey Reveals Most People Don't Know Heart Disease Is the No. 1 Killer of People with Type 2 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2016-11-22-Survey-Reveals-Most-People-Dont-Know-Heart-Disease-Is-the-No-1-Killer-of-People-with-Type-2-Diabetes",
                "content": "A new national survey of more than 1,500 adults, including 501 who have type 2 diabetes, finds that three out of four Americans and two out of every three people with type 2 diabetes don't know...",
                "1d_change": -14.4264556344,
                "index_price": 0.1433248735,
                "norm_price": -14.5697805079
            },
            {
                "index": 809,
                "date": "2016-11-14",
                "press_title": "New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients",
                "release_url": "http://lilly.mediaroom.com/2016-11-14-New-Analyses-of-Phase-3-Trials-Show-Improvements-in-Rheumatoid-Arthritis-Symptoms-Following-Treatment-with-Baricitinib-Across-Diverse-Population-of-Patients",
                "content": "Three post-hoc analyses of two phase 3 studies showed improvements in rheumatoid arthritis symptoms in patients irrespective of age, BMI and number of previously used conventional synthetic DMARDs...",
                "1d_change": -0.892396987,
                "index_price": 0.6764845155,
                "norm_price": -1.5688815025
            },
            {
                "index": 810,
                "date": "2016-11-14",
                "press_title": "Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes",
                "release_url": "http://lilly.mediaroom.com/2016-11-14-Baricitinib-Demonstrates-Early-Response-Compared-to-Placebo-and-Significant-Improvement-Compared-to-Adalimumab-in-Patient-Reported-Outcomes",
                "content": "- Significant improvement in joint pain, severity of morning joint stiffness and tiredness with baricitinib compared to placebo, were seen as early as day 3 - Post-hoc analysis of two phase 3...",
                "1d_change": -0.892396987,
                "index_price": 0.6764845155,
                "norm_price": -1.5688815025
            },
            {
                "index": 811,
                "date": "2016-11-13",
                "press_title": "Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline",
                "release_url": "http://lilly.mediaroom.com/2016-11-13-Jardiance-R-empagliflozin-consistently-reduced-the-risk-of-cardiovascular-death-in-adults-with-type-2-diabetes-regardless-of-the-type-of-cardiovascular-disease-at-baseline",
                "content": "New data presented today at the American Heart Association Scientific Sessions 2016 showed that Jardiance® (empagliflozin) tablets consistently reduced the risk for cardiovascular death,...",
                "1d_change": -0.892396987,
                "index_price": 0.6764845155,
                "norm_price": -1.5688815025
            },
            {
                "index": 812,
                "date": "2016-11-03",
                "press_title": "Lilly Presents Clinical Efficacy, Safety and Patient-Reported Outcomes Data of Baricitinib in Patients with Rheumatoid Arthritis at 2016 American College of Rheumatology Annual Meeting",
                "release_url": "http://lilly.mediaroom.com/2016-11-03-Lilly-Presents-Clinical-Efficacy-Safety-and-Patient-Reported-Outcomes-Data-of-Baricitinib-in-Patients-with-Rheumatoid-Arthritis-at-2016-American-College-of-Rheumatology-Annual-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) announced that new post-hoc analyses of pooled efficacy and safety data from baricitinib phase 3 studies, along with findings from a real-world assessment of...",
                "1d_change": -0.4414134644,
                "index_price": -0.6531866618,
                "norm_price": 0.2117731973
            },
            {
                "index": 813,
                "date": "2016-11-02",
                "press_title": "New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo",
                "release_url": "http://lilly.mediaroom.com/2016-11-02-New-data-from-pivotal-RA-BEACON-study-show-significant-improvement-in-patient-reported-outcomes-in-rheumatoid-arthritis-patients-treated-with-baricitinib-compared-to-placebo",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data from RA-BEACON – a pivotal phase 3 study of baricitinib in the treatment of...",
                "1d_change": -1.442266841,
                "index_price": -0.9944184504,
                "norm_price": -0.4478483907
            },
            {
                "index": 814,
                "date": "2016-10-31",
                "press_title": "New Edition of Online Tool to Measure Cancer Progress to Launch at World Cancer Congress",
                "release_url": "http://lilly.mediaroom.com/2016-10-31-New-Edition-of-Online-Tool-to-Measure-Cancer-Progress-to-Launch-at-World-Cancer-Congress",
                "content": "The 2016 World Cancer Congress (WCC) in Paris – a global gathering of more than 3,500 cancer experts – will be the setting for the introduction of a new, enhanced version of the PACE...",
                "1d_change": -2.2608901127,
                "index_price": -0.8552298053,
                "norm_price": -1.4056603074
            },
            {
                "index": 815,
                "date": "2016-10-25",
                "press_title": "Lilly Reports Third-Quarter 2016 Results",
                "release_url": "http://lilly.mediaroom.com/2016-10-25-Lilly-Reports-Third-Quarter-2016-Results",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2016. $ in millions, except per share data Third Quarter % 2016 2015 Change Revenue $ 5,191.7 $ 4,959.7...",
                "1d_change": -0.1563017701,
                "index_price": -0.4809710713,
                "norm_price": 0.3246693012
            },
            {
                "index": 816,
                "date": "2016-10-19",
                "press_title": "FDA Approves Lilly's LARTRUVO™ (olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma",
                "release_url": "http://lilly.mediaroom.com/2016-10-19-FDA-Approves-Lillys-LARTRUVO-TM-olaratumab-in-Combination-with-Doxorubicin-for-Soft-Tissue-Sarcoma",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of LARTRUVO™ (olaratumab injection, 10 mg/mL), in combination with...",
                "1d_change": -0.2793798939,
                "index_price": 0.0247522241,
                "norm_price": -0.304132118
            },
            {
                "index": 817,
                "date": "2016-10-17",
                "press_title": "Lilly Declares Fourth-Quarter 2016 Dividend",
                "release_url": "http://lilly.mediaroom.com/2016-10-17-Lilly-Declares-Fourth-Quarter-2016-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2016 of $0.51 per share on outstanding common stock. The dividend is payable December...",
                "1d_change": -0.964818894,
                "index_price": 0.3108125902,
                "norm_price": -1.2756314842
            },
            {
                "index": 818,
                "date": "2016-10-17",
                "press_title": "Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative",
                "release_url": "http://lilly.mediaroom.com/2016-10-17-Lilly-Partners-with-the-National-Cancer-Institute-to-Accelerate-Cancer-Research-through-New-Program-under-Cancer-Moonshot-Initiative",
                "content": "With the global prevalence of new cancer cases expected to rise by 70 percent during the next two decades, representatives from government, academic, pharmaceutical and diagnostic companies are...",
                "1d_change": -0.964818894,
                "index_price": 0.3108125902,
                "norm_price": -1.2756314842
            },
            {
                "index": 819,
                "date": "2016-10-12",
                "press_title": "Eli Lilly and Company Sponsors Arthritis Foundation 'Living Your Yes With RA,' an Initiative to Provide Resources for the Rheumatoid Arthritis Community",
                "release_url": "http://lilly.mediaroom.com/2016-10-12-Eli-Lilly-and-Company-Sponsors-Arthritis-Foundation-Living-Your-Yes-With-RA-an-Initiative-to-Provide-Resources-for-the-Rheumatoid-Arthritis-Community",
                "content": "Supported by Eli Lilly and Company (NYSE: LLY), the Arthritis Foundation is launching 'Living Your Yes With RA,' a new initiative designed to empower people living with rheumatoid arthritis (RA)...",
                "1d_change": -2.2624935813,
                "index_price": -0.2400821988,
                "norm_price": -2.0224113825
            },
            {
                "index": 820,
                "date": "2016-10-11",
                "press_title": "Lilly to Participate in Credit Suisse 2016 Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2016-10-11-Lilly-to-Participate-in-Credit-Suisse-2016-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will participate in the Credit Suisse 2016 Healthcare Conference on Monday, November 7, 2016. The following Lilly executives will participate in a fireside chat...",
                "1d_change": -2.5959720056,
                "index_price": -1.0363862192,
                "norm_price": -1.5595857864
            },
            {
                "index": 821,
                "date": "2016-10-11",
                "press_title": "Leading Experts Warn Global Goal to Cure or Treat Alzheimer's Disease By 2025 is at Risk, Offer Solutions to Adjust Course",
                "release_url": "http://lilly.mediaroom.com/2016-10-11-Leading-Experts-Warn-Global-Goal-to-Cure-or-Treat-Alzheimers-Disease-By-2025-is-at-Risk-Offer-Solutions-to-Adjust-Course",
                "content": "Alzheimer's disease (AD) has an enormous impact on the lives of patients and caregivers, in addition to placing a significant burden on health care systems around the world. According to a paper...",
                "1d_change": -2.5959720056,
                "index_price": -1.0363862192,
                "norm_price": -1.5595857864
            },
            {
                "index": 822,
                "date": "2016-10-09",
                "press_title": "New Data on the Combination of Lilly's ALIMTA® (pemetrexed) and Merck's KEYTRUDA® (pembrolizumab) Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/2016-10-09-New-Data-on-the-Combination-of-Lillys-ALIMTA-R-pemetrexed-and-Mercks-KEYTRUDA-R-pembrolizumab-Show-a-Near-Doubling-of-Objective-Response-Rate-Compared-to-Standard-of-Care-Alone-in-First-Line-Metastatic-Non-Small-Cell-Lung-Cancer",
                "content": "Important clinical study results from one of Eli Lilly and Company's (NYSE: LLY) ongoing immuno-oncology collaborations with Merck (known as MSD outside the U.S. and Canada) were announced today...",
                "1d_change": -0.3911271345,
                "index_price": -1.1072953684,
                "norm_price": 0.7161682339
            },
            {
                "index": 823,
                "date": "2016-10-05",
                "press_title": "Lilly Highlights Advancements in its Oncology Portfolio with New Data at ESMO 2016",
                "release_url": "http://lilly.mediaroom.com/2016-10-05-Lilly-Highlights-Advancements-in-its-Oncology-Portfolio-with-New-Data-at-ESMO-2016",
                "content": "Eli Lilly and Company (NYSE: LLY) will present data from several studies which further reinforce the advancement of its diverse clinical cancer portfolio during the European Society of Medical...",
                "1d_change": 0.1473279211,
                "index_price": 0.2600978881,
                "norm_price": -0.112769967
            },
            {
                "index": 824,
                "date": "2016-10-05",
                "press_title": "Elanco Animal Health Enters Agreement to Acquire Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio",
                "release_url": "http://lilly.mediaroom.com/2016-10-05-Elanco-Animal-Health-Enters-Agreement-to-Acquire-Boehringer-Ingelheim-Vetmedicas-U-S-Feline-Canine-and-Rabies-Vaccines-Portfolio",
                "content": "Eight new product lines and a fully integrated manufacturing and R&D site to transfer to Elanco, adding to its growing companion animal business; subject to FTC approval and closing of BI/Sanofi...",
                "1d_change": 0.1473279211,
                "index_price": 0.2600978881,
                "norm_price": -0.112769967
            },
            {
                "index": 825,
                "date": "2016-10-04",
                "press_title": "Lilly Confirms Date And Conference Call For Third-Quarter 2016 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2016-10-04-Lilly-Confirms-Date-And-Conference-Call-For-Third-Quarter-2016-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2016 on Tuesday, October 25, 2016. Lilly will also conduct a conference call on that day with the...",
                "1d_change": 0.8439981701,
                "index_price": -0.1685459179,
                "norm_price": 1.012544088
            },
            {
                "index": 826,
                "date": "2016-09-27",
                "press_title": "Lilly to Present Latest Data for Taltz® (ixekizumab) in Psoriasis at the European Academy of Dermatology and Venereology (EADV) Annual Congress",
                "release_url": "http://lilly.mediaroom.com/2016-09-27-Lilly-to-Present-Latest-Data-for-Taltz-R-ixekizumab-in-Psoriasis-at-the-European-Academy-of-Dermatology-and-Venereology-EADV-Annual-Congress",
                "content": "17 abstracts, including eight oral abstracts with one late-breaker presentation, will feature new sub-analyses for Taltz in moderate-to-severe plaque psoriasis INDIANAPOLIS, Sept. 27, 2016...",
                "1d_change": 0.1115073473,
                "index_price": 1.1665481589,
                "norm_price": -1.0550408116
            },
            {
                "index": 827,
                "date": "2016-09-16",
                "press_title": "CHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma",
                "release_url": "http://lilly.mediaroom.com/2016-09-16-CHMP-Recommends-Approval-of-Lillys-Olaratumab-in-Combination-with-Doxorubicin-for-Advanced-Soft-Tissue-Sarcoma",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the...",
                "1d_change": 0.5810990469,
                "index_price": -0.3440603088,
                "norm_price": 0.9251593557
            },
            {
                "index": 828,
                "date": "2016-09-15",
                "press_title": "Boston Mayor Walsh and the Alzheimer's Association, Massachusetts/New Hampshire Chapter, Receive Alzheimer's Readiness Award",
                "release_url": "http://lilly.mediaroom.com/2016-09-15-Boston-Mayor-Walsh-and-the-Alzheimers-Association-Massachusetts-New-Hampshire-Chapter-Receive-Alzheimers-Readiness-Award",
                "content": "Boston Mayor Martin J. Walsh and the Alzheimer's Association, Massachusetts/New Hampshire Chapter were recognized today for their efforts to ensure the city of Boston is prepared for the fiscal...",
                "1d_change": 0.8629536596,
                "index_price": 0.6451039312,
                "norm_price": 0.2178497285
            },
            {
                "index": 829,
                "date": "2016-09-14",
                "press_title": "Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career",
                "release_url": "http://lilly.mediaroom.com/2016-09-14-Levi-Garraway-M-D-Ph-D-to-become-Senior-Vice-President-of-Global-Oncology-at-Lilly-Succeeding-Richard-Gaynor-M-D-Who-is-Retiring-after-a-Distinguished-Career",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that Levi Garraway, M.D., Ph.D., a world leader in the analysis of cancer genomics and resistance to targeted therapies, will join Lilly as senior...",
                "1d_change": 0.1903184933,
                "index_price": 0.9034724372,
                "norm_price": -0.713153944
            },
            {
                "index": 830,
                "date": "2016-08-31",
                "press_title": "Jamere Jackson Elected to Lilly Board of Directors",
                "release_url": "http://lilly.mediaroom.com/2016-08-31-Jamere-Jackson-Elected-to-Lilly-Board-of-Directors",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Jamere Jackson as a new member, effective October 1, 2016. As a member of Lilly's board, he will serve on the Audit and...",
                "1d_change": -0.8545931742,
                "index_price": -0.1243724164,
                "norm_price": -0.7302207578
            },
            {
                "index": 831,
                "date": "2016-08-24",
                "press_title": "Lilly to Participate in Morgan Stanley Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2016-08-24-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016. Jeffrey Simmons, senior vice president and president, Elanco Animal...",
                "1d_change": -2.1663567272,
                "index_price": -0.5809110072,
                "norm_price": -1.58544572
            },
            {
                "index": 832,
                "date": "2016-08-22",
                "press_title": "Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease",
                "release_url": "http://lilly.mediaroom.com/2016-08-22-Lilly-and-AstraZeneca-Receive-FDA-Fast-Track-Designation-for-AZD3293-an-Investigational-Treatment-for-Early-Alzheimers-Disease",
                "content": "Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced they have received U.S. Food and Drug Administration (FDA) Fast Track designation for the development program in Alzheimer's...",
                "1d_change": 0.3142334651,
                "index_price": 0.2432586975,
                "norm_price": 0.0709747676
            },
            {
                "index": 833,
                "date": "2016-08-10",
                "press_title": "Lilly announces Joshua Smiley, Anat Ashkenazi appointed to new roles, Thomas Grein retires",
                "release_url": "http://lilly.mediaroom.com/2016-08-10-Lilly-announces-Joshua-Smiley-Anat-Ashkenazi-appointed-to-new-roles-Thomas-Grein-retires",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced Joshua Smiley will be appointed to senior vice president, Finance, and treasurer effective October 1. Smiley will replace Thomas Grein, who will...",
                "1d_change": 1.1759018083,
                "index_price": 0.1363342506,
                "norm_price": 1.0395675577
            },
            {
                "index": 834,
                "date": "2016-08-10",
                "press_title": "Lilly Provides Update on MONARCH 2 Phase 3 Trial of Abemaciclib",
                "release_url": "http://lilly.mediaroom.com/2016-08-10-Lilly-Provides-Update-on-MONARCH-2-Phase-3-Trial-of-Abemaciclib",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 2, an independent Data Monitoring Committee (DMC) provided the recommendation to...",
                "1d_change": 1.1759018083,
                "index_price": 0.1363342506,
                "norm_price": 1.0395675577
            },
            {
                "index": 835,
                "date": "2016-07-27",
                "press_title": "New Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's Disease",
                "release_url": "http://lilly.mediaroom.com/2016-07-27-New-Studies-Suggest-Relationship-between-Tau-Pathology-and-Progression-of-Alzheimers-Disease",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced results from two distinct analyses of a phase 2 study using the tau imaging agent flortaucipir ([18F] AV-1451) that evaluated the relationship...",
                "1d_change": 0.8199853874,
                "index_price": 0.0115204185,
                "norm_price": 0.8084649689
            },
            {
                "index": 836,
                "date": "2016-07-27",
                "press_title": "John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor",
                "release_url": "http://lilly.mediaroom.com/2016-07-27-John-C-Lechleiter-to-Retire-as-Lilly-CEO-Board-Elects-David-A-Ricks-as-Successor",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that John C. Lechleiter, Ph.D., chairman, president and chief executive officer, will retire as president and CEO and from the company effective...",
                "1d_change": 0.8199853874,
                "index_price": 0.0115204185,
                "norm_price": 0.8084649689
            },
            {
                "index": 837,
                "date": "2016-07-26",
                "press_title": "Lilly Reports Second-Quarter 2016 Results, Provides Financial Expectations Through the Remainder of the Decade",
                "release_url": "http://lilly.mediaroom.com/2016-07-26-Lilly-Reports-Second-Quarter-2016-Results-Provides-Financial-Expectations-Through-the-Remainder-of-the-Decade",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2016. $ in millions, except per share data Second Quarter % 2016 2015 Change Revenue – Reported $...",
                "1d_change": 0.7793851054,
                "index_price": -0.1103071427,
                "norm_price": 0.8896922481
            },
            {
                "index": 838,
                "date": "2016-07-21",
                "press_title": "Diversity of Lilly's Alzheimer's Disease Pipeline Showcased at the Alzheimer's Association International Conference® 2016 (AAIC® 2016)",
                "release_url": "http://lilly.mediaroom.com/2016-07-21-Diversity-of-Lillys-Alzheimers-Disease-Pipeline-Showcased-at-the-Alzheimers-Association-International-Conference-R-2016-AAIC-R-2016",
                "content": "Eli Lilly and Company (NYSE:LLY) today announced it will present findings from more than 25 research studies at the upcoming Alzheimer's Association International Conference® 2016 (AAIC® 2016)...",
                "1d_change": 1.703618206,
                "index_price": 0.0974753065,
                "norm_price": 1.6061428995
            },
            {
                "index": 839,
                "date": "2016-07-19",
                "press_title": "U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults",
                "release_url": "http://lilly.mediaroom.com/2016-07-19-U-S-FDA-expands-indication-for-type-2-diabetes-treatment-Synjardy-R-empagliflozin-metformin-hydrochloride-to-include-treatment-naive-adults",
                "content": "The U.S. Food and Drug Administration has approved an expanded indication for Synjardy® (empagliflozin and metformin hydrochloride) tablets to include treatment-naïve adults with type 2 diabetes...",
                "1d_change": 0.5356305702,
                "index_price": 0.4247535865,
                "norm_price": 0.1108769837
            },
            {
                "index": 840,
                "date": "2016-07-13",
                "press_title": "Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer",
                "release_url": "http://lilly.mediaroom.com/2016-07-13-Lilly-and-Boehringer-Ingelheim-Announce-Clinical-Trial-Collaboration-in-Metastatic-Breast-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of abemaciclib (LY2835219),...",
                "1d_change": 0.8437518267,
                "index_price": 0.4593849292,
                "norm_price": 0.3843668975
            },
            {
                "index": 841,
                "date": "2016-07-12",
                "press_title": "Lilly and Howard University partner on summer Medical Scientific Fellowship",
                "release_url": "http://lilly.mediaroom.com/2016-07-12-Lilly-and-Howard-University-partner-on-summer-Medical-Scientific-Fellowship",
                "content": "Lilly USA, LLC will partner with Howard University this summer on an inaugural Minority Fellowship program for post-graduate minority professionals embarking on careers in science or medicine. The...",
                "1d_change": -0.340222433,
                "index_price": 0.6007132428,
                "norm_price": -0.9409356757
            },
            {
                "index": 842,
                "date": "2016-07-06",
                "press_title": "Lilly Diabetes Welcomes Acclaimed Singer/Songwriter Crystal Bowersox as Newest Spokesperson",
                "release_url": "http://lilly.mediaroom.com/2016-07-06-Lilly-Diabetes-Welcomes-Acclaimed-Singer-Songwriter-Crystal-Bowersox-as-Newest-Spokesperson",
                "content": "Crystal Bowersox understands how crucial it is to properly manage diabetes and find a healthy balance on and off the stage. Diagnosed with type 1 diabetes at age 6, Crystal – now 30 – rose...",
                "1d_change": -2.07664e-05,
                "index_price": 0.6420692755,
                "norm_price": -0.6420900418
            },
            {
                "index": 843,
                "date": "2016-06-28",
                "press_title": "FDA Advisory Committee recommends approval of Jardiance® (empagliflozin) for cardiovascular indication in 12-11 vote",
                "release_url": "http://lilly.mediaroom.com/2016-06-28-FDA-Advisory-Committee-recommends-approval-of-Jardiance-R-empagliflozin-for-cardiovascular-indication-in-12-11-vote",
                "content": "A U.S. Food and Drug Administration (FDA) Advisory Committee today voted 12-11 that substantial evidence exists to establish that Jardiance® (empagliflozin) reduces cardiovascular (CV) death in...",
                "1d_change": 3.8643594741,
                "index_price": 3.0954656954,
                "norm_price": 0.7688937787
            },
            {
                "index": 844,
                "date": "2016-06-28",
                "press_title": "Lilly Confirms Date And Conference Call For Second-Quarter 2016 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2016-06-28-Lilly-Confirms-Date-And-Conference-Call-For-Second-Quarter-2016-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2016 on Tuesday, July 26, 2016. Lilly will also conduct a conference call on that day with the...",
                "1d_change": 3.8643594741,
                "index_price": 3.0954656954,
                "norm_price": 0.7688937787
            },
            {
                "index": 845,
                "date": "2016-06-27",
                "press_title": "Lilly Convenes Leaders at National Mayor's Conference to Address Impact of Alzheimer's Disease on Local Communities",
                "release_url": "http://lilly.mediaroom.com/2016-06-27-Lilly-Convenes-Leaders-at-National-Mayors-Conference-to-Address-Impact-of-Alzheimers-Disease-on-Local-Communities",
                "content": "With the prevalence of Alzheimer's disease expected to triple by 2050, there is an urgent need for greater awareness of the economic and social impact of the disease on families, communities and...",
                "1d_change": 1.4504454386,
                "index_price": 0.2278884885,
                "norm_price": 1.2225569501
            },
            {
                "index": 846,
                "date": "2016-06-23",
                "press_title": "Diabetes Scholars Foundation Announces 2016 Scholarship Recipients",
                "release_url": "http://lilly.mediaroom.com/2016-06-23-Diabetes-Scholars-Foundation-Announces-2016-Scholarship-Recipients",
                "content": "If the caliber of students receiving a Lilly Diabetes Tomorrow's Leaders Scholarship is any indication, the future is in good hands. The 2016 scholarship winners, announced today online at...",
                "1d_change": 0.9955377338,
                "index_price": -2.7186483682,
                "norm_price": 3.714186102
            },
            {
                "index": 847,
                "date": "2016-06-20",
                "press_title": "Lilly Declares Third-Quarter 2016 Dividend",
                "release_url": "http://lilly.mediaroom.com/2016-06-20-Lilly-Declares-Third-Quarter-2016-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2016 of $0.51 per share on outstanding common stock. The dividend is payable September...",
                "1d_change": -2.5905960355,
                "index_price": 0.6376477975,
                "norm_price": -3.2282438329
            },
            {
                "index": 848,
                "date": "2016-06-14",
                "press_title": "German Supreme Court Grants Lilly Appeal in Alimta® Vitamin Regimen Patent Lawsuit",
                "release_url": "http://lilly.mediaroom.com/2016-06-14-German-Supreme-Court-Grants-Lilly-Appeal-in-Alimta-R-Vitamin-Regimen-Patent-Lawsuit",
                "content": "The German Federal Supreme Court has granted the appeal by Eli Lilly and Company (NYSE: LLY) in the case of Eli Lilly and Company v. Actavis, vacating the prior decision denying infringement. The...",
                "1d_change": 0.2306476381,
                "index_price": -0.2486074025,
                "norm_price": 0.4792550406
            },
            {
                "index": 849,
                "date": "2016-06-13",
                "press_title": "Aarti Shah named chief information officer",
                "release_url": "http://lilly.mediaroom.com/2016-06-13-Aarti-Shah-named-chief-information-officer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced the promotion of Aarti Shah, Ph.D., to senior vice president and chief information officer effective July 1. She has been the global brand...",
                "1d_change": 0.3229726688,
                "index_price": -0.7916818177,
                "norm_price": 1.1146544866
            },
            {
                "index": 850,
                "date": "2016-06-12",
                "press_title": "New Data Show Lilly's Once-Weekly Trulicity® (dulaglutide) in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2016-06-12-New-Data-Show-Lillys-Once-Weekly-Trulicity-R-dulaglutide-in-Combination-with-Insulin-Glargine-Improves-Glycemic-Control-in-People-with-Type-2-Diabetes",
                "content": "New data from a completed Phase 3 trial show Trulicity® (dulaglutide) 1.5 mg significantly reduced hemoglobin A1c (A1C) and body weight as an add-on to insulin glargine without increasing the...",
                "1d_change": 0.3229726688,
                "index_price": -0.7916818177,
                "norm_price": 1.1146544866
            },
            {
                "index": 851,
                "date": "2016-06-12",
                "press_title": "New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes",
                "release_url": "http://lilly.mediaroom.com/2016-06-12-New-Jardiance-R-empagliflozin-data-show-that-reduced-risk-for-cardiovascular-CV-death-was-consistent-across-age-groups-in-adults-with-type-2-diabetes",
                "content": "New analyses showed risk reductions were consistent across age groups for cardiovascular (CV) outcomes, including CV death, with Jardiance® (empagliflozin) compared with placebo when added to...",
                "1d_change": 0.3229726688,
                "index_price": -0.7916818177,
                "norm_price": 1.1146544866
            },
            {
                "index": 852,
                "date": "2016-06-11",
                "press_title": "New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment",
                "release_url": "http://lilly.mediaroom.com/2016-06-11-New-study-results-show-Tradjenta-R-linagliptin-reduces-blood-sugar-in-adults-with-type-2-diabetes-at-risk-for-kidney-impairment",
                "content": "Results from the MARLINA-T2D™ trial demonstrated that Tradjenta® (linagliptin), which is marketed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY), reduced blood sugar in adults...",
                "1d_change": 0.3229726688,
                "index_price": -0.7916818177,
                "norm_price": 1.1146544866
            },
            {
                "index": 853,
                "date": "2016-06-11",
                "press_title": "New Study Findings Underscore Importance of Physician/Patient Communication on Insulin Adherence and Outcomes",
                "release_url": "http://lilly.mediaroom.com/2016-06-11-New-Study-Findings-Underscore-Importance-of-Physician-Patient-Communication-on-Insulin-Adherence-and-Outcomes",
                "content": "New data from a study funded by Eli Lilly and Company (NYSE: LLY) show that how healthcare professionals and people with diabetes communicate - as well as the perceived quality of the personal...",
                "1d_change": 0.3229726688,
                "index_price": -0.7916818177,
                "norm_price": 1.1146544866
            },
            {
                "index": 854,
                "date": "2016-06-09",
                "press_title": "Data in The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase in Overall Survival in Patients with Advanced Soft Tissue Sarcoma, as Reported by Lilly and Memorial Sloan Kettering Researchers",
                "release_url": "http://lilly.mediaroom.com/2016-06-09-Data-in-The-Lancet-Show-Olaratumab-Plus-Doxorubicin-Offered-11-8-Month-Increase-in-Overall-Survival-in-Patients-with-Advanced-Soft-Tissue-Sarcoma-as-Reported-by-Lilly-and-Memorial-Sloan-Kettering-Researchers",
                "content": "Eli Lilly and Company (NYSE: LLY) announced that The Lancet published detailed results from a Phase 2 study evaluating the efficacy and safety of olaratumab, an investigational compound, in...",
                "1d_change": -1.1088430952,
                "index_price": -0.9341211575,
                "norm_price": -0.1747219377
            },
            {
                "index": 855,
                "date": "2016-06-09",
                "press_title": "Lilly and American Migraine Foundation Announce $1 Million Grant for Launch of First Patient Registry to Advance Research and Development in Migraine",
                "release_url": "http://lilly.mediaroom.com/2016-06-09-Lilly-and-American-Migraine-Foundation-Announce-1-Million-Grant-for-Launch-of-First-Patient-Registry-to-Advance-Research-and-Development-in-Migraine",
                "content": "Eli Lilly and Company (NYSE: LLY) and the American Migraine Foundation announced today that Lilly will provide a $1 million grant to the American Migraine Foundation to sponsor the development of...",
                "1d_change": -1.1088430952,
                "index_price": -0.9341211575,
                "norm_price": -0.1747219377
            },
            {
                "index": 856,
                "date": "2016-06-09",
                "press_title": "Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)",
                "release_url": "http://lilly.mediaroom.com/2016-06-09-Patient-reported-outcomes-across-phase-3-studies-of-baricitinib-demonstrate-statistically-significant-improvements-in-physical-function-and-quality-of-life-symptoms-in-patients-with-rheumatoid-arthritis-RA",
                "content": "Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate – the current standard of...",
                "1d_change": -1.1088430952,
                "index_price": -0.9341211575,
                "norm_price": -0.1747219377
            },
            {
                "index": 857,
                "date": "2016-06-09",
                "press_title": "Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs",
                "release_url": "http://lilly.mediaroom.com/2016-06-09-Baricitinib-significantly-reduces-joint-damage-progression-in-rheumatoid-arthritis-in-patients-who-do-not-respond-to-conventional-DMARDs",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress...",
                "1d_change": -1.1088430952,
                "index_price": -0.9341211575,
                "norm_price": -0.1747219377
            },
            {
                "index": 858,
                "date": "2016-06-08",
                "press_title": "Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks: Results Published in the New England Journal of Medicine",
                "release_url": "http://lilly.mediaroom.com/2016-06-08-Studies-Demonstrate-Lillys-Taltz-R-ixekizumab-Maintained-or-Achieved-High-Levels-of-Skin-Clearance-for-Patients-with-Moderate-to-Severe-Plaque-Psoriasis-through-60-Weeks-Results-Published-in-the-New-England-Journal-of-Medicine",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine has published detailed results from three pivotal Phase 3 studies—UNCOVER-1, UNCOVER-2 and...",
                "1d_change": -0.3090296089,
                "index_price": 0.1309404748,
                "norm_price": -0.4399700837
            },
            {
                "index": 859,
                "date": "2016-06-07",
                "press_title": "Results of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Arthritis to be Presented at Annual European Congress of Rheumatology (EULAR 2016)",
                "release_url": "http://lilly.mediaroom.com/2016-06-07-Results-of-Clinical-and-Patient-Reported-Outcomes-Data-for-Baricitinib-in-Patients-with-Rheumatoid-Arthritis-to-be-Presented-at-Annual-European-Congress-of-Rheumatology-EULAR-2016",
                "content": "Eli Lilly and Company (NYSE: LLY) announced that radiographic results from a long-term extension study of baricitinib, RA-BEYOND, and patient-reported outcomes data from baricitinib's phase 3...",
                "1d_change": 0.3871194852,
                "index_price": 0.4218819629,
                "norm_price": -0.0347624777
            },
            {
                "index": 860,
                "date": "2016-06-05",
                "press_title": "Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer",
                "release_url": "http://lilly.mediaroom.com/2016-06-05-Early-Phase-Immuno-Oncology-Studies-of-Lillys-ALIMTA-R-pemetrexed-and-CYRAMZA-R-ramucirumab-with-Mercks-KEYTRUDA-R-pembrolizumab-Show-Encouraging-Results-in-Non-Small-Cell-Lung-Cancer",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that clinical study data from two of its ongoing immuno-oncology clinical collaborations with Merck (known as MSD outside the U.S. and Canada)...",
                "1d_change": -0.5488337108,
                "index_price": 0.5349957301,
                "norm_price": -1.083829441
            },
            {
                "index": 861,
                "date": "2016-06-03",
                "press_title": "Lilly Announces Results from MONARCH 1 Trial of Abemaciclib Monotherapy",
                "release_url": "http://lilly.mediaroom.com/2016-06-03-Lilly-Announces-Results-from-MONARCH-1-Trial-of-Abemaciclib-Monotherapy",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced results from the MONARCH 1 Phase 2 study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in patients with...",
                "1d_change": -0.8818920408,
                "index_price": 0.2531439584,
                "norm_price": -1.1350359992
            },
            {
                "index": 862,
                "date": "2016-06-01",
                "press_title": "Lilly Announces Diabetes Commercial Update Investor Call",
                "release_url": "http://lilly.mediaroom.com/2016-06-01-Lilly-Announces-Diabetes-Commercial-Update-Investor-Call",
                "content": "Eli Lilly and Company (NYSE: LLY) will conduct a call on June 17 to update the investment community and media on the key commercial aspects of the company's diabetes business. The webcast will...",
                "1d_change": 0.7421258678,
                "index_price": 0.5377040511,
                "norm_price": 0.2044218167
            },
            {
                "index": 863,
                "date": "2016-05-31",
                "press_title": "Lilly Announces Webcast to Discuss Abemaciclib Data",
                "release_url": "http://lilly.mediaroom.com/2016-05-31-Lilly-Announces-Webcast-to-Discuss-Abemaciclib-Data",
                "content": "Eli Lilly and Company (NYSE: LLY) will conduct a webcast on June 9 to discuss the abemaciclib data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The webcast will...",
                "1d_change": -0.0933874338,
                "index_price": -0.0380980912,
                "norm_price": -0.0552893426
            },
            {
                "index": 864,
                "date": "2016-05-31",
                "press_title": "U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes",
                "release_url": "http://lilly.mediaroom.com/2016-05-31-U-S-FDA-Approves-Once-daily-Jentadueto-R-XR-linagliptin-and-metformin-hydrochloride-extended-release-Tablets-for-Adults-with-Type-2-Diabetes",
                "content": "The U.S. Food and Drug Administration (FDA) has approved Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of type 2 diabetes (T2D) in adults....",
                "1d_change": -0.0933874338,
                "index_price": -0.0380980912,
                "norm_price": -0.0552893426
            },
            {
                "index": 865,
                "date": "2016-05-25",
                "press_title": "Lilly to Participate in Goldman Sachs 37th Annual Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2016-05-25-Lilly-to-Participate-in-Goldman-Sachs-37th-Annual-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 37th Annual Healthcare Conference on June 8, 2016. Enrique Conterno, Lilly senior vice president and president of Lilly Diabetes,...",
                "1d_change": 0.0397258959,
                "index_price": 0.5344321082,
                "norm_price": -0.4947062123
            },
            {
                "index": 866,
                "date": "2016-05-24",
                "press_title": "Lilly Details Robust R&D Pipeline to Investment Community",
                "release_url": "http://lilly.mediaroom.com/2016-05-24-Lilly-Details-Robust-R-D-Pipeline-to-Investment-Community",
                "content": "In a presentation to the investment community today, Eli Lilly and Company (NYSE: LLY) stated it has the potential to launch 20 new products in the 10 years beginning in 2014 and extending through...",
                "1d_change": -0.0134024202,
                "index_price": 1.8124568777,
                "norm_price": -1.8258592979
            },
            {
                "index": 867,
                "date": "2016-05-23",
                "press_title": "Lilly to Participate in Bernstein Strategic Decisions Conference",
                "release_url": "http://lilly.mediaroom.com/2016-05-23-Lilly-to-Participate-in-Bernstein-Strategic-Decisions-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will attend the Bernstein Strategic Decisions Conference on June 2, 2016. John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer, will...",
                "1d_change": -0.0133654541,
                "index_price": 1.1478510955,
                "norm_price": -1.1612165496
            },
            {
                "index": 868,
                "date": "2016-05-19",
                "press_title": "Lilly's First Volunteer Teams of 2016 Depart in May for Thailand and Ghana",
                "release_url": "http://lilly.mediaroom.com/2016-05-19-Lillys-First-Volunteer-Teams-of-2016-Depart-in-May-for-Thailand-and-Ghana",
                "content": "A team of Eli Lilly and Company (NYSE: LLY) volunteers from its operations worldwide is on the ground in Thailand, working with a local hospital and health volunteers as part of Lilly's Connecting...",
                "1d_change": -0.4143955803,
                "index_price": 0.3951677688,
                "norm_price": -0.8095633491
            },
            {
                "index": 869,
                "date": "2016-05-18",
                "press_title": "Lilly partners with Washington University School of Medicine and Meharry Medical College on unique summer research program",
                "release_url": "http://lilly.mediaroom.com/2016-05-18-Lilly-partners-with-Washington-University-School-of-Medicine-and-Meharry-Medical-College-on-unique-summer-research-program",
                "content": "Lilly USA, LLC will partner with Washington University School of Medicine and Meharry Medical College on a unique summer research program designed to expand diversity in research to reduce...",
                "1d_change": -2.8125822121,
                "index_price": -0.2127392471,
                "norm_price": -2.599842965
            },
            {
                "index": 870,
                "date": "2016-05-18",
                "press_title": "ASCO Data Underscore Lilly's Diverse Oncology Pipeline and Portfolio",
                "release_url": "http://lilly.mediaroom.com/2016-05-18-ASCO-Data-Underscore-Lillys-Diverse-Oncology-Pipeline-and-Portfolio",
                "content": "Several studies will underscore the strength of Eli Lilly and Company's (NYSE: LLY) diverse clinical cancer pipeline and portfolio during the 52nd Annual Meeting of the American Society of...",
                "1d_change": -2.8125822121,
                "index_price": -0.2127392471,
                "norm_price": -2.599842965
            },
            {
                "index": 871,
                "date": "2016-05-04",
                "press_title": "FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma",
                "release_url": "http://lilly.mediaroom.com/2016-05-04-FDA-Grants-Priority-Review-for-Lillys-Olaratumab-an-Investigational-Medicine-for-Advanced-Soft-Tissue-Sarcoma",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the biologics license application (BLA) for olaratumab, a PDGFRα...",
                "1d_change": 0.1328534118,
                "index_price": -0.4715705207,
                "norm_price": 0.6044239325
            },
            {
                "index": 872,
                "date": "2016-05-02",
                "press_title": "Lilly Releases First-Ever Integrated Report",
                "release_url": "http://lilly.mediaroom.com/2016-05-02-Lilly-Releases-First-Ever-Integrated-Report",
                "content": "Eli Lilly and Company (NYSE: LLY) today released its first-ever integrated report, combining two of the company's traditional documents: its annual report and its corporate responsibility report....",
                "1d_change": 0.393487605,
                "index_price": -0.184155264,
                "norm_price": 0.5776428691
            },
            {
                "index": 873,
                "date": "2016-05-02",
                "press_title": "Lilly Declares Second-Quarter 2016 Dividend",
                "release_url": "http://lilly.mediaroom.com/2016-05-02-Lilly-Declares-Second-Quarter-2016-Dividend",
                "content": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2016 of $0.51 per share on outstanding common stock. The dividend is payable June 10,...",
                "1d_change": 0.393487605,
                "index_price": -0.184155264,
                "norm_price": 0.5776428691
            },
            {
                "index": 874,
                "date": "2016-05-02",
                "press_title": "Lilly's Taltz® (ixekizumab) Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis",
                "release_url": "http://lilly.mediaroom.com/2016-05-02-Lillys-Taltz-R-ixekizumab-Now-Available-in-the-U-S-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now available by prescription order...",
                "1d_change": 0.393487605,
                "index_price": -0.184155264,
                "norm_price": 0.5776428691
            },
            {
                "index": 875,
                "date": "2016-04-28",
                "press_title": "Lilly to Participate in Bank of America Merrill Lynch 2016 Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2016-04-28-Lilly-to-Participate-in-Bank-of-America-Merrill-Lynch-2016-Health-Care-Conference",
                "content": "error_http",
                "1d_change": -0.7811912088,
                "index_price": -1.2409762362,
                "norm_price": 0.4597850274
            },
            {
                "index": 876,
                "date": "2016-04-26",
                "press_title": "Lilly Reports First-Quarter 2016 Results, Revises 2016 Financial Guidance",
                "release_url": "http://lilly.mediaroom.com/2016-04-26-Lilly-Reports-First-Quarter-2016-Results-Revises-2016-Financial-Guidance",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2016. $ in millions, except per share data First Quarter % 2016 2015 Change Revenue – Reported $...",
                "1d_change": -0.1438030725,
                "index_price": 0.2534336301,
                "norm_price": -0.3972367025
            },
            {
                "index": 877,
                "date": "2016-04-19",
                "press_title": "Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure",
                "release_url": "http://lilly.mediaroom.com/2016-04-19-Jardiance-R-empagliflozin-to-be-studied-for-the-treatment-of-people-with-chronic-heart-failure",
                "content": "Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to conduct two outcome trials investigating the diabetes medicine Jardiance® (empagliflozin) for the treatment of...",
                "1d_change": -0.6486968774,
                "index_price": 0.3020288152,
                "norm_price": -0.9507256926
            },
            {
                "index": 878,
                "date": "2016-04-12",
                "press_title": "Lilly to Provide Detailed Update of Pipeline and R&D Strategy at Upcoming Investment Community Meeting",
                "release_url": "http://lilly.mediaroom.com/2016-04-12-Lilly-to-Provide-Detailed-Update-of-Pipeline-and-R-D-Strategy-at-Upcoming-Investment-Community-Meeting",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced it will host a meeting for the investment community, including institutional investors, sell-side analysts, ratings agency representatives, and...",
                "1d_change": 1.8360647559,
                "index_price": 1.858412454,
                "norm_price": -0.0223476981
            },
            {
                "index": 879,
                "date": "2016-04-08",
                "press_title": "Eli Lilly and Company and AstraZeneca Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer's Disease",
                "release_url": "http://lilly.mediaroom.com/2016-04-08-Eli-Lilly-and-Company-and-AstraZeneca-Announce-Continuation-of-Pivotal-Clinical-Trial-for-People-with-Early-Alzheimers-Disease",
                "content": "error_http",
                "1d_change": -1.7984957785,
                "index_price": -0.1738524109,
                "norm_price": -1.6246433676
            },
            {
                "index": 880,
                "date": "2016-04-04",
                "press_title": "Lilly Confirms Date and Conference Call for First-Quarter 2016 Financial Results Announcement",
                "release_url": "http://lilly.mediaroom.com/2016-04-04-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2016-Financial-Results-Announcement",
                "content": "Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2016 on Tuesday, April 26, 2016. Lilly will also conduct a conference call on that day with the...",
                "1d_change": -0.7119400338,
                "index_price": -1.3700522137,
                "norm_price": 0.6581121799
            },
            {
                "index": 881,
                "date": "2016-03-31",
                "press_title": "New 2016 ACC/AHA Guideline Focused Update States that it is Reasonable to Choose Effient® (prasugrel) Over Clopidogrel for Certain ACS-PCI Patients with ST-Elevation Myocardial Infarction and NSTE-ACS",
                "release_url": "http://lilly.mediaroom.com/2016-03-31-New-2016-ACC-AHA-Guideline-Focused-Update-States-that-it-is-Reasonable-to-Choose-Effient-R-prasugrel-Over-Clopidogrel-for-Certain-ACS-PCI-Patients-with-ST-Elevation-Myocardial-Infarction-and-NSTE-ACS",
                "content": "A new guideline focused update provided oral antiplatelet therapy Effient® (prasugrel) with a Class IIa recommendation, meaning that it is reasonable to choose Effient over clopidogrel for the...",
                "1d_change": 2.2473504623,
                "index_price": 0.4346823898,
                "norm_price": 1.8126680726
            },
            {
                "index": 882,
                "date": "2016-03-31",
                "press_title": "Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics",
                "release_url": "http://lilly.mediaroom.com/2016-03-31-Phase-3-Study-Findings-Demonstrate-Treatment-with-Baricitinib-Results-in-Significant-Improvements-for-Patients-with-Rheumatoid-Arthritis-Who-Had-Inadequate-Response-to-Biologics",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment...",
                "1d_change": 2.2473504623,
                "index_price": 0.4346823898,
                "norm_price": 1.8126680726
            },
            {
                "index": 883,
                "date": "2016-03-22",
                "press_title": "Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis",
                "release_url": "http://lilly.mediaroom.com/2016-03-22-Lillys-Taltz-R-ixekizumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe...",
                "1d_change": 1.3488677401,
                "index_price": -0.5857452396,
                "norm_price": 1.9346129797
            },
            {
                "index": 884,
                "date": "2016-03-15",
                "press_title": "Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study",
                "release_url": "http://lilly.mediaroom.com/2016-03-15-Lilly-Announces-Change-to-Primary-Endpoint-of-EXPEDITION3-Study",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer's dementia. The...",
                "1d_change": 1.145173471,
                "index_price": 0.589474815,
                "norm_price": 0.555698656
            },
            {
                "index": 885,
                "date": "2016-03-07",
                "press_title": "Studies Show Ixekizumab Improved Work Productivity for Patients with Moderate-to-Severe Plaque Psoriasis: Results Published in JAMA Dermatology",
                "release_url": "http://lilly.mediaroom.com/2016-03-07-Studies-Show-Ixekizumab-Improved-Work-Productivity-for-Patients-with-Moderate-to-Severe-Plaque-Psoriasis-Results-Published-in-JAMA-Dermatology",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that JAMA Dermatology has published detailed results from three pivotal Phase 3 trials that evaluated the effect of ixekizumab on work...",
                "1d_change": -0.2328763185,
                "index_price": -0.8513270365,
                "norm_price": 0.618450718
            },
            {
                "index": 886,
                "date": "2016-03-07",
                "press_title": "Ixekizumab Demonstrates High Levels of Skin Clearance among Patients with Moderate-to-Severe Plaque Psoriasis Who Did Not Respond to Treatment with Etanercept",
                "release_url": "http://lilly.mediaroom.com/2016-03-07-Ixekizumab-Demonstrates-High-Levels-of-Skin-Clearance-among-Patients-with-Moderate-to-Severe-Plaque-Psoriasis-Who-Did-Not-Respond-to-Treatment-with-Etanercept",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their...",
                "1d_change": -0.2328763185,
                "index_price": -0.8513270365,
                "norm_price": 0.618450718
            },
            {
                "index": 887,
                "date": "2016-03-04",
                "press_title": "Ixekizumab Demonstrates Rapid, Clinically Meaningful Improvements as Early as One Week among Patients with Moderate-to-Severe Plaque Psoriasis",
                "release_url": "http://lilly.mediaroom.com/2016-03-04-Ixekizumab-Demonstrates-Rapid-Clinically-Meaningful-Improvements-as-Early-as-One-Week-among-Patients-with-Moderate-to-Severe-Plaque-Psoriasis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that treatment for moderate-to-severe plaque psoriasis with ixekizumab resulted in clinically meaningful improvements as early as one week,...",
                "1d_change": 0.0408880439,
                "index_price": 0.3871592979,
                "norm_price": -0.3462712541
            },
            {
                "index": 888,
                "date": "2016-03-02",
                "press_title": "Lilly to Participate in Barclays Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2016-03-02-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE:LLY) will attend the Barclays Global Healthcare Conference on Wednesday, March 16, 2016. Derica Rice, Lilly's executive vice president for global services and chief...",
                "1d_change": 0.709869947,
                "index_price": 0.8427836171,
                "norm_price": -0.13291367
            },
            {
                "index": 889,
                "date": "2016-03-01",
                "press_title": "Lilly to Present Phase 3 Data at the American Academy of Dermatology (AAD) Annual Meeting for Ixekizumab in Psoriasis and Psoriatic Arthritis",
                "release_url": "http://lilly.mediaroom.com/2016-03-01-Lilly-to-Present-Phase-3-Data-at-the-American-Academy-of-Dermatology-AAD-Annual-Meeting-for-Ixekizumab-in-Psoriasis-and-Psoriatic-Arthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) will showcase results from pivotal Phase 3 data investigating ixekizumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis...",
                "1d_change": 1.8778857687,
                "index_price": 2.4848340791,
                "norm_price": -0.6069483104
            },
            {
                "index": 890,
                "date": "2016-02-26",
                "press_title": "Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis",
                "release_url": "http://lilly.mediaroom.com/2016-02-26-Lilly-Receives-Positive-CHMP-Opinion-for-Ixekizumab-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis",
                "content": "Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for ixekizumab for...",
                "1d_change": -4.7499922232,
                "index_price": -1.1758419512,
                "norm_price": -3.5741502721
            },
            {
                "index": 891,
                "date": "2016-02-25",
                "press_title": "Lilly to Present at Cowen Health Care Conference",
                "release_url": "http://lilly.mediaroom.com/2016-02-25-Lilly-to-Present-at-Cowen-Health-Care-Conference",
                "content": "error_http",
                "1d_change": -0.9103098509,
                "index_price": 0.8305769003,
                "norm_price": -1.7408867512
            },
            {
                "index": 892,
                "date": "2016-02-19",
                "press_title": "Eli Lilly and Company and United Way Announced Global Partnership Agreement",
                "release_url": "http://lilly.mediaroom.com/2016-02-19-Eli-Lilly-and-Company-and-United-Way-Announced-Global-Partnership-Agreement",
                "content": "INDIANAPOLIS, IN – Yesterday top executives from Eli Lilly and Company, United Way Worldwide and United Way of Central Indiana signed a strategic partnership agreement designed to drive...",
                "1d_change": 0.4382978184,
                "index_price": 1.4782837196,
                "norm_price": -1.0399859013
            },
            {
                "index": 893,
                "date": "2016-02-12",
                "press_title": "UK Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit",
                "release_url": "http://lilly.mediaroom.com/2016-02-12-UK-Court-Rules-Against-Lilly-in-Alimta-Vitamin-Regimen-Patent-Lawsuit",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced that the UK High Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not presently be infringed by Actavis marketing...",
                "1d_change": 2.4001342551,
                "index_price": 3.2802589752,
                "norm_price": -0.8801247201
            },
            {
                "index": 894,
                "date": "2016-02-11",
                "press_title": "Lilly Diabetes Helps Inspiring Students with Type 1 Diabetes Attend College Through Scholarship Donation",
                "release_url": "http://lilly.mediaroom.com/2016-02-11-Lilly-Diabetes-Helps-Inspiring-Students-with-Type-1-Diabetes-Attend-College-Through-Scholarship-Donation",
                "content": "Attending college is a major milestone for many young people, but for those with type 1 diabetes, the journey can be extra demanding. Not only do these students juggle class schedules, assignments...",
                "1d_change": -1.3048968244,
                "index_price": 0.9534652354,
                "norm_price": -2.2583620598
            },
            {
                "index": 895,
                "date": "2016-02-03",
                "press_title": "American Diabetes Association® Survey Shows Summer Camp Can Positively Impact Children's Disease Management Skills, Confidence and Stress",
                "release_url": "http://lilly.mediaroom.com/2016-02-03-American-Diabetes-Association-R-Survey-Shows-Summer-Camp-Can-Positively-Impact-Childrens-Disease-Management-Skills-Confidence-and-Stress",
                "content": "A three-year survey by the American Diabetes Association (Association) shows attending summer camp can do much more than lift the spirits of children with type 1 diabetes. Surveys conducted with...",
                "1d_change": -2.934839798,
                "index_price": 0.4374953717,
                "norm_price": -3.3723351696
            },
            {
                "index": 896,
                "date": "2016-01-28",
                "press_title": "Lilly Reports Fourth-Quarter and Full-Year 2015 Results",
                "release_url": "http://lilly.mediaroom.com/2016-01-28-Lilly-Reports-Fourth-Quarter-and-Full-Year-2015-Results",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2015. $ in millions, except per share data Fourth Quarter % Full Year % 2015 2014 Change...",
                "1d_change": -3.5018754154,
                "index_price": 2.835732683,
                "norm_price": -6.3376080983
            },
            {
                "index": 897,
                "date": "2016-01-27",
                "press_title": "Lilly To Present At Leerink Partners Global Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2016-01-27-Lilly-To-Present-At-Leerink-Partners-Global-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Wednesday, February 10, 2016. Derica Rice, Lilly's executive vice president for global...",
                "1d_change": -6.2491855823,
                "index_price": -0.4837978119,
                "norm_price": -5.7653877705
            },
            {
                "index": 898,
                "date": "2016-01-27",
                "press_title": "Lilly and Roche Diagnostics to Collaborate on Alzheimer's Disease Adjunct Diagnostic Tool",
                "release_url": "http://lilly.mediaroom.com/2016-01-27-Lilly-and-Roche-Diagnostics-to-Collaborate-on-Alzheimers-Disease-Adjunct-Diagnostic-Tool",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta...",
                "1d_change": -6.2491855823,
                "index_price": -0.4837978119,
                "norm_price": -5.7653877705
            },
            {
                "index": 899,
                "date": "2016-01-25",
                "press_title": "U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)",
                "release_url": "http://lilly.mediaroom.com/2016-01-25-U-S-FDA-Accepts-Filing-of-Cardiovascular-Outcomes-Data-for-Jardiance-R-empagliflozin",
                "content": "The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application for Jardiance® (empagliflozin) based on cardiovascular risk reduction data from the landmark EMPA-REG...",
                "1d_change": -0.6588929192,
                "index_price": -0.1392090063,
                "norm_price": -0.5196839128
            },
            {
                "index": 900,
                "date": "2016-01-21",
                "press_title": "U.S. Food and Drug Administration Approves Humulin® R U-500 KwikPen®",
                "release_url": "http://lilly.mediaroom.com/2016-01-21-U-S-Food-and-Drug-Administration-Approves-Humulin-R-R-U-500-KwikPen-R",
                "content": "The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Humulin® R U-500 KwikPen®(insulin human injection) 500 units/mL, a pre-filled device containing...",
                "1d_change": -0.0970002433,
                "index_price": 2.3829284648,
                "norm_price": -2.4799287081
            },
            {
                "index": 901,
                "date": "2016-01-19",
                "press_title": "Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis",
                "release_url": "http://lilly.mediaroom.com/2016-01-19-Lilly-and-Incyte-Announce-Submission-of-New-Drug-Application-to-FDA-for-Oral-Once-Daily-Baricitinib-for-Treatment-of-Moderate-to-Severe-Rheumatoid-Arthritis",
                "content": "Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that Lilly has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the...",
                "1d_change": 0.3752379536,
                "index_price": -1.5774541807,
                "norm_price": 1.9526921343
            },
            {
                "index": 902,
                "date": "2016-01-05",
                "press_title": "Lilly Announces 2016 Financial Guidance, Updates 2015 Expectations",
                "release_url": "http://lilly.mediaroom.com/2016-01-05-Lilly-Announces-2016-Financial-Guidance-Updates-2015-Expectations",
                "content": "Eli Lilly and Company (NYSE: LLY) today announced its 2016 financial guidance and highlighted key events for the upcoming year. The company also reaffirmed its commitment to grow revenue and...",
                "1d_change": 0.8135493202,
                "index_price": -1.1817561231,
                "norm_price": 1.9953054433
            },
            {
                "index": 903,
                "date": "2016-01-04",
                "press_title": "Lilly to Present at J.P. Morgan Healthcare Conference",
                "release_url": "http://lilly.mediaroom.com/2016-01-04-Lilly-to-Present-at-J-P-Morgan-Healthcare-Conference",
                "content": "Eli Lilly and Company (NYSE: LLY) will present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016. John C. Lechleiter, Ph.D., Lilly's chairman, president and chief...",
                "1d_change": 0.8441392841,
                "index_price": -1.065596474,
                "norm_price": 1.9097357581
            }
        ]
    }
]